CDC_Test_ID	Test_Case_Name	DOB	gender	Med_History_Text	Med_History_Code	Med_History_Code_Sys	Series_Status	Date_Administered_1	Vaccine_Name_1	CVX_1	MVX_1	Evaluation_Status_1	Evaluation_Reason_1	Date_Administered_2	Vaccine_Name_2	CVX_2	MVX_2	Evaluation_Status_2	Evaluation_Reason_2	Date_Administered_3	Vaccine_Name_3	CVX_3	MVX_3	Evaluation_Status_3	Evaluation_Reason_3	Date_Administered_4	Vaccine_Name_4	CVX_4	MVX_4	Evaluation_Status_4	Evaluation_Reason_4	Date_Administered_5	Vaccine_Name_5	CVX_5	MVX_5	Evaluation_Status_5	Evaluation_Reason_5	Date_Administered_6	Vaccine_Name_6	CVX_6	MVX_6	Evaluation_Status_6	Evaluation_Reason_6	Date_Administered_7	Vaccine_Name_7	CVX_7	MVX_7	Evaluation_Status_7	Evaluation_Reason_7	Forecast_#	Earliest_Date	Recommended_Date	Past_Due_Date	Vaccine_Group	Assessment_Date	Evaluation_Test_Type	Date_Added	Date_Updated	Forecast_Test_Type	Reason_For_Change	Changed_In_Version	General_Description
2013-0001	Newborn Testing	44911	F				Not complete																																											1	44953	44973	45028	DTAP	44911	No Doses Administered	41275	44061.68259271991	Recommended based on age		1.0	This test case describes the forecasting of the DTaP vaccine for a newborn at six weeks of age.
2013-0002	DTaP #2 at age 10 weeks-5 days	44846	F				Not complete	44885	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Not Valid	Age: Too Young																															2	44939	44969	45024	DTAP	44911	Age: Below Absolute Minimum	41275	44001.494036296295	Recommended based on age		1.0	This test case describes when a child is administered a second dose of the DTaP vaccine at 10 weeks - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0003	DTaP #2 at 10 wks-4 days	44845	F				Not complete	44887	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																																3	44943	45027	45084	DTAP	44911	Age: At Absolute Minimum	41275	44001.496824305555	Recommended based on age		1.0	This test case describes when a child is administered a second dose of the DTaP vaccine at 10 weeks - 4 days that the dose is valid.  Another dose should be forecast.
2013-0004	DTaP # 2 at age 10 weeks	44841	F				Not complete	44883	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																																3	44939	45023	45080	DTAP	44911	Age: At Minimum	41275	44001.497852974535	Recommended based on age		1.0	This test case describes when a child is administered a second dose of the DTaP vaccine at 10 weeks that the dose is valid.  Another dose should be forecast.
2013-0005	DTaP # 2 at age 4 months	44789	F				Not complete	44850	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																																3	44939	44973	45028	DTAP	44911	Age: At Recommended	41275	44004.483396111114	Recommended based on age		1.0	This test case describes when a child is administered a second dose of the DTaP vaccine at age 4 months, that the dose is valid. Another dose should be forecast.
2013-0007	# 2 (Tdap) to child age 7.  DTaP # 1 given before age 12 months.  Forecast # 3 (Td) in 4 weeks. 	42354	F				Not complete	42416	DTaP, unspecified formulation	107		Valid		44911	BOOSTRIX	115	SKB	Valid																																3	44939	44939	44939	DTAP	44911	Age: At Minimum	41275	44004.53505899305	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was missing and child is in catch-up.  Past Due Date added to align with Recommended Date.	1.1	This test case describes when a child is administered a Tdap vaccine as a second dose (with a first dose of DTaP vaccine before 12 months of age) that the dose is valid. Another dose should be forecast.
2013-0008	# 2 (Tdap) to child age 7.  DTaP # 1 at ≥ 12 months.  Forecast dose 3 for 6 months. 	42354	F				Not complete	42720	DTaP, unspecified formulation	107		Valid		44911	BOOSTRIX	115	SKB	Valid																																3	45093	45093	45093	DTAP	44911	Age: At Minimum	41275	44004.53518655093	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was missing and child is in catch-up.  Past Due Date added to align with Recommended Date.	1.1	This test case describes when a child is administered a Tdap vaccine as a second dose (with a first dose of DTaP vaccine at greater than or equal to  12 months of age) that the dose is valid. Another dose should be forecast.
2013-0010	# 1 (Td) to # 2 (Tdap) interval 28-4 days in child age > 7 years.  Forecast # 3 in six months. 	41870	F				Not complete	44887	Td, adsorbed	09	MBL	Valid		44911	BOOSTRIX	115	SKB	Valid																																3	45093	45093	45093	DTAP	44911	Interval: At Absolute Minimum	41275	44004.55828789352	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was missing and child is in catch-up.  Past Due Date added to align with Recommended Date.	1.1	This test case describes when a child 8 years of age is administered a Tdap vaccine as a second dose (and at an interval of 28 -4 days from the first dose) that the dose is valid. Another dose should be forecast.
2013-0011	#3 at age 14 weeks-5 days	44818	F				Not complete	44860	DTaP, unspecified formulation	107		Valid		44888	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Not Valid	Age: Too Young																									3	44939	44999	45057	DTAP	44911	Age: Below Absolute Minimum	41275	44004.56034116898	Recommended based on age		1.0	This test case describes when a third dose of the DTaP vaccine is administered at age 14 weeks - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0012	Age 6.  No vaccinations. Forecast DTaP.	42720	F				Not complete																																											1	42762	42782	42837	DTAP	44911	No Doses Administered	41275	44004.57159114583	Recommended based on age		1.0	This test case describes when a child age 6 years has no history of the DTAP/Tdap/Td that the first dose should be forecast.
2013-0013	#3 at age 14 weeks-4 days	44817	F				Not complete	44859	DTaP, unspecified formulation	107		Valid		44885	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																										4	45273	45273	45422	DTAP	44911	Age: At Absolute Minimum	41275	44004.57621521991	Recommended based on age	V3.3: Updated per the 2017 General Best Practice Guidelines which moved the Minimum and Recommended Age to 15 months	3.3	This test case describes when a child is administered a third dose of the DTAP/Tdap/Td at age 14 weeks - 4 days that the dose is valid.  Another dose should be forecast.
2013-0014	#3 at age 14 weeks	44813	F				Not complete	44855	DTaP, unspecified formulation	107		Valid		44883	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																										4	45269	45269	45418	DTAP	44911	Age: At Minimum	41275	44004.582760405094	Recommended based on age	Updated per the 2017 General Best Practice Guidelines which moved the Minimum and Recommended Age to 15 months	3.3	This test case describes when a child is administered a third dose of the DTAP/Tdap/Td at age 14 weeks that the dose is valid.  Another dose should be forecast.
2013-0015	#3 at age 6 months	44728	F				Not complete	44789	DTaP, unspecified formulation	107		Valid		44820	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																										4	45185	45185	45334	DTAP	44911	Age: At Recommended	41275	44004.585792384256	Recommended based on age	Updated per the 2017 General Best Practice Guidelines which moved the Minimum and Recommended Age to 15 months	3.3	This test case describes when a child is administered a third dose of the DTAP/Tdap/Td at age 6 months that the dose is valid.  Another dose should be forecast.
2013-0016	Doses # 2 and #3 at ≥ age 7 years; # 1 at age < 12 mo.  Forecast # 4 in 6 mo. 	42324	F				Not complete	42567	DTaP, unspecified formulation	107		Valid		44881	Td, adsorbed	09	MBL	Valid		44911	BOOSTRIX	115	SKB	Valid																										4	45093	45093	45093	DTAP	44911	All Valid: Forecast Test	41275	44004.59260844907	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered the first dose of DTaP at less than 12 months of age and the second and third dose at greater than 7 years of age that the doses are valid. Another dose should be forecast.
2013-0017	Doses # 2 and # 3 at ≥7 years old; dose # 1 at ≥ 12 months old.	42062	F				Not complete	42489	DTaP, unspecified formulation	107		Valid		44627	Td, adsorbed	09	MBL	Valid		44911	BOOSTRIX	115	SKB	Valid																										4	46080	46080	46837	DTAP	44911	All Valid: Forecast Test	41275	44004.64718865741	Recommended based on interval	V4.0: Updated Forecast per new Tdap Catch-up Job-Aid. Tdap is needed at 11 years.
V1.1: Past Due Date was missing. Added past due date per NIPInfo guidance.	4.0	This test case describes when a child is administered the first dose of DTaP at greater than 12 months of age and the second and third dose at greater than 7 years of age that the doses are valid. Another dose should be forecast.
2013-0019	1 Tdap, 2 Td with appropriate intervals to child ≥ age 7	42140	F				Not complete	44698	BOOSTRIX	115	SKB	Valid		44728	Td, adsorbed	09	MBL	Valid		44911	Td, adsorbed	09	MBL	Valid																										4	46158	46158	46916	DTAP	44911	All Valid: Forecast Test	41275	44151.668528738424	Recommended based on interval	V4.0: Updated Forecast per new Tdap Catch-up Job-Aid. Tdap is needed at 11 years.
V1.1: Past Due Date was missing. Added past due date per NIPInfo guidance.	4.0	This test case describes when a child is administered the first dose, of the Diphtheria, Tetanus, and Pertussis vaccine, as Tdap and the second dose as Td at an age greater than 7 years that the doses are valid. Another dose should be forecast.
2013-0020	1 Tdap, 2 Td to child ≥ 7 years old with 6 mo-5 day interval between doses 2 and 3.	41775	F				Not complete	44697	BOOSTRIX	115	SKB	Valid		44728	Td, adsorbed	09	MBL	Valid		44906	Td, adsorbed	09	MBL	Not Valid	Interval: too short																									3	45088	45088	45088	DTAP	44911	Interval: Below Absolute Minimum	41275	44004.68020658565	Recommended based on minimum interval from invalid dose	Past Due Date was missing and child is in catch-up.  Past Due Date added to align with Recommended Date.	1.1	This test case describes when a child is administered the third dose ( first dose was Tdap, second dose was Td) of the DTaP vaccine at an interval of 6 months - 5 days from the second dose that the dose is not valid.  A repeat dose should be forecast.
2013-0021	1 Tdap, 2 Td to child ≥ 7 years old with 6 mo-4 day interval between doses 2 and 3. 	42110	F				Not complete	44667	Td, adsorbed	09	MBL	Valid		44728	BOOSTRIX	115	SKB	Valid		44907	Td, adsorbed	09	MBL	Valid																										4	46128	46128	46886	DTAP	44911	Interval: At Absolute Minimum	41275	44004.67946623843	Recommended based on interval	V4.2: Mild adjustments to relative date settings to avoid administration dates in the future. Test case expectations (e.g, evaluation status or forecast) have not changed.
V4.0: Updated Forecast per new Tdap Catch-up Job-Aid. Tdap is needed at 11 years.
V1.1: Past Due Date was missing. Added past due date per NIPInfo guidance.	4.2	This test case describes when a child is administered the third dose ( first dose was Tdap, second dose was Td) of the DTaP vaccine at an interval of 6 months - 4 days from the second dose that the dose is valid.  Another dose should be forecast.
2013-0022	Age 7.  Two DTaP˂ 12 months old.  Needs Tdap.	42354	F				Not complete	42442	DTaP, unspecified formulation	107		Valid		42540	DTaP, unspecified formulation	107		Valid																																3	44911	44911	44911	DTAP	44911	All Valid: Forecast Test	41275	44004.693184375	Recommended based on age		1.0	This test case describes a child who is currently age seven years but was administered two doses of the DTaP vaccine at less than 12 months of age that the doses are valid and that another dose should be forecast (preferably Tdap).
2013-0023	Age 7.  No vaccinations.  Forecast Tdap.	42354	F				Not complete																																											1	44911	44911	44911	DTAP	44911	No Doses Administered	41275	44004.689432719904	Recommended based on age	Past Due Date was missing and child is in catch-up.  Past Due Date added to align with Recommended Date.	1.1	This test case describes a child  7 years of age with no history of the DTaP/Tdap/Td vaccine that a first dose should be forecast.
2013-0024	Age 7. Two DTaP˂ 12 mos old & 1 ≥ 12 mo.  Needs Tdap.	42354	F				Not complete	42445	DTaP, unspecified formulation	107		Valid		42567	DTaP, unspecified formulation	107		Valid		43087	DTaP, unspecified formulation	107		Valid																										4	44911	44911	44911	DTAP	44911	All Valid: Forecast Test	41275	44004.69276574074	Recommended based on minimum interval from previous dose (catch-up)	V1.1: Past Due Date was missing and child is in catch-up.  Past Due Date added to align with Recommended Date.	1.1	This test case describes a child who is currently seven years of age but was administered one dose of the DTaP vaccine at less than 12 months of age and another dose at greater than twelve months of age that the doses are valid.  Another dose should be forecast (preferably Tdap).
2013-0025	#4 at age 12 mo-5 days	44551	F				Not complete	44613	DTaP, unspecified formulation	107		Valid		44672	DTaP, unspecified formulation	107		Valid		44729	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Not Valid	Age: Too Young																			4	45093	45093	45155	DTAP	44911	Age: Below Absolute Minimum	41275	44004.69405670139	Recommended based on minimum interval from inValid dose		1.0	This test case describes when a child is administered a fourth dose of the DTaP/Tdap/Td vaccine at age 12 months - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0026	#4 at age 12 mo-4 days	44550	F				Not complete	44612	DTaP, unspecified formulation	107		Valid		44671	DTaP, unspecified formulation	107		Valid		44729	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																				5	46011	46011	47106	DTAP	44911	Age: At Absolute Minimum	41275	44005.49092460648	Recommended based on age		1.0	This test case describes when a child is administered a fourth dose of the DTaP/Tdap/Td vaccine at age 12 months - 4 days that the dose is valid.  Another dose should be forecast.
2013-0027	#4 at age 12 months old	44546	F				Not complete	44608	DTaP, unspecified formulation	107		Valid		44667	DTaP, unspecified formulation	107		Valid		44728	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																				5	46007	46007	47102	DTAP	44911	Age: At Recommended	41275	44005.49981680555	Recommended based on age		1.0	This test case describes when a child is administered a fourth dose of the DTaP/Tdap/Td vaccine at age 12 months that the dose is valid.  Another dose should be forecast.
2013-0028	#4 at age 4 is UTD until age 11.	43450	F				Not complete	43537	DTaP, unspecified formulation	107		Valid		43598	DTaP, unspecified formulation	107		Valid		43659	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																				5	47468	47468	48225	DTAP	44911	All Valid: Forecast Test	41275	44005.5590581713	Recommended based on age	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V1.4: Updated past due date to shift 1 day earlier to align with business rule calculation and other similar tests in the DTaP/Tdap/Td forecasting at 11 years.	3.4	This test case describes when a child is administered a fourth dose of the DTaP/Tdap/Td vaccine at age 4 years that the dose is valid.  Another dose should be forecast.
2013-0029	5 year old with no previous DTP product receives 4 vaccinations prior to age 7 years	42654	F				Not complete	44480	DTaP, unspecified formulation	107		Valid		44541	DTaP, unspecified formulation	107		Valid		44725	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																				5	46671	46671	47429	DTAP	44911	All Valid: Forecast Test	41275	44005.57350980324	Recommended based on age	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V1.4: Updated past due date to shift 1 day earlier to align with business rule calculation and other similar tests in the DTaP/Tdap/Td forecasting at 11 years.	3.4	This test case describes when a child age 5 years has no history of a DTP vaccine that a dose should be forecast.
2013-0030	#5 at age 4 years-5 days	43455	F				Not complete	43517	DTaP, unspecified formulation	107		Valid		43545	DTaP, unspecified formulation	107		Valid		43606	DTaP, unspecified formulation	107		Valid		43821	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Not Valid	Age: Too Young													5	45093	45093	46011	DTAP	44911	Age: Below Absolute Minimum	41275	44005.5951309375	Recommended based on minimum interval from invalid dose		1.0	This test case describes when a child is administered a fifth dose of the DTaP vaccine at an interval of 4 years - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0031	#5 at age 4 years-4 days	43454	F				Not complete	43516	DTaP, unspecified formulation	107		Valid		43544	DTaP, unspecified formulation	107		Valid		43605	DTaP, unspecified formulation	107		Valid		43820	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid														6	47472	47472	48229	DTAP	44911	Age: At Absolute Minimum	41275	44005.58973164352	Recommended based on age	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V1.4: Updated past due date to shift 1 day earlier to align with business rule calculation and other similar tests in the DTaP/Tdap/Td forecasting at 11 years.	3.4	This test case describes when a child is administered a fifth dose of the DTaP vaccine at an interval of 4 years - 4 days that the dose is valid.  Another dose should be forecast.
2013-0032	# 5 at age 4 years	43450	F				Not complete	43512	DTaP, unspecified formulation	107		Valid		43614	DTaP, unspecified formulation	107		Valid		43695	DTaP, unspecified formulation	107		Valid		44261	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid														6	47468	47468	48225	DTAP	44911	Age: At Minimum	41275	44005.590788518515	Recommended based on age	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V1.4: Updated past due date to shift 1 day earlier to align with business rule calculation and other similar tests in the DTaP/Tdap/Td forecasting at 11 years.	3.4	This test case describes when a child is administered a fifth dose of the DTaP vaccine at an age 4 years that the dose is valid.  Another dose should be forecast.
2013-0033	DTaP #1 at age 6 weeks-5 days	44874	F				Not complete	44911	DTaP, unspecified formulation	107		Not Valid	Age: Too Young																																					1	44916	44935	44993	DTAP	44911	Age: Below Absolute Minimum	41275	44005.65501340278	Recommended based on age		1.0	This test case describes when a child is administered a first dose of the DTaP vaccine at 6 weeks - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0034	# 6 DTaP before age 4.  Nothing more until Tdap at age 7 even if some are invalid. 	43632	F				Not complete	43693	DTaP, unspecified formulation	107		Valid		43754	DTaP, unspecified formulation	107		Valid		43815	DTaP, unspecified formulation	107		Valid		44363	DTaP, unspecified formulation	107		Valid		44455	DTaP, unspecified formulation	107		Not Valid	Age: Too Young	44911	DTaP, unspecified formulation	107		Not Valid	Age: Too Young							5	46189	46189	46189	DTAP	44911	Extra Doses	41275	44005.654001400464	Recommended based on age	Updated Forecast number from 6 to 5	3.2	This test case describes when a child who is administered a sixth dose of the DTaP vaccine before age 4 that the dose is not valid.  A repeat dose should be forecast.
2013-0035	Adolescent with Td but no Tdap.  	40276	F				Not complete	40337	DTaP, unspecified formulation	107		Valid		40398	DTaP, unspecified formulation	107		Valid		40459	DTaP, unspecified formulation	107		Valid		40735	DTaP, unspecified formulation	107		Valid		42191	DTaP, unspecified formulation	107		Valid		44911	Td, adsorbed	09	MBL	Valid								7	44911	44911	45051	DTAP	44911	All Valid: Forecast Test	41275	44005.67322179398	Recommended based on minimum interval from previous dose (catch-up)	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V2.2.: New logic concerning Tdap	3.4	This test case describes when an adolescent is administered Td as a sixth dose that another dose (preferably Tdap) should be forecast.
2013-0036	Invalid age for dose # 1 in first of series	44728	F				Not complete	44758	DTaP, unspecified formulation	107		Not Valid	Age: Too Young	44850	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																										3	44939	44939	44969	DTAP	44911	Age: Below Absolute Minimum	41275	44008.702870243054	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered a first dose of the DTaP vaccine at an invalid age but repeats the dose at three months later and the dose is valid. Another dose should be administered.
2013-0037	Invalid age for  dose # 2 in midst of others	44728	F				Not complete	44788	DTaP, unspecified formulation	107		Valid		44810	DTaP, unspecified formulation	107		Not Valid	Interval: too short	44911	DTaP, unspecified formulation	107		Valid																										3	44939	44939	44969	DTAP	44911	Interval: Below Absolute Minimum	41275	44008.72636804398	Recommended based on minimum interval from invalid dose		1.0	This test case describes when a child is administered an invalid second dose of the DTaP vaccine but a repeat is given at an appropriate interval that the dose is valid.  Another dose should be forecast.
2013-0038	Invalid age for dose #3 in midst of others	44545	F				Not complete	44587	DTaP, unspecified formulation	107		Valid		44612	DTaP, unspecified formulation	107		Valid		44637	DTaP, unspecified formulation	107		Not Valid	Age: Too Young	44911	DTaP, unspecified formulation	107		Valid																				4	45093	45093	45149	DTAP	44911	Age: Below Absolute Minimum	41275	44008.71836114583	Recommended based on minimum interval from invalid dose		1.0	This test case describes when a child is administered an invalid third dose of the DTaP vaccine but a repeat is administered at an appropriate age and interval that the dose is valid.  Another dose should be forecast.
2013-0039	Invalid age for dose # 4 in midst of others 	43450	F				Not complete	43512	DTaP, unspecified formulation	107		Valid		43571	DTaP, unspecified formulation	107		Valid		43625	DTaP, unspecified formulation	107		Valid		43810	DTaP, unspecified formulation	107		Not Valid	Age: Too Young	44911	DTaP, unspecified formulation	107		Valid														5	47468	47468	48225	DTAP	44911	Age: Below Absolute Minimum	41275	44008.72771212963	Recommended based on age	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V1.4: Updated past due date to shift 1 day earlier to align with business rule calculation and other similar tests in the DTaP/Tdap/Td forecasting at 11 years.	3.4	This test case describes when a child is administered an invalid fourth dose of the DTaP vaccine but a repeat is administered at an appropriate age and interval that the dose is valid.  Another dose should be forecast.
2013-0040	Invalid age dose 5 in midst of others	40893	F				Not complete	40956	DTaP, unspecified formulation	107		Valid		41018	DTaP, unspecified formulation	107		Valid		41090	DTaP, unspecified formulation	107		Valid		41349	DTaP, unspecified formulation	107		Valid		42015	DTaP, unspecified formulation	107		Not Valid	Age: Too Young	44911	BOOSTRIX	115	SKB	Valid								6	46737	48564	48591	DTAP	44911	Age: Below Absolute Minimum	41275	44008.728264826386	Recommended based on interval	Past Due Date was missing. Added past due date per NIPInfo guidance.	1.1	This test case describes when a child is administered an invalid fifth dose of the DTaP vaccine but a repeat is administered at an appropriate age and interval that the dose is valid.  Another dose should be forecast.
2013-0041	Dose 1 to dose 2 interval 28-5 days	44826	F				Not complete	44887	DTaP, unspecified formulation	107		Valid		44910	DTaP, unspecified formulation	107		Not Valid	Interval: too short																															2	44938	44948	45006	DTAP	44911	Interval: Below Absolute Minimum	41275	44622.57232554398	Recommended based on age		1.0	This test case describes when a child is administered a second dose of the DTaP vaccine at an interval of 28-5 days after the first dose, that the dose is not valid. A repeat dose should be forecast.
2013-0042	Dose 1 to dose 2 interval 28-4 days	44826	F				Not complete	44887	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																																3	44939	45007	45065	DTAP	44911	Interval: At Absolute Minimum	41275	44008.73408993056	Recommended based on age		1.0	This test case describes when a child is administered a second dose of the DTaP vaccine at an interval of 28-4 days after the first dose, that the dose is valid. Another dose should be forecast.
2013-0043	Dose 1 to dose 2 interval 28 days	44789	F				Not complete	44874	DTaP, unspecified formulation	107		Valid		44902	DTaP, unspecified formulation	107		Valid																																3	44930	44973	45028	DTAP	44911	Interval: At Minimum	41275	44656.298658472224	Recommended based on age		1.0	This test case describes when a child is administered a second dose of the DTaP vaccine at an interval of 28 days after the first dose, that the dose is valid. Another dose should be forecast.
2013-0044	DTaP #1 at age 6 weeks-4 days	44873	F				Not complete	44911	DTaP, unspecified formulation	107		Valid																																						2	44943	44993	45051	DTAP	44911	Age: At Absolute Minimum	41275	44011.480306805555	Recommended based on age		1.0	This test case describes when a patient is administered a first dose of the DTaP vaccine at 6 weeks- 4 days that the dose is valid.  Another dose should be forecast.
2013-0045	Dose 2 to dose 3 interval 28-5 days	44760	F				Not complete	44822	DTaP, unspecified formulation	107		Valid		44883	DTaP, unspecified formulation	107		Valid		44906	DTaP, unspecified formulation	107		Not Valid	Interval: too short																									3	44934	44944	45002	DTAP	44911	Interval: Below Absolute Minimum	41275	44704.44941460648	Recommended based on age		1.0	This test case describes when a child is administered dose three of the DTaP vaccine at an interval of 28 -5 days after the second dose that the dose is not valid.  A repeat dose should be forecast.
2013-0046	Dose 2 to dose 3 interval 28-4 days	44798	F				Not complete	44838	DTaP, unspecified formulation	107		Valid		44876	DTaP, unspecified formulation	107		Valid		44900	DTaP, unspecified formulation	107		Valid																										4	45255	45255	45403	DTAP	44911	Interval: At Absolute Minimum	41275	44704.45008030093	Recommended based on age	Updated per the 2017 General Best Practice Guidelines which moved the Minimum and Recommended Age to 15 months	3.3	This test case describes when a child is administered dose three of the DTaP vaccine at an interval of 28 - 4 days after the second dose that the dose is valid.  Another dose should be forecast.
2013-0047	Dose 2 to dose 3 interval 28 days	44806	F				Not complete	44846	DTaP, unspecified formulation	107		Valid		44875	DTaP, unspecified formulation	107		Valid		44903	DTaP, unspecified formulation	107		Valid																										4	45262	45262	45411	DTAP	44911	Interval: At Minimum	41275	44704.450436921295	Recommended based on age	Updated per the 2017 General Best Practice Guidelines which moved the Minimum and Recommended Age to 15 months	3.3	This test case describes when a child is administered dose three of the DTaP vaccine at an interval of 28 days after the second dose that the dose is valid.  Another dose should be forecast.
2013-0049	Dose 3 to dose 4 interval 6 months-4 days	44540	F				Not complete	44603	DTaP, unspecified formulation	107		Valid		44662	DTaP, unspecified formulation	107		Valid		44728	DTaP, unspecified formulation	107		Valid		44907	DTaP, unspecified formulation	107		Valid																				5	46001	46001	47096	DTAP	44911	All Valid: Forecast Test	41275	44798.399084097226	Recommended based on age		1.0	This test case describes when a child is administered dose four of the DTaP vaccine at an interval of 6 months - 4 days months after the third dose that the dose is valid.  Another dose should be forecast.
2013-0050	Dose 3 to dose 4 interval 6 months	44538	F				Not complete	44601	DTaP, unspecified formulation	107		Valid		44660	DTaP, unspecified formulation	107		Valid		44726	DTaP, unspecified formulation	107		Valid		44909	DTaP, unspecified formulation	107		Valid																				5	45999	45999	47094	DTAP	44911	Interval: At Minimum	41275	44656.30286321759	Recommended based on age		1.0	This test case describes when a child is administered dose four of the DTaP vaccine at an interval of 6 months after the third dose that the dose is valid.  Another dose should be forecast.
2013-0052	Dose 3 to dose 4 interval 4 months	44546	F				Not complete	44608	DTaP, unspecified formulation	107		Valid		44667	DTaP, unspecified formulation	107		Valid		44789	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																				5	46007	46007	47102	DTAP	44911	Interval: At Minimum	41275	44011.57060905093	Recommended based on age		1.0	This test case describes when a child is administered dose four of the DTaP vaccine at an interval of 4 months after the third dose that the dose is valid.  Another dose should be forecast.
2013-0053	Invalid dose 1 to dose 2 interval in midst of other vaccines 	44542	F				Not complete	44604	DTaP, unspecified formulation	107		Valid		44624	DTaP, unspecified formulation	107		Not Valid	Interval: too short	44724	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																				4	45093	45093	45146	DTAP	44911	Interval: Below Absolute Minimum	41275	44011.584779467594	Recommended based on minimum interval from invalid dose		1.0	This test case describes when a child is administered an invalid second dose of the DTaP vaccine at an interval less than 4 weeks - 4 days but was administered a valid repeat and third dose that the doses are valid.  Another dose should be forecast.
2013-0054	Invalid dose 2 to dose 3 interval in midst of other vaccines.	44483	F				Not complete	44544	DTaP, unspecified formulation	107		Valid		44602	DTaP, unspecified formulation	107		Valid		44624	DTaP, unspecified formulation	107		Not Valid	Interval: too short	44911	DTaP, unspecified formulation	107		Valid																				4	45093	45093	45093	DTAP	44911	Interval: Below Absolute Minimum	41275	44084.60693587963	Recommended based on minimum interval from invalid dose		1.0	This test case describes when a child is administered an invalid third dose of the DTaP vaccine at an interval of less than 4 weeks - 4 days but was administered a repeat dose at an interval of 4 weeks after the invalid dose, that the dose is valid. Another dose should be forecast.
2013-0055	DTaP #1 at age 6 weeks	44869	F				Not complete	44911	DTaP, unspecified formulation	107		Valid																																						2	44939	44989	45047	DTAP	44911	Age: At Minimum	41275	44011.62993434028	Recommended based on age		1.0	This test case describes when a child is administered a first dose of the DTaP vaccine at 6 weeks of age that the dose is valid.  Another dose should be forecast.
2013-0056	Invalid dose 3 to dose 4 interval in midst of other vaccinations	44546	F				Not complete	44697	DTaP, unspecified formulation	107		Valid		44758	DTaP, unspecified formulation	107		Valid		44811	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Not Valid	Interval: too short																			4	45093	45093	45150	DTAP	44911	Interval: Below Absolute Minimum	41275	44013.63364946759	Recommended based on minimum interval from inValid dose		1.0	This test case describes when a child is administered an invalid fourth dose of the DTaP vaccine at an interval of less than 4 months - 4 days that a repeat dose should be forecast.
2013-0057	Invalid dose 4 to dose 5 interval in midst of others	40892	F				Not complete	40954	DTaP, unspecified formulation	107		Valid		41014	DTaP, unspecified formulation	107		Valid		41075	DTaP, unspecified formulation	107		Valid		42250	DTaP, unspecified formulation	107		Valid		42354	DTaP, unspecified formulation	107		Not Valid	Interval: too short	44911	BOOSTRIX	115	SKB	Valid								6	46737	48564	48591	DTAP	44911	Interval: Below Absolute Minimum	41275	44013.63515297454	Recommended based on interval	V1.4: Updated past due date to align with EIPB guidance clarification on  past due date and other test cases.	1.4	This test case describes when a child is administered an invalid fifth dose of the DTaP vaccine at an interval of less than 6 months - 4 days but was administered another valid dose at age 11 years.  A decennial dose should be forecast.
2013-0058	Tdap as dose #1	44516	F				Not complete	44577	BOOSTRIX	115	SKB	Not Valid	Inadvertent Vaccine	44638	DTaP, unspecified formulation	107		Valid		44701	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																				4	45093	45093	45120	DTAP	44911	Vaccine: Invalid Usage	41275	44375.41989859954	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child has been administered an invalid Tdap vaccine dose as the first dose but has received a valid repeat and valid second and third DTaP doses.  Another dose should be forecast.
2013-0059	Tdap as dose #2	44546	F				Not complete	44608	DTaP, unspecified formulation	107		Valid		44669	BOOSTRIX	115	SKB	Not Valid	Inadvertent Vaccine	44732	DTaP, unspecified formulation	107		Valid		44911	DTaP, unspecified formulation	107		Valid																				4	45093	45093	45150	DTAP	44911	Vaccine: Invalid Usage	41275	44375.462784675925	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child has been administered an invalid Tdap vaccine dose as the second dose but has received a valid repeat and valid third DTaP doses.  Another dose should be forecast.
2013-0060	Tdap as dose 3 to child under age 4=invalid as DTaP 3	44636	F				Not complete	44728	DTaP, unspecified formulation	107		Valid		44789	DTaP, unspecified formulation	107		Valid		44911	BOOSTRIX	115	SKB	Not Valid	Inadvertent Vaccine																									3	44911	44911	44911	DTAP	44911	Vaccine: Invalid Usage	41275	44375.46343989584	Recommended based on minimum interval from invalid dose		1.0	This test case describes when a child is administered an invalid third dose of the DTaP vaccine as Tdap that a repeat dose (DTaP) should be forecast.
2013-0061	Tdap as dose 4 to age 15 months=valid as DTaP	44451	F				Not complete	44542	DTaP, unspecified formulation	107		Valid		44604	DTaP, unspecified formulation	107		Valid		44724	DTaP, unspecified formulation	107		Valid		44911	BOOSTRIX	115	SKB	Valid																				5	45912	45912	47007	DTAP	44911	Vaccine: Off Label	41275	44013.669120949075	Recommended based on age		1.0	This test case describes when a child is administered Tdap as a fourth dose at age 15 months that the dose is valid.  Another dose should be forecast.
2013-0062	Tdap as dose 5 to age 4 years-5 days=invalid as dose 5 of DTaP	43455	F				Not complete	43537	DTaP, unspecified formulation	107		Valid		43598	DTaP, unspecified formulation	107		Valid		43721	DTaP, unspecified formulation	107		Valid		43939	DTaP, unspecified formulation	107		Valid		44911	BOOSTRIX	115	SKB	Not Valid	Age: Too Young													5	45093	45093	46011	DTAP	44911	Age: Below Absolute Minimum	41275	44013.673245011574	Recommended based on minimum interval from invalid dose		1.0	This test case describes when a child is administered Tdap as a fifth at age 4 years - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0063	Tdap as dose 5 to age 4-4 days. Counts as valid DTaP.  Child will need another Tdap in adolescence.	43454	F				Not complete	43536	DTaP, unspecified formulation	107		Valid		43597	DTaP, unspecified formulation	107		Valid		43720	DTaP, unspecified formulation	107		Valid		43938	DTaP, unspecified formulation	107		Valid		44911	BOOSTRIX	115	SKB	Valid														6	47472	47472	48229	DTAP	44911	Age: At Absolute Minimum	41275	44013.674110925924	Recommended based on age	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V1.4: Updated past due date to shift 1 day earlier to align with business rule calculation and other similar tests in the DTaP/Tdap/Td forecasting at 11 years.	3.4	This test case describes when a child is administered Tdap as a fifth at age 4 years - 4 days that the dose is valid.  Another dose should be forecast at age 11 years.
2013-0064	Tdap as dose 5 to age 4 years old=valid as DTaP 5.  	43450	F				Not complete	43532	DTaP, unspecified formulation	107		Valid		43593	DTaP, unspecified formulation	107		Valid		43716	DTaP, unspecified formulation	107		Valid		43934	DTaP, unspecified formulation	107		Valid		44911	BOOSTRIX	115	SKB	Valid														6	47468	47468	48225	DTAP	44911	Vaccine: Off Label	41275	44013.674799050925	Recommended based on age	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V1.1: Past Due Date was missing.  Added past due date of 13 years - 1 day to be consistent with supporting data a logic specficiation business rule calculations.	3.4	This test case describes when a child is administered Tdap as a fifth at age 4 years that the dose is valid.  Another dose should be forecast at age 11 years.
2013-0065	Tdap as dose 1 at age 7 years old	42354	F				Not complete	44911	BOOSTRIX	115	SKB	Valid																																						2	44939	44939	44939	DTAP	44911	All Valid: Forecast Test	41275	44013.68635636574	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered Tdap at age 7 years as the first dose that the dose is valid.  Another dose should be forecast.
2013-0066	DTaP # 1 at age 2 months	44850	F				Not complete	44911	DTaP, unspecified formulation	107		Valid																																						2	44939	44973	45028	DTAP	44911	Age: At Recommended	41275	44013.68377555555	Recommended based on age		1.0	This test case describes when a child is administered a first of the DTaP vaccine at 2 months of age that the dose is valid.  Another dose should be forecast.
2013-0067	Tdap as dose 2 at age ≥7 years	42295	F				Not complete	44883	Td, adsorbed	09	MBL	Valid		44911	BOOSTRIX	115	SKB	Valid																																3	45093	45093	45093	DTAP	44911	Interval: At Minimum	41275	44014.42944505787	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was missing and child is in catch-up.  Past Due Date added to align with Recommended Date.	1.1	This test case describes when a child is administered Tdap at age 7 years as the second dose that the dose is valid.  Another dose should be forecast.
2013-0068	Tdap as dose 3 to ≥ 7 years old	42129	F				Not complete	44696	DTaP, unspecified formulation	107		Valid		44724	DTaP, unspecified formulation	107		Valid		44907	BOOSTRIX	115	SKB	Valid																										4	46147	46147	46905	DTAP	44911	Interval: At Minimum	41275	44831.52722969907	Recommended based on interval	V4.0: Updated Forecast per new Tdap Catch-up Job-Aid. Tdap is needed at 11 years.
V1.1: Past Due Date was missing. Added past due date per NIPInfo guidance.	4.0	This test case describes when a child is administered Tdap at age 7 years as the third dose that the dose is valid.  Another dose should be forecast.
2013-0069	Tdap at age 7 years-5 days. Current age 7 years	42354	F				Not complete	44906	BOOSTRIX	115	SKB	Not Valid	Inadvertent Vaccine																																					1	44911	44911	44911	DTAP	44911	Age: Below Absolute Minimum	41275	44375.42036179398	Recommended based on age	Past Due Date was missing and child is in catch-up.  Past Due Date added to align with Recommended Date.	1.1	This test case describes when a child is administered Tdap at age 7 years - 5 days as a first dose that the dose is not valid.  A repeat dose should be forecast.
2013-0070	Tdap at age 11 to child up-to-date with DTaP	40826	F				Not complete	40889	DTaP, unspecified formulation	107		Valid		40953	DTaP, unspecified formulation	107		Valid		41015	DTaP, unspecified formulation	107		Valid		41224	DTaP, unspecified formulation	107		Valid		42354	DTaP, unspecified formulation	107		Valid		44911	BOOSTRIX	115	SKB	Valid								7	46737	48564	48591	DTAP	44911	All Valid: Forecast Test	41275	44018.452272118055	Recommended based on interval	Past Due Date was missing. Added past due date per NIPInfo guidance.	1.1	This test case describes when a child is up-to-date on DTaP vaccinations and is administered a Tdap dose at age 11 years  that the dose is valid.  The decennial dose should be forecast.
2013-0074	4 doses of Tetramune to child	34824	F				Not complete	34885	DTP-Hib	22		Valid		34947	DTP-Hib	22		Valid		35008	DTP-Hib	22		Valid		35343	DTP-Hib	22		Valid																				5	37381	37381	37381	DTAP	37381	All Valid: Forecast Test	41275	44018.46199336806	Recommended based on age	Updated due to new conditional skip logic which caused the next forecast dose to be administered at age 7 rather than age 8 due to need Pertussis dose. V1.4: Updated past due date to shift 1 day earlier to align with business rule calculation and other similar tests in the DTaP/Tdap/Td forecasting at 11 years.	2.2	This test case describes when a child is administered 4 valid doses of DTaP (Tetramune) that another dose should be forecast.
2013-0075	4 doses of Tetramune with a DTaP booster.  Forecast Tdap.	36506	F				Not complete	36571	DTP-Hib	22		Valid		36631	DTP-Hib	22		Valid		36692	DTP-Hib	22		Valid		36937	DTP-Hib	22		Valid		38322	DTaP, unspecified formulation	107		Valid														6	40524	40524	41282	DTAP	38322	All Valid: Forecast Test	41275	44018.46608355324	Recommended based on age	V1.4: Updated past due date to shift 1 day earlier to align with business rule calculation and other similar tests in the DTaP/Tdap/Td forecasting at 11 years.	1.4	This test case describes when a child is administered 5 valid doses of DTaP that another dose should be forecast.
2013-0076	4 Tetramune and Tdap at age 11=UTD for 10 years	35127	F				Not complete	35190	DTP-Hib	22		Valid		35285	DTP-Hib	22		Valid		35434	DTP-Hib	22		Valid		35889	DTP-Hib	22		Valid		39159	BOOSTRIX	115	SKB	Valid														6	40986	42812	42839	DTAP	39159	All Valid: Forecast Test	41275	44018.477001770836	Recommended based on interval	Past Due Date was missing. Added past due date per NIPInfo guidance.	1.1	This test case describes when a child was administered 4 previous valid doses of DTaP (Tetramune) at appropriate ages and intervals and a Tdap dose at 11 years of age that another dose (decennial) should be forecast.
2013-0077	DTaP #1 at age 6.5 years. 	42537	F				Not complete	44911	DTaP, unspecified formulation	107		Valid																																						2	44939	44939	44939	DTAP	44911	All Valid: Forecast Test	41275	44018.50681028935	Recommended based on minimum interval from previous dose (catch-up)	V3.5: Test case Recommended and Past Due Dates were incorrectly mapped when moving to new test case management tool. These were corrected in this version.	3.5	This test case describes when a child is administered the first dose of DTaP at age 6.5 years that the dose is valid.  Another dose should be forecast.
2013-0078	TriHibit as primary dose.  DTaP=valid.	40664	F				Not complete	40725	TRIHIBIT	50	PMC	Valid																																						2	40753	40787	40844	DTAP	40725	Vaccine: Off Label	41275	44018.5118487037	Recommended based on age		1.0	This test case describes when a child is administered the first dose of DTaP (TriHibit) that the dose is valid.  Another dose should be forecast.
2013-0079	TriHibit as valid dose 4 of DTaP	39480	F				Not complete	39542	DTaP, unspecified formulation	107		Valid		39605	DTaP, unspecified formulation	107		Valid		39668	DTaP, unspecified formulation	107		Valid		39952	TRIHIBIT	50	PMC	Valid																				5	40941	40941	42036	DTAP	39952	Vaccine: Off Label	41275	44018.573480127314	Recommended based on age		1.0	This test case describes when a child is administered the fourth dose of DTaP (TriHibit) that the dose is valid.  Another dose should be forecast.
2013-0080	TriHibit as valid dose 5 of DTaP	38998	F				Not complete	39050	PEDIARIX	110	SKB	Valid		39111	PEDIARIX	110	SKB	Valid		39170	PEDIARIX	110	SKB	Valid		39480	PEDIARIX	110	SKB	Valid		40460	TRIHIBIT	50	PMC	Valid														6	43016	43016	43773	DTAP	40460	All Valid: Forecast Test	41275	44018.602568125	Recommended based on age	V1.4: Updated past due date to align with ACIP and other test cases to be 1 day before the 13th birthday.	1.4	This test case describes when a child is administered the fifth dose of DTaP (TriHibit) that the dose is valid.  Another dose should be forecast.
2013-0081	Pentavalente (Mexico) DTaP/IPV/HIB counts as valid. 	44476	F				Not complete	44599	DTAP/IPV/HIB - non-US	170		Valid		44658	DTAP/IPV/HIB - non-US	170		Valid		44719	DTAP/IPV/HIB - non-US	170		Valid		44911	DTAP/IPV/HIB - non-US	170		Valid																				5	45937	45937	47032	DTAP	44911	Vaccine: Off Label	41275	44018.69080101852	Recommended based on age		1.0	This test case describes when a child is administered  4 doses of Pentavalente (Mexico) at appropriate intervals and age that the doses are valid.  Another DTaP (U.S) dose should be forecast.
2013-0082	Kinrix at age 2 months as Dose 1 of DTaP.  Off label but valid. 	44850	F				Not complete	44911	KINRIX	130	SKB	Valid																																						2	44939	44973	45028	DTAP	44911	Vaccine: Off Label	41275	44025.66324030093	Recommended based on age		1.0	This test case describes when a child is administered a dose of Kinrix as the first dose of the DTaP vaccine series, at two months of age, that the dose is valid.  Another dose should be forecast.
2013-0083	Kinrix at age 4 months as dose 2 of DTaP.  Off label but valid. 	44789	F				Not complete	44856	DTaP, unspecified formulation	107		Valid		44911	KINRIX	130	SKB	Valid																																3	44939	44973	45028	DTAP	44911	Vaccine: Off Label	41275	44025.66981064815	Recommended based on age		1.0	This test case describes when a child is administered a dose of Kinrix as a second dose of DTaP in the vaccine series, at four months of age, that the dose is valid.  Another dose should be forecast.
2013-0084	Kinrix at age 6 months as dose 3 of DTaP.  Off label but valid. 	44728	F				Not complete	44791	DTaP, unspecified formulation	107		Valid		44854	DTaP, unspecified formulation	107		Valid		44911	KINRIX	130	SKB	Valid																										4	45185	45185	45334	DTAP	44911	Vaccine: Off Label	41275	44025.6865809375	Recommended based on age	Updated per the 2017 General Best Practice Guidelines which moved the Minimum and Recommended Age to 15 months	3.3	This test case describes when a child is administered a dose of Kinrix as a third dose of DTaP in the vaccine series, at six months of age, that the dose is valid.  Another dose should be forecast.
2013-0085	Kinrix at age 12 months as dose 4 of DTaP=valid	44546	F				Not complete	44610	DTaP, unspecified formulation	107		Valid		44671	DTaP, unspecified formulation	107		Valid		44720	DTaP, unspecified formulation	107		Valid		44911	KINRIX	130	SKB	Valid																				5	46007	46007	47102	DTAP	44911	Age: At Minimum	41275	44025.678384328705	Recommended based on age		1.0	This test case describes when a child is administered a dose of Kinrix as a fourth dose of DTaP in the vaccine series, at twelve months of age, that the dose is valid.  Another dose should be forecast.
2013-0086	Kinrix at age 4 to child with appropriate DTaP=UTD until adolescence	43450	F				Not complete	43514	PEDIARIX	110	SKB	Valid		43571	PEDIARIX	110	SKB	Valid		43634	PEDIARIX	110	SKB	Valid		43815	PEDIARIX	110	SKB	Valid		44911	KINRIX	130	SKB	Valid														6	47468	47468	48225	DTAP	44911	Age: At Minimum	41275	44025.681754351855	Recommended based on age	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V1.4: Updated past due date to align with ACIP and other test cases to be 1 day before the 13th birthday.	3.4	This test case describes when a child is administered a dose of Kinrix at age four years,that the dose is valid.  Another dose should be forecast.
2013-0087	Kinrix at age 4 years-5 days	43455	F				Not complete	43509	PEDIARIX	110	SKB	Valid		43562	PEDIARIX	110	SKB	Valid		43694	PEDIARIX	110	SKB	Valid		43954	PEDIARIX	110	SKB	Valid		44911	KINRIX	130	SKB	Not Valid	Age: Too Young													5	45093	45093	46011	DTAP	44911	Age: Below Absolute Minimum	41275	44025.69110986111	Recommended based on minimum interval from invalid dose		1.0	This test case describes when a child is administered a dose of Kinrix at age 4 years - 5 days,that the dose is not valid.  A repeat dose should be forecast.
2013-0088	DTaP # 1 at age 7 years (off label but counts as valid). 	42354	F				Not complete	44911	DTaP, unspecified formulation	107		Valid																																						2	44939	44939	44939	DTAP	44911	Vaccine: Off Label	41275	44060.604599722225	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered a first dose of DTaP vaccine at age seven years,that the dose is valid.  Another dose should be forecast.
2013-0089	Kinrix at age 4 years -4 days	43454	F				Not complete	43504	PEDIARIX	110	SKB	Valid		43561	PEDIARIX	110	SKB	Valid		43622	PEDIARIX	110	SKB	Valid		43890	PEDIARIX	110	SKB	Valid		44911	KINRIX	130	SKB	Valid														6	47472	47472	48229	DTAP	44911	Age: At Absolute Minimum	41275	44025.69085179398	Recommended based on age	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V1.1: Past Due Date was missing.  Added past due date of 13 years - 1 day to be consistent with supporting data a logic specficiation business rule calculations.	3.4	This test case describes when a child is administered a dose of Kinrix at age 4 years - 4 days,that the dose is valid.  Another dose should be forecast.
2013-0090	Newborn forecasting	44911	F				Not complete																																											1	44953	44973	45028	DTAP	44911	No Doses Administered	41275	44061.682432974536	Recommended based on age		1.0	This test case describes the forecasting of the DTaP vaccine for a newborn at 6 weeks of age.
2013-0091	# 2 Pediarix at 6 yrs 11.5 mo	42370	F				Not complete	43450	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	45093	45093	45093	DTAP	44911	All Valid: Forecast Test	41275	44060.60419787037	Recommended based on minimum interval from previous dose (catch-up)	V4.0: Forecast updated to reflect new Tdap catch-up Job Aid. Forecast should be in 6 months from previous dose.	4.0	This test case describes when a child is administered, Pediarix as the second dose of the DTaP vaccine, at age 6 years 11.5 months that the dose is valid.  Another dose should be forecast.
2013-0092	# 2 Pediarix at 7 yrs; # 1 at less than 12 mo. 	42354	F				Not complete	42445	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	44939	44939	44939	DTAP	44911	All Valid: Forecast Test	41275	44064.58580547454	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was missing and child is in catch-up.  Past Due Date added to align with Recommended Date.	1.1	This test case describes when a child is administered Pediarix as the second dose of the DTaP vaccine at age 7 years and a first dose at less than 12 months of age, that the dose is valid.  Another dose should be forecast.
2013-0093	# 2 Pediarix at 7 yrs; # 1 ≥ 12 mo. Need 6 mo interval from 2 to 3.	42354	F				Not complete	42751	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	45093	45093	45093	DTAP	44911	All Valid: Forecast Test	41275	44036.6720615625	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was missing and child is in catch-up.  Past Due Date added to align with Recommended Date.	1.1	This test case describes when a child is administered Pediarix as the second dose of the DTaP vaccine at age 7 years and a first dose at greater than 12 months that the dose is valid.  Another dose should be forecast.
2013-0094	# 1 and 2 Pediarix at ≥7 yrs  with 28 day interval.  Off label but does not need repeating. 	42326	F				Not complete	44883	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	45093	45093	45093	DTAP	44911	Interval: At Minimum	41275	44060.60380385417	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered, Pediarix as the first and second dose of the DTaP vaccine series with a 28 day interval that the doses are valid.  Another dose should be forecast.
2013-0095	# 3 Pediarix at 14 wks-5 days	44818	F				Not complete	44856	PEDIARIX	110	SKB	Valid		44884	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Not Valid	Age: Too Young																									3	44939	44999	45057	DTAP	44911	Age: Below Absolute Minimum	41275	44060.603512650465	Recommended based on age		1.0	This test case describes when a child is administered, Pediarix as the third dose of DTaP vaccine, at age 14 weeks - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0096	# 3 Pediarix at 14 wks-4 days.	44817	F				Not complete	44857	PEDIARIX	110	SKB	Valid		44885	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																										4	45273	45273	45422	DTAP	44911	Age: At Absolute Minimum	41275	44060.603339409725	Recommended based on age	Updated per the 2017 General Best Practice Guidelines which moved the Minimum and Recommended Age to 15 months	3.3	This test case describes when a child is administered, Pediarix as the third dose of DTaP vaccine, at age 14 weeks - 4 days that the dose is valid.  Another dose should be forecast.
2013-0097	#3 Pediarix at age 24 weeks- 5 days	44748	F				Not complete	44790	PEDIARIX	110	SKB	Valid		44851	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																										4	45205	45205	45355	DTAP	44911	All Valid: Forecast Test	41275	44060.602910381946	Recommended based on age	Updated per the 2017 General Best Practice Guidelines which moved the Minimum and Recommended Age to 15 months	3.3	This test case describes when a child is administered Pediarix, as the third dose of DTaP vaccine, at age 24 weeks - 5 days that the dose is valid.  Another dose should be forecast.
2013-0099	# 3 Pediarix at 6 yrs 11.5 mo	42366	F				Not complete	43399	PEDIARIX	110	SKB	Valid		43859	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																										4	44923	44923	44923	DTAP	44911	All Valid: Forecast Test	41275	43998.665748506945	Recommended based on minimum interval from previous dose (catch-up)	V4.3: test case updated to reflect changes to current catch-up guidance for children 7 through 9 years of age. (Feb. 2020)	4.3	This test case describes that when a child has received three doses of the DTaP vaccine and the first dose was administered at 12 months or older, and the third dose was administered prior to age 7, that another dose should be forecast at age 7.
2013-0100	# 4 Pediarix at 1 yr -5 days.	44551	F				Not complete	44613	PEDIARIX	110	SKB	Valid		44672	PEDIARIX	110	SKB	Valid		44739	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Not Valid	Age: Too Young																			4	45093	45093	45155	DTAP	44911	Age: Below Absolute Minimum	41275	44060.60256053241	Recommended based on minimum interval from inValid dose		1.0	This test case describes when a child is administered Pediarix, as the fourth dose of DTaP vaccine, at age 1 yr - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0101	# 1 Pediarix at 6 wks-5 days	44874	F				Not complete	44911	PEDIARIX	110	SKB	Not Valid	Age: Too Young																																					1	44916	44935	44993	DTAP	44911	Age: Below Absolute Minimum	41275	44060.60239712963	Recommended based on age		1.0	This test case describes when a patient is administered Pediarix, as a first dose of the DTaP vaccine, at age 6 weeks- 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0102	# 4 Pediarix at 1 yr -4 days	44550	F				Not complete	44612	PEDIARIX	110	SKB	Valid		44701	PEDIARIX	110	SKB	Valid		44776	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																				5	46011	46011	47106	DTAP	44911	Age: At Absolute Minimum	41275	44060.60227163194	Recommended based on age		1.0	This test case describes when a child is administered Pediarix, as the fourth dose of DTaP vaccine, at age 1 yr - 4 days that the dose is valid.  Another dose should be forecast.
2013-0103	# 4 Pediarix at 3 yrs 11.5 mo. 	43467	F				Not complete	43526	PEDIARIX	110	SKB	Valid		43618	PEDIARIX	110	SKB	Valid		43710	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																				5	45093	45093	46023	DTAP	44911	All Valid: Forecast Test	41275	44060.60200951389	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered Pediarix, as the fourth dose of the DTaP/Tdap/Td vaccine, at 3 years and 11.5 months that the dose is valid.  Another dose should be forecast.
2013-0104	# 4 Pediarix at 4 yrs=complete until age 11	43450	F				Not complete	43574	PEDIARIX	110	SKB	Valid		43749	PEDIARIX	110	SKB	Valid		44247	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																				5	47468	47468	48225	DTAP	44911	All Valid: Forecast Test	41275	44060.60189835648	Recommended based on age	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V1.1: Past Due Date was missing.  Added past due date of 13 years - 1 day to be consistent with supporting data a logic specficiation business rule calculations.	3.4	This test case describes when a child is administered Pediarix, as the fourth dose of the DTaP/Tdap/Td vaccine, at 4 years that the dose is valid.  Another dose should be forecast.
2013-0105	# 5 Pediarix at 4 yrs -5 days.	43455	F				Not complete	43517	PEDIARIX	110	SKB	Valid		43545	PEDIARIX	110	SKB	Valid		43668	PEDIARIX	110	SKB	Valid		43920	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Not Valid	Age: Too Young													5	45093	45093	46011	DTAP	44911	Age: Below Absolute Minimum	41275	44060.60169059028	Recommended based on minimum interval from invalid dose		1.0	This test case describes when a child is administered Pediarix, as the fifth dose of the DTaP/Tdap/Td vaccine, at 4 years - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0106	# 5 Pediarix at 4 yrs -4 days	43454	F				Not complete	43516	PEDIARIX	110	SKB	Valid		43544	PEDIARIX	110	SKB	Valid		43667	PEDIARIX	110	SKB	Valid		43919	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid														6	47472	47472	48229	DTAP	44911	Age: At Absolute Minimum	41275	44060.60153756945	Recommended based on age	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions. 
V1.1: Past Due Date was missing.  Added past due date of 13 years - 1 day to be consistent with supporting data a logic specficiation business rule calculations.	3.4	This test case describes when a child is administered Pediarix, as the fifth dose of the DTaP/Tdap/Td vaccine, at 4 years - 4 days that the dose is valid.  Another dose should be forecast.
2013-0107	# 5 Pediarix at 6 yrs 11.5 mo	42371	F				Not complete	42431	PEDIARIX	110	SKB	Valid		42492	PEDIARIX	110	SKB	Valid		42553	PEDIARIX	110	SKB	Valid		42768	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid														6	46389	46389	47147	DTAP	44911	All Valid: Forecast Test	41275	44060.60139793981	Recommended based on age	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V1.1: Past Due Date was missing.  Added past due date of 13 years - 1 day to be consistent with supporting data a logic specficiation business rule calculations.	3.4	This test case describes when a child is administered Pediarix, as the fifth dose of the DTaP/Tdap/Td vaccine, at 6 years and 11.5 months of age that the dose is valid.  Another dose should be forecast.
2013-0108	# 5 Pediarix at 7 yrs.  Off label but valid. 	42354	F				Not complete	42445	PEDIARIX	110	SKB	Valid		42537	PEDIARIX	110	SKB	Valid		42629	PEDIARIX	110	SKB	Valid		42917	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid														6	46372	46372	47130	DTAP	44911	Vaccine: Off Label	41275	44060.60128023148	Recommended based on age	V4.0: Updated forecast to recommend Tdap at 11-12 year dose per new Tdap Catch-up Job Aid
V1.4: Updated to reflect 10 year recurring dose since the DTaP at age 7 can count as the adolescent (11 - 12 year) Tdap dose per conversation with EIPB and guidance in MMWRs	4.0	This test case describes when a child is administered Pediarix, as the fifth dose of the DTaP/Tdap/Td vaccine, at 7 years of age that the dose is valid.  Another dose should be forecast.
2013-0109	Invalid age dose 1 as first of others. 	44820	F				Not complete	44857	PEDIARIX	110	SKB	Not Valid	Age: Too Young	44911	PEDIARIX	110	SKB	Valid																																2	44939	44942	45000	DTAP	44911	Age: Below Absolute Minimum	41275	44060.63620354167	Recommended based on age		1.0	This test case describes when a child is administered Pediarix, at less than 6 weeks - 4 days but another dose is administered at age 3 months that, that the dose is valid.  Another dose should be forecast.
2013-0110	Invalid age dose 2 in midst of others	44728	F				Not complete	44766	PEDIARIX	110	SKB	Valid		44792	PEDIARIX	110	SKB	Not Valid	Age: Too Young	44911	PEDIARIX	110	SKB	Valid																										3	44939	44939	44969	DTAP	44911	Age: Below Absolute Minimum	41275	44060.636107638886	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered a second dose of Pediarix, at less than 10 weeks - 4 days, but is administered a repeat dose at 6 months later, that the dose is valid.  Another dose should be forecast.
2013-0111	invalid age dose 3 in midst of others	44546	F				Not complete	44590	PEDIARIX	110	SKB	Valid		44616	PEDIARIX	110	SKB	Valid		44638	PEDIARIX	110	SKB	Not Valid	Interval: too short	44911	PEDIARIX	110	SKB	Valid																				4	45093	45093	45150	DTAP	44911	Interval: Below Absolute Minimum	41275	44060.635892638886	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered a third dose of Pediarix, at less than 14 weeks - 4 days, but is administered a repeat dose that the dose is valid.  Another dose should be forecast.
2013-0112	# 1 Pediarix at 6 wks-4 days	44873	F				Not complete	44911	PEDIARIX	110	SKB	Valid																																						2	44943	44993	45051	DTAP	44911	Age: At Absolute Minimum	41275	44060.638277569444	Recommended based on age		1.0	This test case describes when a child is administered Pediarix, as a first dose of the DTaP/Tdap/Td vaccine, at 6 weeks - 4 days that the dose is valid. Another dose should be forecast.
2013-0113	dose 1 to 2 Pediarix, interval 28-5 days	44825	F				Not complete	44888	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Not Valid	Interval: too short																															2	44939	44947	45005	DTAP	44911	Interval: Below Absolute Minimum	41275	44060.66227644676	Recommended based on minimum interval from invalid dose		1.0	This test case describes when a child is administered a second dose of the DTaP vaccine (Pediarix) at an interval of 28-5 days after the first dose, that the dose is not valid. A repeat dose should be forecast.
2013-0114	dose 1 to 2 Pediarix, interval 28-4 days	44828	F				Not complete	44887	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	44939	45009	45067	DTAP	44911	Interval: At Absolute Minimum	41275	44060.66205497685	Recommended based on age		1.0	This test case describes when a child is administered a second dose of the DTaP vaccine (Pediarix) at an interval of 28-4 days after the first dose, that the dose is valid. Another dose should be forecast.
2013-0115	dose 2 to 3 Pediarix, interval 28-5 days	44765	F				Not complete	44827	PEDIARIX	110	SKB	Valid		44888	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Not Valid	Interval: too short																									3	44939	44949	45007	DTAP	44911	Interval: Below Absolute Minimum	41275	44060.67604648148	Recommended based on age		1.0	This test case describes when a child is administered dose three of the DTaP vaccine (Pediarix) at an interval of 28 -5 days after the second dose that the dose is not valid.  A repeat dose should be forecast.
2013-0116	dose 2 to 3 Pediarix, interval 28-4 days.	44764	F				Not complete	44826	PEDIARIX	110	SKB	Valid		44887	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																										4	45221	45221	45371	DTAP	44911	Interval: At Absolute Minimum	41275	44060.67696398148	Recommended based on age	Updated per the 2017 General Best Practice Guidelines which moved the Minimum and Recommended Age to 15 months	3.3	This test case describes when a child is administered dose three of the DTaP vaccine (Pediarix) at an interval of 28 -4 days after the second dose that the dose is valid.  Another dose should be forecast.
2013-0117	dose 3 to 4 Pediarix, interval 6m-5 days	44485	F				Not complete	44546	PEDIARIX	110	SKB	Valid		44608	PEDIARIX	110	SKB	Valid		44728	PEDIARIX	110	SKB	Valid		44906	PEDIARIX	110	SKB	Valid																				5	45946	45946	47041	DTAP	44911	All Valid: Forecast Test	41275	44061.652723032406	Recommended based on age		1.0	This test case describes when a child is administered dose four of the DTaP vaccine (Pediarix) at an interval of 6 months - 5 days months after the third dose that the dose is not valid.  A repeat dose should be forecast.
2013-0118	dose 3 to 4 Pediarix, interval 6m-4 days	44485	F				Not complete	44546	PEDIARIX	110	SKB	Valid		44608	PEDIARIX	110	SKB	Valid		44728	PEDIARIX	110	SKB	Valid		44907	PEDIARIX	110	SKB	Valid																				5	45946	45946	47041	DTAP	44911	All Valid: Forecast Test	41275	44076.634922627316	Recommended based on age		1.0	This test case describes when a child is administered dose four of the DTaP vaccine (Pediarix) at an interval of 6 months - 4 days after the third dose that the dose is valid.  Another dose should be forecast.
2013-0120	dose 3 to 4 Pediarix, interval 4 mo	44485	F				Not complete	44546	PEDIARIX	110	SKB	Valid		44608	PEDIARIX	110	SKB	Valid		44789	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																				5	45946	45946	47041	DTAP	44911	Interval: At Absolute Minimum	41275	44061.65307302083	Recommended based on age		1.0	This test case describes when a child is administered dose four of the DTaP vaccine (Pediarix) at an interval of 4 months after the third dose that the dose is valid.  Another dose should be forecast.
2013-0121	invalid dose 1-2 interval in midst of others	44789	F				Not complete	44850	PEDIARIX	110	SKB	Valid		44869	PEDIARIX	110	SKB	Not Valid	Interval: too short	44911	PEDIARIX	110	SKB	Valid																										3	44939	44973	45028	DTAP	44911	Interval: Below Absolute Minimum	41275	44084.60554186343	Recommended based on age		1.0	This test case describes when a child is administered an invalid second dose of the DTaP vaccine (Pediarix) at an interval less than 4 weeks - 4 days but was administered a repeat vaccine dose at 4 weeks after the invalid dose, that the dose is valid..    Another dose should be forecast.
2013-0122	invalid dose 2-3 interval in midst of others	44546	F				Not complete	44608	PEDIARIX	110	SKB	Valid		44667	PEDIARIX	110	SKB	Valid		44690	PEDIARIX	110	SKB	Not Valid	Interval: too short	44911	PEDIARIX	110	SKB	Valid																				4	45093	45093	45150	DTAP	44911	Interval: Below Absolute Minimum	41275	44084.605959155095	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered an invalid third dose of the DTaP vaccine (Pediarix) at an interval of less than 4 weeks - 4 days but was administered a repeat dose at an interval of 4 weeks after the invalid dose that the dose is valid.  Another dose should be forecast.
2013-0123	# 1 Pediarix at 6 wks	44869	F				Not complete	44911	PEDIARIX	110	SKB	Valid																																						2	44939	44989	45047	DTAP	44911	Age: At Minimum	41275	44061.66952326389	Recommended based on age		1.0	This test case describes when a child is administered Pediarix as a first dose of the DTaP vaccine at 6 weeks of age that the dose is valid.  Another dose should be forecast.
2013-0124	invalid dose 3-4 interval in midst of others	43448	F				Not complete	43510	PEDIARIX	110	SKB	Valid		43569	PEDIARIX	110	SKB	Valid		43777	PEDIARIX	110	SKB	Valid		43893	PEDIARIX	110	SKB	Not Valid	Interval: too short	44911	PEDIARIX	110	SKB	Valid														5	47466	47466	48223	DTAP	44911	Interval: Below Absolute Minimum	41275	44061.672084641206	Recommended based on age	V3.5: Dose 4 - intended to be invalid - was modified to be 4 months - 5 days from the previous dose. 
V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V3.3: Updated per 2017 General Best Practice Guidelines which allows for an allowable interval of 4 months - 4 days.	3.5	This test case describes when the fourth dose of DTaP vaccine (Pediarix) is administered at less than 4 months - 4 days from dose #3, that the dose is not valid.
2013-0127	# 1 Pediarix at 6 yrs 11.5 mo	42370	F				Not complete	44911	PEDIARIX	110	SKB	Valid																																						2	44939	44939	44939	DTAP	44911	All Valid: Forecast Test	41275	44061.67290074074	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered Pediarix as the first dose of DTaP vaccine at age 6 years and 11.5 months that the dose is valid.  Another dose should be forecast.
2013-0128	# 1 Pediarix at 7 years	42354	F				Not complete	44911	PEDIARIX	110	SKB	Valid																																						2	44939	44939	44939	DTAP	44911	All Valid: Forecast Test	41275	44061.67609667824	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered Pediarix as the first dose of DTaP vaccine at age 7 years that the dose is valid.  Another dose should be forecast.
2013-0129	# 2 Pediarix at 10 wks-5 days.	44846	F				Not complete	44884	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Not Valid	Age: Too Young																															2	44939	44969	45024	DTAP	44911	Age: Below Absolute Minimum	41275	44061.67739034722	Recommended based on age		1.0	This test case describes when a child is administered Pediarix as a second dose of the DTaP vaccine at 10 weeks - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0130	# 2 Pediarix at 10 wks-4 days	44845	F				Not complete	44887	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	44943	45027	45084	DTAP	44911	Age: At Absolute Minimum	41275	44061.67783806713	Recommended based on age		1.0	This test case describes when a child is administered Pediarix as a second dose of the DTaP vaccine at 10 weeks - 4 days that the dose is valid.  Another dose should be forecast.
2013-0131	# 2 Pediarix at 10 wks	44841	F				Not complete	44883	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	44939	45023	45080	DTAP	44911	Age: At Minimum	41275	44061.6781137963	Recommended based on age		1.0	This test case describes when a child is administered Pediarix as a second dose of the DTaP vaccine at 10 weeks that the dose is valid.  Another dose should be forecast.
2013-0132	Newborn	44911	F				Not complete																																											1	44953	44973	45028	DTAP	44911	No Doses Administered	41275	44061.68210255787	Recommended based on age		1.0	This test case describes the forecasting of the DTaP vaccine for a newborn at 6 weeks of age.
2013-0133	# 2 Pentacel at 6 yrs 11.5 mo. Off label but counts. Current Age 7 years	42354	F				Not complete	43349	PENTACEL	120	PMC	Valid		44895	PENTACEL	120	PMC	Valid																																3	45076	45076	45076	DTAP	44911	All Valid: Forecast Test	41275	44064.56163846065	Recommended based on minimum interval from previous dose (catch-up)	V4.0: Updated forecast to align with new Tdap Catch-up Job Aid. Forecast in 6 months.
Past Due Date was missing and child is in catch-up.  Past Due Date added to align with Recommended Date.
Interval Priority Flag with Override allows for a vaccine to be given sooner than a previous date set by multiple vaccines.	4.0	This test case describes when a child is administered, Pentacel, as the second dose of the DTaP vaccine, at age 6 years 11.5 months that the dose is valid.  Another dose should be forecast.
2013-0134	# 2 Pentacel at 7 yrs; # 1 at age < 12 mo	42350	F				Not complete	42511	INFANRIX	20	SKB	Valid		44911	PENTACEL	120	PMC	Valid																																3	44939	44939	44939	DTAP	44911	All Valid: Forecast Test	41275	44064.58750028935	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was missing and child is in catch-up.  Past Due Date added to align with Recommended Date.	1.1	This test case describes when a child is administered Pentacel, as the second dose of the DTaP vaccine, at age 7 years and a first dose (Infanrix) at less than 12 months of age, that the dose is valid.  Another dose should be forecast.
2013-0135	# 2 Pentacel at 7 yrs; # 1 at age ≥ 12 mo.	42350	F				Not complete	42781	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																																3	45093	45093	45093	DTAP	44911	All Valid: Forecast Test	41275	44064.58713274306	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was missing and child is in catch-up.  Past Due Date added to align with Recommended Date.	1.1	This test case describes when a child is administered Pentacel, as the second dose of the DTaP vaccine, at age 7 years and a first dose at greater than 12 months of age, that the dose is valid.  Another dose should be forecast.
2013-0136	# 3 Pentacel at 14 wks-5 days	44818	F				Not complete	44856	PENTACEL	120	PMC	Valid		44884	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Not Valid	Age: Too Young																									3	44939	44999	45057	DTAP	44911	Age: Below Absolute Minimum	41275	44064.59323028935	Recommended based on age		1.0	This test case describes when a third dose of the DTaP vaccine (Pentacel) is administered at age 14 weeks - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0137	# 3 Pentacel at 14 wks-4 days	44817	F				Not complete	44855	PENTACEL	120	PMC	Valid		44883	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																										4	45273	45273	45422	DTAP	44911	Age: At Absolute Minimum	41275	44064.61794681713	Recommended based on age	Updated per 2017 General Best Practice Guidelines which allows for an allowable interval of 4 months - 4days.	3.3	This test case describes when a third dose of the DTaP vaccine (Pentacel) is administered at age 14 weeks - 4 days that the dose is valid.  Another dose should be forecast.
2013-0138	# 3 Pentacel at 6 yrs 11.5 mo	42370	F				Not complete	42426	DTaP-Hib-IPV	120		Valid		43617	DTaP-Hib-IPV	120		Valid		44911	PENTACEL	120	PMC	Valid																										4	45093	45093	45093	DTAP	44911	All Valid: Forecast Test	41275	44064.65554675926	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes that when a child is administered a third dose of the DTaP vaccine (Pentacel) at 6 years and 11.5 months that the dose is valid.  Another dose should be forecast.
2013-0139	# 4 Pentacel at 1 yr -5 days.  	44551	F				Not complete	44613	PENTACEL	120	PMC	Valid		44672	PENTACEL	120	PMC	Valid		44733	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Not Valid	Age: Too Young																			4	45093	45093	45155	DTAP	44911	Age: Below Absolute Minimum	41275	44064.66239557871	Recommended based on minimum interval from invalid dose		1.0	This test case describes when a child is administered Pentacel, as the fourth dose of DTaP vaccine, at age 1 yr - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0140	# 4 Pentacel at 1 yr -4 days	44550	F				Not complete	44612	PENTACEL	120	PMC	Valid		44671	PENTACEL	120	PMC	Valid		44732	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																				5	46011	46011	47106	DTAP	44911	Age: At Absolute Minimum	41275	44064.65880877315	Recommended based on age		1.0	This test case describes when a child is administered Pentacel, as the fourth dose of the DTaP vaccine, at age 1 yr - 4 days that the dose is valid.  Another dose should be forecast.
2013-0141	# 4 Pentacel at age 12 mo	44546	F				Not complete	44608	PENTACEL	120	PMC	Valid		44667	PENTACEL	120	PMC	Valid		44728	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																				5	46007	46007	47102	DTAP	44911	Age: At Minimum	41275	44064.66503340278	Recommended based on age		1.0	This test case describes when a child is administered a fourth dose of the DTaP/Tdap/Td vaccine (Pentacel) at age 12 months that the dose is valid.  Another dose should be forecast.
2013-0142	# 4 Pentacel at 4 yrs	43450	F				Not complete	43580	PENTACEL	120	PMC	Valid		43807	PENTACEL	120	PMC	Valid		44724	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																				5	47468	47468	48225	DTAP	44911	All Valid: Forecast Test	41275	44067.6099740162	Recommended based on age	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V1.4: Updated past due date to shift 1 day earlier to align with business rule calculation and other similar tests in the DTaP/Tdap/Td forecasting at 11 years.	3.4	This test case describes when a child is administered Pentacel, as the fourth dose of the DTaP/Tdap/Td vaccine, at 4 years that the dose is valid.  Another dose should be forecast.
2013-0143	# 5 Pentacel at ≥ 4 yrs	43428	F				Not complete	43762	PENTACEL	120	PMC	Valid		43854	PENTACEL	120	PMC	Valid		43945	PENTACEL	120	PMC	Valid		44099	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid														6	47446	47446	48203	DTAP	44911	All Valid: Forecast Test	41275	44067.62861652778	Recommended based on age	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V1.4: Updated past due date to align with ACIP and other test cases to be 1 day before the 13th birthday.	3.4	This test case describes when a child is administered Pentacel, as a fifth dose of the DTaP/Tdap/Td vaccine, at 4 years that the dose is valid.  Another dose should be forecast.
2013-0144	# 4 Pentacel at 5 yrs=off label but counts. 	43085	F				Not complete	43206	PENTACEL	120	PMC	Valid		43386	PENTACEL	120	PMC	Valid		43449	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																				5	47103	47103	47860	DTAP	44911	All Valid: Forecast Test	41275	44067.63149515046	Recommended based on age	V3.4: Updated Past Due Date to include missing 4 week buffer all other past due dates have. This was simply missing since the earliest of versions
V1.4: Updated past due date to shift 1 day earlier to align with business rule calculation and other similar tests in the DTaP/Tdap/Td forecasting at 11 years.	3.4	This test case describes when a child is administered Pentacel, as a fourth of the DTaP/Tdap/Td vaccine, at 5 years of age that the dose is valid.  Another dose should be forecast.
2013-0145	invalid age dose 2 in midst of others	44544	F				Not complete	44582	PENTACEL	120	PMC	Valid		44609	PENTACEL	120	PMC	Not Valid	Age: Too Young	44685	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																				4	45093	45093	45148	DTAP	44911	Age: Below Absolute Minimum	41275	44067.68197136574	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered a second dose of Pentacel, at less than 10 weeks - 4 days, but is administered a repeat dose at, an interval at least 4 weeks from the previous dose, that the dose is valid.
2013-0146	invalid age dose 3 in midst of others	44510	F				Not complete	44548	PENTACEL	120	PMC	Valid		44576	PENTACEL	120	PMC	Valid		44603	PENTACEL	120	PMC	Not Valid	Age: Too Young	44911	PENTACEL	120	PMC	Valid																				4	45093	45093	45114	DTAP	44911	Age: Below Absolute Minimum	41275	44067.66511512732	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered an invalid third dose of the DTaP vaccine, Pentacel, but a repeat is administered at an appropriate age and interval that the dose is valid.  Another dose should be forecast.
2013-0147	dose 1 to 2 Pentacel, interval 28-5 days	44833	F				Not complete	44888	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Not Valid	Interval: too short																															2	44939	44955	45013	DTAP	44911	Interval: Below Absolute Minimum	41275	44067.69991730324	Recommended based on age		1.0	This test case describes when a child is administered a second dose of the DTaP vaccine (Pentacel) at an interval of 28-5 days after the first dose, that the dose is not valid. A repeat dose should be forecast.
2013-0148	dose 1 to 2 Pentacel, interval 28-4 days	44824	F				Not complete	44887	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																																3	44939	45005	45063	DTAP	44911	Interval: At Absolute Minimum	41275	44070.56226148148	Recommended based on age		1.0	This test case describes when a child is administered a second dose of the DTaP vaccine (Pentacel) at an interval of 28-4 days after the first dose, that the dose is valid. Another dose should be forecast.
2013-0149	dose 2 to 3 Pentacel, interval 28-5 days	44762	F				Not complete	44824	PENTACEL	120	PMC	Valid		44885	PENTACEL	120	PMC	Valid		44908	PENTACEL	120	PMC	Not Valid	Interval: too short																									3	44936	44946	45004	DTAP	44911	Interval: Below Absolute Minimum	41275	44704.450797094905	Recommended based on age		1.0	This test case describes when a child is administered dose three of the DTaP vaccine (Pentacel) at an interval of 28 -5 days after the second dose that the dose is not valid.  A repeat dose should be forecast.
2013-0150	dose 2 to 3 Pentacel, interval 28-4 days	44761	F				Not complete	44823	PENTACEL	120	PMC	Valid		44884	PENTACEL	120	PMC	Valid		44908	PENTACEL	120	PMC	Valid																										4	45218	45218	45368	DTAP	44911	Interval: At Absolute Minimum	41275	44704.45102734954	Recommended based on age	Updated per 2017 General Best Practice Guidelines which allows for an allowable interval of 4 months - 4days.	3.3	This test case describes when a child is administered dose three of the DTaP vaccine (Pentacel) at an interval of 28 -4 days after the second dose that the dose is valid.  Another dose should be forecast.
2013-0152	# 1 Pentacel at 6 wks-4 days	44873	F				Not complete	44911	PENTACEL	120	PMC	Valid																																						2	44943	44993	45051	DTAP	44911	Age: At Absolute Minimum	41275	44076.61068459491	Recommended based on age		1.0	This test case describes when a child is administered Pentacel as a first dose of the DTaP vaccine at 6 weeks - 4 days of age that the dose is valid.  Another dose should be forecast.
2013-0153	dose 3 to 4 Pentacel, interval 6m-4 days	44488	F				Not complete	44549	PENTACEL	120	PMC	Valid		44670	PENTACEL	120	PMC	Valid		44731	PENTACEL	120	PMC	Valid		44910	PENTACEL	120	PMC	Valid																				5	45949	45949	47044	DTAP	44911	All Valid: Forecast Test	41275	44798.39991512732	Recommended based on age		1.0	This test case describes when a child is administered dose four of the DTaP vaccine (Pentacel) at an interval of 6 months - 4 days after the third dose that the dose is valid.  Another dose should be forecast.
2013-0155	dose 3 to 4 Pentacel, interval 4 mo.	44513	F				Not complete	44574	PENTACEL	120	PMC	Valid		44694	PENTACEL	120	PMC	Valid		44786	PENTACEL	120	PMC	Valid		44908	PENTACEL	120	PMC	Valid																				5	45974	45974	47069	DTAP	44911	Interval: At Absolute Minimum	41275	44592.39995122685	Recommended based on age		1.0	This test case describes when a child is administered dose four of the DTaP vaccine (Pentacel) at an interval of 4 months after the third dose that the dose is valid.  Another dose should be forecast.
2013-0156	invalid dose 1-2 interval in midst of others	44737	F				Not complete	44798	PENTACEL	120	PMC	Valid		44821	PENTACEL	120	PMC	Not Valid	Interval: too short	44911	PENTACEL	120	PMC	Valid																										3	44939	44939	44978	DTAP	44911	Interval: Below Absolute Minimum	41275	44084.581729212965	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered an invalid second dose of the DTaP vaccine (Pentacel) at an interval less than 4 weeks - 4 days but was administered a valid dose at an interval of 4 weeks after the invalid dose.   Another dose should be forecast.
2013-0157	invalid dose 2-3 interval in midst of others	44543	F				Not complete	44605	PENTACEL	120	PMC	Valid		44664	PENTACEL	120	PMC	Valid		44685	PENTACEL	120	PMC	Not Valid	Interval: too short	44911	PENTACEL	120	PMC	Valid																				4	45093	45093	45147	DTAP	44911	Interval: Below Absolute Minimum	41275	44084.62156633102	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered an invalid third dose of the DTaP vaccine (Pentacel) at an interval of less than 4 weeks - 4 days but was administered a repeat dose at an interval of 4 weeks after the invalid dose that the dose is valid.  Another dose should be forecast.
2013-0161	# 1 Pentacel at 6 wks	44869	F				Not complete	44911	PENTACEL	120	PMC	Valid																																						2	44939	44989	45047	DTAP	44911	Age: At Minimum	41275	44084.62202570602	Recommended based on age		1.0	This test case describes when a child is administered Pentacel as a first dose of the DTaP vaccine at 6 weeks of age that the dose is valid.  Another dose should be forecast.
2013-0162	# 1 Pentacel at 6 yrs 11.5 mo	42366	F				Not complete	44911	PENTACEL	120	PMC	Valid																																						2	44939	44939	44939	DTAP	44911	All Valid: Forecast Test	41275	44084.62385462963	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered Pentacel as the first dose of DTaP vaccine at age 6 years and 11.5 months that the dose is valid.  Another dose should be forecast.
2013-0163	# 1 Pentacel at 7 yrs.  Off label use but counts as dose 1. 	42354	F				Not complete	44911	PENTACEL	120	PMC	Valid																																						2	44939	44939	44939	DTAP	44911	All Valid: Forecast Test	41275	44084.643066944445	Recommended based on age		1.0	This test case describes when a child is administered a first dose of DTaP vaccine (Pentacel) at age seven years,that the dose is valid.  Another dose should be forecast.
2013-0164	# 2 Pentacel at 10 wks-5 days	44846	F				Not complete	44884	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Not Valid	Age: Too Young																															2	44939	44969	45024	DTAP	44911	Age: Below Absolute Minimum	41275	44084.645153391204	Recommended based on age		1.0	This test case describes when a child is administered Pentacel as a second dose of the DTaP vaccine at 10 weeks - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0165	# 2 Pentacel at 10 wks-4 days	44845	F				Not complete	44883	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																																3	44943	45027	45084	DTAP	44911	Age: At Absolute Minimum	41275	44084.646550046295	Recommended based on age		1.0	This test case describes when a child is administered Pentacel as a second dose of the DTaP vaccine at 10 weeks - 4 days that the dose is valid.  Another dose should be forecast.
2013-0166	# 2 Pentacel at 6 yrs .  Off label but counts. 	42720	F				Not complete	43085	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																																3	44939	44939	44939	DTAP	44911	All Valid: Forecast Test	41275	44084.650968298614	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered a second dose of DTaP (Pentacel) vaccine at age six years of age,that the dose is valid.  Another dose should be forecast.
2016-0001	Dose #1 received at 4 months, dose #2 received at 8 months, dose #3 received at 2 years, and dose #4 received at 3 years. Current Age is 7 yrs.	42354	F				Not complete	42476	DTaP, unspecified formulation	107		Valid		42598	DTaP, unspecified formulation	107		Valid		43085	DTaP, unspecified formulation	107		Valid		43450	DTaP, unspecified formulation	107		Valid																				5	44911	44911	44911	DTAP	44911	All Valid: Forecast Test	42444	44088.545392858796	Recommended based on age	New logic concerning Tdap	2.2	This test case describes when a patient has been administered dose #1 at 4 months dose #2 at 8 months, and dose #3 at two years of age and dose #4 at three years of age and patient is now 7 years of age that another dose should be forecast.
2016-0002	Dose #1 received at 2 years, dose #2 received at 3 years, and dose #3 received at 4 years. Current age 7 yrs	42354	F				Not complete	43147	DTaP, unspecified formulation	107		Valid		43526	DTaP, unspecified formulation	107		Valid		43967	DTaP, unspecified formulation	107		Valid																										4	44911	44911	44911	DTAP	44911	All Valid: Forecast Test	42444	44088.57192420139	Recommended based on age	New logic concerning Tdap	2.2	This test case describes when a patient has been administered dose #1 at 2 years of age #2 at 3 years of age, and dose #3 at 4 years of age and patient is now 7 years of age that another dose should be forecast.
2016-0003	3 Dose received at < 12 months.  Current age is 7 years. 	42354	F				Not complete	42416	DTaP, unspecified formulation	107		Valid		42476	DTaP, unspecified formulation	107		Valid		42598	DTaP, unspecified formulation	107		Valid																										4	44911	44911	44911	DTAP	44911	All Valid: Forecast Test	42444	44088.57390476852	Recommended based on age	New logic concerning Tdap	2.2	This test case describes when a patient has been administered three doses (at ages 2, 4, and 8 months) of the DTaP vaccine at less than 12 months of age and patient is now 7 years of age that another dose should be forecast.
2016-0004	Dose #1 given at < 12 months. Current age is 7. 	42354	F				Not complete	42506	DTaP, unspecified formulation	107		Valid																																						2	44911	44911	44911	DTAP	44911	All Valid: Forecast Test	42444	44088.57665483796	Recommended based on age	New logic concerning Tdap	2.2	This test case describes when a patient has been administered a dose of the DTaP vaccine at less than 12 months of age and patient is now 7 years of age that another dose should be forecast.
2016-0005	Dose #1 given at 3 months, dose #2 given at 1 year, dose #3 given at 2 years, and dose # 4 given at 3 years. Current age is 7 yrs 	42354	F				Not complete	42445	DTaP, unspecified formulation	107		Valid		42720	DTaP, unspecified formulation	107		Valid		43085	DTaP, unspecified formulation	107		Valid		43450	DTaP, unspecified formulation	107		Valid																				5	44911	44911	44911	DTAP	44911	All Valid: Forecast Test	42444	44088.61463604167	Recommended based on age	New logic concerning Tdap	2.2	This test case describes when a patient has been administered dose #1 at 3 months, dose #2 at 1 year of age, dose #3 at 2 years, #3 at 2 years of age, and dose #4 at three years of age and patient is now 7 years of age that another dose should be forecast.
2016-0006	Dose #1 given at 5 months, dose #2 given at 1 year, dose #3 given at 2 years. Current age is 7 yrs 	42354	F				Not complete	42506	DTaP, unspecified formulation	107		Valid		42710	DTaP, unspecified formulation	107		Valid		43085	DTaP, unspecified formulation	107		Valid																										4	44911	44911	44911	DTAP	44911	All Valid: Forecast Test	42444	44088.62804819444	Recommended based on age	New logic concerning Tdap	2.2	This test case describes when a patient has been administered dose #1 at 5 months, dose #2 at 1 year of age, dose #3 at 2 years, and patient is now 7 years of age that another dose should be forecast.
2016-0007	Dose #1 at 9 months, dose #2 at 2 years, and dose #3 at 5 years. Current Age is 7 yrs	42354	F				Not complete	42629	DTaP, unspecified formulation	107		Valid		43085	DTaP, unspecified formulation	107		Valid		44181	DTaP, unspecified formulation	107		Valid																										4	44911	44911	44911	DTAP	44911	All Valid: Forecast Test	42444	44089.65035525463	Recommended based on age	New logic concerning Tdap	2.2	This test case describes when a patient has been administered dose #1 at 9 months, dose #2 at 2 year of age, dose #3 at 5 years, and patient is now 7 years of age that another dose should be forecast.
2016-0008	Dose 1 given at < 12 mo Dose 2 given at 2 yrs Current age 7 yrs	42354	F				Not complete	42416	DTaP, unspecified formulation	107		Valid		43085	DTaP, unspecified formulation	107		Valid																																3	44911	44911	44911	DTAP	44911	All Valid: Forecast Test	42444	44091.66949634259	Recommended based on age	New logic concerning Tdap	2.2	This test case describes a child who is currently age seven years but was administered a first dose of the DTaP vaccine at less than 12 months of age and a second dose at age 2 years that the doses are valid and that another dose should be forecast.
2016-0009	3 doses at < 12 mos, 1 dose at 1.5 yrs. Current Age is 7 yrs.	42354	F				Not complete	42416	DTaP, unspecified formulation	107		Valid		42537	DTaP, unspecified formulation	107		Valid		42598	DTaP, unspecified formulation	107		Valid		42871	DTaP, unspecified formulation	107		Valid																				5	44911	44911	44911	DTAP	44911	All Valid: Forecast Test	42444	44091.67166525463	Recommended based on age	New logic concerning Tdap	2.2	This test case describes a child who is currently age seven years but was administered three dose of the DTaP vaccine at less than 12 months of age and one dose at 1.5 years that the doses are valid and that another dose should be forecast.
2016-0010	Dose 1 and 2 given at < 12 months of age. Dose # 3 given at 2 years and dose #4 given at 3 years. Current age is 7 years. 	42354	F				Not complete	42445	DTaP, unspecified formulation	107		Valid		42629	DTaP, unspecified formulation	107		Valid		43097	DTaP, unspecified formulation	107		Valid		43495	DTaP, unspecified formulation	107		Valid																				5	44911	44911	44911	DTAP	44911	All Valid: Forecast Test	42444	44095.444277476854	Recommended based on age	New logic concerning Tdap	2.2	This test case describes a child who is currently age seven years but was administered a first and second dose of the DTaP vaccine at less than 12 months of age, a third dose was administered at age 2 years, and a fourth dose was administered at 3 years that the doses are valid and that another dose should be forecast.
2017-0003	DTaP - Dose 3 to dose 4 interval 4 months-4 days	44516	F				Not complete	44577	DTaP, unspecified formulation	107		Valid		44636	DTaP, unspecified formulation	107		Valid		44789	DTaP, unspecified formulation	107		Valid		44907	DTaP, unspecified formulation	107		Valid																				5	45977	45977	47072	DTAP	44911	All Valid: Forecast Test	42898	43999.67727638889	Recommended based on interval	Updated to allow the grace period for dose #4 of DTaP.	3.3	This test case describes when  dose #4 of DTaP is administered at least 4 months -4 days from Dose #3 that the dose is considered to be valid.
2017-0005	DTaP - Dose 3 to dose 4 interval 4 months-5 days	44516	F				Not complete	44577	DTaP, unspecified formulation	107		Valid		44636	DTaP, unspecified formulation	107		Valid		44789	DTaP, unspecified formulation	107		Valid		44906	DTaP, unspecified formulation	107		Not Valid	Interval: too short																			4	45088	45088	45120	DTAP	44911	Interval: Below Absolute Minimum	42898	44000.380725497685	Recommended based on interval		3.3	This test case describes when  dose #4 of DTaP is administered at least 4 months -5 days from Dose #3 that the dose is not valid.
2020-0002	Decennial dose as Tdap.	36876	F				Not complete	36938	DTaP, unspecified formulation	107		Valid		36997	DTaP, unspecified formulation	107		Valid		37058	DTaP, unspecified formulation	107		Valid		37331	DTaP, unspecified formulation	107		Valid		38337	DTaP, unspecified formulation	107		Valid		41259	Tdap	115		Valid		44911	Tdap	115		Valid		8	46737	48564	48591	DTAP	44911	All Valid: Forecast Test	43870.791666666664	44357.62804773148	Recommended based on interval		4.3	This test case describes when a patient receives Tdap as the decennial dose, that the dose is considered to be valid and another dose should be forecast.
2020-0003	Adult with no previous dose of the Tdap vaccine	33588	F				Not complete																																											1	36145	36145	36145	DTAP	44911	No doses administered	43870.791666666664	44000.38103774306	Recommended based on age		4.3	This test case describes when a patient has no previous doses of the tetanus, diphtheria, or pertussis vaccines, that the first dose should be forecast.
2020-0004	Adult patient with dose #1 of DTaP/Tdap/Td	33588	F				Not complete	44911	Tdap	115		Valid																																						2	44939	44939	44939	DTAP	44911	All Valid: Forecast Test	43870.791666666664	44000.381264386575	Recommended based on minimum interval from previous dose (catch-up)		4.3	This test case describes when a patient has received the first dose of the DTaP/Tdap/Td vaccine that another dose should be forecast.
2020-0005	Adult patient with dose #2 of DTaP/Tdap/Td at 4 weeks	33560	F				Not complete	44883	Tdap	115		Valid		44911	Td(adult) unspecified formulation	139		Valid																																3	45093	45093	45093	DTAP	44911	All Valid: Forecast Test	43870.791666666664	44000.38154052083	Recommended based on interval		4.3	This test case describes when a patient has received the second dose of  DTaP/Tdap/Td vaccine at 4 weeks that another dose should be forecast.
2020-0006	Adult patient with dose #2 of DTaP/Tdap/Td at 4 weeks - 4 days	33564	F				Not complete	44887	Tdap	115		Valid		44911	Td(adult) unspecified formulation	139		Valid																																3	45093	45093	45093	DTAP	44911	Interval: At Absolute minimum	43870.791666666664	44000.3821694213	Recommended based on interval		4.3	This test case describes when a patient has received the second dose of DTap/Tdap/Td vaccine at 4 weeks - 4 days that the dose should be considered valid and that another dose should be forecast.
2020-0007	Adult patient with dose #2 of DTaP/Tdap/Td at 4 weeks - 5 days	33565	F				Not complete	44888	Tdap	115		Valid		44911	Td(adult) unspecified formulation	139		Not Valid	Interval: too short																															2	44939	44939	44939	DTAP	44911	Interval: Below Absolute Minimum	43870.791666666664	44000.38231184028	Recommended based on interval		4.3	This test case describes when a patient has received the second dose of DTaP/Tdap/Td vaccine at 4 weeks - 5 days that the dose should not be considered to be valid.  Another dose should be forecast.
2020-0008	Adult patient with dose #3 of Td at 6 mos	33374	F				Not complete	44697	Tdap	115		Valid		44725	Td(adult) unspecified formulation	139		Valid		44908	Td(adult) unspecified formulation	139		Valid																										4	46734	48561	48588	DTAP	44911	All Valid: Forecast Test	43870.791666666664	44000.38241337963	Recommended based on interval		4.3	This test case describes when a patient has received the third dose of DTaP/Tdap/Td vaccine at 6 months that the dose is considered to be valid.  Forecast another dose.
2020-0009	Adult patient with dose #3 of Td at 6 mos - 4 days	33374	F				Not complete	44697	Tdap	115		Valid		44725	Td(adult) unspecified formulation	139		Valid		44904	Td(adult) unspecified formulation	139		Valid																										4	46730	48557	48584	DTAP	44911	All Valid: Forecast Test	43870.791666666664	44000.38252009259	Recommended based on interval		4.3	This test case describes when a patient has received the third dose of DTaP/Tdap/Td vaccine at 6 months - 4 days that the dose is considered to be valid.  Forecast another dose.
2020-0010	Adult patient with dose #3 of Td at 6 mos - 5 days	33374	F				Not complete	44697	Tdap	115		Valid		44725	Td(adult) unspecified formulation	139		Valid		44903	Td(adult) unspecified formulation	139		Not Valid	Interval: too short																									3	45085	45085	45085	DTAP	44911	All Valid: Forecast Test	43870.791666666664	44000.38262384259	Recommended based on interval		4.3	This test case describes when a patient has received the third dose of DTaP/Tdap/Td vaccine at 6 months - 5 days that the dose is not valid.  Forecast a repeat dose.
2022-0001	Dose #1 Tdap at 9 years, Dose #2 Td at 4 weeks, Dose #3 Td at 10 years	41259	M				Not complete	44667	BOOSTRIX	115	SKB	Valid		44695	Tenivac	113	PMC	Valid		44911	Tenivac	113	PMC	Valid																										4	45276	45276	46034	DTAP	44911	All Valid: Forecast Test	44564.791666666664	44592.35980222222	Recommended based on age		4.18	This test case describes when a child is administered a first dose of Tdap at 9 years of age, a second dose of Td at 4 weeks after first dose, and a third dose of Td at 10 years that another Tdap should be forecast at 11 years.
2022-0002	Dose #1 Tdap at 9 years, Dose #2 Td at 4 weeks, Dose #3 Tdap at 10 years	41259	M				Not complete	44667	BOOSTRIX	115	SKB	Valid		44695	Tenivac	113	PMC	Valid		44911	BOOSTRIX	115	SKB	Valid																										4	46737	48564	48591	DTAP	44911	All Valid: Forecast Test	44564.791666666664	44592.3599412037	Recommended based on age		4.18	This test case describes when a child is administered a first dose of Tdap at 9 years of age, a second dose of Td at 4 weeks after the first dose, and a third dose of Tdap at 10 years of age that another dose (decennial) should be forecast.
2013-0167	Newborn	44774	F				Not complete																																											1	44958	44958		FLU	44774	No Doses Administered	41275	44798.368717129626	Recommended based on age	v4.26:  Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.
V4.1:  Rolled test cases forward from 2018-19 season to 2019-2020 season.
V3.5: Rolled test cases forward from 2017-18 season to 2018-19 season.	4.26	This test case describes when assessing a newborn for the first dose of the Influenza vaccine that it should be administered at the recommended age of 6 months.
2013-0168	# 1 to # 2 interval 28 days	44317	F				Not complete	44531	influenza, unspecified formulation	88		Valid		44559	influenza, unspecified formulation	88		Valid																																3	44743	44743		FLU	44559	Interval: At Minimum	41275	44798.3693027662	Recommended based on seasonal start date	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.
V4.1: Rolled test cases forward from 2018-19 season to 2019-20 season.
V3.5: Rolled test cases forward from 2017-18 season to 2018-19 season.	4.26	This test case describes when a newborn receives the first dose of the Influenza vaccine at 6 months and a second dose at 28 days later that the next dose of influenza is recommended at the next seasonal flu begin date.
2013-0169	Child under 9 needs two in first season	42248	F				Not complete	44805	Afluria, quadrivalent	158	SEQ	Valid																																						2	44833	44833		FLU	44805	All Valid: Forecast Test	41275	44798.369605810185	Recommended based on interval	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season. Updated Administered vaccine to quadrivalent as trivalent will eventually phase out.
V4.1: Rolled test cases forward from 2018-19 season to 2019-2020 season.
V3.5: Rolled test cases forward from 2017-18 season to 2018-19 season.	4.26	This test case describes when a child under the age of 9 receives dose 1 of the influenza vaccine in his first season, that a second dose is recommended at 4 weeks later.
2013-0170	Child under 9 received only one in first season	42464	F				Not complete	44849	influenza, unspecified formulation	88		Valid																																						2	44877	44877		FLU	44849	All Valid: Forecast Test	41275	44798.369818136576	Recommended based on interval	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.
V4.1: Rolled test cases forward from 2018-2019 season to 2019-2020 season.
V3.5: Rolled test cases forward from 2017-18 season to 2018-19 season.	4.26	This test case describes when a child under the age of 9 receives only one influenza dose in his first season, that a second dose is recommended at 4 weeks later.
2013-0171	Child under 9 received two in first season	42500	F				Complete	44774	influenza, unspecified formulation	88		Valid		44808	influenza, unspecified formulation	88		Valid																																				FLU	44808	All Valid: Forecast Test	41275	44798.37011549769	Recommended based on seasonal start date	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.
V4.1: Rolled test cases forward from 2018-19 season to 2019-20 season.
V3.5: Rolled test cases forward from 2016-17 season to 2017-18 season.	4.26	This test case describes when a child under 9 years of age receives two doses of the Influenza vaccine in his first season, that no additional doses are needed during that season.
2013-0172	Invalid dose 1st season	44682	F				Not complete	44805	Afluria, quadrivalent	158	SEQ	Not Valid	Age: Too Young																																					1	44866	44866		FLU	44805	Age: Below Absolute Minimum	41275	44798.37046690972	Recommended based on age	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season. Updated CVX and MVX  codes to use quadrivalent.
V4.1: Rolled test cases forward from 2018-19 season to 2019-20 season.
V3.5: Rolled test cases forward from 2017-18 season to 2018-19 season.	4.26	This test case describes when a child receives his first dose of the influenza vaccine before the age of 6 months, that the dose is not valid and should be repeated at the recommended age.
2013-0178	# 1 at 6 mo-4 days	44652	F				Not complete	44831	influenza, unspecified formulation	88		Valid																																						2	44859	44859		FLU	44831	Age: At Absolute Minimum	41275	44798.37068773148	Recommended based on interval	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.
V4.1: Rolled test cases forward from 2018-19 season to 2019-20 season.
V3.5: Rolled test cases forward from 2017-18 season to 2018-19 season.	4.26	This test case describes when a child receives his first dose of the influenza vaccine at 6 months - 4 days, that the dose is considered to be valid, and the next dose should be forecasted.
2013-0179	# 1 at 6 mo	44652	F				Not complete	44835	influenza, unspecified formulation	88		Valid																																						2	44863	44863		FLU	44835	Age: At Minimum	41275	44798.37086630787	Recommended based on interval	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.
V4.1: Rolled test cases forward from 2018-19 season to 2019-20 season.
V3.5: Rolled test cases forward from 2017-18 season to 2018-19 season.	4.26	This test case describes when a child receives his first dose of the Influenza vaccine at 6 months of age, that the dose is considered to be valid, and the second dose should be forecasted.
2013-0183	# 1 to # 2 interval 23 days	44593	F				Not complete	44805	influenza, unspecified formulation	88		Valid		44828	influenza, unspecified formulation	88		Not Valid	Interval: too short																															2	44856	44856		FLU	44828	Interval: Below Absolute Minimum	41275	44798.371051828704	Recommended based on minimum interval from invalid dose	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.
V4.1: Rolled test cases forward from 2018-19 season to 2019-20 season.
V3.5: Rolled test cases forward from 2017-18 season to 2018-19 season.	4.26	This test case describes when a child receives the second dose of the Influenza vaccine at less than 4 weeks - 4 days from the previous dose, that the dose is not valid and a repeat dose should be recommended at 4 weeks later.
2013-0184	# 1 to # 2 interval 24 days	44570	F				Complete	44805	influenza, unspecified formulation	88		Valid		44829	influenza, unspecified formulation	88		Valid																																				FLU	44829	Interval: At Absolute Minimum	41275	44798.371280775464	Recommended based on seasonal start date	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.
V4.1: Rolled test cases forward from 2018-19 season to 2019-20 season.
V3.5: Rolled test cases forward from 2017-18 season to 2018-19 season.	4.26	This test case describes when a child receives the second dose of the influenza vaccine 24 days after the first dose, that the dose is considered to be valid. 
2016-0012	Child under 9 received one in previous season and one in current season	44348	M				Not complete	44531	influenza, unspecified formulation	88		Valid		44805	influenza, unspecified formulation	88		Valid																																3	44833	44833		FLU	44805	Interval: At Minimum	42640	44798.37147197917	Recommended based on interval	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.
V4.1: Rolled test cases forward from 2018-19 season to 2019-20 season.
V3.5: Rolled test cases forward from 2017-18 season to 2018-19 season.	4.26	This test case describes when a child under 9 years of age received one dose of the Influenza vaccine in a previous season and one in the current season that an additional dose is recommended in the current season. Forecast second dose at 4 weeks later.
2018-0024	Patient 9 years or older with no current seasonal dose	41131	M				Not complete																																											1	44743	44743		FLU	44892	No Doses Administered	43430.791666666664	44798.371767881945	Recommended based on age	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.
V4.2: Updated forecast dose number from #2 to #1
V4.1: Rolled test case forward from 2018-19 season to 2019-20 season.	4.26	This test case describes when a patient is 9 years or older and does not have a current seasonal dose that a dose should be forecast.
2018-0025	Patient 9 years or older with one current seasonal dose	41496	M				Complete	44814	influenza, unspecified formulation	88		Valid																																						-				FLU	44814	All Valid: Forecast Test	43430.791666666664	44798.37265197917	Recommended based on seasonal start date	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.
V4.1: Rolled test cases forward from 2018-19 season to 2019-20 season.	4.26	This test case describes when a patient is 9 years or older and has been administered a dose of the flu vacccine in the current season that no additional doses should be forecast for the season.
2018-0026	Child under 9 years with dose in current season and two doses in previous different seasons	43530	M				Complete	43723	influenza, unspecified formulation	88		Valid		43751	influenza, unspecified formulation	88		Valid		44808	influenza, unspecified formulation	88		Valid																										-				FLU	44808	All Valid: Forecast Test	43430.791666666664	44798.37306331019	Recommended based on seasonal start date	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.
V4.1: Rolled test cases forward from 2018-19 season to 2019-20 season.	4.26	This test case describes when a child under 9 years of age receives a flu vaccine in the current season and two vaccine doses in previous different season, that the series is complete for the season.
2019-0004	Child received first dose at 9 years.  Series complete	41496	M				Complete	44791	influenza, unspecified formulation	88		Valid																																										FLU	44791	All Valid: Forecast Test	43430.791666666664	44798.373640625	Recommended based on seasonal start date	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.	4.26	This test case describes when a child age 9 years is administered a first dose of the Flu vaccine that no additional doses are needed.  Series is complete for season.
2019-0005	Child entered season at 8 years of age, received dose before 9. Forecast another dose	41518	M				Not complete	44804	influenza, unspecified formulation	88		Valid																																						2	44832	44832		FLU	44805	All Valid: Forecast Test	43430.791666666664	44798.373939398145	Recommended based on interval.	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.	4.26	This test case describes when a child enters the flu season at age 8 years, received their first dose, but is now 9 years old. Per flu recommendations, the patient needs a second dose.
2019-0015	Adult with no previous dose of the Influenza vaccine	31291	M				Not complete																																											1	44743	44743		FLU	44805	No Doses Administered 	43430.791666666664	44798.37411427083	Recommended based on seasonal date	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.	4.26	This test case describes when an adult patient has not received any doses of the influenza vaccine, that a dose should be forecast.
2019-0016	Adult with a dose of the influenza vaccine	31291	M				Complete	44805	Fluzone, Quadrivalent	158	PMC	Valid																																						-				FLU	44805	All Valid: Forecast Test	43430.791666666664	44798.374297476854	Not Recommended: series complete	V4.26: Rolled test cases forward from 2021-2022 season to 2022-2023 season.
V4.10: Rolled test cases forward from 2020-2021 season to 2021-2022 season.
V4.4: Rolled test cases forward from 2019-2020 season to 2020-2021 season.	4.26	This test case describes when an adult patient has received a dose of the  influenza vaccine in the current season, that no additional doses are needed. Series is complete for the season.
2013-0185	Infant forecasting	44911	F				Not complete																																											1	45276	45276	45669	HepA	44911	No Doses Administered	41275	43054.29176467592	Recommended based on age		1.0	This test case describes when assessing a newborn for the first dose of the 2-dose Hep A vaccine that it is not recommended until at least 12 months of age.
2013-0186	Dose 1 to dose 2 interval 6 months.  Series complete. 	44302	F				Complete	44728	Hep A, unspecified formulation	85		Valid		44911	Hep A, unspecified formulation	85		Valid																																-				HepA	44911	Interval: At Minimum	41275	43054.29221141204	Not recommended: series complete		1.0	This test case describes when the second dose of the 2 dose Hep A vaccine is administered at least 6 months after the first dose, that no additional doses are recommended and that the series is considered complete.
2013-0188	Adult dose mistakenly given to a child.  Counts as valid. 	44546	F				Not complete	44911	HAVRIX-ADULT	52	SKB	Valid																																						2	45093	45093	45303	HepA	44911	Vaccine: Off Label	41275	43054.293481608795	Recommended based on age	Past Due Date was previously calculated based on an interval, but should have been calculated based on age of 24 months + 4 weeks - 1 day	1.1	This test case describes when an adult dose of the Hep A vaccine is erroneously administered to a child, that the dose is considered valid.  The second (age appropriate ) dose should be forecasted.
2013-0189	Dose # 1 at age 12 months-5 days	44551	F				Not complete	44911	Hep A, unspecified formulation	85		Not Valid	Age: Too Young																																					1	44916	44916	45308	HepA	44911	Age: Below Absolute Minimum	41275	43054.294822951386	Recommended based on age		1.0	This test case describes when  a dose of the Hep A  2 dose vaccine is administered to a child at 12 months - 5 days, that the dose is not considered to be valid.
2013-0190	Dose # 1 at age 12 months-4 days	44550	F				Not complete	44911	Hep A, unspecified formulation	85		Valid																																						2	45097	45097	45307	HepA	44911	Age: At Absolute Minimum	41275	43980.35363136574	Recommended based on age	V1.1: Past Due Date was previously calculated based on an interval, but should have been calculated based on age of 24 months + 4 weeks - 1 day	1.1	This test case describes when a first dose of the Hep A 2 dose vaccine is administered to a child at 12 months - 4 days, that the dose is considered to be valid.  The second dose should be forecasted.
2013-0191	Dose # 1 at age 12 months.	44546	F				Not complete	44911	Hep A, unspecified formulation	85		Valid																																						2	45093	45093	45303	HepA	44911	Age: At Minimum	41275	43054.29570383102	Recommended based on age	Past Due Date was previously calculated based on an interval, but should have been calculated based on age of 24 months + 4 weeks - 1 day	1.1	This test case describes when a first dose of the Hep A 2 dose vaccine is administered to a child at 12 months of age, that the dose is considered to be valid.  Forecast second dose.
2013-0192	Dose 1 to dose 2 interval 6 mo-5 days=invalid	44368	F				Not complete	44733	Hep A, unspecified formulation	85		Valid		44911	Hep A, unspecified formulation	85		Not Valid	Interval: too short																															2	45093	45093	45125	HepA	44911	Interval: Below Absolute Minimum	41275	43054.29732650463	Recommended based on minimum interval from invalid dose	V1.1: Past Due Date was previously calculated based on an interval, but should have been calculated based on age of 24 months + 4 weeks - 1 day	1.1	This test case describes when the second dose of the 2 dose Hep A vaccine is administered at 6 months - 5 days after the first dose, that the dose is not considered to be valid.  A repeat dose should be forecasted.
2013-0193	Dose 1 to Dose 2 interval 6 mo-4 days.  Series complete.	43271	F				Complete	44732	Hep A, unspecified formulation	85		Valid		44911	Hep A, unspecified formulation	85		Valid																																-				HepA	44911	Interval: At Absolute Minimum	41275	43980.353809849534	Not recommended: series complete	V3.5: Lowered Age from 8 years to 4 years to better associate with new Age Groupings. No Effective change to test case other than Age of patient and vaccinations.	3.5	This test case describes when the second dose of the HepA 2 dose vaccine is administered at 6 months - 4 days, that the dose is considered valid and the series is considered complete.
2013-0194	Dose # 2 at 18 months=series complete. 	44363	F				Complete	44728	Hep A, unspecified formulation	85		Valid		44911	Hep A, unspecified formulation	85		Valid																																-				HepA	44911	Age: At Minimum	41275	43054.297964895835	Not recommended: series complete		1.0	This test case describes when the second dose of a HepA 2 dose vaccine is administered to child at 18 months of age and at an interval of 6 months from the previous dose, that the dose is considered valid and the series is considered complete.
2013-0196	Dose 1 to dose 2 interval 6 mo-5 days	44302	F				Not complete	44728	Hep A, unspecified formulation	85		Valid		44906	Hep A, unspecified formulation	85		Not Valid	Interval: too short																															2	45088	45088	45088	HepA	44911	Interval: Below Absolute Minimum	41275	43336.351380520835	Recommended based on minimum interval from invalid dose	Child is lapse enough that the Past Due Date should have been aligned with the earliest and recommended.	1.1	This test case describes when a second dose of the Hep A 2 dose vaccine is administered to a child at 6 months -5 days, that the dose is not considered valid.  A repeat dose should be forecasted.
2013-0197	Dose 1 to dose 2 interval 6 months-4 days.  Series complete. 	44302	F				Complete	44728	Hep A, unspecified formulation	85		Valid		44907	Hep A, unspecified formulation	85		Valid																																-				HepA	44911	Interval: At Absolute Minimum	41275	43980.354093981485	Not recommended: series complete		1.0	This test case describes when a second dose of the Hep A 2 dose vaccine is administered to a child at 18 months age and with an interval of at least 6 months -4 days after the previous dose, that the dose is considered valid and no additional doses are recommended.  The series is complete. 
2019-0010	No doses of Hep A vaccine at age 18 years	38337	F				Not complete																																											1	38702	38702	39094	HepA	44911	No Doses Administered	43727.833333333336	43980.35428888889	Recommended based on age	Added a past due date.	4.3	This test case describes when a patient is 18 years of age and has no previous doses of the Hep A vaccine that the first dose should be forecast.
2019-0011	Dose #1 of Hep A at age 18 years	38337	F				Not complete	44911	Hep A, adult	52		Valid																																						2	45093	45093	45093	HepA	44911	Age: At Minimum	43727.833333333336	43980.35437030093	Recommended based on age		4.3	This test case describes when dose #1 of the Hep A vaccine is administered to an adolescent that a second dose should be forecast.
2019-0012	Dose 2 of Hep A at 6 months	38154	F				Complete	44728	HAVRIX-ADULT	52	SKB	Valid		44911	HAVRIX-ADULT	52	SKB	Valid																																-				HepA	44911	Interval: At Minimum	43727.833333333336	43872.7945730787	Not recommended: series complete		4.3	This test case describes when an adolescent receives a second dose of the Hep A vaccine at an interval of 6 month, that no additional doses are needed.  The series is complete.
2019-0013	Dose 2 of Hep A at 6 months -4 days	38154	F				Complete	44728	HAVRIX-ADULT	52	SKB	Valid		44907	HAVRIX-ADULT	52	SKB	Valid																																-				HepA	44911	Interval: At Absolute Minimum	43727.833333333336	43980.35446594907	Not recommended: series complete		4.3	This test case describes when an adolescent receives a second dose of the Hep A vaccine at an interval of 6 month- 4 days, that no additional dose  are needed.  The series is complete.
2019-0014	Dose 2 of Hep A at 6 months -5 days	38154	F				Not complete	44728	HAVRIX-ADULT	52	SKB	Valid		44906	HAVRIX-ADULT	52	SKB	Not Valid	Interval: too short																															2	45088	45088	45088	HepA	44911	Interval: Below Absolute Minimum	43727.833333333336	43872.79515737268	Recommended based on minimum interval from previous dose (catch-up)		4.3	This test case describes when an adolescent receives a second dose of the Hep A vaccine at an interval of 6 month- 5 days, that  another dose should be forecast.
2020-0001	Dose#3 administered at least 6 months after 1st valid dose	44363	F				Complete	44728	Hep A, unspecified formulation	85		Valid		44881	Hep A, unspecified formulation	85		Not Valid	Interval: too short	44911	Hep A, unspecified formulation	85		Valid																														HepA	44911	Interval: Below Absolute Minimum	41275	43867.45184100694	Recommended based on minimum interval from invalid dose		4.3	This test case describes when a third dose is administered at least 6 months after the first dose, that the dose is considered to be valid.  The series is complete. The invalid dose (2nd dose administered) is not considered in the spacing.
2013-0198	Newborn Testing.  No vaccinations to date. 	44911	F				Not complete																																											1	44911	44911	44938	HepB	44911	No Doses Administered	41275	43140.39883918982	Recommended based on age		1.0	This test case describes the forecasting of the Hep B vaccine for a newborn.
2013-0199	Dose 1 to dose 2 interval 28-5 days	44857	F				Not complete	44888	RECOMBIVAX-PEDS	08	MSD	Valid		44911	RECOMBIVAX-PEDS	08	MSD	Not Valid	Interval: too short																															2	44939	44939	44976	HepB	44911	Interval: Below Absolute Minimum	41275	44000.3354128125	Recommended based on minimum interval from invalid dose		1.0	This test case describes when dose #2 of the Hep B vaccine is administered at an interval 28-5 days after dose #1 that the dose is not valid.  A repeat dose should be forecast.
2013-0200	Dose 1 to dose 2 interval 28-4 days	44887	F				Not complete	44887	RECOMBIVAX-PEDS	08	MSD	Valid		44911	Hep B, adolescent or pediatric	08		Valid																																3	45055	45068	45492	HepB	44911	Interval: At Absolute Minimum	41275	44000.33403322917	Recommended based on age		1.0	This test case desribes when dose #2 of the Hep B vaccine is administered at an interval of 28-4 days after dose #1 that the dose is considered to be valid.
2013-0201	Dose 1 to dose 2 interval 28 days	44883	F				Not complete	44883	RECOMBIVAX-PEDS	08	MSD	Valid		44911	RECOMBIVAX-PEDS	08	MSD	Valid																																3	45051	45064	45488	HepB	44911	Interval: At Minimum	41275	43140.40056834491	Recommended based on age		1.0	This test case desribes when dose #2 of the Hep B vaccine is administered at an interval of 28 days after dose #1 that the dose is considered to be valid.
2013-0202	Dose 2 to dose 3 interval 8 wks-5 days. 4th dose needed.	44677	F				Not complete	44768	RECOMBIVAX-PEDS	08	MSD	Valid		44860	RECOMBIVAX-PEDS	08	MSD	Valid		44911	RECOMBIVAX-PEDS	08	MSD	Valid																										4	44916	44916	45283	HepB	44911	All Valid: Forecast Test	41275	44000.33556331018	Recommended based on interval 	V4.2: Updated Forecast Test Type to "Recommended based on interval"
V4.1: Changed forecast to reflect new 4-dose guidance from CEB.
v3.1: Changed dose 3 from not valid to valid due to Hep B 4 dose series	4.2	This test case describes when dose #3 of the Hep B vaccine is administered at an interval of 8 weeks - 5 days after dose #2, that the dose is considered valid, but a 4th dose is needed to complete the series.
2013-0203	Dose 2 to dose 3 interval 8 wks-4 days.  Series complete	44686	F				Complete	44704	Hep B, adolescent or pediatric	08		Valid		44857	Hep B, adolescent or pediatric	08		Valid		44909	Hep B, adolescent or pediatric	08		Valid																										-				HepB	44911	Interval: At Absolute Minimum	41275	44000.33424902778	Not recommended: series complete		1.0	This test case describes when dose #3 of the Hep B vaccine is administered at an interval of 8 weeks - 4 days after dose #2, that the dose is considered to be valid. The series is complete.
2013-0204	Dose 2 to dose 3 interval is 8 weeks.  Series complete.	44667	F				Complete	44728	Hep B, adolescent or pediatric	08		Valid		44850	Hep B, adolescent or pediatric	08		Valid		44906	Hep B, adolescent or pediatric	08		Valid																										-				HepB	44911	Interval: At Minimum	41275	43336.353715625	Not recommended: series complete		1.0	This test case describes when dose #3 of the Hep B vaccine is administered at an interval of 8 weeks after dose #2, that the dose is considered to be valid. The series is complete.
2013-0205	Dose 1 to dose 3 interval 16 weeks-5 days. 4th dose needed	44712	F				Not complete	44804	RECOMBIVAX-PEDS	08	MSD	Valid		44841	RECOMBIVAX-PEDS	08	MSD	Valid		44911	RECOMBIVAX-PEDS	08	MSD	Valid																										4	44916	44916	45318	HepB	44911	All Valid: Forecast Test	41275	44000.33568260416	Recommended based on interval 	V4.2: Updated Forecast Test Type to "Recommended based on interval".
V4.1: Changed forecast to reflect new 4 dose guidance from CEB.
V3.1: Changed dose 3 from valid to not valid due to Hep B 4 dose series	4.2	This test case describes when dose #3 of the Hep B vaccine is administered at an interval less than 16 weeks - 4 days from dose #1 that the dose is considered to be valid, but a 4th dose is needed to complete the series.
2013-0206	Dose 1 to dose 3 interval 16 weeks-4 days. Series complete. 	44714	F				Complete	44803	RECOMBIVAX-PEDS	08	MSD	Valid		44857	RECOMBIVAX-PEDS	08	MSD	Valid		44911	RECOMBIVAX-PEDS	08	MSD	Valid																										-				HepB	44911	Interval: At Absolute Minimum	41275	44000.334387800925	Not recommended: series complete		1.0	This test case describes when dose #3 of the Hep B vaccine is administered at an interval of 16 weeks - 4 days from dose #1 that the dose is considered to be valid.  The series is complete.
2013-0207	Dose 1 to dose 3 interval 16 weeks.  Series complete. 	44707	F				Complete	44799	Hep B, adolescent or pediatric	08		Valid		44845	Hep B, adolescent or pediatric	08		Valid		44911	Hep B, adolescent or pediatric	08		Valid																										-				HepB	44911	Interval: At Minimum	41275	43140.4066821875	Not recommended: series complete		1.0	This test case describes when dose #3 of the Hep B vaccine is administered at an interval of 16 weeks from dose #1 that the dose is considered to be valid.  The series is complete.
2013-0208	Recombivax Hep B ages 11-15.  Dose 2 recommended in 4-6 months. 	40324	F				Not complete	44911	RECOMBIVAX-ADULT	43	MSD	Valid																																						2	45032	45032	45150	HepB	44911	All Valid: Forecast Test	41275	44000.64175193287	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when dose #1 of the Hep B Recombivax vaccine is administered at age 12 years, that dose #2 should be administered at 4 months - 6 months later.
2013-0209	Dose # 1 at age 0 days. 	44911	F				Not complete	44911	Hep B, unspecified formulation	45		Valid																																						2	44939	44942	45028	HepB	44911	Age: At Minimum	41275	43140.407123460645	Recommended based on age		1.0	This test case describes when dose #1 of the Hep B vaccine is administered at 0 days that the dose is considered to be valid. 
2013-0210	Doses 1 and 2 of Recombvx at ages 11-15 years with ≥ 4 mo interval = series complete. 	40219	F				Complete	44783	RECOMBIVAX-ADULT	43	MSD	Valid		44905	RECOMBIVAX-ADULT	43	MSD	Valid																																-				HepB	44911	Interval: At Minimum	41275	44592.39384134259	Not recommended: series complete		1.0	This test case describes when dose #2 of the Hep B Recombivax vaccine is administered at an interval of 6 months from dose #1  to a child age 12 years, that dose is considered to be valid.  The series is complete.
2013-0211	Dose 1 to dose 2 Recombivax interval  4 months-5 days.  Two dose adolescent schedule no longer applies.  	40776	F				Not complete	44794	RECOMBIVAX-ADULT	43	MSD	Valid		44911	RECOMBIVAX-ADULT	43	MSD	Valid																																3	44967	44967	44967	HepB	44911	All Valid: Forecast Test	41275	44770.720325092596	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when dose #2 of the Hep B Recombivax vaccine is administered at an interval of 4 months - 5 days after dose #1 to a child age 11 years of age, that dose is valid.
2013-0212	Dose 2 to dose 3 interval 8 wks-5 days in adolescent with two Recombivax not meeting rules for two dose adoles. 4th dose needed	39888	F				Not complete	44758	RECOMBIVAX-ADULT	43	MSD	Valid		44850	RECOMBIVAX-ADULT	43	MSD	Valid		44901	RECOMBIVAX-PEDS	08	MSD	Valid																										4	44906	44906	44906	HepB	44911	All Valid: Forecast Test	41275	44000.3360271875	Recommended based on interval 	V4.2: Updated Forecast Test Type to "Recommended base on interval"
V4.1: Changed forecast to reflect new 4-dose guidance from CEB.
V3.1: Changed dose 3 from not valid to valid due to recent clarifications.  Also changed test case name to reflect a 4th dose is required.	4.2	This test case describes when dose #3 of the Hep B Recomibivax vaccine is administered at an interval of 8 weeks - 5 days from dose #2 to an adolescent child, that the dose is valid, but a fourth dose is required.
2013-0213	Hep at birth.  Comvax at 6 wks and 6 mo. Hep series complete. 	38021	F				Complete	38021	RECOMBIVAX-PEDS	08	MSD	Valid		38059	COMVAX	51	MSD	Valid		38203	COMVAX	51	MSD	Valid																										-				HepB	38203	All Valid: Forecast Test	41275	43157.42106019676	Not recommended: series complete		1.0	This test case describes when dose #1 of the Hep B vaccine is administered at birth, dose #2 is administered at an interval of 6 weeks after previous dose , and dose #3 is administered at 6 months after dose #2, that the series is complete. 
2013-0216	Hep B at birth. Comvax at 4 weeks and 6 months.  Series complete for Hep B.  	38750	F				Complete	38750	Hep B, unspecified formulation	45		Valid		38778	COMVAX	51	MSD	Valid		38931	COMVAX	51	MSD	Valid																										-				HepB	38931	Interval: At Minimum	41275	43157.42334141204	Not recommended: series complete		1.0	This test case describes when dose #1 of the Hep B vaccine is administered at birth, dose #2 is administered at an interval of 4 weeks after previous dose , and dose #3 is administered at 6 months after dose #2, that the series is complete. 
2013-0219	Hep B at birth. Comvax at 5 mo and 8 wks-4 days later.  Series complete for Hep B. 	38842	F				Complete	38842	RECOMBIVAX-PEDS	08	MSD	Valid		38995	COMVAX	51	MSD	Valid		39047	COMVAX	51	MSD	Valid																										-				HepB	39047	Interval: At Absolute Minimum	41275	44000.341060983796	Not recommended: series complete		1.0	This test case describes when dose #1 of the Hep B vaccine is administered at birth, dose #2 is administered at an interval of 5 months after previous dose , and dose #3 is administered at 8 weeks - 4 days after dose #2, that the series is complete. 
2013-0220	Dose # 1 at age 1 day	44910	F				Not complete	44911	RECOMBIVAX-PEDS	08	MSD	Valid																																						2	44939	44941	45027	HepB	44911	All Valid: Forecast Test	41275	43698.326286331016	Recommended based on age	V4.1: Updated Forecast Recommended Age to 1 month instead of 4 weeks after birth.	4.1	This test case describes when a newborn is administered dose #1 for he Hep B vaccine at age 1 day that the dose is considered to be valid.
2013-0221	Hep at birth.  Comvax at 5 mo and 8 wks later.  Series complete for Hep B. 	38874	F				Complete	38874	RECOMBIVAX-PEDS	08	MSD	Valid		39027	COMVAX	51	MSD	Valid		39083	COMVAX	51	MSD	Valid																										-				HepB	39083	Interval: At Minimum	41275	43157.51837784722	Not recommended: series complete		1.0	This test case describes when dose #1 of the Hep B vaccine is administered at birth, dose #2 is administered at an interval of 5 months after previous dose , and dose #3 is administered at 8 weeks after dose #2, that the series is complete. 
2013-0222	Dose 1 to dose 3 interval of Comvax 16 wks-5 days. 4th dose needed	37391	F				Not complete	37469	COMVAX	51	MSD	Valid		37519	COMVAX	51	MSD	Valid		37576	COMVAX	51	MSD	Valid																										4	37581	37581	37997	HepB	37576	All Valid: Forecast Test	41275	44000.33622532408	Recommended based on interval	V4.2: Updated Forecast Test Type to "Recommended based on interval"
V4.1: Changed forecast to reflect new 4 dose guidance from CEB.
v3.1: Changed dose 3 from not valid to valid due to recent clarifications.	4.2	This test case describes when dose #3 of the Hep B vaccine is administered at an interval of 16 weeks - 5 days from dose #1 that the dose is valid, but a 4th dose is needed to complete the series.
2013-0223	Dose 1 to dose 3 interval of Comvax 16 wks-4 days=valid Hep B # 3.  Hep B series complete. 	38905	F				Complete	39008	COMVAX	51	MSD	Valid		39060	COMVAX	51	MSD	Valid		39116	COMVAX	51	MSD	Valid																										-				HepB	39116	Interval: At Absolute Minimum	41275	44000.34142002315	Not recommended: series complete		1.0	This test case describes when dose #3 of the Hep B vaccine is administered at an interval of 16 weeks - 4 days from dose #1 that the dose is considered to be valid.  The series is complete.
2013-0224	Dose 1 to dose 3 interval of Comvax is 16 weeks.   Series complete for Hep B. 	38937	F				Complete	39021	COMVAX	51	MSD	Valid		39073	COMVAX	51	MSD	Valid		39133	COMVAX	51	MSD	Valid																										-				HepB	39133	Interval: At Minimum	41275	43157.43761512732	Not recommended: series complete		1.0	This test case describes when dose #3 of the Hep B vaccine is administered at an interval of 16 weeks from dose #1 that the dose is considered to be valid.  The series is complete.
2013-0225	Comvax given at birth.	39000	F				Not complete	39000	COMVAX	51	MSD	Valid																																						2	39028	39031	39119	HepB	39000	Age: At Minimum	41275	43157.43792380787	Recommended based on age		1.0	This test case describes when dose #1 of the Hep B vaccine (Comvax) is administered at birth that the dose is considered to be valid. 
2013-0227	Dose # 2 at 28-5 days	44888	F				Not complete	44888	RECOMBIVAX-PEDS	08	MSD	Valid		44911	RECOMBIVAX-PEDS	08	MSD	Not Valid	Age: Too Young																															2	44939	44939	45007	HepB	44911	Age: Below Absolute Minimum	41275	44000.336664131944	Recommended based on minimum interval from invalid dose		1.0	This test case describes when dose #2 of the Hep B vaccine is administered at an interval of 28 - 5 days that the dose is not valid. 
2013-0228	Dose # 2 at 28-4 days	44887	F				Not complete	44887	RECOMBIVAX-PEDS	08	MSD	Valid		44911	RECOMBIVAX-PEDS	08	MSD	Valid																																3	45055	45068	45492	HepB	44911	Age: At Absolute Minimum	41275	44000.341543599534	Recommended based on age		1.0	This test case describes when dose #2 of the Hep B vaccine is administered at an interval of 28 - 4 days that the dose is considered to be valid.
2013-0229	Dose # 2 at 28 days	44883	F				Not complete	44883	RECOMBIVAX-PEDS	08	MSD	Valid		44911	RECOMBIVAX-PEDS	08	MSD	Valid																																3	45051	45064	45488	HepB	44911	Interval: At Minimum	41275	43140.527920925924	Recommended based on age		1.0	This test case describes when dose #2 of the Hep B vaccine is administered at an interval of 28 days that the dose is considered to be valid.
2013-0230	Dose # 3 at age 24 weeks-5 days. 4th dose needed.	44748	F				Not complete	44748	ENGERIX B-PEDS	08	SKB	Valid		44776	ENGERIX B-PEDS	08	SKB	Valid		44911	ENGERIX B-PEDS	08	SKB	Valid																										4	44916	44932	45355	HepB	44911	All Valid: Forecast Test	41275	43783.27231818287	Recommended based on interval	V4.2: Updated Forecast Test Type to "Recommended based on interval".
V4.1: Changed forecast to reflect new 4-dose guidance from CEB.
V3.1: Changed dose 3 to valid due to recent clarifications.	4.2	This test case describes when dose #3 of the Hep B vaccine is administered at 24 weeks - 5 days of age, that the dose is valid, but a 4th dose is needed to completed the series.
2013-0231	Dose # 3 at age 24 weeks-4 days.  Series complete. 	44747	F				Complete	44747	RECOMBIVAX-PEDS	08	MSD	Valid		44778	RECOMBIVAX-PEDS	08	MSD	Valid		44911	RECOMBIVAX-PEDS	08	MSD	Valid																										-				HepB	44911	Age: At Absolute Minimum	41275	44000.34182325232	Not recommended: series complete		1.0	This test case describes when dose #3 of the Hep B vaccine is administered at 24 weeks - 4 days of age, that the series is complete. 
2013-0232	Dose # 3 at 24 weeks.  Series complete.	44743	F				Complete	44743	RECOMBIVAX-PEDS	08	MSD	Valid		44805	RECOMBIVAX-PEDS	08	MSD	Valid		44911	Hep B, unspecified formulation	45		Valid																										-				HepB	44911	Age: At Minimum	41275	43140.529898217595	Not recommended: series complete		1.0	This test case describes when dose #3 of the Hep B vaccine is administered at 24 weeks of age, that the series is complete. 
2013-0233	Newborn forecasting	44911	F				Not complete																																											1	44911	44911	44938	HepB	44911	No Doses Administered	41275	43140.53034513889	Recommended based on age		1.0	This test case describes the forecasting of the Hep B vaccine for a newborn.
2013-0234	# 2 Pediarix at 6 yrs 11.5 mo	42371	F				Not complete	43451	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	44967	44967	44967	HepB	44911	All Valid: Forecast Test	41275	44000.33680329861	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when dose #2 of the Hep B vaccine is administered at 6 years and 11 months after dose #1, that the dose is considered to b valid.
2013-0235	# 2 Pediarix at 7 yrs; # 1 at less than 12 mo. 	42354	F				Not complete	42445	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	44967	44967	44967	HepB	44911	All Valid: Forecast Test	41275	44000.336944386574	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when dose #2 of the Hep B vaccine is administered at 7 years after dose #1 (child less than 12 months), that the dose is considered to b valid.
2013-0236	# 2 Pediarix at 7 yrs; # 1 ≥ 12 mo.	42354	F				Not complete	42751	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	44967	44967	44967	HepB	44911	All Valid: Forecast Test	41275	44000.337101377314	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when dose #2 of the Hep B vaccine is administered at 7 years after dose #1 (child is 12 months of age), that the dose is considered to b valid.
2013-0237	# 1 and 2 Pediarix at ≥7 yrs  with 28 day interval.	42326	F				Not complete	44883	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	44995	44995	44995	HepB	44911	Interval: At Minimum	41275	44000.337292523145	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when dose #2 of the Hep B Vaccine (Pediarix) is administered at an interval of 28 days after dose #1 that the dose is considered to be valid. 
2013-0238	# 3 Pediarix at 14 wks-5 days	44818	F				Not complete	44856	PEDIARIX	110	SKB	Valid		44884	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																										4	44986	44999	45423	HepB	44911	All Valid: Forecast Test	41275	44770.72324160879	Recommended based on age		1.0	This test case describes when dose #3 of the HepB vaccine (Pediarix) is administered at 14 weeks - 5 days from dose #2 that the dose is valid.
2013-0239	# 3 Pediarix at 14 wks-4 days	44817	F				Not complete	44857	PEDIARIX	110	SKB	Valid		44885	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																										4	44985	44998	45422	HepB	44911	All Valid: Forecast Test	41275	43140.53532582176	Recommended based on age		1.0	This test case describes when dose #3 of the HepB vaccine (Pediarix) is administered at 14 weeks - 4 days from dose #2 that the dose is not valid.
2013-0241	# 3 Pediarix at 24 weeks-4 days. Valid for dose 3	44747	F				Complete	44789	Hep B, adolescent or pediatric	08		Valid		44850	Hep B, adolescent or pediatric	08		Valid		44911	PEDIARIX	110	SKB	Valid																										-				HepB	44911	Age: At Absolute Minimum	41275	44000.342558958335	Not recommended: series complete		1.0	This test case describes when dose #3 of the HepB vaccine (Pediarix) is administered at 24 weeks - 4 days from dose #2, that the dose is considered to be valid.
2013-0244	# 1 Pediarix at 6 wks-5 days	44874	F				Not complete	44911	PEDIARIX	110	SKB	Valid																																						2	44939	44939	44993	HepB	44911	All Valid: Forecast Test	41275	44000.337414201385	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when dose #1 is administered to a patient at 6 weeks - 5 days, that the dose is considered to be valid.
2013-0251	# 5 Pediarix at 7 yrs	42354	F				Complete	42445	PEDIARIX	110	SKB	Valid		42537	PEDIARIX	110	SKB	Valid		42629	PEDIARIX	110	SKB	Valid		42917	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Extraneous	Series Already Complete													-				HepB	44911	Extra Doses	41275	44572.29088888889	Not recommended: series complete	v4.18  Updated fourth dose Evaluation Status from "Extraneous" to "Valid". ACIP acknowledges a 4 dose HepB series and this dose fits that series.	4.18	This test case describes when dose # 5 of the HepB vaccine (Pediarix) is administered at age 7 years, that the dose is considered to be extraneous. The series is complete.
2013-0255	# 1 Pediarix at 6 wks-4 days	44873	F				Not complete	44911	PEDIARIX	110	SKB	Valid																																						2	44939	44939	44992	HepB	44911	All Valid: Forecast Test	41275	44000.33754201389	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when dose #1 of the HepB vaccine is administered at 6 weeks - 4 days that the dose is considered to be valid.
2013-0256	dose 1 to 2 Pediarix, interval 28-5 days	44827	F				Not complete	44888	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Not Valid	Interval: too short																															2	44939	44939	44945	HepB	44911	Interval: Below Absolute Minimum	41275	44000.33765943287	Recommended based on minimum interval from invalid dose		1.0	This test case describes when dose #2 of the HepB vaccine is administered at an interval of 28 - 5 days that the dose is not valid.
2013-0257	dose 1 to 2 Pediarix, interval 28-4 days	44826	F				Not complete	44887	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	44999	45007	45431	HepB	44911	Interval: At Absolute Minimum	41275	44000.34337949074	Recommended based on age		1.0	This test case describes when dose #2 of the HepB vaccine is administered at an interval of 28 - 4 days that the dose is considered to be valid.
2013-0258	dose 2 to 3 Pediarix, interval 8 weeks-5 days. 4th dose needed.	44743	F				Not complete	44797	PEDIARIX	110	SKB	Valid		44860	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																										4	44916	44927	45350	HepB	44911	All Valid: Forecast Test	41275	43783.272630625	Recommended based on interval	V4.2: Updated Forecast Test Type to "Recommended based on interval"
V4.1: Changed forecast to reflect new 4-dose guidance from CEB.
V3.1: Changed dose 3 from not valid to valid due to recent clarifications.	4.2	This test case describes when dose #3 of the HepB vaccine is administered at an interval of 8 weeks - 5 days that the dose is valid, but a 4th dose is needed to complete the series.
2013-0259	dose 2 to 3 Pediarix, interval 8 weeks-4 days 	44743	F				Complete	44798	PEDIARIX	110	SKB	Valid		44859	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																										-				HepB	44911	Interval: At Absolute Minimum	41275	44000.34350003472	Not recommended: series complete		1.0	This test case describes when dose #3 of the HepB vaccine (Pediarix) is administered at an interval of 8 weeks - 4 days that the dose is considered to be valid. The series is complete.
2013-0262	dose 3 to 4 Pediarix, interval 4 mo-1 day	44485	F				Complete	44546	PEDIARIX	110	SKB	Valid		44608	PEDIARIX	110	SKB	Valid		44789	PEDIARIX	110	SKB	Valid		44910	PEDIARIX	110	SKB	Valid																				-				HepB	44911	All Valid: Forecast Test	41275	44572.293798391205	Not recommended: series complete	v4.18  Updated fourth dose Evaluation Status from "Extraneous" to "Valid". ACIP acknowledges a 4 dose HepB series and this dose fits that series.	4.18	This test case describes when a fourth dose of the HepB vaccine is administered at an interval of 4 months - 1 day from dose 3, that the dose is considered to be valid. The series is complete.
2013-0264	invalid dose 1-2 interval in midst of others	44789	F				Not complete	44850	PEDIARIX	110	SKB	Valid		44869	PEDIARIX	110	SKB	Not Valid	Interval: too short	44911	PEDIARIX	110	SKB	Valid																										3	44967	44973	45394	HepB	44911	Interval: Below Absolute Minimum	41275	43144.35979768518	Recommended based on age		1.0	This test case describes when dose #2 of the HepB vaccine is administered at an interval less than 4 weeks - 4 days in the midst of other valid doses (first and third), that the dose is not valid. 
2013-0266	# 1 Pediarix at 6 wks	44869	F				Not complete	44911	PEDIARIX	110	SKB	Valid																																						2	44939	44939	44988	HepB	44911	All Valid: Forecast Test	41275	44000.33780320602	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when dose # 1 of the HepB vaccine is administered at 6 weeks, that the dose is considered to be valid. 
2013-0267	# 1 Pediarix at 6 yrs 11.5 mo	42370	F				Not complete	44911	PEDIARIX	110	SKB	Valid																																						2	44939	44939	44939	HepB	44911	All Valid: Forecast Test	41275	44000.337894525466	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when dose # 1 of the HepB vaccine is administered at 6 years and 11.5 months that the dose is considered to be valid.
2013-0268	# 1 Pediarix at 7 yrs	42354	F				Not complete	44911	PEDIARIX	110	SKB	Valid																																						2	44939	44939	44939	HepB	44911	All Valid: Forecast Test	41275	44000.338057002315	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when dose #1 of the HepB vaccine (Pediarix) is administered at 7 years that the dose is considered to be valid.
2013-0269	# 2 Pediarix at 10 wks-5 days	44846	F				Not complete	44884	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	45014	45028	45451	HepB	44911	All Valid: Forecast Test	41275	44000.655686412036	Recommended based on age		1.0	This test case describes when dose #2 of the HepB vaccine is administered at an interval of 10 weeks - 5 days, that the dose is considered to be valid. 
2013-0270	# 2 Pediarix at 10 wks-4 days	44845	F				Not complete	44876	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	45013	45027	45450	HepB	44911	All Valid: Forecast Test	41275	43144.3628312037	Recommended based on age		1.0	This test case describes when dose #2 of the HepB vaccine is administered at an interval of 10 weeks - 4 days, that the dose is considered to be valid. 
2013-0271	# 2 Pediarix at 10 wks	44841	F				Not complete	44872	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	45009	45023	45446	HepB	44911	All Valid: Forecast Test	41275	43144.363195949074	Recommended based on age		1.0	This test case describes when dose #2 of the HepB vaccine is administered at an interval of 10 weeks, that the dose is considered to be valid. 
2016-0022	Hep B- Dose #4 administered < 8 weeks after dose #3.	44676	F				Complete	44767	RECOMBIVAX-PEDS	08	MSD	Valid		44831	RECOMBIVAX-PEDS	08	MSD	Valid		44880	RECOMBIVAX-PEDS	08	MSD	Valid		44907	RECOMBIVAX-PEDS	08	MSD	Valid																				-				HepB	44911	All Valid: Forecast Test	42706	44000.34553287037	Recommended based on interval	v3.3: Updated the evaluation type to All Valid: Forecast Test	3.3	This test cases describes when a patient is administered dose #4 at less than 8 weeks after dose #3  and at least 16 weeks after dose #1 that the dose is considered to be valid. The series is complete.
2017-0002	Hep B- Dose #4 administered at 24 weeks of age and at least 16 weeks from dose #1.	44653	F				Complete	44744	PEDIARIX	110	SKB	Valid		44806	PEDIARIX	110	SKB	Valid		44855	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																				-				HepB	44911	All Valid: Forecast Test	42399	44000.34048266204	Not recommended: series complete	Updated dose #3 to valid since the interval is now at 0 days in the third dose of the HepB 4 dose series and the fourth dose was administered at least 16 weeks from dose #1..	3.3	This test case describes when dose #4 of the HepB vaccine is administered  at least 24 weeks of age and at least 16 weeks from dose  #1,  that the dose is considered to be valid. Patient series is complete.
2018-0015	Hep B: Patient is 18 years and has received the first dose of the Hep B (Heplisav) vaccine	38337	F				Not complete	44911	Hep B, adjuvanted	189		Valid																																						2	44939	44939	44966	HepB	44911	Age: At Minimum	43187.833333333336	44000.345697777775	Recommended based on interval		3.4	This test case describes when a patient is administered the first dose of the Hep B (Heplisav) vaccine that the second dose should be forecast.
2018-0016	Hep B: Patient is 18 years and has received the second dose of the Hep B (Heplisav) vaccine at 4 weeks.	38309	F				Complete	44883	Hep B, adjuvanted	189		Valid		44911	Hep B, adjuvanted	189		Valid																																-				HepB	44911	All Valid: Forecast Test	43187.833333333336	44000.65211851852	Not recommended: series complete		3.4	This test case describes that when a patient is administered the second dose of the Hep B (Heplisav) vaccine at 4 weeks that the dose is considered to be valid, and the series is Complete.
2018-0017	Hep B: Patient is 18 years and has received the second dose of the Hep B (Heplisav) vaccine at 4 weeks - 5 days	38314	F				Not complete	44888	Hep B, adjuvanted	189		Valid		44911	Hep B, adjuvanted	189		Not Valid	Interval: too short																															2	44939	44939	44966	HepB	44911	Interval: Below Absolute Minimum	43187.833333333336	44000.34602101852	Recommended based on minimum interval from invalid dose	V3.5: Updated the earliest and recommended forecast to reflect 4 weeks after the second dose.	3.5	This test case describes when a patient is administered the second dose of the Hep B (Heplisav) vaccine at 4 weeks - 5 days that the vaccine dose is not valid. A repeat dose is recommended.
2018-0018	Hep B: Patient is 18 years and has received the second dose of the Hep B  (Heplisav) vaccine at 4 weeks - 4 days.	38313	F				Complete	44887	Hep B, adjuvanted	189		Valid		44911	Hep B, adjuvanted	189		Valid																																-				HepB	44911	All Valid: Forecast Test	43187.833333333336	44000.65250452546	Not recommended: series complete		3.4	This test case describes when a patient is administered the second dose of the Hep B (Heplisav) vaccine at 4 weeks - 4 days that the dose is considered to be valid.  The series is complete.
2018-0019	Hep B: Patient is 18 years - 4 days with first dose of Heplisav	38341	F				Not complete	44911	Hep B, adjuvanted	189		Valid																																						2	44939	44939	44966	HepB	44911	Interval: At Absolute Minimum	43201.833333333336	44000.34659929398	Recommended based on interval		3.4	This test case describes when a patient is administered the first dose of the Hep B (Heplisav) vaccine at 18 years - 4 days, that the dose is considered to be valid.
2018-0020	Hep B: Patient is 18 years and has received a previous dose of Hep B vaccine and one dose of Heplisav B vaccine	38337	F				Not complete	43815	RECOMBIVAX-PEDS	08	MSD	Valid		44911	HEPLISAV-B	189	DVX	Valid																																3	44967	44967	44967	HepB	44911	All Valid: Forecast Test	43201.833333333336	44774.66415429398	Recommended based on interval		3.4	This test case describes when a patient is administered a previous dose of Hep B Vaccine, (at age 15)  and one dose of the Hep B (Heplisav) vaccine that the doses are considered to be valid.  Another dose of the vaccine should be forecasted.
2018-0021	Hep B: Patient is 18 years and has received a previous dose of Hep B vaccine and two doses of Hep B (Heplisav) vaccine	38281	F				Complete	43759	Hep B, adolescent or pediatric	08		Valid		44855	HEPLISAV-B	189	DVX	Valid		44911	HEPLISAV-B	189	DVX	Valid																										-				HepB	44911	All Valid: Forecast Test	43201.833333333336	44000.346974189815	Not recommended: series complete	V4.2: Mild adjustments to relative date settings to avoid administration dates in the future. Test case expectations (e.g, evaluation status or forecast) have not changed.
v4.1: Updated dose #1 to reflect a valid dose based on Ask the Expert guidance
v3.5: Updated dose #1 to reflect an invalid dose reason of Vaccine Dose Administered was administered at too young of an age.	4.2	This test case describes when a patient is administered a previous dose of Hep B vaccine (at age 15) and two doses of the Hep B (Heplisav) vaccine at 8 weeks a part, that the doses are considered valid.  The series is complete.
2018-0022	Hep B: Patient is 18 years - 5 days with first dose of Hep B (Hepislav) vaccine	38342	F				Not complete	44911	HEPLISAV-B	189	DVX	Not Valid	Inadvertent Vaccine																																					1	44911	44911	44911	HepB	44911	Interval: Below Absolute Minimum	43202.833333333336	44375.42110607639	Recommended based on age	v4.1: Updated forecast dates to reflect a 0 day interval for administration of any age appropriate HepB vaccine. 
v4.0: Updated dose #1 to reflect an invalid dose reason of 'Vaccine product was not a preferable or allowable vaccine for this series'.
v3.5: Updated dose #1 to reflect an invalid dose reason of Vaccine Dose Administered was administered at too young of an age.	4.1	This test cases describes when a patient is administered a dose of the Hep B (Heplisav) vaccine at 18 years - 5 days that the dose is not valid.
2018-0023	Hep B: Patient is 18 years and has received a dose of Hep B (Heplisav) vaccine, and one dose of Hep B (alum) 	38309	M				Not complete	44883	HEPLISAV-B	189	DVX	Valid		44911	RECOMBIVAX-PEDS	08	MSD	Valid																																3	44995	44995	44995	HepB	44911	All Valid: Forecast Test	43202.833333333336	44000.33939509259	Recommended based on interval		3.4	This test case describes when a patient is administered Hep B (Heplisav) as a first dose, and Hep B (alum) as a second dose, that a third dose should be forecasted.
2022-0013	Hep B: Patient is 23 years and has not received any doses of the Hep B vaccine	36482	M				Not complete																																											1	36482	36482	36509	HepB	44911	All Valid: Forecast Test	43202.833333333336	44655.527578194444	Recommended based on interval		4.22	This test case describes when a patient that is greater than or equal to 19 years of age has not been administered any dose of the Hep B vaccine, that the first dose should be forecast.
2022-0014	Hep B: Patient is 23 years and has received two doses of the Hep B vaccine	36482	M				Complete	44883	HEPLISAV-B	189	DVX	Valid		44911	HEPLISAV-B	189	DVX	Valid																																				HepB	44911	All Valid: Forecast Test	43202.833333333336	44655.529020208334	Not Recommended: series complete		4.22	This test case describes when an adult patient has been administered two doses of the Hep B (Heplisav) vaccine at least four weeks apart, that the doses are valid and that no further doses should be forecast.  The series is complete.
2022-0015	Hep B: Patient is 41 years and has received a fourth dose of the Hep B vaccine	29814	M				Complete	44789	ENGERIX-B-ADULT	43	SKB	Valid		44817	HEPLISAV-B	189	DVX	Valid		44845	ENGERIX-B-ADULT	43	SKB	Valid		44901	HEPLISAV-B	189	DVX	Valid																								HepB	44911	All Valid: Forecast Test	43202.833333333336	44655.53025819444	Not Recommended: series complete		4.22	This test case describes when an adult patient has been administered four doses of the Hep B vaccine, that no further doses should be forecast.  The series is complete.
2022-0047	Hep B: Patient is 62 years and has been administered the first dose of a Hep B vaccine	22266	M				Not complete	44911	ENGERIX-B-ADULT	43	SKB	Valid																																						2	44939	44939		HepB	44911	All Valid: Forecast Test	43202.833333333336	44798.360952731484	Recommended based on interval		4.26	This test case describes when a patient that is 62 years has been administered the first dose of a HepB vaccine that the dose is valid.  Another dose should be forecast. .
2022-0048	Hep B: Patient is 62 years and has been administered the first and second dose of a Hep B vaccine	22238	M				Not complete	44883	ENGERIX-B-ADULT	43	SKB	Valid		44911	ENGERIX-B-ADULT	43	SKB	Valid																																3	44995	45064		HepB	44911	All Valid: Forecast Test	43202.833333333336	44909.35955324074	Recommended based on interval	v4.29 - Updated the Forecast Earliest and Recommended intervals based on clarification from CDC SME.	4.29	This test case describes when a patient that is 62 years has been administered the first and second doses of a HepB vaccine that the dose are valid.  Another dose should be forecast. .
2022-0049	Hep B: Patient is 62 years and has been administered three doses of a Hep B vaccine	22082	M				Complete	44727	ENGERIX-B-ADULT	43	SKB	Valid		44755	ENGERIX-B-ADULT	43	SKB	Valid		44908	ENGERIX-B-ADULT	43	SKB	Valid																														HepB	44911	All Valid: Forecast Test	43202.833333333336	44798.36341135417	Recommended based on interval		4.26	This test case describes when a patient that is 62 years has been administered three doses of a HepB vaccine that the doses are valid.  No additional doses should be forecast.  The series is complete.
2013-0273	Child<2 months, no shots, #1 forecasted at 2 months of age	44911	F				Not complete																																											1	44953	44973	45028	HIB	44911	No Doses Administered	41275	43980.33862260417	Recommended based on age		1.0	This test case describes when a child < 2 months of age with no history of the Hib vaccine, that the first dose should be forecast.
2013-0274	# 1 at 6 wks-5 days	44874	F				Not complete	44911	ACTHIB	48	PMC	Not Valid	Age: Too Young																																					1	44916	44935	44993	HIB	44911	Age: Below Absolute Minimum	41275	43980.33887962963	Recommended based on age		1.0	This test case describes when a child is administered the first dose of the Hib vaccine at 6 weeks - 5 days that the dose is not valid.  Another dose should be forecast.
2013-0275	# 1 at 6 wks-4 days	44873	F				Not complete	44911	ACTHIB	48	PMC	Valid																																						2	44943	44993	45051	HIB	44911	Age: At Absolute Minimum	41275	43980.339055613425	Recommended based on age		1.0	This test case describes when a child is administered the first dose of the Hib vaccine at 6 weeks - 4 days that the dose is valid.  Another dose should be forecast.
2013-0276	# 1 at 6 wks -3 days	44872	F				Not complete	44911	ACTHIB	48	PMC	Valid																																						2	44942	44992	45050	HIB	44911	All Valid: Forecast Test	41275	43980.33927001157	Recommended based on age		1.0	This test case describes when a child is administered the first dose of the Hib vaccine at 6 weeks - 3 days that the dose is valid.  Another dose should be forecast.
2013-0277	# 1 at 3 months	44820	F				Not complete	44911	ACTHIB	48	PMC	Valid																																						2	44939	44942	45000	HIB	44911	All Valid: Forecast Test	41275	43980.33947369213	Recommended based on age		1.0	This test case describes when a child is administered the first dose of the Hib vaccine at 3 months of age that the dose is valid.  Another dose should be forecast.
2013-0278	#1 at 3 months and 3 days-catchup- #2 recommended at +28 days	44817	F				Not complete	44911	ACTHIB	48	PMC	Valid																																						2	44939	44939	44997	HIB	44911	All Valid: Forecast Test	41275	43980.34001817129	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered the first dose of the Hib vaccine at 3 months and 3 days of age that the dose is valid.  Another dose should be forecast.
2013-0279	#1 at 6 months - catchup- #2 recommended at +28 days	44728	F				Not complete	44911	ACTHIB	48	PMC	Valid																																						2	44939	44939	44939	HIB	44911	All Valid: Forecast Test	41275	43970.689395127316	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered the first of the Hib vaccine at 6 months and a second dose at 28 days later that the doses are valid.
2013-0280	#1 at 7 and <11 months - catchup- drop to 3 dose schedule	44697	F				Not complete	44911	ACTHIB	48	PMC	Valid																																						2	44939	44939	44939	HIB	44911	All Valid: Forecast Test	41275	43970.690969641204	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered the first dose of the Hib vaccine at 7 months that the dose is valid. Another dose should be forecast.
2013-0281	#1 at 12 months, drop to 2-dose schedule	44546	F				Not complete	44911	ACTHIB	48	PMC	Valid																																						2	44967	44967	44967	HIB	44911	All Valid: Forecast Test	41275	43970.69199694444	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was incorrect.  Should be in alignment with the earliest and recommended.  Child is in catch-up schedule.	1.1	This test case describes when a child is administered the first dose of the Hib vaccine at 12 months of age that the dose is valid.  Another dose should be forecast.
2013-0282	#1 at 15m -drop to 1 dose schedule	44455	F				Complete	44911	ACTHIB	48	PMC	Valid																																						-				HIB	44911	All Valid: Forecast Test	41275	43970.69664165509	Not recommended: series complete		1.0	This test case describes when a child is administered the first dose of the Hib vaccine at 15 months of age that the dose is valid.  No additional doses should be forecast. The series is complete.
2013-0283	#1 at 3 years -drop to 1 dose schedule	43815	F				Complete	44911	ACTHIB	48	PMC	Valid																																						-				HIB	44911	All Valid: Forecast Test	41275	43970.696001041666	Not recommended: series complete		1.0	This test case describes when a child is administered a dose of the Hib at 3 years of age that the dose is valid.  No additional doses should be forecast.  The series is complete.
2013-0284	#1 at  5 years	43085	F				Aged out	44911	ACTHIB	48	PMC	Extraneous	Age: Too Old																																					-				HIB	44911	Age: Too Old	41275	43970.69803559028	Not recommended: too old	v1.6: Updated Series Status from "Not Complete" to "Aged Out" to align with updated CDSi Logic Specification Series Statuses.

v1.2:Within the scope of the CDSi effort, Hib on or after 5 years is not recommended.  The last administered dose was changed to Extraneous to reflect this.	1.6	This test case describes when a child is administered the first dose of the Hib vaccine at 5 years that the dose is considered to be extraneous.  No further doses should be forecast.
2013-0285	#1 at 6 years	42720	F				Aged out	44911	ACTHIB	48	PMC	Extraneous	Age: Too Old																																					-				HIB	44911	Age: Too Old	41275	43970.698734363425	Not recommended: too old	v3.5: Lowered Age to be 6 year old to better align with new Age Groupings. No real effective change in test case other than age of patient and vaccination. Expectations remained the same.
v1.6: Updated Series Status from "Not Complete" to "Aged Out" to align with updated CDSi Logic Specification Series Statuses.
v1.2: Within the scope of the CDSi effort, Hib on or after 5 years is not recommended.  The last administered dose was changed to Extraneous to reflect this.	3.5	This test case describes when a child is administered the first dose of the Hib vaccine at age 6 years that the dose is considered to be extraneous.  No further doses should be forecast.
2013-0286	# 2 at 10 wks-5 days	44846	F				Not complete	44884	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Not Valid	Age: Too Young																															2	44939	44969	45024	HIB	44911	Age: Below Absolute Minimum	41275	43970.70191056713	Recommended based on age		1.0	This test case describes when a child is administered the second dose of the Hib vaccine at 10 wks - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0287	# 2 at 10 wks-4 days	44845	F				Not complete	44883	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																																3	44943	45027	45084	HIB	44911	Age: At Absolute Minimum	41275	43970.70316087963	Recommended based on age		1.0	This test case describes when a child is administered the second dose of the Hib vaccine at 10 wks - 4 days that the dose is valid.   Another dose should be forecast.
2013-0288	# 2 at 10 wks -3 days	44844	F				Not complete	44882	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																																3	44942	45026	45083	HIB	44911	All Valid: Forecast Test	41275	43970.70304702546	Recommended based on age		1.0	This test case describes when a child is administered the second dose of the Hib vaccine at 10 wks - 3 days that the dose is valid.  Another dose should be forecast.
2013-0289	# 2 at 4 months	44789	F				Not complete	44850	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																																3	44939	44973	45028	HIB	44911	Age: At Recommended	41275	43970.704203402776	Recommended based on age		1.0	This test case describes when a child is administered the second dose of the Hib vaccine at 4 months that the dose is valid. Another dose should be forecast.
2013-0290	#2 at 5 months	44758	F				Not complete	44820	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																																3	44939	44942	45000	HIB	44911	All Valid: Forecast Test	41275	43973.49633267361	Recommended based on age		1.0	This test case describes when a child is administered the second dose of the Hib vaccine 5 months after the first dose that the dose is valid.  Another dose should be forecast.
2013-0291	#2 at 5 months and 3 days-catchup-#3 at +28 days	44755	F				Not complete	44817	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																																3	44939	44939	44997	HIB	44911	All Valid: Forecast Test	41275	43970.707352453705	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when child is administered the second dose of the Hib vaccine at 5 months and 3 days and the third dose at 28 days later that the doses are valid.
2013-0292	#2 at 12 m - 5 days	44551	F				Not complete	44613	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																																3	44967	44967	45064	HIB	44911	All Valid: Forecast Test	41275	43698.332049606484	Recommended based on minimum interval from previous dose (catch-up)	V4.1: updated forecast dose number from 4 to 3.
V4.0: updated forecast to recommend a dose in 8 weeks - previously 4 weeks - since the patient will be over 12 months old at the time of the next dose and the spacing should be 8 weeks.	4.1	This test case describes when a second dose of Hib is administered to a child at age 12 m- 5 days that the dose is valid. Forecast another dose.
2013-0293	#2 at 12 m - 4 days 	44550	F				Not complete	44612	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																																3	44967	44967	45063	HIB	44911	All Valid: Forecast Test	41275	43970.708476087966	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when child is administered the second dose of the Hib vaccine at 12 months - 4 days that the dose is valid.  Another dose should be forecast.
2013-0294	#2 at 15 months	44455	F				Complete	44516	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																																-				HIB	44911	All Valid: Forecast Test	41275	43970.71128844907	Not recommended: series complete		1.0	This test case describes when child is administered the second dose of the Hib vaccine at 15 months of age that the dose is valid. No further doses should be forecast.  The series is complete.
2013-0295	#2 at 5 years	43085	F				Aged out	43147	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Extraneous	Age: Too Old																															-				HIB	44911	Age: Too Old	41275	43970.71224783565	Not recommended: too old	v1.6: Updated Series Status from "Not Complete" to "Aged Out" to align with updated CDSi Logic Specification Series Statuses.

v1.2: Within the scope of the CDSi effort, Hib on or after 5 years is not recommended.  The last administered dose was changed to Extraneous to reflect this.	1.6	This test case describes when a child is administered the second dose of the Hib vaccine at 5 years of age that the dose is Extraneous.  No further does should be forecast.  The series is complete.
2013-0296	dose 1 to 2, interval 4 weeks -5 days	44827	F				Not complete	44888	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Not Valid	Interval: too short																															2	44939	44949	45007	HIB	44911	Interval: Below Absolute Minimum	41275	43973.50343611111	Recommended based on age		1.0	This test case describes when a child is administered the second dose of the Hib vaccine at an interval of 4 weeks - 5 days that the dose is Extraneous.  No further does should be forecast.  The series is complete.
2013-0297	dose 1 to 2, interval 4 weeks -4 days	44826	F				Not complete	44887	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																																3	44939	45007	45065	HIB	44911	Interval: At Absolute Minimum	41275	43978.35624988426	Recommended based on age		1.0	This test case describes when a child is administered the second dose of the Hib vaccine at an interval of 4 weeks - 4 days that the dose is valid.  Another dose should be forecast.
2013-0298	dose 1 to 2, interval 25 days	44825	F				Not complete	44886	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																																3	44939	45006	45064	HIB	44911	Interval: At Minimum	41275	43978.356703136575	Recommended based on age		1.0	This test case describes when a child is administered the second dose of the Hib vaccine at an interval of 25 days that the dose is valid.  Another dose should be forecast.
2013-0299	#3 at 14 weeks-5 days	44818	F				Not complete	44856	ACTHIB	48	PMC	Valid		44884	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Not Valid	Age: Too Young																									3	44939	44999	45057	HIB	44911	Age: Below Absolute Minimum	41275	43973.52058200232	Recommended based on age	Changed Doses 2 and 3 to be ACTHIB rather than PRP-OMP vaccines to avoid possible confusion with PRP-OMP product specific schedule	1.1	This test case describes when a child is administered the third dose of the Hib vaccine at an interval of 14 weeks - 5 days after the second dose that the dose is not valid.   A repeat dose should be forecast.
2013-0300	#3  at 6 months	44728	F				Not complete	44789	ACTHIB	48	PMC	Valid		44850	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																										4	45093	45093	45242	HIB	44911	Age: At Recommended	41275	43973.52722863426	Recommended based on age		1.0	This test case describes when a child is administered the third dose of the Hib vaccine at an interval of 6 months after the second dose that the dose is valid.  Another dose should be forecast.
2013-0301	Dose 2 to 3, interval 4 weeks-5 days	44762	F				Not complete	44824	ACTHIB	48	PMC	Valid		44885	ACTHIB	48	PMC	Valid		44908	ACTHIB	48	PMC	Not Valid	Interval: too short																									3	44936	44946	45004	HIB	44911	Interval: Below Absolute Minimum	41275	44704.45142136574	Recommended based on age		1.0	This test case describes when a child is administered the third dose of the Hib vaccine at an interval of 4 weeks - 5 days after the second dose  that the dose is not valid.  A repeat dose should be forecast.
2013-0302	Dose 2 to 3, interval 4 weeks -4 days	44761	F				Not complete	44823	ACTHIB	48	PMC	Valid		44884	ACTHIB	48	PMC	Valid		44908	ACTHIB	48	PMC	Valid																										4	45126	45126	45276	HIB	44911	Interval: At Absolute Minimum	41275	44704.45181936343	Recommended based on age		1.0	This test case describes when a child is administered the third dose of the Hib vaccine at an interval of 4 weeks - 4 days after the second dose  that the dose is valid.  Another dose should be forecast.
2013-0303	Dose 2 to 3, interval 4 weeks	44760	F				Not complete	44822	ACTHIB	48	PMC	Valid		44883	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																										4	45125	45125	45275	HIB	44911	Interval: At Minimum	41275	43973.528661296295	Recommended based on age		1.0	This test case describes when a child is administered the third dose of the Hib vaccine at an interval of 4 weeks after the second dose that the dose is valid.  Another dose should be forecast.
2013-0304	#4 at 12 months - 5 days of age, interval between #3-4 >8 weeks	44551	F				Not complete	44613	ACTHIB	48	PMC	Valid		44672	ACTHIB	48	PMC	Valid		44733	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Not Valid	Age: Too Young																			4	44967	44967	45064	HIB	44911	Age: Below Absolute Minimum	41275	43973.53325741898	Recommended based on minimum interval from inValid dose		1.0	This test case describes when a child is administered the fourth dose of the Hib vaccine at age 12 months -5 days and at an interval of 4 - 8 weeks after the third dose that the dose is not valid.  A repeat dose should be forecast.
2013-0305	#4 at 12 months - 4 days of age, interval between #3-4 >8 weeks	44550	F				Complete	44612	ACTHIB	48	PMC	Valid		44671	ACTHIB	48	PMC	Valid		44732	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																				-				HIB	44911	Age: At Absolute Minimum	41275	43978.358941053244	Not recommended: series complete		1.0	This test case describes when a child is administered the fourth dose of the Hib vaccine at age 12 months -4 days and at an interval of 4 - 8 weeks after the third dose that the dose is valid. The series is complete.
2013-0306	#4 at 12 months - 3 days of age, interval between #3-4 >8 weeks	44549	F				Complete	44611	ACTHIB	48	PMC	Valid		44670	ACTHIB	48	PMC	Valid		44731	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																				-				HIB	44911	All Valid: Forecast Test	41275	43978.3590640162	Not recommended: series complete		1.0	This test case describes when a child is administered the fourth dose of the Hib vaccine at age 12 months -3 days and at an interval of 4 - 8 weeks after the third dose that the dose is valid. The series is complete.
2013-0307	#4 at 15 months of age, interval between #3-4 > 8 weeks	44455	F				Complete	44516	ACTHIB	48	PMC	Valid		44577	ACTHIB	48	PMC	Valid		44636	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																				-				HIB	44911	All Valid: Forecast Test	41275	43973.541696064814	Not recommended: series complete		1.0	This test case describes when a child is administered the fourth dose of the Hib vaccine at age 15 months and at an interval of 4 - 8 weeks after the third dose that the dose is valid. The series is complete.
2013-0308	#4 at 12 months of age, interval between #3-4 8 weeks -5 days	44546	F				Not complete	44608	ACTHIB	48	PMC	Valid		44667	ACTHIB	48	PMC	Valid		44860	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Not Valid	Interval: too short																			4	44967	44967	45059	HIB	44911	Interval: Below Absolute Minimum	41275	43973.54235782407	Recommended based on minimum interval from inValid dose		1.0	This test case describes when a child is administered the fourth dose of the Hib vaccine at age 12 months and at an interval of 4 - 8 weeks - 5 days  after the third dose that the dose is not valid. A repeat dose should be forecast.
2013-0309	#4 at 12 months of age, interval between #3-4 8 weeks -4 days	44546	F				Complete	44608	ACTHIB	48	PMC	Valid		44667	ACTHIB	48	PMC	Valid		44859	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																				-				HIB	44911	Interval: At Absolute Minimum	41275	43978.35977311343	Not recommended: series complete		1.0	This test case describes when a child is administered the fourth dose of the Hib vaccine at age 12 months and at an interval of 4 - 8 weeks - 4 days  after the third dose that the dose is valid.  The series is complete.
2013-0310	# 4 at 15 months of age	44452	F				Complete	44513	ACTHIB	48	PMC	Valid		44574	ACTHIB	48	PMC	Valid		44664	ACTHIB	48	PMC	Valid		44908	ACTHIB	48	PMC	Valid																				-				HIB	44911	Age: At Recommended	41275	44592.40058353009	Not recommended: series complete		1.0	This test case describes when a child is administered the fourth dose of the Hib vaccine at age 15 months that the dose is valid.  The series is complete.
2013-0313	#4 at 5 years	43085	F				Aged out	43147	ACTHIB	48	PMC	Valid		43206	ACTHIB	48	PMC	Valid		43297	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Extraneous	Age: Too Old																			-				HIB	44911	Age: Too Old	41275	43977.46839903935	Not recommended: too old	v1.6: Updated Series Status from "Not Complete" to "Aged Out" to align with updated CDSi Logic Specification Series Statuses.

v1.2: Within the scope of the CDSi effort, Hib on or after 5 years is not recommended.  The last administered dose was changed to Extraneous to reflect this.	1.6	This test case describes when a child is administered the fourth dose of the Hib vaccine at 5 years of age that the dose is considered to be Extraneous.  No further doses should be forecast.  Series is complete.
2013-0314	#4 at 7 years	42720	F				Aged out	42782	ACTHIB	48	PMC	Valid		42841	ACTHIB	48	PMC	Valid		42963	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Extraneous	Age: Too Old																			-				HIB	44911	Age: Too Old	41275	43977.4682549537	Not recommended: too old	V3.5: Lowered age of last vaccination from 7 years to 6 years to better align with new Age Groupings. No impact on test case expectations.
v1.6: Updated Series Status from "Not Complete" to "Aged Out" to align with updated CDSi Logic Specification Series Statuses.
v1.2: Within the scope of the CDSi effort, Hib on or after 5 years is not recommended.  The last administered dose was changed to Extraneous to reflect this.	3.5	This test case describes when a child is administered the fourth dose of the Hib vaccine at 7 years of age that the dose is considered to be Extraneous.  No further doses should be forecast.  Series is complete.
2013-0315	Child<2 months, no shots, #1 forecasted at 2 months of age	44911	F				Not complete																																											1	44953	44973	45028	HIB	44911	No Doses Administered	41275	43977.47881083333	Recommended based on age		1.0	This test case describes when a child is less than two months of age and has not received any doses of the Hib vaccine that the first dose should be forecast at 2 months of age.
2013-0317	# 2 at 10 wks-4 days, PRP-OMP series	44845	F				Not complete	44883	PEDVAXHIB	49	MSD	Valid		44911	PEDVAXHIB	49	MSD	Valid																																3	45210	45210	45360	HIB	44911	Interval: At Absolute Minimum	41275	43977.48326440972	Recommended based on age		1.0	This test case describes when a child is administered a second dose of the HIb vaccine at 10 weeks - 4 days that the dose is valid.  Another dose should be forecast.
2013-0318	# 2 at 10 wks-3 days, PRP-OMP series	44844	F				Not complete	44882	PEDVAXHIB	49	MSD	Valid		44911	PEDVAXHIB	49	MSD	Valid																																3	45209	45209	45359	HIB	44911	All Valid: Forecast Test	41275	43977.48480923611	Recommended based on age		1.0	This test case describes when a child is administered a second dose of the HIb vaccine at 10 weeks - 3 days that the dose is valid.  Another dose should be forecast.
2013-0319	# 2 at 12 months	44546	F				Not complete	44608	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																																3	44967	44967	45059	HIB	44911	All Valid: Forecast Test	41275	43977.49349443287	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered the second dose of the Hib vaccine at 12 months that the dose is valid.  Another dose should be forecast.
2013-0320	#3 at 5m (#1, #2 at 2 and 4m)	44758	F				Not complete	44820	ACTHIB	48	PMC	Valid		44881	PEDVAXHIB	49	MSD	Valid		44911	ACTHIB	48	PMC	Valid																										4	45123	45123	45273	HIB	44911	All Valid: Forecast Test	41275	43977.531107222225	Recommended based on age		1.0	This test case describes when a child is administered a third dose of the Hib vaccine at 5 months that the dose is valid.  Another dose should be forecast.
2013-0321	#3 at 10 months and 9 days (#1,2 at 2 and 3 m)	44599	F				Not complete	44658	ACTHIB	48	PMC	Valid		44688	ACTHIB	48	PMC	Valid		44911	PEDVAXHIB	49	MSD	Valid																										4	44967	44967	45111	HIB	44911	All Valid: Forecast Test	41275	43980.34307672454	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered a third dose of the Hib vaccine at 10 months that the dose is valid.  Another dose should be forecast.
2013-0322	#3 at 11 months	44577	F				Not complete	44636	ACTHIB	48	PMC	Valid		44697	PEDVAXHIB	49	MSD	Valid		44911	ACTHIB	48	PMC	Valid																										4	44967	44967	45089	HIB	44911	All Valid: Forecast Test	41275	43980.34318443287	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered a third dose of the Hib vaccine at 11 months that the dose is valid.  Another dose should be forecast.
2013-0323	#3 at 12 months -5 days	44551	F				Not complete	44613	ACTHIB	48	PMC	Valid		44672	ACTHIB	48	PMC	Valid		44911	PEDVAXHIB	49	MSD	Valid																										4	44967	44967	45064	HIB	44911	All Valid: Forecast Test	41275	43980.34349290509	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered a third dose of the Hib vaccine at 12 months - 5 days that the dose is valid.  Another dose should be forecast.
2013-0324	#3 at 12 months - 3 days	44549	F				Complete	44611	ACTHIB	48	PMC	Valid		44670	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																										-				HIB	44911	All Valid: Forecast Test	41275	43980.344341585645	Not recommended: series complete	V3.5: Patient's age was incorrect.  Age should have been 12 Months, not 12 years. No effective change to test case.
V1.1: This patient should have been marked complete for Hib.  No Further Doses Needed.	3.5	This test case describes when a child is administered a third dose of the Hib vaccine at 12 months - 3 days that the dose is valid and the patient is complete
2013-0325	#3 at 15 months	44455	F				Complete	44516	ACTHIB	48	PMC	Valid		44577	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																										-				HIB	44911	All Valid: Forecast Test	41275	43977.57185969908	Not recommended: series complete		1.0	This test case describes when a child is administered a third dose of the Hib vaccine at 15 months that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0326	#3 at 59 months	43086	F				Complete	43148	ACTHIB	48	PMC	Valid		43207	PEDVAXHIB	49	MSD	Valid		44911	ACTHIB	48	PMC	Valid																										-				HIB	44911	All Valid: Forecast Test	41275	43977.58035966435	Not recommended: series complete		1.0	This test case describes when a child is administered a third dose of the Hib vaccine at 59 months that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0327	#1 at 7 months-5 days	44702	F				Not complete	44911	ACTHIB	48	PMC	Valid																																						2	44939	44939	44939	HIB	44911	All Valid: Forecast Test	41275	43980.34501376157	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered the first dose of the Hib vaccine at 7 months-5 days that the dose is valid.  Another dose should be forecast.
2013-0328	#1 at 7 months- 3 days	44700	F				Not complete	44911	ACTHIB	48	PMC	Valid																																						2	44939	44939	44939	HIB	44911	All Valid: Forecast Test	41275	43977.59639767361	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was incorrect.  Should be in alignment with the earliest and recommended.  Child is in catch-up schedule.	1.1	This test case describes when a child is administered the first dose of the Hib vaccine at 7 months-3 days that the dose is valid.  Another dose should be forecast.
2013-0329	Dose 2 to 3, interval 8 weeks -3 days, #3 after 12 months of age	44540	F				Complete	44602	ACTHIB	48	PMC	Valid		44858	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																										-				HIB	44911	All Valid: Forecast Test	41275	43977.60356447917	Not recommended: series complete	This patient should have been marked complete for Hib.  No Further Doses Needed.	1.1	This test case describes when a child is administered the second and third  dose of the Hib vaccine at 8 weeks - 3 days and after 12 months of age that the doses are valid.  No further doses of the Hib vaccine should be forecast.  The series is complete.
2013-0330	# 1 at 7 months -4 days	44701	F				Not complete	44911	ACTHIB	48	PMC	Valid																																						2	44939	44939	44939	HIB	44911	All Valid: Forecast Test	41275	43977.67117368056	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was incorrect.  Should be in alignment with the earliest and recommended.  Child is in catch-up schedule.	1.1	This test case describes when a child is administered the first dose of the Hib vaccine at 7 months- 4 days that the dose is valid.  Another dose should be forecast.
2013-0331	# 1 at 12 months minus 5 days	44551	F				Not complete	44911	ACTHIB	48	PMC	Valid																																						2	44939	44939	44939	HIB	44911	All Valid: Forecast Test	41275	43977.60691726852	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered the first dose of the Hib vaccine at 12 months- 5 days that the dose is valid.  Another dose should be forecast.
2013-0332	# 1 at 12 months -4 days	44550	F				Not complete	44911	ACTHIB	48	PMC	Valid																																						2	44967	44967	44967	HIB	44911	All Valid: Forecast Test	41275	43977.619875833334	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was incorrect.  Should be in alignment with the earliest and recommended.  Child is in catch-up schedule.	1.1	This test case describes when a child is administered the first dose of the Hib vaccine at 12 months- 4 days that the dose is valid.  Another dose should be forecast.
2013-0333	# 1 at 12 months -3 days	44549	F				Not complete	44911	ACTHIB	48	PMC	Valid																																						2	44967	44967	44967	HIB	44911	All Valid: Forecast Test	41275	43977.621986342594	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was incorrect.  Should be in alignment with the earliest and recommended.  Child is in catch-up schedule.	1.1	This test case describes when a child is administered the first dose of the Hib vaccine at 12 months- 3 days that the dose is valid.  Another dose should be forecast.
2013-0334	#2 at 7 m and 23 days (#1 at 7 m)	44674	F				Not complete	44888	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Not Valid	Interval: too short																															2	44939	44939	44939	HIB	44911	Interval: Below Absolute Minimum	41275	43977.64256028935	Recommended based on minimum interval from invalid dose		1.0	This test case describes when a child is administered the second dose of the Hib vaccine at 7 months and 23 days that the dose is not valid.  A repeat dose should be forecast.
2013-0335	#2 at 7 m and 24 days (#1 at 7 m)	44673	F				Not complete	44887	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																																3	45038	45038	45187	HIB	44911	Interval: At Absolute Minimum	41275	43980.345966215275	Recommended based on age		1.0	This test case describes when a child is administered the second dose of the Hib vaccine at 7 months and 24 days that the dose is valid. Another dose should be forecast.
2013-0336	#2 at 11 m (#1 at 7 m)	44577	F				Not complete	44789	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																																3	44967	44967	45089	HIB	44911	All Valid: Forecast Test	41275	43977.63297824074	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered the second dose of the Hib vaccine at 11 months that the dose is valid.  Another dose should be forecast.
2013-0337	#2 at 12 m  (#1 at 7 m)	44546	F				Not complete	44758	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																																3	44967	44967	45059	HIB	44911	All Valid: Forecast Test	41275	43977.63338315972	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered the second dose of the Hib vaccine at 12 months that the dose is valid.  Another dose should be forecast.
2013-0338	#3 at 365 d -5 days (#1 at 7m, #2 at 8m)	44551	F				Not complete	44763	ACTHIB	48	PMC	Valid		44794	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Not Valid	Age: Too Young																									3	44967	44967	45064	HIB	44911	Age: Below Absolute Minimum	41275	43977.64017479167	Recommended based on minimum interval from invalid dose	Dose 3 was too young by 1 day according to the cath-up schedule.  Evaluation of dose 3 was changed from valid to not valid with a reason of Age: Too Young which aligns with original test case evaluation test type and forecast test type	1.2	This test case describes when a child is administered the third dose of the Hib vaccine at 365 days - 5 days that the dose is not valid.  Another dose should be forecast.
2013-0339	#3 at 365 d -4 days (#1 at 7m, #2 at 8m)	44550	F				Complete	44762	ACTHIB	48	PMC	Valid		44793	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																										-				HIB	44911	Age: At Absolute Minimum	41275	43977.64213541667	Not recommended: series complete		1.0	This test case describes when a child is administered the third dose of the Hib vaccine at 365 days - 4 days that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0340	#3 at 365 days - 3 days (#1 at 7m, #2 at 8m)	44549	F				Complete	44761	ACTHIB	48	PMC	Valid		44792	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																										-				HIB	44911	All Valid: Forecast Test	41275	43977.67444621528	Not recommended: series complete		1.0	This test case describes when a child is administered the third dose of the Hib vaccine at 365 days - 3 days that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0341	#3 at 59 months (#1 at 7m, #2 at 8m)	43116	F				Complete	43328	ACTHIB	48	PMC	Valid		43359	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																										-				HIB	44911	All Valid: Forecast Test	41275	43977.67606327546	Not recommended: series complete		1.0	This test case describes when a child is administered the third dose of the Hib vaccine at 59 months that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0342	#3 at 5 years (#1 at 7m, #2 at 8m)	43085	F				Aged out	43297	ACTHIB	48	PMC	Valid		43328	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Extraneous	Age: Too Old																									-				HIB	44911	Age: Too Old	41275	43978.636680891206	Not recommended: too old	v1.6: Updated Series Status from "Not Complete" to "Aged Out" to align with updated CDSi Logic Specification Series Statuses.

v1.2: Within the scope of the CDSi effort, Hib on or after 5 years is not recommended.  The last administered dose was changed to Extraneous to reflect this.	1.6	This test case describes when a child is administered the third dose of the Hib vaccine at 5 years that the dose is extraneous.  No further doses should be forecast.  The series is complete
2013-0343	Dose 2 to 3, interval 8 weeks-5 days, #3 after 12 months of age	44509	F				Not complete	44570	ACTHIB	48	PMC	Valid		44857	PEDVAXHIB	49	MSD	Valid		44908	PEDVAXHIB	49	MSD	Not Valid	Interval: too short																									3	44964	44964	45021	HIB	44911	All Valid: Forecast Test	41275	43980.34721552084	Recommended based on minimum interval from previous dose (catch-up)	Dose 3 should be invalid due to an interval violation	1.1	This test case describes when a child greater than 12 months of age is administered a third dose of the Hib vaccine at an interval of 8 weeks - 5 days from the second dose that the dose is not valid.  Another dose should be forecast.
2013-0344	Dose 2 to 3, interval 8 weeks -4 days, #3 after 12 months of age	44509	F				Complete	44570	ACTHIB	48	PMC	Valid		44857	PEDVAXHIB	49	MSD	Valid		44909	PEDVAXHIB	49	MSD	Valid																										-				HIB	44911	All Valid: Forecast Test	41275	43978.64670828704	Not recommended: series complete		1.0	This test case describes when a child greater than 12 months of age is administered a third dose of the Hib vaccine at an interval of 8 weeks - 4 days from the second dose that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0346	#1 at 15 months -5 days	44460	F				Not complete	44911	ACTHIB	48	PMC	Valid																																						2	44967	44967	44967	HIB	44911	All Valid: Forecast Test	41275	43978.64860746528	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was incorrect.  Should be in alignment with the earliest and recommended.  Child is in catch-up schedule.	1.1	This test case describes when a child is administered the first dose of the Hib vaccine at 15 months - 5 days that the dose is valid.  Another dose should be forecast.
2013-0347	#1 at 15 months -4 days	44459	F				Complete	44911	ACTHIB	48	PMC	Valid																																						-				HIB	44911	All Valid: Forecast Test	41275	43980.347485590275	Not recommended: series complete		1.0	This test case describes when a child is administered the first dose of the Hib vaccine at 15 months - 4 days that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0348	Dose 1 to 2 at 8 weeks -5 days (#1 at 1 year)	44495	F				Not complete	44860	ACTHIB	48	PMC	Valid		44911	PEDVAXHIB	49	MSD	Not Valid	Interval: too short																															2	44967	44967	44967	HIB	44911	Interval: Below Absolute Minimum	41275	43978.65258084491	Recommended based on minimum interval from invalid dose	Condensed the past due date to align with the earliest and recommended date since this child is in catch-up	1.2	This test case describes when a child greater than 12 months of age is administered a second dose of the Hib vaccine at an interval of 8 weeks - 5 days from the first dose that the dose is not valid.  Another dose should be forecast.
2013-0349	Dose 1 to 2 at 8 weeks -4 days (#1 at >=1 year)	44494	F				Complete	44859	HIBERIX	48	SKB	Valid		44911	HIBERIX	48	SKB	Valid																																-				HIB	44911	Interval: At Absolute Minimum	41275	43978.66424681713	Not recommended: series complete		1.0	This test case describes when a child greater than 12 months of age is administered a second dose of the Hib vaccine at an interval of 8 weeks - 4 days from the first dose that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0350	Dose 1 to 2 at 8 weeks - 3 days (#1 at >=1 year)	44493	F				Complete	44858	ACTHIB	48	PMC	Valid		44911	Hib (PRP-OMP)	49		Valid																																-				HIB	44911	Interval: At Absolute Minimum	41275	43978.664892256944	Not recommended: series complete		1.0	This test case describes when a child greater than 12 months of age is administered a second dose of the Hib vaccine at an interval of 8 weeks - 3 days from the first dose that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0351	# 3 (#1 at  one year, #2 at 15 months)	44398	F				Complete	44763	ACTHIB	48	PMC	Valid		44855	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Extraneous	Series Already Complete																									-				HIB	44911	Extra Doses	41275	43978.67474180555	Not recommended: series complete		1.0	This test case describes when a child is administered a first dose of the Hib vaccine at one year of age, a second dose of the Hib vaccine at 15 months of age, and a third dose at greater than 15 months that the third dose is extraneous.  No further doses should be forecast.  The series is complete.
2013-0352	# 1 at 15 m - 3 days	44458	F				Complete	44911	ACTHIB	48	PMC	Valid																																						-				HIB	44911	All Valid: Forecast Test	41275	43978.678304085646	Not recommended: series complete		1.0	This test case describes when a child is administered a first dose of the Hib vaccine at 15 months - 3 days that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0353	# 1 at 5 years - 1 day	43086	F				Complete	44911	ACTHIB	48	PMC	Valid																																						-				HIB	44911	All Valid: Forecast Test	41275	43978.67947292824	Not recommended: series complete		1.0	This test case describes when a child is administered a first dose of the Hib vaccine at 5 years - 1 day that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0354	#2 at 2 years, #1 at 15 m	44181	F				Complete	44636	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Extraneous	Series Already Complete																															-				HIB	44911	Extra Doses	41275	43978.68462635417	Not recommended: series complete		1.0	This test case describes when a child is administered a first dose of the Hib vaccine at 15 months and a second dose at 2 years that the second dose is extraneous. No further doses should be forecast.  The series is complete.
2013-0355	#2 at 5 months	44758	F				Not complete	44820	ACTHIB	48	PMC	Valid		44911	ACTHIB	48	PMC	Valid																																3	44939	44942	45000	HIB	44911	All Valid: Forecast Test	41275	43978.68580439815	Recommended based on age		1.0	This test case describes when a child is administered a second dose of the Hib vaccine at 5 months that the dose is valid. Another dose should be forecast.
2013-0356	# 2 Pentacel at 6 yrs 11.5 mo.	42371	F				Complete	43366	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Extraneous	Series Already Complete																															-				HIB	44911	Age: Too Old	41275	43980.34869543982	Not recommended: series complete		1.0	This test case describes when a child is administered a first dose of the Hib vaccine at  2 years of age and a second dose at 6 years, 11.5 months that the second dose is extraneous.  No further doses should be forecast.  The series is complete.
2013-0357	# 3 Pentacel at 14 wks-5 days	44818	F				Not complete	44856	PENTACEL	120	PMC	Valid		44884	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Not Valid	Age: Too Young																									3	44939	44999	45057	HIB	44911	Age: Below Absolute Minimum	41275	43980.538178773146	Recommended based on age	Past Due Date was incorrectly calculated as it was missing the 4 week buffer for overdue.	1.1	This test case describes when a child is administered a third dose of the Hib vaccine at an interval of 14 weeks - 5 days from the previous dose that the dose is not valid.  Another dose should be forecast.
2013-0358	invalid age dose 1 as first of others	44728	F				Not complete	44763	PENTACEL	120	PMC	Not Valid	Age: Too Young	44850	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																										3	44939	44939	44969	HIB	44911	Age: Below Absolute Minimum	41275	43980.57375962963	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered the first dose of the Hib vaccine at less than 6 weeks - 4 days of age that the dose is not valid.
2013-0359	dose 1 to 2 Pentacel, interval 28-4 days	44824	F				Not complete	44887	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																																3	44939	45005	45063	HIB	44911	Interval: At Absolute Minimum	41275	43980.57808508102	Recommended based on age	Past Due Date was incorrectly calculated as it was missing the 4 week buffer for overdue.	1.1	This test case describes when a child is administered a second dose of the Hib vaccine at 28-4 days from the first dose that the dose is valid.  Another dose should be forecast.
2013-0360	dose 2 to 3 Pentacel, interval 28-5 days	44763	F				Not complete	44825	PENTACEL	120	PMC	Valid		44886	PENTACEL	120	PMC	Valid		44909	PENTACEL	120	PMC	Not Valid	Interval: too short																									3	44937	44947	45005	HIB	44911	Interval: Below Absolute Minimum	41275	44704.452225347224	Recommended based on age	Past Due Date was incorrectly calculated as it was missing the 4 week buffer for overdue.	1.1	This test case describes when a child is administered a third dose of the Hib vaccine at 28-5 days from the second dose that the dose is not valid.  A repeat dose should be forecast.
2013-0365	# 1 Pentacel at 6 wks	44869	F				Not complete	44911	PENTACEL	120	PMC	Valid																																						2	44939	44989	45047	HIB	44911	Age: At Minimum	41275	43980.588159733794	Recommended based on age		1.0	This test case describes when a child is administered the first dose of the Hib vaccine at 6 weeks that the dose is valid.  Another dose should be forecast.
2013-0366	# 1 Pentacel at 6 wks-4 days	44873	F				Not complete	44911	PENTACEL	120	PMC	Valid																																						2	44943	44993	45051	HIB	44911	Age: At Absolute Minimum	41275	43980.58918005787	Recommended based on age		1.0	This test case describes when a child is administered the first dose of the Hib vaccine at 6 weeks - 4 days that the dose is valid.  Another dose should be forecast.
2013-0367	# 1 Pentacel at 6 wks-5 days.  	44874	F				Not complete	44911	PENTACEL	120	PMC	Not Valid	Age: Too Young																																					1	44916	44935	44993	HIB	44911	Age: Below Absolute Minimum	41275	43980.589986747684	Recommended based on age		1.0	This test case describes when a child is administered the first dose of the Hib vaccine at 6 weeks - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0368	# 2 Pentacel at 10 wks-4 days	44845	F				Not complete	44883	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																																3	44943	45027	45084	HIB	44911	Age: At Absolute Minimum	41275	43980.59167585648	Recommended based on age		1.0	This test case describes when a child is administered the second dose of the Hib vaccine at 10 weeks -4 days that the dose is  valid.  Another dose should be forecast.
2013-0369	# 2 Pentacel at 10 wks-5 days	44846	F				Not complete	44884	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Not Valid	Age: Too Young																															2	44939	44969	45024	HIB	44911	Age: Below Absolute Minimum	41275	43980.592821261576	Recommended based on age		1.0	his test case describes when a child is administered the second dose of the Hib vaccine at 10 weeks - 5 days that the dose is  not valid.  A repeat dose should be forecast.
2013-0370	# 3 Pentacel at 14 wks-4 days	44817	F				Not complete	44855	PENTACEL	120	PMC	Valid		44883	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																										4	45182	45182	45331	HIB	44911	Age: At Absolute Minimum	41275	43980.59458575232	Recommended based on age	Past Due Date was incorrect based on recommendations.	1.1	This test case describes when a child is administered the third dose of the Hib vaccine at 14 weeks - 4 days that the dose is   valid.  Another dose should be forecast.
2013-0371	# 4 Pentacel ≥ age 12 mo	44546	F				Complete	44608	PENTACEL	120	PMC	Valid		44667	PENTACEL	120	PMC	Valid		44728	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																				-				HIB	44911	Age: At Minimum	41275	43980.59887354167	Not recommended: series complete		1.0	This test case describes when a child is administered the fourth dose of the Hib vaccine at 12 months of age that the dose is   valid.  No further doses should be forecast.  The series is complete.
2013-0372	# 4 Pentacel at 1 yr -4 days	44550	F				Complete	44612	PENTACEL	120	PMC	Valid		44671	PENTACEL	120	PMC	Valid		44732	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																				-				HIB	44911	Age: At Absolute Minimum	41275	43980.60047568287	Not recommended: series complete		1.0	This test case describes when a child is administered the fourth dose of the Hib vaccine at 1 year - 4 days of age that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0373	# 4 Pentacel at 1 yr -5 days.  	44551	F				Not complete	44613	PENTACEL	120	PMC	Valid		44672	PENTACEL	120	PMC	Valid		44714	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Not Valid	Age: Too Young																			4	44967	44967	45064	HIB	44911	Age: Below Absolute Minimum	41275	43980.60089094908	Recommended based on minimum interval from invalid dose	Past Due Date was incorrect based on recommendations.	1.1	This test case describes when a child is administered the fourth dose of the Hib vaccine at 1 year - 5 days of age that the dose is not valid.  A repeat dose should be forecast.
2013-0374	# 4 Pentacel at 4 yrs	43446	F				Complete	43576	PENTACEL	120	PMC	Valid		43803	PENTACEL	120	PMC	Valid		44760	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Extraneous	Series Already Complete																			-				HIB	44911	Extra Doses	41275	43980.60197199074	Not recommended: series complete		1.0	This test case describes when a child is administered the fourth dose of the Hib vaccine at 4 years of age that the dose is extraneous. No further dose should be forecast.  The series is complete.
2013-0375	# 4 Pentacel at 5 yrs	43085	F				Aged out	43206	PENTACEL	120	PMC	Valid		43386	PENTACEL	120	PMC	Valid		43445	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Extraneous	Age: Too Old																			-				HIB	44911	Age: Too Old	41275	43980.606660590274	Not recommended: too old	v1.6: Updated Series Status from "Not Complete" to "Aged Out" to align with updated CDSi Logic Specification Series Statuses.

v1.1: Changed Dose 3 vaccination date from 2/7/08 to 2/3/08 to avoid completion of series on dose 3 to properly test off-label usage on dose 4 as test case name indicates.  Within the scope of the CDSi effort, Hib on or after 5 years is not recommended.  The last administered dose was changed to Extraneous to reflect this.	1.6	This test case describes when a child is administered the fourth dose of the Hib vaccine (Pentacel) at 5 years of age that the dose is extraneous. No further dose should be forecast.  The series is complete.
2013-0376	# 5 Pentacel at ≥ 4 yrs is off label but counts	43428	F				Complete	43762	PENTACEL	120	PMC	Valid		43854	PENTACEL	120	PMC	Valid		43945	PENTACEL	120	PMC	Valid		44099	PENTACEL	120	PMC	Extraneous	Series Already Complete	44911	PENTACEL	120	PMC	Extraneous	Series Already Complete													-				HIB	44911	Extra Doses	41275	43980.60617273148	Not recommended: series complete		1.0	This test case describes when a child is administered a fifth dose of the Hib vaccine (Pentacel) at greater than or equal to 4 years of age that the dose is extraneous. No further dose should be forecast.  The series is complete.
2013-0378	dose 1 to 2 Pentacel, interval 28-5 days	44833	F				Not complete	44888	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Not Valid	Interval: too short																															2	44939	44955	45013	HIB	44911	Interval: Below Absolute Minimum	41275	43980.60931020833	Recommended based on age		1.0	This test case describes when a child is administered the second dose of the Hib vaccine (Pentacel) at 28-5 days after the previous dose that the dose is not valid.  A repeat dose should be forecast.
2013-0379	dose 2 to 3 Pentacel, interval 28-4 days	44762	F				Not complete	44824	PENTACEL	120	PMC	Valid		44885	PENTACEL	120	PMC	Valid		44909	PENTACEL	120	PMC	Valid																										4	45127	45127	45277	HIB	44911	Interval: At Absolute Minimum	41275	44704.45240930556	Recommended based on age	Past Due Date was incorrect based on recommendations.	1.1	This test case describes when a child is administered the third dose of the Hib vaccine (Pentacel) at 28-4 days from the second dose that the dose is valid.  Another dose should be forecast.
2013-0380	invalid age dose 2 in midst of others	44544	F				Complete	44582	PENTACEL	120	PMC	Valid		44609	PENTACEL	120	PMC	Not Valid	Age: Too Young	44685	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																				-				HIB	44911	Age: Below Absolute Minimum	41275	43980.6149428125	Not recommended: series complete	This patient should have been marked complete for Hib.  No Further Doses Needed.	1.1	This test case describes when a child is administered the second dose of the Hib vaccine at less than 10 weeks - 4 days of age that the dose is not valid.
2013-0381	invalid age dose 3 in midst of others	44510	F				Complete	44548	PENTACEL	120	PMC	Valid		44576	PENTACEL	120	PMC	Valid		44603	PENTACEL	120	PMC	Not Valid	Age: Too Young	44911	PENTACEL	120	PMC	Valid																				-				HIB	44911	Age: Below Absolute Minimum	41275	43980.61768618056	Not recommended: series complete	This patient should have been marked complete for Hib.  No Further Doses Needed.	1.1	This test case describes when a child is administered the third dose of the Hib vaccine at less than 14 weeks - 4 days of age that the dose is not valid.
2013-0382	invalid dose 1-2 interval in midst of others	44737	F				Not complete	44798	PENTACEL	120	PMC	Valid		44821	PENTACEL	120	PMC	Not Valid	Interval: too short	44911	PENTACEL	120	PMC	Valid																										3	44939	44939	44978	HIB	44911	Interval: Below Absolute Minimum	41275	43980.6197640625	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered the second dose of the Hib vaccine at an interval less than 4 weeks - 4 days that the dose is not valid.
2013-0383	Newborn	44911	F				Not complete																																											1	44953	44973	45028	HIB	44911	No Doses Administered	41275	43980.6213468287	Recommended based on age		1.0	This test case describes when a child is a newborn and has not received any doses of the Hib vaccine that the first dose should be forecast at 2 months of age.
2013-0384	Pentacel at 6 yrs	42720	F				Aged out	42880	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Extraneous	Age: Too Old																															-				HIB	44911	Age: Too Old	41275	43980.63280478009	Not recommended: too old	V3.5: Changed age of patient and vaccination from 7 years to 6 years to better align with new Age Groupings. No effective change of test case expectations.
v1.6: Updated Series Status from "Not Complete" to "Aged Out" to align with updated CDSi Logic Specification Series Statuses.
v1.2: Within the scope of the CDSi effort, Hib on or after 5 years is not recommended.  The last administered dose was changed to Extraneous to reflect this.	3.5	This test case describes when a child is administered a second dose of the Hib vaccine at 6 years that the dose is extraneous.  No further doses should be forecast.  The series is complete.
2013-0392	#1 @ 9 yrs - 4 days, female, gardasil 	41628	F				Not complete	44911	HPV9	165		Valid																																						2	45062	45093	45334	HPV	44911	Age: At Absolute Minimum	41275	43990.63292283565	Recommended based on interval	Updated to reflect current ACIP Recommendations for the 2 dose HPV vaccine.	3.2	This test case describes when the first dose of the HPV vaccine is administered at 9 years - 4 days that the CDSi engine forecasts the second dose of the HPV 2 dose series.
2013-0394	#1 @ 9 yrs - 0 days, female, gardasil	41624	F				Not complete	44911	HPV9	165		Valid																																						2	45062	45093	45334	HPV	44911	Age: At Minimum	41275	43144.55818320602	Recommended based on interval	Updated to reflect current ACIP Recommendations for the 2 dose HPV vaccine.	3.2	This test case describes whether or not the first dose is valid at age 9 years - 0 days and thus forecast the second dose of the HPV 2 dose series.
2013-0395	#1 @ 11 yrs - 0 days, female, gardasil 	40893	F				Not complete	44911	HPV9	165		Valid																																						2	45062	45093	45334	HPV	44911	Age: At Recommended	41275	43144.558405474534	Recommended based on interval	Updated to reflect current ACIP Recommendations for the 2 dose HPV vaccine.	3.2	This test case describes whether or not the first dose is valid at age 11 years - 0 days and thus forecast the second dose.
2013-0396	#1 @ 9 yrs - 4 days, male, gardasil 	41628	M				Not complete	44911	HPV9	165		Valid																																						2	45062	45093	45334	HPV	44911	Age: At Absolute Minimum	41275	43990.63350532408	Recommended based on interval	Updated to reflect current ACIP Recommendations for the 2 dose HPV vaccine.	3.2	This test case describes whether or not the first dose is valid at age 9 years - 4 days and thus forecast the second dose of the HPV 2 dose series.
2013-0398	#1 @ 9 yrs - 0 days, male, gardasil 	41624	M				Not complete	44911	HPV9	165		Valid																																						2	45062	45093	45334	HPV	44911	Age: At Minimum	41275	43144.55929174768	Recommended based on interval	Updated to reflect current ACIP Recommendations for the 2 dose HPV vaccine.	3.2	This test case describes when the first dose is administered at age 9 years - 0 days that the CDS engine should forecast a second dose of the HPV 2 dose series.
2013-0399	#1 @ 11 yrs - 0 days, male, gardasil 	40893	M				Not complete	44911	HPV9	165		Valid																																						2	45062	45093	45334	HPV	44911	Age: At Recommended	41275	43144.55949208333	Recommended based on interval	Updated to reflect current ACIP Recommendations for the 2 dose HPV vaccine.	3.2	This test case describes when the first dose is administered at age 11 years - 0 days that the second dose of the HPV 2 dose series should be forecasted.
2013-0400	#2 @ 9 yrs, 4 wks - 4 days, female, gardasil 	41600	F				Not complete	44883	HPV9	165		Valid		44911	HPV9	165		Valid																																3	45034	45064	45305	HPV	44911	Interval: At Minimum	41275	43990.63399712963	Recommended based on interval	Updated to reflect current ACIP Recommendations for the 2 dose HPV vaccine.	3.2	This test case describes when the second dose is administered at an interval of 4 weeks - 4 days (less than 5 months) that a third dose of the HPV vaccine should be forecasted at 5 to 6 months from the first dose.
2013-0402	#2 @ 9 yrs, 4 wks - 0 days, female gardasil 	41596	F				Not complete	44883	HPV9	165		Valid		44911	HPV9	165		Valid																																3	45034	45064	45305	HPV	44911	Interval: At Minimum	41275	43997.33741539352	Recommended based on interval	Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when the second dose is administered 4 weeks (less than 5 months) after the first dose, that a third dose of the HPV vaccine should be forecasted.
2013-0403	#2 @ 11 yrs + 2 mo, female, gardasil 	40832	F				Not complete	44850	HPV9	165		Valid		44911	HPV9	165		Valid																																3	45001	45032	45273	HPV	44911	Interval: At Minimum	41275	43997.33762332176	Recommended based on interval	Updated to reflect current ACIP Recommendations for the 2 dose HPV vaccine.	3.2	This test case describes when the second dose is administered 2 months (less than 5 months) after the first dose, that a third dose of the HPV vaccine should be forecasted.
2013-0404	#2 @ 9 yrs, 4 wks - 4 days, male, gardasil 	41600	M				Not complete	44884	HPV9	165		Valid		44911	HPV9	165		Valid																																3	45035	45065	45306	HPV	44911	Interval: At Absolute Minimum	41275	43990.63494616898	Recommended based on interval	Updated to reflect current ACIP Recommendations for the 2 dose HPV vaccine.	3.2	This test case describes when the second dose is administered at an interval of 4 weeks - 4 days  that a repeat dose of the HPV vaccine should be forecasted 5 to 6 months from the first dose.
2013-0405	#2 @ 9 yrs, 4 wks - 5 days, male gardasil 	41605	M				Not complete	44888	HPV9	165		Valid		44911	HPV9	165		Not Valid	Interval: too short																															2	45039	45069	45310	HPV	44911	Interval: Below Absolute Minimum	41275	43252.35328200232	Recommended based on interval	V3.5: Updated test case Forecast number from 3 to 2.  There is only 1 valid dose, so this should be forecast dose number 2.
V3.3: Updated test case Forecast number from 2 to 3	3.5	This test case describes when the second dose is administered at an interval of 4 weeks - 5 day  that a repeat dose of the HPV vaccine should be forecasted at least 5 to 6 months from the first dose.
2013-0406	#2 @ 9 yrs, 4 wks - 0 days, male gardasil	41596	M				Not complete	44883	HPV9	165		Valid		44911	HPV9	165		Valid																																3	45034	45064	45305	HPV	44911	Interval: At Minimum	41275	43997.337956585645	Recommended based on interval	Updated to reflect current ACIP Recommendations for the 2 dose HPV vaccine.	3.2	This test case describes when the second dose is administered at an interval of 4 weeks that a repeat dose of the HPV vaccine should be forecasted at least 5 to 6 months from the first dose.
2013-0407	#2 @ 11 yrs + 2 mo, male, gardasil	40832	M				Not complete	44850	HPV9	165		Valid		44911	HPV9	165		Valid																																3	45001	45032	45273	HPV	44911	Interval: At Minimum	41275	43997.338013796296	Recommended based on interval	Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when the second dose is administered 2 months (less than 5 months) after the first dose, that a third dose of the HPV vaccine should be forecasted.
2013-0409	#3 @ 9 yrs, 16 weeks - 1 days, female, gardasil	37377	F				Complete	40663	GARDASIL	62	MSD	Valid		40691	GARDASIL	62	MSD	Valid		40775	GARDASIL	62	MSD	Valid																										-				HPV	40775	Interval: At Absolute Minimum	41275	43997.338426469905	Not recommended: series complete	v2.1 Removal of Age requirements to allow for a more aligned dosing schedule based on intervals rather than age.	2.1	This test case describes when a child is administered a third dose of the HPV vaccine at 16 weeks - 1 day, after the first dose, that the dose is considered to be valid.  The series is complete. (Prior to 12/16/16, 16 weeks - 4 days was allowed to be used as an Absolute Minimum Interval from Target Dose #1).
2013-0410	#3 @ 9 yrs, 24 weeks, 0 days, female, gardasil	41456	F				Complete	44743	HPV9	165		Valid		44771	HPV9	165		Valid		44911	HPV9	165		Valid																										-				HPV	44911	Age: At Minimum	41275	43768.71703260417	Not recommended: series complete	Added a description.	4.2	This test case describes when a third dose of the HPV vaccine is administered at 24 weeks from dose number 1, that the dose is valid.  The series is complete.
2013-0411	#3 @ 11 yrs + 6 mo, female, gardasil 	40710	F				Complete	44728	HPV9	165		Valid		44789	HPV9	165		Valid		44911	HPV9	165		Valid																										-				HPV	44911	Age: At Recommended	41275	43768.71688896991	Not recommended: series complete	Added Description.	4.2	This test case describes when the third dose of the HPV vaccine is administered at 6 months from dose number 1, that the dose is valid.  The series is complete.
2013-0413	#3 @ 9 yrs, 16 weeks - 1 days, male, gardasil	37377	M				Complete	40663	GARDASIL	62	MSD	Valid		40691	GARDASIL	62	MSD	Valid		40775	GARDASIL	62	MSD	Valid																										-				HPV	40775	Interval: At Absolute Minimum	41275	43997.35690990741	Not recommended: series complete	v2.1 Removal of Age requirements to allow for a more aligned dosing schedule based on intervals rather than age.	2.1	This test case describes when a child is administered a third dose of the HPV vaccine at 16 weeks - 1 day, after the first dose,  that the dose is considered to be valid.  The series is complete. (Prior to 12/16/16, 16 weeks - 4 days was allowed to be used as an Absolute Minimum Interval from Target Dose #1).
2013-0414	#3 @ 9 yrs, 24 weeks, 0 days, male, gardasil	41456	M				Complete	44743	HPV9	165		Valid		44771	HPV9	165		Valid		44911	HPV9	165		Valid																										-				HPV	44911	Age: At Minimum	41275	43997.357454652774	Not recommended: series complete	v1.1 Dose 1 must be Gardasil for it to be valid and match test case purpose.	1.1	This test case describes when a child is administered a third dose of the HPV vaccine at 24 weeks that the dose is considered to be valid.  The series is complete.
2013-0415	#3 @ 11 yrs + 6 mo, male, gardasil	40710	M				Complete	44728	HPV9	165		Valid		44789	HPV9	165		Valid		44911	HPV9	165		Valid																										-				HPV	44911	Age: At Recommended	41275	43997.35762361111	Not recommended: series complete		1.0	This test case describes when a child is administered a third dose of the HPV vaccine at 6 months after the first dose that the dose is considered to be valid.  The series is complete.
2013-0416	Any dose 26 yrs, female, gardasil	35414	F				Not complete	44911	HPV9	165		Valid																																						2	44939	44939	45022	HPV	44911	Age: At Recommended	41275	43186.36581898148	Recommended based on interval	V3.4: Earliest Recommended Date was changed from 8 weeks to 4 weeks on Dose 2 per HPV MMWR language. 
V3.0 Updated test came name and date of birth to reflect the age of 26 and to reflect that the second dose of the HPV vaccine should be forecasted.	3.4	This test case describes when a female receives the first dose of the HPV vaccine at age 26 years that a second dose should forecast at an interval of 4 - 8 weeks.
2013-0418	#1 @ 9 yrs - 4 days, female, Cervarix 	37377	F				Not complete	40660	CERVARIX	118	SKB	Valid																																						2	40813	40843	41083	HPV	40660	Age: At Absolute Minimum	41275	43997.35795385417	Recommended based on interval	v3.2 - Updated to reflect ACIP recommendations for the HPV 2 dose series and to add plus 4 weeks to the latest recommended interval.	3.2	This test case describes when a child is administered the first dose of the HPV vaccine at age 9 years -4 days, that another dose should be forecast.
2013-0421	#1 @ 9 yrs - 0 days, female, Cervarix 	37377	F				Not complete	40664	CERVARIX	118	SKB	Valid																																						2	40817	40848	41088	HPV	40664	Age: At Minimum	41275	43997.35820717592	Recommended based on interval	Updated to reflect ACIP recommendations for the HPV 2 dose series and to add plus 4 weeks to the latest recommended interval.	3.2	This test case describes when a child is administered the first dose of the HPV vaccine at age 9 years, that another dose should be forecast.
2013-0422	#1 @ 11 yrs - 0 days, female, Cervarix 	36647	F				Not complete	40664	CERVARIX	118	SKB	Valid																																						2	40817	40848	41088	HPV	40664	Age: At Recommended	41275	43997.36079594908	Recommended based on interval	v3.2 - Updated to reflect ACIP recommendations for the HPV 2 dose series and to add plus 4 weeks to the latest recommended interval.	3.2	This test case describes when a child is administered the first dose of the HPV vaccine at age 11 years -0 days, that another dose should be forecast.
2013-0423	#1 @ 9 yrs - 4 days, male, Cervarix 	37377	M				Not complete	40661	CERVARIX	118	SKB	Not Valid	Inadvertent Vaccine																																					1	40664	41395	42152	HPV	40661	Inadvertent vaccine	41275	44375.45899394676	Recommended based on age		3.2	This test case describes when a male receives Cervarix that the dose should not count as a valid dose and a repeat dose should be given at the correct age or interval.
2013-0424	#1 @ 9 yrs - 5 days, male, Cervarix 	37377	M				Not complete	40660	CERVARIX	118	SKB	Not Valid	Inadvertent Vaccine																																					1	40664	41395	42152	HPV	40660	Inadvertent vaccine	41275	44375.459208506945	Recommended based on age		3.2	This test case describes when a vaccine dose is given less than the vaccine grace period and that vaccine (Cervarix)  is administered to a male that the dose is not valid and that a subsequent dose of a preferred or allowed vaccine should be administered as soon as possible.
2013-0425	#1 @ 9 yrs - 0 days, male, Cervarix	37377	M				Not complete	40664	CERVARIX	118	SKB	Not Valid	Inadvertent Vaccine																																					1	40664	41395	42152	HPV	40664	Inadvertent vaccine	41275	44375.45942701389	Recommended based on age		3.2	This test case describes when the Cervarix vaccine is administered to a male that the dose is not valid and that a subsequent dose of a preferred or allowed vaccine should be administered as soon as possible.
2013-0426	#1 @ 11 yrs - 0 days, male, Cervarix 	36647	M				Not complete	40664	CERVARIX	118	SKB	Not Valid	Inadvertent Vaccine																																					1	40664	40664	41422	HPV	40664	Inadvertent vaccine	41275	44375.459748877314	Recommended based on age	Updated the Earliest date to 05/01/2011	3.3	This test case describes when a male receives Cervarix that the dose should not count as a valid dose and a repeat dose should be given at the correct age or interval.
2013-0427	#2 @ 9 yrs, 4 wks - 4 days, female, Cervarix 	37377	F				Not complete	40661	CERVARIX	118	SKB	Valid		40688	CERVARIX	118	SKB	Valid																																3	40814	40844	41084	HPV	40688	Interval: At Absolute Minimum	41275	43990.649511365744	Recommended based on interval	Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when a second dose is administered at an interval of 4 weeks -4 days but before 5 months that a repeat dose or third dose should be forecasted.
2013-0428	#2 @ 9 yrs, 4 wks - 0 days, female Cervarix 	37377	F				Not complete	40664	CERVARIX	118	SKB	Valid		40692	CERVARIX	118	SKB	Valid																																3	40817	40848	41088	HPV	40692	Interval: At Minimum	41275	43997.36166181713	Recommended based on interval	Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when a second dose is administered at an interval of 4 weeks -4 days but before 5 months that a repeat dose or third dose should be forecasted.
2013-0429	#2 @ 11 yrs + 2 mo, female, Cervarix 	36647	F				Not complete	40664	CERVARIX	118	SKB	Valid		40725	CERVARIX	118	SKB	Valid																																3	40817	40848	41088	HPV	40725	Interval: At Minimum	41275	44109.653477037034	Recommended based on interval	Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when a patient is administered a second dose of the HPV vaccine at 11 years and 2 months of age (8 weeks after the previous dose) that the dose is valid.  Another dose should be forecast.
2013-0430	#2 @ 9 yrs, 4 wks - 4 days, male, Cervarix 	37377	M				Not complete	40661	CERVARIX	118	SKB	Not Valid	Inadvertent Vaccine	40685	CERVARIX	118	SKB	Not Valid	Inadvertent Vaccine																															1	40685	41395	42152	HPV	40685	Inadvertent vaccine	41275	44375.4602728588	Recommended based on age	Updated the Earliest date to 05/22/2011	3.3	This test case describes when the first and second dose are given at an invalid age or interval and the vaccine administered was to a male that the vaccine dose should be repeated as soon as possible.
2013-0433	#3 @ 9 yrs, 24 weeks, 0 days, female, Cervarix 	37377	F				Complete	40664	CERVARIX	118	SKB	Valid		40692	CERVARIX	118	SKB	Valid		40832	CERVARIX	118	SKB	Valid																										-				HPV	40832	Interval: At Minimum	41275	43997.363205625	Not recommended: series complete		1.0	This test case describes when a child is administered the third dose of the HPV vaccine at 24 weeks from dose one, that the dose is valid.  Series is complete.
2013-0434	#3 @ 11 yrs + 6 mo, female, Cervarix 	36647	F				Complete	40664	CERVARIX	118	SKB	Valid		40725	CERVARIX	118	SKB	Valid		40848	CERVARIX	118	SKB	Valid																										-				HPV	40848	Age: At Recommended	41275	43997.36332853009	Not recommended: series complete		1.0	This test case describes when a child is administered the third dose of the HPV vaccine at 6 months from dose one, that the dose is valid.  Series is complete.
2013-0437	#3 @ 9 yrs, 24 weeks, 0 days, male, Cervarix 	37377	M				Not complete	40664	CERVARIX	118	SKB	Not Valid	Inadvertent Vaccine	40692	CERVARIX	118	SKB	Not Valid	Inadvertent Vaccine	40835	CERVARIX	118	SKB	Not Valid	Inadvertent Vaccine																									1	40835	41395	42152	HPV	40835	Inadvertent vaccine	41275	44375.460814907405	Recommended based on age	Updated the Earliest date to reflect the last dose received.	3.3	This test case describes when an invalid vaccine is administered in doses 1, 2, and 3 that a repeat dose should be administered as soon as possible.
2013-0438	#3 @ 11 yrs + 6 mo, male, Cervarix 	36647	M				Not complete	40664	CERVARIX	118	SKB	Not Valid	Inadvertent Vaccine	40725	CERVARIX	118	SKB	Not Valid	Inadvertent Vaccine	40848	CERVARIX	118	SKB	Not Valid	Inadvertent Vaccine																									1	40848	40848	41422	HPV	40848	Inadvertent vaccine	41275	44375.46110570602	Recommended based on age	Updated the Earliest Date to reflect the last dose received.	3.3	This test case describes when an invalid vaccine is administered in doses 1, 2, and 3 that a repeat dose should be administered as soon as possible.
2013-0439	Any dose 26 yrs, female, Cervarix	31533	F				Not complete	41031	CERVARIX	118	SKB	Valid																																						2	41059	41059	41142	HPV	41031	Age: At Recommended	41275	43997.36358153935	Recommended based on interval	V3.5: Updated Recommended Date to reflect change in supporting data (v3.6) from 8 weeks to 4 weeks.
V3.0 Updated test came name and date of birth to reflect the age of 26 and to reflect that the second dose of the HPV vaccine should be forecast.	3.5	This test case describes when a patient 26 years of age has received dose number one of the HPV vaccine, that another dose should be forecast.
2013-0440	#2 with interval of 4 weeks from #1	40865	F				Not complete	44883	HPV9	165		Valid		44911	HPV9	165		Valid																																3	45034	45064	45305	HPV	44911	Interval: At Minimum	41275	43997.36383728009	Recommended based on interval	Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when a second dose is administered at an interval of 4 weeks -4 days but before 5 months that a repeat dose or third dose should be forecasted.
2013-0441	#2 with interval of 4 weeks - 4 days from #1	40869	F				Not complete	44887	HPV9	165		Valid		44911	HPV9	165		Valid																																3	45038	45068	45309	HPV	44911	Interval: At Absolute Minimum	41275	43990.651683275464	Recommended based on interval	Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when a second dose is administered at an interval of 4 weeks -4 days ( less than 5 months) that a repeat or third dose should be forecasted.
2013-0442	#2 with interval of 4 weeks - 5 days from #1	40870	F				Not complete	44888	HPV9	165		Valid		44911	HPV9	165		Not Valid	Interval: too short																															2	45039	45069	45310	HPV	44911	Interval: Below Absolute Minimum	41275	43997.364266655095	Recommended based on interval	v3.2: Updated to reflect ACIP recommendations for the HPV 2 dose series and to add plus 4 weeks to the latest recommended interval.	3.2	This test case describes when an adolescent child is administered dose two of the HPV vaccine at 4 weeks - 5 days from dose number one, that the dose is not valid, and another dose should be forecast.
2013-0443	#2 with interval of 2 mo from #1	40832	F				Not complete	44850	HPV9	165		Valid		44911	HPV9	165		Valid																																3	45001	45032	45273	HPV	44911	Interval: At Recommended	41275	44109.6657981713	Recommended based on interval	Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when a adolescent child has been administered a second dose of the HPV vaccine at 8 weeks after the first dose, that the dose is valid.  Another dose should be forecast.
2013-0444	#3 with interval of 12 weeks from #2	37377	F				Complete	40664	HPV, unspecified formulation	137		Valid		40692	HPV, unspecified formulation	137		Valid		40776	HPV, unspecified formulation	137		Valid																										-				HPV	40776	Interval: At Minimum	41275	43997.36454912037	Not recommended: series complete		1.0	This test case describes when a child is administered the third dose of the HPV vaccine at 12 weeks from dose number 2 and at least 16 weeks - 4 days from dose number one, that the dose is considered to be valid.  The series is complete. (Prior to 12/16/16, 16 weeks - 4 days was allowed to be used as an Absolute Minimum Interval from Target Dose #1, and 12 weeks -4 days was allowed to be used as an Absolute Minimum Interval from Target Dose #2).
2013-0445	#3 with interval of 12 weeks - 4 days from #2	36647	F				Complete	40664	HPV, unspecified formulation	137		Valid		40700	HPV, unspecified formulation	137		Valid		40780	HPV, unspecified formulation	137		Valid																										-				HPV	40780	Interval: At Absolute Minimum	41275	43997.36574325232	Not recommended: series complete		1.0	This test case describes when a child is administered the third dose of the HPV vaccine at 12 weeks - 4 days from dose number 2 and at least 16 weeks - 4 days from dose number one, that the dose is considered to be valid.  The series is complete. (Prior to 12/16/16, 16 weeks - 4 days was allowed to be used as an Absolute Minimum Interval from Target Dose #1, and 12 weeks -4 days was allowed to be used as an Absolute Minimum Interval from Target Dose #2).
2013-0446	#3 with interval of 12 weeks - 5 days from #2	40778	F				Not complete	44796	HPV9	165		Valid		44832	HPV9	165		Valid		44911	HPV9	165		Not Valid	Interval: too short																									3	44995	44995	45219	HPV	44911	Interval: At Below Absolute Minimum	41275	43144.59193701389	Recommended based on minimum interval from invalid dose	Updated the Forecasted Recommended Date to reflect current ACIP recommendation for interval from invalid dose.	3.2	This test case describes when a third dose is administered an at an interval of 12 weeks - 5 days that a repeat dose should be forecasted 12 weeks later.
2013-0447	#3 with interval of 4 mo from #2	40708	F				Complete	44726	HPV9	165		Valid		44787	HPV9	165		Valid		44909	HPV9	165		Valid																										-				HPV	44911	Interval: At Recommended	41275	44592.39520803241	Not recommended: series complete		1.0	This test case describes when a child is administered the third dose of the HPV vaccine four months after the second dose that the dose is valid.  The series is complete.
2013-0448	#3 with interval of 24 weeks from #1 	41091	F				Complete	44743	HPV9	165		Valid		44771	HPV9	165		Valid		44911	HPV9	165		Valid																										-				HPV	44911	Interval: At Minimum	41275	43997.36606313657	Not recommended: series complete		1.0	This test case describes when a child is administered the third dose of the HPV vaccine 24 weeks after dose number one that the dose is valid.  The series is complete.
2013-0450	#3 with interval of 16 weeks from #1 	36647	F				Complete	40299	HPV, unspecified formulation	137		Valid		40327	HPV, unspecified formulation	137		Valid		40411	HPV, unspecified formulation	137		Valid																										-				HPV	40411	Interval: At Minimum	41275	43997.36665172454	Not recommended: series complete		1.0	This test case describes when a child is administered a third dose of the HPV vaccine at 16 weeks after the first dose that the dose is  valid.  The series is complete. (Prior to 12/16/16, 16 weeks - 4 days was allowed to be used as an Absolute Minimum Interval from Target Dose #1).
2013-0451	#1 @ 8 yrs - 5 days, #2 @ 9 yrs - 5 days	41629	F				Not complete	44546	HPV9	165		Not Valid	Age: Too Young	44911	HPV9	165		Not Valid	Age: Too Young																															1	44916	45647	46404	HPV	44911	Age: Below Absolute Minimum	41275	43997.366975543984	Recommended based on age		1.0	This test case describes when a child is administered dose number one of the HPV vaccine at 8 years - 5 days and dose number two at 9 years - 5 days that the doses are not valid.  Another dose should be forecast.
2013-0452	#1 @ 9 yrs - 5 days, #2 @ 9 yrs - 4 days	41628	F				Not complete	44910	HPV9	165		Not Valid	Age: Too Young	44911	HPV9	165		Valid																																2	45062	45093	45334	HPV	44911	Age: Below Absolute Minimum	41275	43997.367492523146	Recommended based on interval	v3.2: Updated to reflect ACIP recommendations for the HPV 2 dose series and to add plus 4 weeks to the latest recommended interval.	3.2	This test case describes when a child is administered dose number one of the HPV vaccine at 9 years - 5 days and another dose  at 9 years - 4 days that the second dose is valid.  Another dose should be forecast.
2013-0453	#1 @ 9 yrs, #2 @ 9 yrs + 2 weeks	41610	F				Not complete	44897	HPV9	165		Valid		44911	HPV9	165		Not Valid	Interval: too short																															2	45048	45079	45320	HPV	44911	Interval: Below Absolute Minimum	41275	43997.36765702546	Recommended based on interval	v3.2: Updated to reflect ACIP recommendations for the HPV 2 dose series and to add plus 4 weeks to the latest recommended interval.	3.2	This test case describes when a child is administered dose number two of the HPV vaccine at 2 weeks from dose number one that the the dose is not valid.  Another dose should be forecast.
2013-0454	#1 @ 9 yrs, #2 @ 12 yrs, 2 mo, 3 days	40464	F				Complete	43751	HPV9	165		Valid		44911	HPV9	165		Valid																																-				HPV	44911	All Valid: Forecast Test	41275	43997.36802449074	Not recommended: series complete	v3.2: Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when an adolescent child is administered dose number two of the HPV vaccine at greater than 5 months after dose number one that the dose is valid. Series is complete.
2013-0455	#1 @ 9 yrs, #2 @ 11 yr, 6 mo	40710	F				Complete	43998	HPV9	165		Valid		44911	HPV9	165		Valid																																-				HPV	44911	All Valid: Forecast Test	41275	43997.3682821412	Not recommended: series complete	v3.2: Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when an adolescent child is administered dose number two of the HPV vaccine at greater than 5 months after dose number one that the dose is valid. Series is complete.
2013-0456	#1 @ 8 yrs - 5 days, #2 @ 9 yrs - 6 days, #3 @ 9 yrs - 5 days	41629	F				Not complete	44546	HPV9	165		Not Valid	Age: Too Young	44910	HPV9	165		Not Valid	Age: Too Young	44911	HPV9	165		Not Valid	Age: Too Young																									1	44916	45647	46404	HPV	44911	Age: Below Absolute Minimum	41275	43997.36863907408	Recommended based on age		1.0	This test case describes when a child is administered three doses of the HPV vaccine before 9 years - 4 days that the doses are not valid.  Another dose should be forecast.
2013-0457	#1 @ 8 yrs - 5 days, #2 @ 9 yrs - 6 days, #3 @ 9 yrs - 0 days	41624	F				Not complete	44541	HPV9	165		Not Valid	Age: Too Young	44905	HPV9	165		Not Valid	Age: Too Young	44911	HPV9	165		Valid																										2	45062	45093	45334	HPV	44911	Age: Below Absolute Minimum	41275	43997.368963946756	Recommended based on interval	v3.2: Updated to reflect ACIP recommendations for the HPV 2 dose series and to add plus 4 weeks to the latest recommended interval.	3.2	This test case describes when a child is administered dose number one of the HPV vaccine at seven years of age, dose number two at 9 years - 6 days and dose three at 9 years of age that another dose should be forecast.
2013-0458	#1 @ 9 yrs - 5 days, #2 @ 9 yrs + 4 weeks, #3 @ 9 yrs, 8 weeks	41568	F				Not complete	44850	HPV9	165		Not Valid	Age: Too Young	44883	HPV9	165		Valid		44911	HPV9	165		Valid																										3	45034	45064	45305	HPV	44911	Age: At Minimum	41275	43997.36532819444	Recommended based on interval	Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when a valid second dose is administered at an interval of 4 weeks -4 days but before 5 months that a repeat dose  should be forecasted.
2013-0459	#1 @ 9 yrs - 5 days, #2 @ 9 yrs + 4 weeks, #3 @ 9 yrs, 8 weeks, #4 @ 9 yrs, 24 weeks	37377	F				Complete	40659	HPV, unspecified formulation	137		Not Valid	Age: Too Young	40692	HPV, unspecified formulation	137		Valid		40720	HPV, unspecified formulation	137		Valid		40835	HPV, unspecified formulation	137		Valid																				-				HPV	40835	Age: Below Absolute Minimum	41275	43997.36921128472	Not recommended: series complete		1.0	This test case describes when a child is administered three valid dose that no further dose should be forecast.  Series is complete.
2013-0460	Adolescent male, no HPV yet given.	41659	M				Not complete																																											1	44946	45677	46434	HPV	44911	No Doses Administered	41275	43997.3694716088	Recommended based on age		1.0	This test case describes when a child is eight years of age and has no history of the HPV vaccine that the first dose should be forecast.
2013-0462	# 2 at age 9 years 4 weeks-4 days	41600	F				Not complete	44886	HPV9	165		Valid		44911	HPV9	165		Valid																																3	45037	45067	45308	HPV	44911	Interval: At Absolute Minimum	41275	43990.65665304398	Recommended based on interval	Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when a second dose is administered at an interval of 4 weeks -4 days but before 5 months that a repeat dose  should be forecasted.
2013-0463	# 2 at age 9 years 4 weeks	41596	F				Not complete	44883	HPV9	165		Valid		44911	HPV9	165		Valid																																3	45034	45064	45305	HPV	44911	Interval: At Minimum	41275	43997.36972967593	Recommended based on interval	Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when a second dose is administered at an interval of 4 weeks -4 days but before 5 months that a repeat dose  should be forecasted.
2013-0465	# 3 at age 9 years 16 weeks-1 days. 	37226	F				Complete	40512	HPV, unspecified formulation	137		Valid		40540	HPV, unspecified formulation	137		Valid		40624	HPV, unspecified formulation	137		Valid																										-				HPV	40624	Interval: At Absolute Minimum	41275	43997.369968611114	Not recommended: series complete	v2.1 Removal of Age requirements to allow for a more aligned dosing schedule based on intervals rather than age.	2.1	This test case describes when an adolescent child is administered a third dose of the HPV vaccine at 16 weeks minus 1 day after the first dose that the dose is considered to be valid.  The series is complete. (Prior to 12/16/16, 16 weeks - 4 days was allowed to be used as an Absolute Minimum Interval from Target Dose #1).
2013-0466	# 3 at age 9 years 16 weeks	37591	F				Complete	40878	HPV, unspecified formulation	137		Valid		40906	HPV, unspecified formulation	137		Valid		40990	HPV, unspecified formulation	137		Valid																										-				HPV	40990	Age: At Absolute Minimum	41275	43997.37064961805	Not recommended: series complete		1.0	This test case describes when an adolescent child is administered a third dose of the HPV vaccine at 16 weeks after the first dose that the dose is considered to be valid.  The series is complete. (Prior to 12/16/16, 16 weeks - 4 days was allowed to be used as an Absolute Minimum Interval from Target Dose #1).
2013-0467	# 2 at age 26 yrs 11 months 15 days; forecast # 3; female	35065	F				Not complete	44197	HPV9	165		Valid		44911	HPV9	165		Valid																																3	44995	45032	45089	HPV	44911	All Valid: Forecast Test	41275	44621.32494450232	Recommended based on interval	v4.21: Updated test case to forecast a third dose.
V4.2: Updated test case to remove forecast dose for the third dose of HPV because patient will have reached age 27 before administration of the dose based on newly published MMWR for Shared Clinical Decision Making starting at 27 years.
V4.0: Updated recommended and past due to reflect general best practice recommendations timing and spacing table 3-1 (Rec. Date in 4 months)	4.21	This test case describes when a patient is administered the second dose of the HPV vaccine after age 26 years that a third dose should be forecast.
2013-0468	Dose 1 to dose 2 interval 28-5 days	40505	F				Not complete	44888	HPV9	165		Valid		44911	HPV9	165		Not Valid	Interval: too short																															2	45039	45069	45310	HPV	44911	Interval: Below Absolute Minimum	41275	43997.37118447917	Recommended based on minimum interval from previous dose (catch-up)	v3.2 Updated to reflect ACIP recommendations for the HPV 2 dose series and to add plus 4 weeks to the latest recommended interval.	3.2	This test case describes when an adolescent child is administered a second dose of the HPV vaccine at 28 - 5 days after the first dose that the dose is not valid.   Another dose of the HPV vaccines should be forecast.
2013-0469	Dose 1 to dose 2 interval 28 days	40500	F				Not complete	44883	HPV9	165		Valid		44911	HPV9	165		Valid																																3	45034	45064	45305	HPV	44911	Interval: At Minimum	41275	43990.65841575232	Recommended based on minimum interval from previous dose (catch-up)	Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when a second dose is administered at an interval of 4 weeks -4 days but before 5 months that a repeat dose  should be forecasted.
2013-0470	Adolescent female, no HPV yet  given.	41829	F				Not complete																																											1	45116	45847	46604	HPV	44911	No Doses Administered	41275	43997.37192224537	Recommended based on age		1.0	This test case describes when a child has no history of the HPV vaccine that a dose should be forecast.
2013-0471	Dose 2 to dose 3 interval 12 weeks-5 days	41118	F				Not complete	44770	HPV9	165		Valid		44832	HPV9	165		Valid		44911	HPV9	165		Not Valid	Interval: too short																									3	44995	44995	45193	HPV	44911	Interval: Below Absolute Minimum	41275	43213.61906538194	Recommended based on interval	Updated to reflect ACIP recommendations for the HPV 2 dose series and to add plus 4 weeks to the latest recommended interval.	3.2	This test case describes when a second and third dose is administered less than 5 months- 4 days from target dose #1, that a repeat dose of the vaccine should be give 12 weeks later. 
2013-0472	Dose 2 to dose 3 interval 12 weeks-4 days	36785	F				Complete	40441	HPV, unspecified formulation	137		Valid		40502	HPV, unspecified formulation	137		Valid		40582	HPV, unspecified formulation	137		Valid																										-				HPV	40582	Interval: At Absolute Minimum	41275	43997.37230662037	Not recommended: series complete		1.0	This test case describes when a child is administered a third dose of the HPV vaccine at 12 weeks minus 4 days after the second dose and at least 16 weeks - 4 days from dose number one, that the dose is considered to be valid.  The series is complete. (Prior to 12/16/16, 16 weeks - 4 days was allowed to be used as an Absolute Minimum Interval from Target Dose #1).
2013-0473	Dose 2 to dose 3 interval 12 weeks	36785	F				Complete	40441	HPV, unspecified formulation	137		Valid		40502	HPV, unspecified formulation	137		Valid		40586	HPV, unspecified formulation	137		Valid																										-				HPV	40586	Interval: At Minimum	41275	43997.37311168981	Not recommended: series complete		1.0	This test case describes when a child is administered a third dose of the HPV vaccine at 12 weeks after the second dose and at least 16 weeks - 4 days from dose number one, that the dose is considered to be valid.  The series is complete. (Prior to 12/16/16, 16 weeks - 4 days was allowed to be used as an Absolute Minimum Interval from Target Dose #1).
2013-0474	Dose 1 to dose 3 interval 16 weeks -5 days	35145	F				Not complete	39556	HPV, unspecified formulation	137		Valid		39584	HPV, unspecified formulation	137		Valid		39660	HPV, unspecified formulation	137		Not Valid	Interval: too short																									3	39744	39744	39978	HPV	39667	Interval: Below Absolute Minimum	41275	43698.33314768518	Recommended based on minimum interval from invalid dose	V4.1: Updated to meet ACIP recommendation concerning the 4 day grace period for the third dose prior to December 16.2016. 
V3.2: Updated to reflect current ACIP recommendations for forecasting of the earliest and recommended date which is set by 12 weeks from invalid dose.	4.1	This test case describes when the third dose of the HPV vaccine is administered at 16 weeks - 5 days from target dose #1, that a repeat dose of the vaccine should be give 12 weeks later.
2013-0475	Dose 1 to dose 3 interval 16 weeks=valid when administered prior to 12/16/2016	35145	F				Complete	39556	HPV, unspecified formulation	137		Valid		39584	HPV, unspecified formulation	137		Valid		39668	HPV, unspecified formulation	137		Valid																										-				HPV	39668	Interval: At Minimum	41275	43997.37350583333	Not recommended: series complete		1.0	This test case describes when a adolescent child is administered a third dose of the HPV vaccine at 12 weeks after the second dose and at least 16 weeks - 4 days from dose number one, that the dose is considered to be valid.  The series is complete. (Prior to 12/16/16, 16 weeks - 4 days was allowed to be used as an Absolute Minimum Interval from Target Dose #1).
2013-0476	# 2 to # 3 interval 12 wks-4 days	39815	F				Complete	44744	HPV9	165		Valid		44828	HPV9	165		Valid		44908	HPV9	165		Valid																										-				HPV	44911	Interval: At Absolute Minimum	41275	43997.374507962966	Not recommended: series complete		1.0	This test case describes when an adolescent child is administered a third dose of the HPV vaccine at 12 weeks - 4 days after the second dose and at least 5 months from dose number one, that the dose is considered to be valid.  The series is complete.
2013-0477	Invalid dose 1 of three doses given	41335	F				Complete	44604	HPV9	165		Not Valid	Age: Too Young	44714	HPV9	165		Valid		44911	HPV9	165		Valid																										-				HPV	44911	Age: Below Absolute Minimum	41275	43997.37466465278	Not recommended: series complete	v3.2: Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when a child is administered a first dose of the HPV vaccine at less than 9 years - 4 days, but receives a second and third dose of the vaccine at valid intervals and age, that the doses are considered to be valid.  The series is complete.
2013-0478	Invalid dose 2 in midst of others	40649	F				Complete	44728	HPV9	165		Valid		44749	HPV9	165		Not Valid	Interval: too short	44911	HPV9	165		Valid																										-				HPV	44911	Interval: Below Absolute Minimum	41275	43997.37478359954	Not recommended: series complete	v3.2: Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when a child is administered a second dose of the HPV vaccine too soon, but receives a third dose of the vaccine 12 weeks from the previous dose and at least 5 months from the first dose that the doses are considered to be valid.  The series is complete.
2013-0480	Adult female age 27 years, No Doses	35049	F				Aged out																																											-				HPV	44911	No Doses Administered	41275	43997.3748977662	Not recommended: too old	v1.6: Updated Series Status from "Not Complete" to "Aged Out" to align with updated CDSi Logic Specification Series Statuses.	1.6	This test case describes when an adult patient has no history of the HPV vaccine and is at age 27 that no doses should be forecast. The patient has aged out.
2013-0481	Male age 27. HPV not recommended.	35049	M				Aged out																																											-				HPV	44911	No Doses Administered	41275	43997.37498695602	Not recommended: too old	v1.6: Updated Series Status from "Not Complete" to "Aged Out" to align with updated CDSi Logic Specification Series Statuses.

v1.1: Gender should be M rather than F based on test case name; Also changed birth date to make patient 27 years old based on MMWR language allowing Males to be vaccinated through 26 years.	1.6	This test case describes when an adult patient has no history of the HPV vaccine and is at age 27 that no doses should be forecast. The patient has aged out.
2013-0482	Female, age 14.  HPV recommended	39798	F				Not complete																																											1	43085	43815	44573	HPV	44911	No Doses Administered	41275	43997.37509179398	Recommended based on age		1.0	This test case describes when an adolescent, age 14 years, has no history of the HPV vaccine that the first dose should be forecast.
2013-0483	HPV bivalent to male adolescent. Not valid. Forecast quadrivalent	36695	M				Not complete	40714	CERVARIX	118	SKB	Not Valid	Inadvertent Vaccine																																					1	40714	40714	41470	HPV	40714	Inadvertent vaccine	41275	44375.4614147338	Recommended based on age		3.2	This test case describes when an invalid vaccine is administered (Cervarix) that a repeat dose should be administered as soon as possible.
2013-0484	# 1 at age 9 years-5 days	41629	F				Not complete	44911	HPV9	165		Not Valid	Age: Too Young																																					1	44916	45647	46404	HPV	44911	Age: Below Absolute Minimum	41275	43997.375329699076	Recommended based on age		1.0	This test case describes when a child is administered dose number one of the HPV vaccine at 9 years - 5 days that the dose is not valid.  Another dose should be forecast.
2013-0485	# 1 at age  9 years-4 days	41628	F				Not complete	44911	HPV9	165		Valid																																						2	45062	45093	45334	HPV	44911	Age: At Absolute Minimum	41275	43997.37543569444	Recommended based on interval	v3.2: Updated to reflect ACIP recommendations for the HPV 2 dose series and to add plus 4 weeks to the latest recommended interval.	3.2	This test case describes when a child is administered the first dose of the HPV vaccine at 9 years - 4 days that the dose is valid.  Another dose should be forecast.
2013-0486	# 1 at age 9 years	41624	F				Not complete	44911	HPV9	165		Valid																																						2	45062	45093	45334	HPV	44911	Age: At Minimum	41275	43997.375514548614	Recommended based on interval	v3.2: Updated to reflect ACIP recommendations for the HPV 2 dose series and to add plus 4 weeks to the latest recommended interval.	3.2	This test case describes when a child is administered the first dose of the HPV vaccine at 9 years that the dose is valid.  Another dose should be forecast.
2016-0013	Female age 26, No HPV doses	35415	F				Not complete																																											1	38702	39432	40190	HPV	44911	No Doses Administered	42656	43997.37668042824	Recommended based on age		1.0	This test case describes when an adult age 26 years has no history of the HPV vaccine that the first dose should be forecast.
2016-0015	Adolescent child with first dose of HPV vaccine at 13 years and second dose after 15 years of age. 	39402	M				Complete	44165	Gardasil 9	165	MSD	Valid		44911	HPV9	165		Valid																																-				HPV	44911	All Valid: Forecast Test	42706	43997.37690659722	Not recommended: series complete		1.0	This test case describes when an adolescent child has received the first dose of the HPV vaccine at 13 years and a second dose 2 years later that the doses are valid.  The series is complete.
2016-0016	Adolescent child age 15 with no previous doses.	39279	F				Not complete																																											1	42567	43297	44055	HPV	44911	No Doses Administered	42706	43997.37709030093	Recommended based on age		1.0	This test case describes when an adolescent child age 15 years has no previous history of the HPV vaccine that the first dose should be forecast.
2016-0017	Adolescent child age 15 with one dose of the HPV vaccine	39279	F				Not complete	44911	Gardasil 9	165	MSD	Valid																																						2	44939	44939	45022	HPV	44911	All Valid: Forecast Test	42706	43997.38166465278	Recommended based on interval	v3.4: Earliest Recommended Date was changed from 8 weeks to 4 weeks on Dose 2 per HPV MMWR language.	3.4	This test case describes when an adolescent child age 15 years has been administered the first dose of the HPV vaccine that another dose should be forecast.
2016-0018	Adolescent child age 15 with two previous doses of the HPV vaccine.	39251	F				Not complete	44883	Gardasil 9	165	MSD	Valid		44911	HPV9	165		Valid																																3	45034	45064	45122	HPV	44911	All Valid: Forecast Test	42706	43997.3825547338	Recommended based on interval		1.0	This test case describes when an adolescent age 15 years old has been administered a first and second dose of the HPV vaccine that another dose should be forecast.
2016-0019	Adolescent child age 15 with three doses of the HPV vaccine	39098	F				Complete	44728	Gardasil 9	165	MSD	Valid		44756	HPV9	165		Valid		44909	HPV9	165		Valid																										-				HPV	44911	All Valid: Forecast Test	42706	43997.38268835648	Not recommended: series complete		1.0	This test case describes when an adolescent child age 15 years old has been administered all three doses of the HPV vaccine at valid intervals that the doses are valid.   The series is complete.
2016-0020	Adolescent child with a history of 2 doses of the HPV vaccine 1st dose given at 11 years and the 2nd dose give at 2 months later.	40435	M				Not complete	44848	Gardasil 9	165	MSD	Valid		44909	HPV9	165		Valid																																3	44999	45030	45271	HPV	44911	All Valid: Forecast Test	42706	44592.394387465276	Recommended based on interval	Updated to reflect ACIP recommendations for the HPV 2 dose series.	3.2	This test case describes when an adolescent child is administered a second dose of the HPV vaccine at an interval of 2 months after the first dose that the doses are valid.  Another dose should be forecast.
2016-0021	Adolescent child 15 years -1 days with no previous history of HPV vaccine	39433	M				Not complete																																											1	42721	43451	44209	HPV	44911	No Doses Administered	42706	43997.38287075231	Recommended based on interval	v1.0 Corrected forecast dates to match test case title	1.0	This test case describes when an adolescent child age 15 years - 1 day has no previous history of the HPV vaccine that the first dose should be forecast.
2016-0023	Adolescent child age 11 with 2nd dose of HPV at 5 months - 5 days	40695	F				Not complete	44761	Gardasil 9	165	MSD	Valid		44909	HPV9	165		Valid																																3	44993	44993	45184	HPV	44911	Interval: Below Absolute Minimum	42706	43997.383227673614	Recommended based on interval	Updated to reflect current ACIP recommendations for forecasting of the earliest and recommended date which is set by 12 weeks from invalid dose.	3.2	This test case describes when a second dose is administered at an interval of 4 weeks -4 days but before 5 months that a repeat dose  should be forecasted.
2016-0024	Adolescent child age 11 with 2nd dose of HPV at 5 months - 4 days	40693	F				Complete	44760	Gardasil 9	165	MSD	Valid		44909	HPV9	165		Valid																																-				HPV	44911	All Valid: Forecast Test	42706	43997.38337228009	Not recommended: series complete		1.0	This test case describes when an adolescent child age 11 years old is administered the second dose of the the HPV vaccine at 5 months - 4 days that the dose is valid.  The series is complete.
2017-0001	Child is age 9 with 3rd dose of HPV at 5 months from first dose	41380	F				Complete	44758	Gardasil 9	165	MSD	Valid		44818	Gardasil 9	165	MSD	Valid		44911	Gardasil 9	165	MSD	Valid																										-				HPV	44911	All Valid: Forecast Test	42796	43151.42220591435	Recommended based on interval		3.2	This test case describes when a third dose is administered an at an interval at least 5 months from the first dose and 12 weeks from the previous dose that no further doses are recommended.  Series is complete.
2019-0006	Any dose 26 years, Male, gardasil	35415	M				Not complete	44911	HPV9	165		Valid																																						2	44939	44939	45022	HPV	44911	All Valid: Forecast Test	43647.833333333336	43783.27436697917	Recommended based on interval	v4.2: Added past due date.	4.2	This test case describes when a male receives the first dose of the HPV vaccine at age 26 years that a second dose should be forecast.
2019-0007	Male age 26, No HPV doses	35415	M				Not complete																																											1	38702	39432	40190	HPV	44911	No Doses Administered	43647.833333333336	43703.49605141204	Recommended based on age		4.1	This test case describes when a male, age 26 years has no previous doses of the HPV vaccine that the first dose should be forecast.
2013-0487	#1 @ 11 yrs, 0 days, MCV4	40893	F				Not complete	44911	MENACTRA	114	PMC	Valid																																						2	46737	46737	47130	MCV	44911	Age: At Minimum	41275	43054.30047043981	Recommended based on age	v1.6: An EIPB clarification has resulted in a change to when dose 2 of MCV should be forecasted and validated.  The second dose must come on or after 16 years (- 4 days) of age to be considered valid.	1.6	This test case describes when dose 1 of a Mening vaccine is given at 11 years that the dose is considered to be valid.
2013-0488	#2 @ 16 yr - 4 days, MCV4	39071	F				Complete	43089	MENACTRA	114	PMC	Valid		44911	MENACTRA	114	PMC	Valid																																-				MCV	44911	Age: At Absolute Minimum	41275	43983.41223545139	Not recommended: series complete	v1.6: Updated Test case to reflect new absolute minimum age on dose 2 based on EIPB clarification	1.6	This test case describes when dose #2 of a Mening vaccine is given at 16 years - 4 days, that the dose is considered valid.  The series is complete. 
2013-0489	#2 @ 10 16 yr - 5 days, MCV4	39072	F				Not complete	43090	MENACTRA	114	PMC	Valid		44911	MENACTRA	114	PMC	Not Valid	Age: Too Young																															2	44967	44967	45308	MCV	44911	Age: Below Absolute Minimum	41275	43054.302748622686	Recommended based on minimum interval from invalid dose	v1.6: Updated Test case to reflect new absolute minimum age on dose 2 based on EIPB clarification	1.6	This test case describes when dose #2 of a Mening vaccine is given at 16 years - 5 days, that the dose is considered invalid.  
2013-0491	#2 @ 16 years, MCV4	39067	F				Complete	43085	MENACTRA	114	PMC	Valid		44911	MENACTRA	114	PMC	Valid																																-				MCV	44911	Age: At Recommended	41275	43054.303360578706	Not recommended: series complete		1.0	This test case describes when dose #1 and dose #2 of a Mening vaccine are administered at the recommended ages (11 and 16 years), that the doses are considered valid.  The series is complete.
2013-0495	#2 with interval of 5 years of #1	38337	F				Complete	43085	MENACTRA	114	PMC	Valid		44911	MENACTRA	114	PMC	Valid																																-				MCV	44911	Interval: At Recommended	41275	43983.504624340276	Not recommended: series complete	Test case was set to have the first dose at age 16 and second dose at 21 years.  Test case was adjusted to be at 13 years and 18 years to avoid the 16 year age skip dose which is tested in another test	1.2	This test case describes when dose #2 of a Mening vaccine is administered 5 years after dose #1 (age 13), that the dose in considered valid. The series is complete.
2013-0497	#1 @ 10 yrs - 1 day, #2 @ 10 yrs + 8 weeks - 5 days	41208	F				Not complete	44859	MENACTRA	114	PMC	Not Valid	Age: Too Young	44911	MENACTRA	114	PMC	Valid																																2	47052	47052	47444	MCV	44911	Age: Below Absolute Minimum	41275	43984.30500233796	Recommended based on age	v1.6: An EIPB clarification has resulted in a change to when dose 2 of MCV should be forecasted and validated.  The second dose must come on or after 16 years (- 4 days) of age to be considered valid.
v1.2: Same test case as previous version rolled younger to allow for the 10 year clarification by NIPInfo	1.6	This test case describes when dose #1 of a Mening vaccine is administered before 10 years of age and a repeat dose is administered at one month + 20 days later that the dose is considered valid.
2013-0498	#1 @ 10 yrs - 1 day, #2 @ 10 yrs + 8 weeks	41203	F				Not complete	44854	MENACTRA	114	PMC	Not Valid	Age: Too Young	44911	MENACTRA	114	PMC	Valid																																2	47047	47047	47439	MCV	44911	Age: Below Absolute Minimum	41275	43984.305135092596	Recommended based on minimum interval from invalid dose	v1.6: An EIPB clarification has resulted in a change to when dose 2 of MCV should be forecasted and validated.  The second dose must come on or after 16 years (- 4 days) of age to be considered valid.
v1.2: Same test case as previous version rolled younger to allow for the 10 year clarification by NIPInfo	1.6	This test case describes when dose #1 of a Mening vaccine is administered at 10 years - 1 day and a repeat dose is administered at one month + 25 days later that the dose is considered valid.
2013-0499	#1 @ 10 yrs, MCV4	41259	F				Not complete	44911	MENACTRA	114	PMC	Valid																																						2	47103	47103	47495	MCV	44911	Age: At Absolute Minimum	41275	43983.46921488426	Recommended based on age	v1.6: An EIPB clarification has resulted in a change to when dose 2 of MCV should be forecasted and validated.  The second dose must come on or after 16 years (- 4 days) of age to be considered valid.
v1.2: Same test case as previous version rolled younger to allow for the 10 year clarification by NIPInfo	1.6	This test case describes when dose #1 of a Mening vaccine is administered at age 10 years + 0 months that the dose is considered valid.
2013-0500	#1 @ 10 yrs - 1 day, MCV4	41260	F				Not complete	44911	MENACTRA	114	PMC	Not Valid	Age: Too Young																																					1	45277	45277	46035	MCV	44911	Age: Below Absolute Minimum	41275	43054.30777164352	Recommended based on age	Same test case as previous version rolled younger to allow for the 10 year clarification by NIPInfo	1.2	This test case describes when dose #1 of a Mening vaccine is administered at 10 years-1 day that the dose is considered invalid.
2013-0501	#1 @ 10 yrs - 1 day, #2 @ 10 yrs, 8 weeks - 4 days	41207	F				Not complete	44858	MENACTRA	114	PMC	Not Valid	Age: Too Young	44911	MENACTRA	114	PMC	Valid																																2	47051	47051	47443	MCV	44911	Age: Below Absolute Minimum	41275	43984.30569065972	Recommended based on age	v1.6: An EIPB clarification has resulted in a change to when dose 2 of MCV should be forecasted and validated.  The second dose must come on or after 16 years (- 4 days) of age to be considered valid.
v1.2: Same test case as previous version rolled younger to allow for the 10 year clarification by NIPInfo	1.6	This test case describes when dose #1 of a Mening vaccine is administered at 10 years - 1 day and a repeat dose is administered at one month + 21 days later that the dose is considered valid.
2013-0502	10 year old	41259	F				Not complete																																											1	45276	45276	46034	MCV	44911	No Doses Administered	41275	43249.32155479167	Recommended based on age		1.0	This test case describes when a newborn is assessed for the first dose of a Mening that a CDS engine should forecast the dose at the recommended age.
2013-0503	Dose 1 to dose 2 interval 8 wks-5 days	40781	F				Not complete	44860	meningococcal MCV4, unspecified formulation	147		Valid		44911	meningococcal MCV4, unspecified formulation	147		Not Valid	Interval: too short																															2	46625	46625	47018	MCV	44911	Interval: Below Absolute Minimum	41275	43213.612373310185	Recommended based on age	v1.6: An EIPB clarification has resulted in a change to when dose 2 of MCV should be forecasted and validated.  The second dose must come on or after 16 years (- 4 days) of age to be considered valid.	1.6	This test case describes when dose #2 of a Mening vaccine is administered too early (8 weeks - 5 days after dose #1), that the dose is not valid.
2013-0504	Dose 1 to dose 2 interval 8 wks-4 days	39025	F				Complete	44855	meningococcal MCV4, unspecified formulation	147		Valid		44907	meningococcal MCV4, unspecified formulation	147		Valid																																-				MCV	44911	Interval: At Absolute Minimum	41275	43983.5144040625	Not recommended: series complete	v1.6: updated to reflect interval without also testing age attributes.  Simply made the patient older	1.6	This test case describes when dose #2 of a Mening vaccine is administered at an interval of 8 wks - 4 days from dose #1 (age 15 years + 11 months) that the dose is considered valid.  The series is complete.
2013-0505	Dose 1 to dose 2 interval 8 weeks	39017	F				Complete	44850	meningococcal MCV4, unspecified formulation	147		Valid		44906	meningococcal MCV4, unspecified formulation	147		Valid																																-				MCV	44911	Interval: At Minimum	41275	43983.51495858796	Not recommended: series complete	v1.6: updated to reflect interval without also testing age attributes.  Simply made the patient older	1.6	This test case describes when dose #2 of a Mening vaccine is administered at an interval of 8 wks from dose #1 (age 15 years + 11 months) that the dose is considered valid.  The series is complete.
2013-0507	# 1 at age 11 years	40893	F				Not complete	44911	meningococcal MCV4, unspecified formulation	147		Valid																																						2	46737	46737	47130	MCV	44911	Age: At Minimum	41275	43054.31377138889	Recommended based on age	v1.6: An EIPB clarification has resulted in a change to when dose 2 of MCV should be forecasted and validated.  The second dose must come on or after 16 years (- 4 days) of age to be considered valid.	1.6	This test case describes when dose #1 of a Mening vaccine is administered at age 11 years + 0 days that the dose is considered to be valid.  
2013-0508	age 22.  No doses; No forecast	36876	F				Aged out																																											-				MCV	44911	No Doses Administered	41275	43054.31407857639	Not recommended: too old	v1.6: Updated Series Status from "Not Complete" to "Aged Out" to align with updated CDSi Logic Specification Series Statuses.	1.6	This test case describes when an individual, age 22 years, is assessed for the first dose of a Mening vaccine that a CDS engine should not forecast a dose.  A dose is not recommended. The series status is Aged Out.
2013-0509	# 1 at age 15 years	39424	F				Not complete	44911	meningococcal MCV4, unspecified formulation	147		Valid																																						2	45268	45268	45661	MCV	44911	All Valid: Forecast Test	41275	43983.515765474534	Recommended based on age	v1.6: An EIPB clarification has resulted in a change to when dose 2 of MCV should be forecasted and validated.  The second dose must come on or after 16 years (- 4 days) of age to be considered valid.	1.6	This test case describes when the first dose of a Mening vaccine is administered at 15 years + 8 days, that the dose is considered to be valid.
2013-0510	# 1 at age 16 years -5 days	39072	F				Not complete	44911	meningococcal MCV4, unspecified formulation	147		Valid																																						2	44967	44967	45308	MCV	44911	All Valid: Forecast Test	41275	43983.51589621528	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a first dose of a Mening vaccine is administered at 16 years - 5 days that the dose is considered to be valid.
2013-0511	# 1 at age 16 years -4 days	39071	F				Complete	44911	meningococcal MCV4, unspecified formulation	147		Valid																																						-				MCV	44911	All Valid: Forecast Test	41275	43983.51604109954	Not recommended: series complete		1.0	This test case describes when a dose of a Mening vaccine is administered at 16 years - 4 days, that the dose is considered to be valid. The series is complete.
2013-0512	# 1 at age 16 years	39067	F				Complete	44911	meningococcal MCV4, unspecified formulation	147		Valid																																						-				MCV	44911	All Valid: Forecast Test	41275	43983.51615400463	Not recommended: series complete		1.0	This test case describes when a dose of a Mening vaccine is administered at 16 years + 0 days, that the dose is considered to be valid. The series is complete.
2013-0523	#1 at 15 months	44455	F				Not complete	44911	M-M-R II	03	MSD	Valid																																						2	44939	45916	47039	MMR	44911	All Valid: Forecast Test	41275	43104.4502681713	Recommended based on age	Renamed to better reflect test case.	1.1	This test case describes when a child receives the first dose of the MMR vaccine at 15 months of age, that the dose is considered to be valid.
2013-0524	#2 at 4 years	43450	F				Complete	43906	M-M-R II	03	MSD	Valid		44911	M-M-R II	03	MSD	Valid																																-				MMR	44911	Age: At Recommended	41275	43104.45058135417	Not recommended: series complete	Renamed to better reflect test case.	1.1	This test case describes when the second dose of the MMR vaccine is administered at 4 years of age, that the dose is considered valid.  The series is complete.
2013-0525	#1 at 7 years	42354	F				Not complete	44911	M-M-R II	03	MSD	Valid																																						2	44939	44939	44939	MMR	44911	All Valid: Forecast Test	41275	43980.68220737269	Recommended based on minimum interval from previous dose (catch-up)	Renamed to better reflect test case.	1.1	This test case describes when a child receives the first dose of the MMR vaccine at 7 years, that the dose is considered to be valid.
2013-0528	5 single antigen doses: 1 Measles; 2 Mumps; 2 Rubella	43024	F				Not complete	43389	mumps	07		Valid		43417	MERUVAX II	06	MSD	Valid		43445	ATTENUVAX	05	MSD	Valid		44878	MERUVAX II	06	MSD	Valid		44908	mumps	07		Valid														2	44936	44936	45608	MMR	44911	Single Antigen Administration	41275	43178.54562484954	Recommended based on minimum interval from live virus vaccine	Renamed to better reflect test case.	1.1	This test case describes when a child is administered  single antigen doses of Measles, Mumps, and Rubella, at the minimum age of 12 months and a second dose of the Mumps and Rubella antigens at 5 years of age, that the second dose of the Measles vaccine is recommended.
2013-0530	4 single antigen doses: 1 Measles; 2 Mumps; 1 Rubella	43085	F				Not complete	43450	mumps	07		Valid		43478	MERUVAX II	06	MSD	Valid		43506	ATTENUVAX	05	MSD	Valid		44911	mumps	07		Valid																				2	44939	44939	45669	MMR	44911	Single Antigen Administration	41275	43178.55585174768	Recommended based on minimum interval from live virus vaccine	Renamed to better reflect test case.	1.1	This test case describes when a child is administered single antigen doses of Measles, Mumps, and Rubella, at the minimum age of 12 months and a second dose of the Mumps antigen at 5 years of age, that the second dose of the Measles and Rubella vaccine is recommended.
2013-0531	1 single antigen dose at 12M: 1 Measles	44546	F				Not complete	44911	ATTENUVAX	05	MSD	Valid																																						1	44942	44942	45059	MMR	44911	Single Antigen Administration	41275	43699.30990180556	Recommended based on minimum interval from previous dose (catch-up)	Renamed to better reflect test case. V1.4: Updated Earliest and Recommended date to adjust dates out 3 days.  Previous recommendation was 4 weeks from single dose administration, but this would result in the dose being forecasted too early for the second Measles at 13 months.	1.4	This test case describes when a child is administered single antigen dose of Measles, at the minimum age of 12 months that the a second dose is recommended.
2013-0534	2 single antigen doses: 1 Measles; 1 Mumps	44508	F				Not complete	44873	ATTENUVAX	05	MSD	Valid		44911	mumps	07		Valid																																1	44939	44939	45020	MMR	44911	Single Antigen Administration	41275	43698.335013206015	Recommended based on minimum interval from live virus vaccine	V1.1: Renamed to better reflect test case.	1.1	This test case describes when a child is administered single antigen dose of Measles and Mumps, at the minimum age of 12 months, that the second dose of the vaccines is recommended.
2013-0535	7 single antigen doses: 2 Measles; 3 Mumps; 2 Rubella	42994	F				Complete	43359	mumps	07		Valid		43387	MERUVAX II	06	MSD	Valid		43415	ATTENUVAX	05	MSD	Valid		44820	mumps	07		Valid		44848	MERUVAX II	06	MSD	Valid		44876	mumps	07		Extraneous	Series Already Complete	44911	ATTENUVAX	05	MSD	Valid		-				MMR	44911	Single Antigen Administration	41275	43178.56780034722	Not recommended: series complete	Renamed to better reflect test case.	1.1	This test case describes when a child is administered single antigen doses of Measles, Mumps, and Rubella at the minimum age of 12 months, a second dose of the Measles, Mumps, and Rubella antigens at 5 years of age, and an inadvertentent dose of the Mumps vaccine that the series is complete.
2013-0536	3 single antigen doses: 1 Measles; 1 Mumps; 1 Rubella	44431	F				Not complete	44796	mumps	07		Valid		44827	MERUVAX II	06	MSD	Valid		44911	ATTENUVAX	05	MSD	Valid																										2	44939	45892	47015	MMR	44911	Single Antigen Administration	41275	43178.56924658565	Recommended based on age	Renamed to better reflect test case.	1.1	This test case describes when a child is administered single antigen doses of Measles, Mumps, and Rubella, at the minimum age of 12 months, that a second doses of the vaccines are recommended.
2013-0537	3 single antigen doses on same day: 1 Measles; 1 Mumps; 1 Rubella 	44546	F				Not complete	44911	mumps	07		Valid		44911	MERUVAX II	06	MSD	Valid		44911	ATTENUVAX	05	MSD	Valid																										2	44942	46007	47130	MMR	44911	Single Antigen Administration	41275	43178.569969386575	Recommended based on age	V1.1: Renamed to better reflect test case. V1.4: Updated Earliest date to reflect the earliest date of 13 months and not 12 months + 4 weeks to align with ACIP.	1.4	This test case describes when a child is administered single antigen doses of Measles, Mumps, and Rubella, at the minimum age of 12 months, on the same day, that a second dose of the vaccines are recommended.
2013-0538	6 single antigen doses: 2 Measles; 2 Mumps; 2 Rubella	43029	F				Complete	43394	mumps	07		Valid		43422	MERUVAX II	06	MSD	Valid		43450	ATTENUVAX	05	MSD	Valid		44855	mumps	07		Valid		44883	MERUVAX II	06	MSD	Valid		44911	ATTENUVAX	05	MSD	Valid								-				MMR	44911	Single Antigen Administration	41275	43178.57063835648	Not recommended: series complete	Renamed to better reflect test case.	1.1	This test case describes when a child is administered single antigen doses of Measles, Mumps, and Rubella at the minimum age of 12 months, a second dose of the Measles, Mumps, and Rubella antigens at 5 years of age, that the series is complete.
2013-0539	3 single antigen doses: 2 Measles; 1 Rubella	44200	F				Not complete	44604	ATTENUVAX	05	MSD	Valid		44771	MERUVAX II	06	MSD	Valid		44911	ATTENUVAX	05	MSD	Valid																										1	44939	44939	44939	MMR	44911	Single Antigen Administration	41275	43699.31079127315	Recommended based on minimum interval from live virus vaccine	Renamed to better reflect test case.	1.1	This test case describes when a child is administered single antigen dose of Measles and Rubella, at the minimum age of 12 months, and a second dose of the Measles vaccine  at least 4 weeks later, that a second dose of the Rubella vaccine is recommended.
2013-0540	MMR # 1 at 12 months-5 days	44551	F				Not complete	44911	M-M-R II	03	MSD	Not Valid	Age: Too Young																																					1	44939	44939	45064	MMR	44911	Age: Below Absolute Minimum	41275	43104.45144582176	Recommended based on minimum interval from live virus vaccine		1.0	This test case describes when a child is administered the first dose of the MMR vaccine before 12 months of age, that the dose is not valid. 
2013-0541	MMR # 1 at 12 months-4 days	44550	F				Not complete	44911	M-M-R II	03	MSD	Valid																																						2	44946	46011	47134	MMR	44911	Age: At Absolute Minimum	41275	43980.64984319444	Recommended based on age		1.0	This test case describes when a child is administered the first dose of the MMR vaccine at 12 months - 4 days, that the dose is considered to be valid. 
2013-0542	MMR # 1 at 12 months	44546	F				Not complete	44911	M-M-R II	03	MSD	Valid																																						2	44942	46007	47130	MMR	44911	Age: At Minimum	41275	43104.451931828706	Recommended based on age		1.0	This test case describes when a child is administered the first dose of the MMR vaccine at 12 months, that the dose is considered to be valid. 
2013-0543	Newborn forecasting	44911	F				Not complete																																											1	45276	45276	45425	MMR	44911	No Doses Administered	41275	43104.452145324074	Recommended based on age		1.0	This test case describes the forecasting of the first dose of the MMR vaccine for a newborn.
2013-0544	Dose 1 to dose 2 interval 28 days 	44153	F				Complete	44883	M-M-R II	03	MSD	Valid		44911	M-M-R II	03	MSD	Valid																																-				MMR	44911	Interval: At Minimum	41275	43104.45240756944	Not recommended: series complete		1.0	This test case describes when the second dose of the MMR vaccine is administered to a 2 year old child at 28 days after the first dose, that the dose is considered to be valid. The series is complete.
2013-0545	MMR and VZ given at age 12 months	44546	F				Not complete	44911	M-M-R II	03	MSD	Valid		44911	VARIVAX	21	MSD	Valid																																2	44942	46007	47130	MMR	44911	Age: At Minimum	41275	43104.453253148145	Recommended based on age		1.0	This test case describes when a dose of the Varicella vaccine is administered at the same time of a MMR vaccine, both are valid.
2013-0546	Doses 1 and 2 of MMR and VZ at ages 12 and 13 months	44516	F				Complete	44881	M-M-R II	03	MSD	Valid		44881	VARIVAX	21	MSD	Valid		44911	M-M-R II	03	MSD	Valid		44911	VARIVAX	21	MSD	Valid																				-				MMR	44911	Age: At Minimum	41275	43104.454047534724	Not recommended: series complete		1.0	This test case describes when the first doses of the MMR  and Varicella vaccines are administered at 12 months of age, and the second doses of those vaccines are administered at 13 months of age, that the doses are considered to be valid.  The series are complete.
2013-0547	VZ to MMR interval 28-1 day = invalid MMR	44517	F				Not complete	44884	VARIVAX	21	MSD	Valid		44911	M-M-R II	03	MSD	Not Valid	Live Virus Conflict																															1	44939	44939	45029	MMR	44911	Live Virus: Below Minimum	41275	43104.454746944444	Recommended based on minimum interval from live virus vaccine		1.0	This test case describes when the first doses of the Varicella vaccine is administered at 12 months of age, and the first dose of the MMR vaccine is administered at an interval of 28-1 day that the MMR vaccine dose is not valid.
2013-0548	VZ given at age 12 mo; MMR at age 12 mo+28 days	44518	F				Not complete	44883	VARIVAX	21	MSD	Valid		44911	M-M-R II	03	MSD	Valid																																2	44939	45979	47102	MMR	44911	Live Virus: At Minimum	41275	43104.45508921296	Recommended based on age		1.0	This test case describes when the first dose of the Varicella vaccine is administered at 12 months of age and the first dose of the MMR vaccine is administered at 28 days later, that the doses are considered to be valid.
2013-0549	Dose 1 MMRV at 12 m-5 days	44551	F				Not complete	44911	PROQUAD	94	MSD	Not Valid	Age: Too Young																																					1	44939	44939	45064	MMR	44911	Age: Below Absolute Minimum	41275	43104.45746460648	Recommended based on minimum interval from live virus vaccine		1.0	This test case describes when a child is administered the first dose of the MMR vaccine (ProQuad) at 12 months -5 days, that the dose is not valid.
2013-0550	Dose 1 MMRV at 12 m-4 days	44550	F				Not complete	44911	PROQUAD	94	MSD	Valid																																						2	44946	46011	47134	MMR	44911	Age: At Absolute Minimum	41275	43980.653001990744	Recommended based on age		1.0	This test case describes when a child is administered the first dose of the MMR vaccine (ProQuad) at 12 months -4 days, that the dose is considered to be valid.
2013-0551	Dose 1 to dose 2 MMRV interval 28 days age < 15 months old= valid MMR	44518	F				Complete	44883	PROQUAD	94	MSD	Valid		44911	PROQUAD	94	MSD	Valid																																-				MMR	44911	Interval: At Minimum	41275	43980.656587604164	Not recommended: series complete		1.0	This test case describes when a child is administered the first dose of the MMR vaccine (ProQuad) at 12 months and the second dose at 28 days later,  that the doses are considered to be valid.  The series is complete.
2013-0552	Dose 1 to 2 MMRV interval 28 days in child ≥ 15 months old=valid MMR	43787	F				Complete	44883	PROQUAD	94	MSD	Valid		44911	PROQUAD	94	MSD	Valid																																-				MMR	44911	Interval: At Minimum	41275	43104.45888041666	Not recommended: series complete		1.0	This test case describes when a child is administered the first dose of the MMR vaccine (ProQuad) at 3 years of age and the second dose at 28 days later,  that the doses are considered to be valid.  The series is complete.
2013-0554	Dose 1 to 2 MMRV interval 28-4 days	44491	F				Not complete	44887	PROQUAD	94	MSD	Valid		44911	PROQUAD	94	MSD	Not Valid	Live Virus Conflict																															2	44939	45952	47075	MMR	44911	Live Virus: Below Minimum	41275	43984.30116462963	Recommended based on age	Shifted dates of administration and forecast to strictly test the Live Virus conflict only.  Previously it was testing a couple conditions	1.1	This test case describes when a child is administered the first dose of the MMR vaccine (ProQuad) at 13 months of age and the second dose at 24 days later, that the second dose is not valid.
2013-0555	MMR to MMRV interval 28 days=valid MMR # 2 	44518	F				Complete	44883	M-M-R II	03	MSD	Valid		44911	PROQUAD	94	MSD	Valid																																-				MMR	44911	Interval: At Minimum	41275	43984.30164655093	Not recommended: series complete		1.0	This test case describes when a child is administered the first dose of the MMR vaccine at 12 months of age and the second dose (ProQuad) at 28 days later,  that the doses are considered to be valid.  The series is complete.
2013-0556	MMR to MMRV interval 24 days=not valid MMR # 2	44491	F				Not complete	44887	M-M-R II	03	MSD	Valid		44911	PROQUAD	94	MSD	Not Valid	Live Virus Conflict																															2	44939	45952	47075	MMR	44911	Live Virus: Below Minimum	41275	43104.46040761574	Recommended based on age	V1.4: Final Guidance for MMRV live virus spacing is 28 days.  Grace period can't be applied.	1.4	This test case describes when a child is administered the first dose of the MMR vaccine at 12 months of age and the second dose (ProQuad) at 24 days later,  that the second dose is not valid.
2013-0557	MMRV to MMR interval 28 days=valid MMR dose 2	44487	F				Complete	44883	PROQUAD	94	MSD	Valid		44911	M-M-R II	03	MSD	Valid																																-				MMR	44911	Interval: At Minimum	41275	43980.66063951389	Not recommended: series complete		1.0	This test case describes when a child is administered the first dose of the MMR vaccine (ProQuad) at 13 months of age and the second dose (MMR II) at 28 days later,  that the doses are considered to be valid.  The series is complete.
2013-0558	Dose 1 to dose 2 interval 4 wks between VZ and MMRV in any age child=valid MMR	44508	F				Not complete	44883	VARIVAX	21	MSD	Valid		44911	PROQUAD	94	MSD	Valid																																2	44939	45969	47092	MMR	44911	Interval: At Minimum	41275	43104.461246666666	Recommended based on age		1.0	This test case describes when a child is administered the first dose of the Varicella vaccine at 12 months of age and a dose of the MMRV vaccine at 4 weeks later, that the doses are considered to be valid.  
2013-0559	28 day interval between invalid VZ and subsequent MMRV=valid MMR and VZ	44523	F				Not complete	44883	VARIVAX	21	MSD	Not Valid	Age: Too Young	44911	PROQUAD	94	MSD	Valid																																2	44939	45984	47107	MMR	44911	Live Virus: At Minimum	41275	43104.46217914352	Recommended based on age		1.0	This test case describes when the first dose of the Varicella vaccine is administered before 12 months - 4 days and a MMRV vaccine is administered at 28 days later, that the MMRV (PRoQuad) vaccine dose is considered to be valid. 
2013-0562	Interval of < 24 days between an invalid MMR and a subsequent MMRV=no valid MMR's	44528	F				Not complete	44888	M-M-R II	03	MSD	Not Valid	Age: Too Young	44911	PROQUAD	94	MSD	Not Valid	Live Virus Conflict																															1	44939	44939	45040	MMR	44911	Live Virus: Below Minimum	41275	43104.4631900463	Recommended based on minimum interval from live virus vaccine		1.0	This test case describes when the first dose of the MMR vaccine is administered before 12 months - 4 days and a MMRV vaccine (ProQuad)  is administered less than 28 days later, that neither are the doses are valid.
2013-0563	Interval of < 24 days between an invalid VZ and a subsequent MMRV=no valid MMR or VZ	44528	F				Not complete	44888	VARIVAX	21	MSD	Not Valid	Age: Too Young	44911	PROQUAD	94	MSD	Not Valid	Live Virus Conflict																															1	44939	44939	45040	MMR	44911	Live Virus: Below Minimum	41275	43104.464136863426	Recommended based on minimum interval from live virus vaccine		1.0	This test case describes when the first dose of the Varicella vaccine is administered before 12 months - 4 days and a MMRV (ProQuad) vaccine is administered less than 28 days later, that the doses are not valid.
2013-0565	Correctly administered single antigen M, M and R followed by MMR=series complete	43809	F				Complete	44243	mumps	07		Valid		44302	MERUVAX II	06	MSD	Valid		44546	ATTENUVAX	05	MSD	Valid		44175	M-M-R II	03	MSD	Valid																				-				MMR	44911	Single Antigen Administration	41275	43178.573164849535	Not recommended: series complete		1.0	This test case describes when single antigens M, M, and R are administered to a child >  12 months of age followed by a MMR (4rth )dose a year later, that the doses are considered to be valid.  The series is complete.  
2013-0570	Dose 2 at age 13 mo -5 days	44521	F				Not complete	44884	M-M-R II	03	MSD	Valid		44911	M-M-R II	03	MSD	Not Valid	Age: Too Young																															2	44939	45982	47105	MMR	44911	Age: Below Absolute Minimum	41275	43984.30257284722	Recommended based on age		1.0	This test case describes when a child is administered the second dose of the MMR vaccine at 13 months - 5 days, that the dose is not valid.
2013-0571	Dose 2 at age 13 mo - 4 days 	44520	F				Complete	44885	M-M-R II	03	MSD	Valid		44911	M-M-R II	03	MSD	Valid																																-				MMR	44911	Age: At Absolute Minimum	41275	43980.66919677083	Not recommended: series complete		1.0	This test case describes when a child is administered the second dose of the MMR vaccine at 13 months - 4 days, that the dose is considered to be valid. The series is complete.
2013-0572	Dose 2 at age 13 mo 	44516	F				Complete	44881	M-M-R II	03	MSD	Valid		44911	M-M-R II	03	MSD	Valid																																-				MMR	44911	Age: At Minimum	41275	43104.46706005787	Not recommended: series complete		1.0	This test case describes when a child is administered the second dose of the MMR vaccine at 13 months, that the dose is considered to be valid. The series is complete.
2013-0573	Dose 1 to dose 2 interval 28 days-5 days	44066	F				Not complete	44888	M-M-R II	03	MSD	Valid		44911	M-M-R II	03	MSD	Not Valid	Interval: too short																															2	44939	45527	46649	MMR	44911	Interval: Below Absolute Minimum	41275	43104.467562199075	Recommended based on age		1.0	This test case describes when a child is administered the second dose of the MMR vaccine at an interval of 28 -5 days, that the dose is not valid. 
2013-0574	Dose 1 to dose 2 interval 28-4 days 	44491	F				Complete	44887	M-M-R II	03	MSD	Valid		44911	M-M-R II	03	MSD	Valid																																-				MMR	44911	Interval: At Absolute Minimum	41275	43980.673601030096	Not recommended: series complete		1.0	This test case describes when a child is administered the second dose of the MMR vaccine at an interval of 28 -4 days, that the dose is considered to be valid. The series is complete. 
2015-0024	MMR: Patient is born before 01/01/1957	20618	F				Immune																																											-				MMR	42086	No Doses Administered	42178	43160.33077685185	Not recommended: immune	New test case for version 2.0 which expanded scope into Adult recommendations	1.0	This test case describes when a patient was born before January 1, 1957, that the patient is considered to be Immune.
2019-0017	Adult with no previous doses of the MMR vaccine	32127	M				Not complete																																											1	32493	32493	32641	MMR	44911	No Doses Administered	43390.833333333336	43980.35926972222	Recommended based on age		4.2	This test cases describes when an adult patient has no known history of the MMR vaccine that a dose should be forecast.
2019-0018	Adult with a dose of the MMR vaccine	32127	M				Complete	44911	MMR	03		Valid																																						-				MMR	44911	All Valid: Forecast Test	43730.833333333336	43783.28443947917	Not recommended: series complete		4.2	This test case describes when an adult patient received a dose of the MMR vaccine, that no additional doses are needed. Series is complete.
2019-0019	Adolescent with no dose of MMR vaccine	39067	F				Not complete																																											1	39432	39432	39581	MMR	44911	No Doses Administered	43780.791666666664	43980.68108178241	Recommended based on age		4.2	This test case describes when an adolescent patient has no known history of the MMR vaccine that a dose should be forecast.
2019-0020	Adolescent with 2nd dose of MMR vaccine at 4 weeks	39039	F				Complete	44883	MMR	03		Valid		44911	MMR	03		Valid																																				MMR	44911	All Valid: Forecast Test	43780.791666666664	44357.59096528935	Not recommended: series complete		4.2	This test case describes when a patient receives the 2nd dose of the MMR vaccine at 4 weeks after the first dose, that the dose is considered to be valid.  The series is complete.
2019-0021	Adolescent with 2nd dose of MMR vaccine at 4 weeks - 5 days	39044	F				Not complete	44888	MMR	03		Valid		44911	MMR	03		Not Valid	Interval: too short																															2	44939	44939	44939	MMR	44911	Interval: Below Absolute Minimum	43780.791666666664	43984.3035846412	Recommended based on interval		4.2	This test case describes when a patient is administered the second dose of the MMR vaccine at less than 4 weeks - 4 days, that another dose should be forecast.
2019-0022	Adolescent with 2nd dose of MMR vaccine at 4 weeks - 4 days	39043	F				Complete	44887	MMR	03		Valid		44911	MMR	03		Valid																																				MMR	44911	All Valid: Forecast Test	43780.791666666664	44357.59152755787	Not recommended: series complete		4.2	This test case describes when a patient receives the 2nd dose of the MMR vaccine at 4 weeks - 4 days after the first dose, that the dose is considered to be valid.  The series is complete.
2013-0575	Newborn Testing	44911	F				Not complete																																											1	44953	44973	45028	PCV	44911	No Doses Administered	41275	43178.57663645833	Recommended based on age		1.0	This test case describes the forecasting of a newborn for the first dose of the Pneumoccocal vaccine.
2013-0576	Dose # 1 PCV 13 at age 18 months	44363	F				Not complete	44911	PREVNAR 13	133	PFR	Valid																																						2	44967	44967	44967	PCV	44911	All Valid: Forecast Test	41275	43980.30751537037	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when dose #1 of the Pneumococcal 13 vaccine is administered at age 18 months that the dose is considered to be valid and the patient is on a catch-up schedule.
2013-0577	Dose # 1 of PCV 7 at age 24 months.  Need one dose PCV 13. 	39508	F				Not complete	40238	PREVNAR 7	100	WAL	Valid																																						2	40294	40294	40294	PCV	40238	All Valid: Forecast Test	41275	43980.307939895836	Recommended based on minimum interval from previous dose (catch-up)	V1.3: The first dose was PCV7 and was marked as not valid.  This dose is valid, but the patient still needs a valid PCV13.	1.3	This test case describes when dose #1 of the Pneumococcal 7 vaccine is administered at age 24 months that the dose is considered to be valid. Forecast another dose.
2013-0578	Dose # 1 of PCV 13 at age 24 months.  Series complete.	44181	F				Complete	44911	PREVNAR 13	133	PFR	Valid																																						-				PCV	44911	All Valid: Forecast Test	41275	43980.30822731482	Not recommended: series complete		1.0	This test case describes when dose #1 of the Pneumococcal 13 vaccine is administered at age 24 months that the dose is considered to be valid.  No additional dose should be forecasted.  The series is complete.
2013-0579	Dose # 2 PCV 13 at age 10 weeks-5 days	44846	F				Not complete	44884	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Not Valid	Age: Too Young																															2	44939	44969	45024	PCV	44911	Age: Below Absolute Minimum	41275	43104.401850358794	Recommended based on age		1.0	This test case describes when dose #2 of the Pneumococcal 13 vaccine is administered at  age 10 weeks - 5 days, that the dose is not valid.  
2013-0580	Dose # 2 PCV 13 at age 10 weeks-4 days	44845	F				Not complete	44884	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																																3	44943	45027	45084	PCV	44911	Age: At Absolute Minimum	41275	43980.30846407407	Recommended based on age		1.0	This test case describes when dose #2 of the Pneumococcal 13 vaccine is administered at  age 10 weeks - 4 days, that the dose is considered to be valid.   
2013-0581	Dose PCV 13 # 2 at age 10 weeks	44841	F				Not complete	44883	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																																3	44939	45023	45080	PCV	44911	Age: At Minimum	41275	43104.40289982639	Recommended based on age		1.0	This test case describes when dose #2 of the Pneumococcal 13 vaccine is administered at  age 10 weeks, that the dose is considered to be valid.   
2013-0582	Dose # 2 PCV 13 at age 4 months	44789	F				Not complete	44850	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																																3	44939	44973	45028	PCV	44911	Age: At Recommended	41275	43104.403408969905	Recommended based on age		1.0	This test case describes when dose #2 of the Pneumococcal 13 vaccine is administered at  age 4 months, that the dose is considered to be valid.   
2013-0583	Dose # 1 PCV 13 at  age 7 months, dose # 2 at age 8 mos and current age ≥ 12 mos.	44546	F				Not complete	44758	PREVNAR 13	133	PFR	Valid		44789	PREVNAR 13	133	PFR	Valid																																3	44911	44911	45059	PCV	44911	All Valid: Forecast Test	41275	43980.31070069444	Recommended based on age		1.0	This test case describes when a child is currently 12 months of age and was administered dose #1 at age 7 months and dose #2 at age 8 months of age that the doses are considered to be valid. A final dose is recommended at age 12 months.
2013-0584	Dose # 1 PCV 13 at 12 mo; dose # 2 at 1 yr 8 wks-5 days	44495	F				Not complete	44860	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Not Valid	Interval: too short																															2	44967	44967	44967	PCV	44911	Interval: Below Absolute Minimum	41275	43980.311259918984	Recommended based on minimum interval from invalid dose	V1.2: Condensed the past due date to align with the earliest and recommended date since this child is in catch-up	1.2	This test case describes when dose #1 of the Pneumococcal 13 vaccine is administered at 12 months, and the #2 of the Pneumococcal 13 vaccine is administered at 1 yr, 8 weeks - 5 days, that the second dose is not valid.
2013-0585	Dose # 1 PCV 13 at age 12 mos; # 2 at 1 yr 8 wks-4 days	44494	F				Complete	44859	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																																-				PCV	44911	Interval: At Absolute Minimum	41275	43980.31221550926	Not recommended: series complete		1.0	This test case describes when dose #1 of the Pneumococcal 13 vaccine is administered at 12 months, and the #2 dose of the Pneumococcal 13 vaccine is administered at 1 yr, 8 weeks - 4 days, that the second dose is valid. The patient is complete.
2013-0587	Dose # 1 PCV 13 at age 12 months; # 2 at age 14 mos.  Series complete. 	44485	F				Complete	44850	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																																-				PCV	44911	All Valid: Forecast Test	41275	43980.31269708333	Not recommended: series complete		1.0	This test case describes when dose #1 of the Pneumococcal 13 vaccine is administered at 12 months, and the #2 dose of the Pneumococcal 13 vaccine is administered at 14 months, that the second dose is considered to be valid.
2013-0588	Dose # 1 PCV 13 at 24 mo-5 days.  Valid but child needs another. 	44186	F				Not complete	44911	PREVNAR 13	133	PFR	Valid																																						2	44967	44967	44967	PCV	44911	All Valid: Forecast Test	41275	43980.31332084491	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered the first dose of the Pneumococcal 13 vaccine at 24 months - 5 days, that the dose is considered to be valid, but a second dose is still needed.
2013-0589	Dose 1 PCV 13 at 24 m-4 days.  Series complete. 	44185	F				Complete	44911	PREVNAR 13	133	PFR	Valid																																						-				PCV	44911	All Valid: Forecast Test	41275	43980.31366107639	Not recommended: series complete		1.0	This test case describes when a child is administered the first  dose of the Pneumococcal 13 vaccine at 24 months - 4 days, that the dose is considered to be valid. No additional doses are recommended.  The series is complete.
2013-0590	Dose # 3 PCV 13 at age 14 weeks-5 days.	44818	F				Not complete	44857	PREVNAR 13	133	PFR	Valid		44885	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Not Valid	Age: Too Young																									3	44939	44999	45057	PCV	44911	Age: Below Absolute Minimum	41275	43104.410779212965	Recommended based on age		1.0	This test case describes when dose #3 of the Pneumococcal 13 vaccine is administered to a child at 14 weeks- 5 days, that the dose is not valid.
2013-0591	Dose # 3 PCV 13 at age 14 weeks-4 days.	44817	F				Not complete	44856	PREVNAR 13	133	PFR	Valid		44884	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																										4	45182	45182	45331	PCV	44911	Age: At Absolute Minimum	41275	43980.31397070602	Recommended based on age		1.0	This test case describes when dose #3 of the Pneumococcal 13 vaccine is administered to a child at 14 weeks- 4 days, that the dose is considered to be valid.
2013-0592	Dose # 3 PCV 13 at age 14 weeks	44813	F				Not complete	44855	PREVNAR 13	133	PFR	Valid		44883	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																										4	45178	45178	45327	PCV	44911	Age: At Minimum	41275	43104.41306708333	Recommended based on age		1.0	This test case describes when dose #3 of the Pneumococcal 13 vaccine is administered to a child at 14 weeks, that the dose is considered to be valid.
2013-0593	Dose # 3 PCV 13 at 6 mo.	44728	F				Not complete	44789	PREVNAR 13	133	PFR	Valid		44850	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																										4	45093	45093	45242	PCV	44911	Age: At Recommended	41275	43104.413653449075	Recommended based on age		1.0	This test case describes when dose #3 of the Pneumococcal 13 vaccine is administered to a child at 6 months, that the dose is considered to be valid.
2013-0594	Mixed vaccines: dose # 1 PCV 7 at 6 mo; # 2 PCV 13 at 8 mo; # 3 PCV 13 at 12 months.  Series complete. 	40241	F				Complete	40425	PREVNAR 7	100	WAL	Valid		40486	PREVNAR 13	133	PFR	Valid		40606	PREVNAR 13	133	PFR	Valid																										-				PCV	40606	All Valid: Forecast Test	41275	43161.36422474537	Not recommended: series complete		1.0	This test case describes when dose #1 of PCV 7 is administered at 6 months, dose #2 of PCV 13 is administered at 8 months, and dose #3 of PCV 13 is administered at 12 months, that the doses are considered to be valid.  The series is complete.
2013-0595	Mixed vaccines: dose # 1 PCV 7 at 7 mo; # 2 PCV 7 at 8 mo; #3 PCV 13 at 12 months.  Series complete. 	39965	F				Complete	40179	PREVNAR 7	100	WAL	Valid		40210	PREVNAR 7	100	WAL	Valid		40330	PREVNAR 13	133	PFR	Valid																										-				PCV	40330	All Valid: Forecast Test	41275	43980.315548935185	Not recommended: series complete	Minor typo in test case name corrected.	1.1	This test case describes when dose #1 of PCV 7 is administered at 7 months, dose #2 of PCV 13 is administered at 8 months, and dose #3 of PCV 13 is administered at 12 months, that the doses are considered to be valid.  The series is complete.
2013-0596	Dose # 1 PCV 13 at age 6 weeks-5 days	44874	F				Not complete	44911	PREVNAR 13	133	PFR	Not Valid	Age: Too Young																																					1	44916	44935	44993	PCV	44911	Age: Below Absolute Minimum	41275	43390.594409212965	Recommended based on age		1.0	This test case describes when dose #1 of the Pneumococcal vaccine is administered at age 6 weeks - 5 days that the dose is not valid.
2013-0597	Dose # 1 PCV 13 at 6 mo; # 2 at 11 mo, # 3 at 12 mo	44546	F				Not complete	44728	PREVNAR 13	133	PFR	Valid		44881	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Not Valid	Interval: too short																									3	44967	44967	45059	PCV	44911	Interval: Below Absolute Minimum	41275	44054.334083333335	Recommended based on minimum interval from invalid dose	V4.4 Updated the Evaluation test type from All valid doses: to Interval: Below Absolute Minimum
V1.2: At 12 Months of age and after the spacing must be 8 weeks or more.  Dose 3 was given on 12 Months, but wasn't spaced 8 weeks.  The forecast in this case remains unchanged.	4.4	This test case describes when dose #1 of PCV 13 is administered at 6 months, dose #2 of PCV 13 is administered at 11 months, and dose #3 of PCV 13 is administered at 12 months, that dose #3 is not valid.
2013-0598	Dose # 4 PCV 13 at age 12 mo-5 days	44551	F				Not complete	44613	PREVNAR 13	133	PFR	Valid		44672	PREVNAR 13	133	PFR	Valid		44733	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Not Valid	Age: Too Young																			4	44967	44967	45064	PCV	44911	Age: Below Absolute Minimum	41275	43104.415090787035	Recommended based on minimum interval from inValid dose		1.0	This test case describes when dose #4 of the PCV13 vaccine is administered at age 12 months - 5 days that the dose is not valid.
2013-0599	Dose # 4 PCV 13 at age 12 months-4 days.  Series complete. 	44550	F				Complete	44612	PREVNAR 13	133	PFR	Valid		44671	PREVNAR 13	133	PFR	Valid		44732	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																				-				PCV	44911	Age: At Absolute Minimum	41275	43980.31699774306	Not recommended: series complete		1.0	This test case describes when dose #4 of the PCV13 vaccine is administered at age 12 months - 4 days that the dose is considered to be valid.  The series is complete.
2013-0600	Dose # 4 PCV 13 at 1 year.  Series complete. 	44546	F				Complete	44608	PREVNAR 13	133	PFR	Valid		44667	PREVNAR 13	133	PFR	Valid		44728	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																				-				PCV	44911	Age: At Minimum	41275	43104.41674311343	Not recommended: series complete		1.0	This test case describes when dose #4 of the PCV13 vaccine is administered at age 12 months that the dose is considered to be valid.  The series is complete.
2013-0601	4 doses of PCV 7, no PCV 13.  Needs one PCV 13. 	39965	F				Not complete	40026	PREVNAR 7	100	WAL	Valid		40087	PREVNAR 7	100	WAL	Valid		40148	PREVNAR 7	100	WAL	Valid		40360	PREVNAR 7	100	WAL	Valid																				5	40416	40416	40416	PCV	40360	All Valid: Forecast Test	41275	43161.36570618056	Recommended based on minimum interval from previous dose (catch-up)	The fourth dose of PCV7 was marked as Not Valid.  In fact this was a valid administration with a need for a subsequent PCV13 in 8 weeks time.  V1.3: Updated Eval and Forecast Test Type and adjusted the past due date to align with the earliest and recommended date per the subsequent dose recommendations of ACIP.	1.3	This test case describes when 4 doses of PCV 7 is administered that one dose of Pneumococcal 13 is needed.
2013-0602	Dose 1 invalid (age) as first of others	44728	F				Not complete	44759	PREVNAR 13	133	PFR	Not Valid	Age: Too Young	44835	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																										3	44939	44939	44969	PCV	44911	Age: Below Absolute Minimum	41275	43980.31809648148	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when the first dose of the Pneumococcal vaccine is  not valid.
2013-0603	Dose 2 invalid (age) in midst of others.   	44758	F				Not complete	44798	PREVNAR 13	133	PFR	Valid		44823	PREVNAR 13	133	PFR	Not Valid	Age: Too Young	44911	PREVNAR 13	133	PFR	Valid																										3	44939	44942	45000	PCV	44911	Age: Below Absolute Minimum	41275	43104.417783032404	Recommended based on age		1.0	This test case describes when the second dose of the Pneumococcal vaccine is  not valid.
2013-0604	Dose # 3 invalid (age) in midst of others.   Four valid doses not required in this scenario.	44534	F				Complete	44575	PREVNAR 13	133	PFR	Valid		44602	PREVNAR 13	133	PFR	Valid		44613	PREVNAR 13	133	PFR	Not Valid	Age: Too Young	44911	PREVNAR 13	133	PFR	Valid																				-				PCV	44911	Age: Below Absolute Minimum	41275	43104.41867810185	Not recommended: series complete		1.0	This test case describes when the third dose of the Pneumococcal vaccine is  not valid.
2013-0605	Dose 1 to dose 2 interval 28-5 days.	44827	F				Not complete	44888	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Not Valid	Interval: too short																															2	44939	44949	45007	PCV	44911	Interval: Below Absolute Minimum	41275	43104.419178842596	Recommended based on age		1.0	This test case describes when the interval between dose #1 and dose #2 of the Pnuemococal vaccine is 28 - 5 days that the second dose is not valid.
2013-0606	Dose 1 to dose 2 interval 28-4 days	44826	F				Not complete	44887	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																																3	44939	45007	45065	PCV	44911	Interval: At Absolute Minimum	41275	43980.31916564815	Recommended based on age		1.0	This test case describes when dose #1 and dose #2 of the Pnuemococal 13 vaccine is administered at  28 - 4 days that the second dose is considered to be valid.
2013-0607	Dose # 1 PCV 13 at age 6 weeks-4 days	44873	F				Not complete	44911	PREVNAR 13	133	PFR	Valid																																						2	44943	44993	45051	PCV	44911	Age: At Absolute Minimum	41275	43980.31936443287	Recommended based on age		1.0	This test case describes when dose #1 of the Pneumococcal 13 vaccine is administered at 6 weeks - 4 days that the dose is considered to be valid.
2013-0608	Dose 1 PCV 13 to dose 2 interval 28 days	44822	F				Not complete	44883	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																																3	44939	45003	45061	PCV	44911	Interval: At Minimum	41275	43104.4204840625	Recommended based on age		1.0	This test case describes when dose #1 to dose #2 of the Pneumococcal 13 vaccine is administered at an interval of 28 days, that the second dose is considered to be valid.
2013-0609	Dose 2 to dose 3  interval  28-5 days	44765	F				Not complete	44827	PREVNAR 13	133	PFR	Valid		44888	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Not Valid	Interval: too short																									3	44939	44949	45007	PCV	44911	Interval: Below Absolute Minimum	41275	43104.421070613425	Recommended based on age		1.0	This test case describes when dose #2 to dose #3 of the Pnuemococcal 13 vaccine is administered at 28-5 days that dose #3 is not valid.
2013-0610	Dose 2 to dose 3 PCV 13 interval 28-4 days	44734	F				Not complete	44795	PREVNAR 13	133	PFR	Valid		44887	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																										4	45099	45099	45248	PCV	44911	Interval: At Absolute Minimum	41275	43980.31957590278	Recommended based on age		1.0	This test case describes when dose #2 to dose #3 of the Pnuemococcal 13 vaccine is administered at an interval of 28-4 days that dose #3 is considered to be valid.
2013-0611	Dose 2 to dose 3 PCV 13 interval 28 days	44730	F				Not complete	44791	PREVNAR 13	133	PFR	Valid		44883	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																										4	45095	45095	45244	PCV	44911	Interval: At Minimum	41275	43104.4229859375	Recommended based on age		1.0	This test case describes when dose #2 to dose #3 of the Pnuemococcal vaccine is administered at an interval of 28 days that dose #3 is considered to be valid.
2013-0612	Dose 3 PCV 13 to dose 4 interval 8 weeks-5 days	44526	F				Not complete	44707	PREVNAR 13	133	PFR	Valid		44830	PREVNAR 13	133	PFR	Valid		44860	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Not Valid	Interval: too short																			4	44967	44967	45038	PCV	44911	Interval: Below Absolute Minimum	41275	43332.44152357639	Recommended based on minimum interval from inValid dose		1.0	This test case describes when dose #3 to dose #4 of the Pnuemococcal 13 vaccine is administered at an interval of 8 weeks -5 days that dose #4 is not valid.
2013-0613	Dose 3 PCV 13 to dose 4 interval 8 wks-4 days.  Series complete.	44525	F				Complete	44706	PREVNAR 13	133	PFR	Valid		44829	PREVNAR 13	133	PFR	Valid		44859	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																				-				PCV	44911	Interval: At Absolute Minimum	41275	43980.32004711805	Not recommended: series complete		1.0	This test case describes when dose #3 to dose #4 of the Pnuemococcal 13 vaccine is administered at an interval of 8 weeks -4 days that dose #4 is considered to be valid. The series is complete.
2013-0614	Dose 3 PCV 13 to dose 4 interval 8 weeks.  Series complete.	44521	F				Complete	44702	PREVNAR 13	133	PFR	Valid		44825	PREVNAR 13	133	PFR	Valid		44855	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																				-				PCV	44911	Interval: At Minimum	41275	43213.624700914355	Not recommended: series complete		1.0	This test case describes when dose #3 to dose #4 of the Pnuemococcal 13 vaccine is administered at an interval of 8 weeks that dose #4 is considered to be valid. The series is complete.
2013-0615	Invalid dose 2 (interval) in midst of others	44546	F				Complete	44594	PREVNAR 13	133	PFR	Valid		44617	PREVNAR 13	133	PFR	Not Valid	Interval: too short	44728	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 13	133	PFR	Valid																				-				PCV	44911	Interval: Below Absolute Minimum	41275	43104.42962065972	Not recommended: series complete		1.0	This test case describes when the second dose of the Pneumococcal vaccine is  not valid, but the patient is still complete since the last was after 12 months and 8 weeks from the previous dose.
2013-0616	Invalid dose 3 (interval) in midst of others	44516	F				Complete	44636	PREVNAR 13	133	PFR	Valid		44736	PREVNAR 13	133	PFR	Valid		44758	PREVNAR 13	133	PFR	Not Valid	Interval: too short	44911	PREVNAR 13	133	PFR	Valid																				-				PCV	44911	Interval: Below Absolute Minimum	41275	43104.43087362269	Not recommended: series complete		1.0	This test case describes when the third dose of the Pneumococcal 13 vaccine is  not valid, but the patient is still complete since the last dose was after 12 months of age and 8 weeks since the previous dose.
2013-0617	InValid dose 4 (interval) in midst of others	44467	F				Complete	44528	PREVNAR 13	133	PFR	Valid		44648	PREVNAR 13	133	PFR	Valid		44821	PREVNAR 13	133	PFR	Valid		44851	PREVNAR 13	133	PFR	Not Valid	Interval: too short	44907	PREVNAR 13	133	PFR	Valid														-				PCV	44911	Interval: Below Absolute Minimum	41275	43104.432575416664	Not recommended: series complete		1.0	This test case describes when the fourth dose of the Pneumococcal 13 vaccine is  not valid.
2013-0618	Dose # 1 PCV 13 at age 6 weeks	44869	F				Not complete	44911	PREVNAR 13	133	PFR	Valid																																						2	44939	44989	45047	PCV	44911	Age: At Minimum	41275	43104.43342479166	Recommended based on age		1.0	This test case describes when the dose #1 of the Pneumococcal 13 vaccine is administered at age 6 weeks, that the dose is considered to be valid.
2013-0619	4 doses of PCV 7 and 1 dose of PCV 13=series complete	39605	F				Complete	39666	PREVNAR 7	100	WAL	Valid		39727	PREVNAR 7	100	WAL	Valid		39788	PREVNAR 7	100	WAL	Valid		40153	PREVNAR 7	100	WAL	Valid		40973	PREVNAR 13	133	PFR	Valid														-				PCV	40973	All Valid: Forecast Test	41275	43161.36601834491	Not recommended: series complete	The fourth dose of PCV7 was marked as Not Valid.  In fact this was a valid administration.  The PCV13 which followed completed the series. V1.3 updated Evaluation Test Type	1.3	This test case describes when 4 doses of the PCV 7 vaccine and 1 dose of the PCV13 vaccine has been administered that the doses are considered to be valid.  The series is complete.
2013-0622	Dose # 1 PCV 13 at age 2 months	44850	F				Not complete	44911	PREVNAR 13	133	PFR	Valid																																						2	44939	44973	45028	PCV	44911	Age: At Recommended	41275	43104.43371680556	Recommended based on age		1.0	This test case describes when dose #1 of the Pneumococcal 13 vaccine is administered at age 2 months, that the dose is considered to be valid.
2013-0624	Dose # 1 PCV 13 at age 11 months	44577	F				Not complete	44911	PREVNAR 13	133	PFR	Valid																																						2	44939	44939	44939	PCV	44911	All Valid: Forecast Test	41275	43980.321138576386	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when dose #1 of the Pneumococcal 13 vaccine is administered at age 11 months, that the dose is considered to be valid, but the patient is now on the catch-up schedule.
2013-0625	Dose # 1 PCV 13 at age 12 months	44546	F				Not complete	44911	PREVNAR 13	133	PFR	Valid																																						2	44967	44967	44967	PCV	44911	All Valid: Forecast Test	41275	43980.321421458335	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was incorrect.  Should be in alignment with the earliest and recommended.  Child is in catch-up schedule.	1.1	This test case describes when dose #1 of the Pneumococcal 13 vaccine is administered at age 12 months, that the dose is considered to be valid.
2015-0021	Pneumococcal: Patient has received PCV13 and PPSV23	20799	F				Complete	44546	PREVNAR 13	133	PFR	Valid		44911	PNEUMOVAX 23	33	MSD	Valid																																-				PCV	44911	All Valid: Forecast Test	42178	43104.43606309028	Not recommended: series complete	New test case for version 2.0 which expanded scope into Adult recommendations. Update due to  MMWR (9/4/2015 / Vol.64 / No. 34) changing the minimal and recommended interval from PCV13 to PPSV23 in adults 65+ from 6-12 months to 1 year.	1.0	This test case describes the assessment of a patient > age 65 years with a history of PCV13 and PPSV23 vaccine, that no additional doses are recommended.  The series is complete.
2015-0022	Adult Patient has received PCV13 but has no history of PPSV23	21170	F				Not complete	44911	PREVNAR 13	133	PFR	Valid																																						2	45276	45276		PCV	44911	All Valid: Forecast Test	42178	43167.76461583333	Recommended based on interval	New test case for version 2.0 which expanded scope into Adult recommendations. Update due to  MMWR (9/4/2015 / Vol.64 / No. 34) changing the minimal and recommended interval from PCV13 to PPSV23 in adults 65+ from 6-12 months to 1 year.	1.0	This test case describes the assessment of a patient > age 65 years with a history of PCV13 vaccine, but no history of the PPSV23 vaccine. 
2015-0023	Adult Patient has received PPSV23 at age 65 but has no history of PCV.	21154	F				Not complete	44911	PNEUMOVAX 23	33	MSD	Valid																																						2	45276	45276		PCV	44911	All Valid: Forecast Test	42178	44592.362320532404	Recommended based on interval	v4.19 Test case update per the new PCV recommendation (Jan 2022, MMWR) for healthy individuals >-65 years.
v4.2 Test case updated per the new PCV recommendation (June 2019, ACIP Meeting) for healthy individuals >- 65 years.	4.19	This test case describes when a patient age 65 years with a history of PCV23 vaccine, but has not received a PCV vaccine that one should be forecast.
2019-0008	Adult Patient 65 years with no history of Pneumococcal vaccine	21170	M				Not complete																																											1	44911	44911		PCV	44911	No Doses Administered	43647.833333333336	44819.44207480324	Recommended based on age	V4.27: Revived test case for updated Pneumococcal recommendations for those 65 years and older.	4.27	This test cases describes when an adult patient 65 years of age or older with no known history of Pneumococcal vaccine that a dose should be forecast.
2019-0009	Adult Patient 65 years with a dose of PPSV23 vaccine and PCV	20805	M				Complete	44546	pneumococcal polysaccharide PPV23	33		Valid		44911	Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF	216		Valid																																				PCV	44911	All Valid: Forecast Test	43647.833333333336	44592.36521215278	Not recommended: series complete	4.19 - Updated test case title and dose to reflect description per the new MMWR 1/2022.	4.19	This test cases describes when an adult patient age 65 years has received a dose of PPSV23 vaccine, and  a dose of PCV that no additional doses should be forecast.  Series is complete.
2022-0003	 Adult Patient 65 years has received PCV15	21170	F				Not complete	44911	Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF	215		Valid																																						2	45276	45276		PCV	44911	All Valid: Forecast Test	42178	44592.36624715278	Recommended based on interval		4.19	This test case describes when a patient has received PCV15, that a dose of PPSV should be forecast.
2022-0004	Adult Patient 65 years has received PCV20	21170	M				Complete	44911	Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF	216		Valid																																										PCV	44911	All Valid: Forecast Test	42178	44592.3785121412	Not recommended: series complete		4.19	This test case describes when a patient has received PCV20, that no additional doses should be forecast.  Series is complete.
2022-0010	Adult Patient 66 years has received PCV13 and PCV20	20805	M				Complete	44546	PREVNAR 13	133	PFR	Valid		44911	PREVNAR 20	216	PFR	Valid																																				PCV	44911	All Valid: Forecast Test	42178	44621.33467532408	Not recommended: series complete		4.21	This test case describes when a patient has received PCV20 (due to provider not having PPSV23 vaccine in stock) after a previous dose of PCV13, that the dose is valid.  No additional doses should be forecast.  Series is complete.
2022-0011	Adult Patient 66 years has received PCV15 and PCV20	20805	M				Complete	44546	VAXNEUVANCE	215	MSD	Valid		44911	PREVNAR 20	216	PFR	Valid																																				PCV	44911	All Valid: Forecast Test	42178	44621.333820092594	Not recommended: series complete		4.21	This test case describes when a patient has received PCV20 (due to provider not having PPSV23 vaccine in stock) after a previous dose of PCV15, that the dose is valid.  No additional doses should be forecast.  Series is complete.
2022-0012	Adult Patient 66 years has received PCV15 and PPSV	20805	F				Complete	44546	Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF	215		Valid		44911	PNEUMOVAX 23	33	MSD	Valid																																				PCV	44911	All Valid: Forecast Test	42178	44655.53112074074	Not recommended: series complete		4.22	This test case describes when a patient has been administered a dose of PCV15 and a dose of PPSV that the doses are valid.  The series is complete.
2022-0072	Dose # 1 PCV15 at age 18 months	44363	F				Not complete	44911	VAXNEUVANCE	215	MSD	Valid																																						2	44967	44967	44967	PCV	44911	All Valid: Forecast Test	41275	44819.38848833333	Recommended based on minimum interval from previous dose (catch-up)		4.27	This test case describes when dose #1 of the PCV15 vaccine is administered at age 18 months that the dose is considered to be valid and the patient is on a catch-up schedule.
2022-0073	Dose # 4 PCV15 at 1 year.  Series complete. 	44546	F				Complete	44608	VAXNEUVANCE	215	MSD	Valid		44667	VAXNEUVANCE	215	MSD	Valid		44728	VAXNEUVANCE	215	MSD	Valid		44911	VAXNEUVANCE	215	MSD	Valid																				-				PCV	44911	Age: At Minimum	41275	44819.39304112268	Not recommended: series complete		4.27	This test case describes when dose #4 of the PCV15 vaccine is administered at age 12 months that the dose is considered to be valid.  The series is complete.
2022-0074	Dose # 1 PCV15 at age 6 weeks-4 days	44873	F				Not complete	44911	VAXNEUVANCE	215	MSD	Valid																																						2	44943	44993	45051	PCV	44911	Age: At Absolute Minimum	41275	44819.39275517361	Recommended based on age		4.27	This test case describes when dose #1 of the PCV15 vaccine is administered at 6 weeks - 4 days that the dose is considered to be valid.
2013-0626	Newborn Testing	44911	F				Not complete																																											1	44953	44973	45028	POL	44911	No Doses Administered	41275	43984.60458194445	Recommended based on age		1.0	This test case describes when a child is a newborn and has not been administered a dose of the Polio vaccine that the first dose should be forecast.
2013-0627	Dose # 2 at age 10 weeks	44841	F				Not complete	44883	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																																3	44939	45023	45446	POL	44911	Age: At Minimum	41275	43994.39154855324	Recommended based on age	Typo on Past Due Date by one year.  	1.1	This test case describes when a child is administered a second dose of the Polio vaccine at age 10 weeks that the dose is valid.  Another dose should be forecast.
2013-0628	Dose # 2 at age 4 months	44789	F				Not complete	44850	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																																3	44939	44973	45394	POL	44911	Age: At Recommended	41275	43994.39143884259	Recommended based on age	Typo on Past Due Date by one year.  	1.1	This test case describes when a child is administered a second dose of the Polio vaccine at age 4 months that the dose is valid.  Another dose should be forecast.
2013-0629	Dose # 2 at age 3 years 9 months	43540	F				Not complete	43601	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																																3	44939	44939	44939	POL	44911	All Valid: Forecast Test	41275	43994.39134357639	Recommended based on minimum interval from previous dose (catch-up)	Rolled all birth dates forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a second dose of the Polio vaccine at age 3 years 9 months that the dose is valid.  Another dose should be forecast.
2013-0630	Dose # 2 at age 4 years 0 months	43450	F				Not complete	44181	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																																3	45093	45093	46034	POL	44911	All Valid: Forecast Test	41275	43994.391219606485	Recommended based on minimum interval from previous dose (catch-up)	Updated Forecast dose number to 3.

Polio should continue to be recommended in 4 weeks.  The dose should not be skipped until 4 years AND 6 months from previous dose. V2.1	3.3	This test case describes when a child is administered a second dose of the Polio vaccine at age 4 years that the dose is valid.  Another dose should be forecast.
2013-0631	Dose # 3 at age 14 weeks-5 days	44818	F				Not complete	44856	IPOL	10	PMC	Valid		44884	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Not Valid	Age: Too Young																									3	44939	44999	45423	POL	44911	Age: Below Absolute Minimum	41275	43994.39110019676	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at 14 weeks - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0632	Dose # 3 at age 14 weeks - 4 days	44817	F				Not complete	44859	IPOL	10	PMC	Valid		44887	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																										4	46278	46278	47401	POL	44911	Age: At Absolute Minimum	41275	43994.39099710648	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at 14 weeks - 4 days that the dose is valid.  Another dose should be forecast.
2013-0633	Dose # 3 at age 14 weeks	44813	F				Not complete	44855	IPOL	10	PMC	Valid		44883	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																										4	46274	46274	47397	POL	44911	Age: At Minimum	41275	43994.39086939815	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at 14 weeks that the dose is valid.  Another dose should be forecast.
2013-0634	Dose # 3 at age 6 months	44728	F				Not complete	44789	IPOL	10	PMC	Valid		44850	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																										4	46189	46189	47312	POL	44911	Age: At Recommended	41275	43994.39074003472	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at 6 months of age that the dose is valid.  Another dose should be forecast.
2013-0635	Dose # 3 at age 3 yrs 11.5 months old.	43466	F				Not complete	43525	IPOL	10	PMC	Valid		43586	IPOL	10	PMC	Valid		44901	IPOL	10	PMC	Valid																										4	45083	45083	46050	POL	44911	All Valid: Forecast Test	41275	43994.39060488426	Recommended based on minimum interval from previous dose (catch-up)	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at 3 yrs 11.5 of age that the dose is valid.  Another dose should be forecast.
2013-0636	Dose # 3 at age 4 years-5 days.   Is valid as a dose but child will need another. 	43455	F				Not complete	43517	IPOL	10	PMC	Valid		43576	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																										4	45093	45093	46039	POL	44911	All Valid: Forecast Test	41275	43994.39050318287	Recommended based on minimum interval from previous dose (catch-up)	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at 4 years - 5 days of age that the dose is valid.  Another dose should be forecast.
2013-0637	# 1 and # 2 at ≥ 4 years.	43422	F				Not complete	44883	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																																3	45093	45093	46006	POL	44911	All Valid: Forecast Test	41275	43994.39037804398	Recommended based on minimum interval from previous dose (catch-up)	Updated Forecast dose number to 3.

	3.3	This test case describes when a child is administered a first and second dose of the Polio vaccine at greater than 4 years that the doses are valid.  Another dose should be forecast.
2013-0638	Dose # 3 at 4 years-4 days but not six months after dose 2.  Child will need another. 	43454	F				Not complete	43819	IPOL	10	PMC	Valid		44762	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																										4	45093	45093	46038	POL	44911	All Valid: Forecast Test	41275	43994.39023244213	Recommended based on minimum interval from previous dose (catch-up)	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third of the Polio vaccine at 4 years - 4 days but less than the six month interval from the second dose that the doses are valid.  Another dose should be forecast.
2013-0639	Dose # 3 at 4 years-4 days and ≥ 6 months since dose 2.  Series complete.	43454	F				Complete	43819	IPOL	10	PMC	Valid		44701	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																										-				POL	44911	All Valid: Forecast Test	41275	43994.390119537034	Not recommended: series complete	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at 4 years - 4 days and with an interval 6 months after the second dose that the doses are valid.  No further dose should be forecast.  The series is complete.
2013-0640	Dose # 3 at age 4 years but < 6 months after dose 2.  Valid but child will need a dose # 4. 	43450	F				Not complete	43815	IPOL	10	PMC	Valid		44789	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																										4	45093	45093	46034	POL	44911	All Valid: Forecast Test	41275	43994.39002219908	Recommended based on minimum interval from previous dose (catch-up)	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  
Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at 4 years but less than less 6 months after the second dose that the doses are valid.  Another dose should be forecast.
2013-0641	Dose # 3 at 4 years 0 months and ≥ 6 mo since dose 2.   Series complete. 	43450	F				Complete	43512	IPOL	10	PMC	Valid		43571	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																										-				POL	44911	All Valid: Forecast Test	41275	43994.38993092593	Not recommended: series complete	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at 4 years and greater than or equal to 6 months after the second dose that the doses are valid.  No further doses should be forecast.  The series is complete.
2013-0642	Dose # 4 at age 18 months.   	44363	F				Not complete	44424	IPOL	10	PMC	Valid		44485	IPOL	10	PMC	Valid		44546	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																				5	45824	45824	46947	POL	44911	All Valid: Forecast Test	41275	43994.38982060185	Recommended based on age	Updated the 4rth dose as valid due to the new 5 dose IPV supporting data document	3.1	This test case describes when a child is administered a fourth dose of the Polio vaccine at 18 months after the third dose that the doses are valid.  Another dose should be forecast.
2013-0643	Dose # 4 at age 4 yrs-5 days	43455	F				Not complete	43545	IPOL	10	PMC	Valid		43667	IPOL	10	PMC	Valid		44552	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																				5	45093	45093	46039	POL	44911	All Valid: Forecast Test	41275	43994.38972481481	Recommended based on age	Updated the 4rth dose as valid due to the new 5 dose IPV supporting data document	3.1	This test case describes when a child is administered a fourth dose of the Polio vaccine at age 4 years - 5 days that the doses are valid.  Another dose should be forecast.
2013-0644	Dose # 4 at age 4 years-4 days.  Series complete.	43454	F				Complete	43544	IPOL	10	PMC	Valid		43666	IPOL	10	PMC	Valid		44551	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																				-				POL	44911	Age: At Absolute Minimum	41275	43994.389634074076	Not recommended: series complete	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a fourth dose of the Polio vaccine at age 4 years - 4 days that the doses are valid.  No further doses should be forecast.  The series is complete.
2013-0645	Dose # 4 at age 4 years 0 days.  Series complete. 	43450	F				Complete	43512	IPOL	10	PMC	Valid		43571	IPOL	10	PMC	Valid		43694	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																				-				POL	44911	Age: At Minimum	41275	43994.3895199537	Not recommended: series complete	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a fourth dose of the Polio vaccine at age 4 years - 0 days that the doses are valid.  No further doses should be forecast.  The series is complete.
2013-0646	Invalid dose 1 (age) as first of others	44721	F				Not complete	44752	IPOL	10	PMC	Not Valid	Age: Too Young	44844	IPOL	10	PMC	Valid		44905	IPOL	10	PMC	Valid																										3	44933	44933	45327	POL	44911	Age: Below Absolute Minimum	41275	43986.56380298611	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered an invalid first dose of the Polio vaccine at age one month and two valid doses at the appropriate ages and intervals that another dose should be forecast.
2013-0647	Invalid dose # 2 (age) in midst of others	44728	F				Not complete	44766	IPOL	10	PMC	Valid		44793	IPOL	10	PMC	Not Valid	Age: Too Young	44911	IPOL	10	PMC	Valid																										3	44939	44939	45334	POL	44911	Age: Below Absolute Minimum	41275	43986.6631356713	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a child is administered an invalid second dose of the Polio vaccine at less than 10 weeks - 4 days of age but is administered a valid third dose at 4 weeks later that the dose is valid.  Another dose should be forecast.
2013-0648	Invalid dose 3 (age) in midst of others.  No additional dose required. The next dose  was at age 4 and ≥ 6 months since previous dose.  Series complete.	43450	F				Complete	43492	IPOL	10	PMC	Valid		43517	IPOL	10	PMC	Valid		43543	IPOL	10	PMC	Not Valid	Age: Too Young	44911	IPOL	10	PMC	Valid																				-				POL	44911	Age: Below Absolute Minimum	41275	43986.68888755787	Not recommended: series complete	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered an invalid third dose of the Polio vaccine at less than 14 weeks - 4 days of age but is administered a valid fourth dose at 6 months later that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0649	Dose 1 to dose 2 interval 28-5 days	44827	F				Not complete	44888	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Not Valid	Interval: too short																															2	44939	44949	45007	POL	44911	Interval: Below Absolute Minimum	41275	43993.61839502315	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a second dose of the Polio vaccine at an interval of 28-5 days after the first dose that the dose is not valid.  A repeat dose should be forecast.
2013-0650	Dose 1 to dose2  interval 28-4 days	44826	F				Not complete	44887	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																																3	44939	45007	45431	POL	44911	Interval: At Absolute Minimum	41275	43993.629138425924	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a second dose of the Polio vaccine at an interval of 28-4 days after the first dose that the dose is valid.  A repeat dose should be forecast.
2013-0651	Dose 1 to dose 2 interval 28 days	44822	F				Not complete	44883	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																																3	44939	45003	45427	POL	44911	Interval: At Minimum	41275	43993.635245300924	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a second dose of the Polio vaccine at an interval of 28 days after the first dose that the dose is valid.  Another dose should be forecast.
2013-0652	Dose 2 to dose 3 interval 28-5 days	44765	F				Not complete	44827	IPOL	10	PMC	Valid		44888	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Not Valid	Interval: too short																									3	44939	44949	45372	POL	44911	Interval: Below Absolute Minimum	41275	43993.671160185186	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at an interval of 28-5 days after the second dose that the dose is not valid.  A repeat dose should be forecast.
2013-0653	Dose 2 to dose 3 interval 28-4 days	44813	F				Not complete	44853	IPOL	10	PMC	Valid		44887	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																										4	46274	46274	47397	POL	44911	Interval: At Absolute Minimum	41275	43993.67071475695	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at an interval of 28-4 days after the second dose that the dose is valid.  Another dose should be forecast.
2013-0654	Dose 2 to dose 3 interval 28 days	44760	F				Not complete	44822	IPOL	10	PMC	Valid		44883	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																										4	46221	46221	47344	POL	44911	Interval: At Minimum	41275	43993.67169895834	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at an interval of 28 days after the second dose that the dose is valid.  Another dose should be forecast.
2013-0655	Dose 3 to dose 4 interval 6 m-5 days	43420	F				Not complete	43785	IPOL	10	PMC	Valid		44151	IPOL	10	PMC	Valid		44728	IPOL	10	PMC	Valid		44906	IPOL	10	PMC	Valid																				5	45088	45088	46004	POL	44911	All Valid: Forecast Test	41275	43993.67271550926	Recommended based on minimum interval 	V3.1: Updated the 4th dose as valid due to the new 5 dose IPV supporting data
11/17/2016 Updated the Forecast # to Dose number 5 due to vaccine being administered too early	3.1	This test case describes when a child is administered a fourth dose of the Polio vaccine at an interval of 6 months - 5 days after the third dose that the dose is not valid.  A repeat dose should be forecast.
2013-0656	Dose 3 to dose 4 interval 6 months-4 days.  Series complete.	43446	F				Complete	43811	IPOL	10	PMC	Valid		44177	IPOL	10	PMC	Valid		44728	IPOL	10	PMC	Valid		44907	IPOL	10	PMC	Valid																				-				POL	44911	Interval: At Absolute Minimum	41275	44798.400530625	Not recommended: series complete	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a fourth dose of the Polio vaccine at an interval of 6 months - 4 days after the third dose that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0657	Dose 3 to dose 4 interval 6 months.  Series complete. 	43446	F				Complete	43811	IPOL	10	PMC	Valid		44177	IPOL	10	PMC	Valid		44728	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																				-				POL	44911	Interval: At Minimum	41275	43993.674769930556	Not recommended: series complete	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a fourth dose of the Polio vaccine at an interval of 6 months after the third dose that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0658	Dose # 1 at age 6 weeks-5 days	44874	F				Not complete	44911	IPOL	10	PMC	Not Valid	Age: Too Young																																					1	44916	44935	44993	POL	44911	Age: Below Absolute Minimum	41275	43994.38911576389	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a first dose of the Polio vaccine at an interval of 6 weeks- 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0659	Invalid dose 1 to dose 2 interval in midst of others. 	44728	F				Not complete	44789	IPOL	10	PMC	Valid		44811	IPOL	10	PMC	Not Valid	Interval: too short	44911	IPOL	10	PMC	Valid																										3	44939	44939	45334	POL	44911	Interval: Below Absolute Minimum	41275	43993.679015127316	Recommended based on minimum interval from previous dose (catch-up)	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a second dose of the Polio vaccine at an interval less than 4 weeks - 4 days from the first dose and a repeat dose of the vaccine at 4 weeks later that the dose is valid.  Another dose should be forecast.
2013-0660	Invalid dose 3 (interval) in midst of others makes no difference in forecasting if # 4 is ≥ 4 years old and ≥ 6 months after previous dose.  Series complete.	43448	F				Complete	43510	IPOL	10	PMC	Valid		43569	IPOL	10	PMC	Valid		43592	IPOL	10	PMC	Not Valid	Interval: too short	44911	IPOL	10	PMC	Valid																				-				POL	44911	Interval: Below Absolute Minimum	41275	43993.68087350694	Not recommended: series complete	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at an interval less than 4 weeks - 4 days from the second dose and a repeat dose of the vaccine at age 4 years that the dose is valid.  No further doses of the vaccine should be forecast.  The series is complete.
2013-0661	Mixed OPV/IPV where # 3 is after age 4 and ≥ 6 months after previous dose. Patient Complete	40832	F				Complete	40893	OPV	02		Valid		40955	OPV	02		Valid		42659	IPOL	10	PMC	Valid																										-				POL	42659	All Valid: Forecast Test	41275	43993.68445444445	Not recommended: series complete	v3.3: Changed test case to mark patient complete per updated recommendations from ACIP in January 2017.
v1.5:Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	3.3	This test case describes when a child is administered a third dose of the Polio vaccine at age 4 years and at an interval of 6 months from the previous that the dose is valid.  No further doses of the vaccine should be forecast.  The series is complete.
2013-0662	4 doses of mixed OPV/IPV with one after age 4=polio series complete	40646	F				Complete	40707	OPV	02		Valid		40768	OPV	02		Valid		41742	IPOL	10	PMC	Valid		42477	IPOL	10	PMC	Valid																				-				POL	42477	All Valid: Forecast Test	41275	43993.684348807874	Not recommended: series complete	V3.5: Updated Assessment Date which wasn't rolled forward when other dates were rolled forward.
V1.5: Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	3.5	This test case describes when a child is administered four doses of mixed OPV/IPV Polio vaccine with one dose given at age 4 years and at an interval of 6 months from the previous that the dose is valid.  No further doses of the vaccine should be forecast.  The series is complete.
2013-0664	Dose 1 given as Kinrix at age 2 mos.  Off-label but valid as IPV # 1. 	44850	F				Not complete	44911	KINRIX	130	SKB	Valid																																						2	44939	44973	45028	POL	44911	Vaccine: Off Label	41275	43994.38886111111	Recommended based on age		1.0	This test case describes when a child is administered a first dose of the Polio (Kinrix - allowable) vaccine that the dose is valid.  Another dose should be forecast.
2013-0665	Dose 2 given as Kinrix at age 4 mo.  Off label but valid as IPV 2. 	44789	F				Not complete	44856	IPOL	10	PMC	Valid		44911	KINRIX	130	SKB	Valid																																3	44939	44973	45394	POL	44911	Vaccine: Off Label	41275	43993.687042337966	Recommended based on age		1.0	This test case describes when a child is administered a second dose of the Polio (Kinrix - allowable) vaccine at age 4 months that the dose is valid.  Another dose should be forecast.
2013-0666	Dose 3 given as Kinrix at age 6 mos.  Off label but valid.	44728	F				Not complete	44791	IPOL	10	PMC	Valid		44854	IPOL	10	PMC	Valid		44911	KINRIX	130	SKB	Valid																										4	46189	46189	47312	POL	44911	Vaccine: Off Label	41275	43993.687969756946	Recommended based on age		1.0	This test case describes when a child is administered a third dose of the Polio (Kinrix - allowable) vaccine at age 6 months that the dose is valid.  Another dose should be forecast.
2013-0667	Kinrix at 12 months old.  	44521	F				Not complete	44584	IPOL	10	PMC	Valid		44645	IPOL	10	PMC	Valid		44695	IPOL	10	PMC	Valid		44911	KINRIX	130	SKB	Valid																				5	45982	45982	47105	POL	44911	All Valid: Forecast Test	41275	43994.38859916667	Recommended based on age	Updated the 4rth dose as valid due to the new 5 dose IPV supporting data document
Previous dates were before the ACIP recommendations were published.
11/17/2016 Updated the Forecast # to Dose number 5 due to vaccine being administered too early	3.1	This test case describes when a child is administered a fourth dose of the Polio (Kinrix - allowable) vaccine at 12 months of age that the dose is valid.  Another dose should be forecast.
2013-0668	Kinrix at age 4 years as dose 4=polio series complete	43450	F				Complete	43514	PEDIARIX	110	SKB	Valid		43571	PEDIARIX	110	SKB	Valid		43634	PEDIARIX	110	SKB	Valid		44911	KINRIX	130	SKB	Valid																				-				POL	44911	Age: At Minimum	41275	43994.38849346065	Not recommended: series complete	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a fourth dose of the Polio (Kinrix - allowable) vaccine at 4 years of age that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0669	Dose # 1 at age 6 weeks-4 days	44873	F				Not complete	44911	IPOL	10	PMC	Valid																																						2	44943	44993	45051	POL	44911	Age: At Absolute Minimum	41275	43994.388380254626	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a first dose of the Polio vaccine at 6 weeks - 4 days of age that the dose is valid.  Another dose should be forecast.
2013-0670	Kinrix as dose 4 at age 4 years-5 days	43455	F				Not complete	43509	PEDIARIX	110	SKB	Valid		43564	PEDIARIX	110	SKB	Valid		43696	PEDIARIX	110	SKB	Valid		44911	KINRIX	130	SKB	Valid																				5	45093	45093	46039	POL	44911	All Valid: Forecast Test	41275	43994.38827077546	Recommended based on age	Updated the 4th dose as valid due to the new 5 dose IPV supporting data document
Previous dates were before the ACIP recommendations were published.
11/17/2016 Updated the Forecast # to Dose number 5 due to vaccine being administered too early	3.1	This test case describes when a child is administered a fourth dose of the Polio (Kinrix - allowable) vaccine at 4 years - 5 days of age that the dose is not valid.  Another dose should be forecast.
2013-0671	Kinrix as dose 4 at age 4 years-4 days= polio series complete	43454	F				Complete	43504	PEDIARIX	110	SKB	Valid		43563	PEDIARIX	110	SKB	Valid		43624	PEDIARIX	110	SKB	Valid		44911	KINRIX	130	SKB	Valid																				-				POL	44911	Age: At Absolute Minimum	41275	43994.388165902776	Not recommended: series complete	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a fourth dose of the Polio (Kinrix - allowable) vaccine at 4 years - 4 days of age that the dose is valid.  Another dose should be forecast.
2013-0672	Dose # 1 at age 6 weeks	44869	F				Not complete	44911	IPOL	10	PMC	Valid																																						2	44939	44989	45047	POL	44911	Age: At Minimum	41275	43994.38806337963	Recommended based on age		1.0	This test case describes when a child is administered a first dose of the Polio vaccine at 6 weeks of age that the dose is valid.  Another dose should be forecast.
2013-0673	Dose # 1 at age 2 months	44850	F				Not complete	44911	IPOL	10	PMC	Valid																																						2	44939	44973	45028	POL	44911	Age: At Recommended	41275	43994.38793309028	Recommended based on age		1.0	This test case describes when a child is administered a first dose of the Polio vaccine at 2 months of age that the dose is valid.  Another dose should be forecast.
2013-0674	Dose # 2 at age 10 weeks-5 days	44846	F				Not complete	44884	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Not Valid	Age: Too Young																															2	44939	44969	45024	POL	44911	Age: Below Absolute Minimum	41275	43993.69850388889	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a second dose of the Polio vaccine at 10 weeks - 5 days of age that the dose is not valid.  A repeat dose should be forecast.
2013-0675	Dose # 2 at age 10 weeks-4 days	44845	F				Not complete	44887	IPOL	10	PMC	Valid		44911	IPOL	10	PMC	Valid																																3	44943	45027	45450	POL	44911	Age: At Absolute Minimum	41275	43993.69971259259	Recommended based on age	Typo on Past Due Date by one year.  	1.1	This test case describes when a child is administered a second dose of the Polio vaccine at 10 weeks - 4 days of age that the dose is valid.  Another dose should be forecast.
2013-0676	Newborn forecasting	44911	F				Not complete																																											1	44953	44973	45028	POL	44911	No Doses Administered	41275	43994.37248409722	Recommended based on age		1.0	This test case describes when a child is a newborn and has not been administered a dose of the Polio vaccine that the first dose should be forecast.
2013-0677	# 2 Pediarix at 6 yrs 11.5 mo	42371	F				Not complete	43451	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	45093	45093	45093	POL	44911	All Valid: Forecast Test	41275	43994.37470706018	Recommended based on minimum interval from previous dose (catch-up)	Updated the Forecast number dose to 3. Updated DOB to curb future date issues.	3.3	This test case describes when a child is administered a second dose of the Polio vaccine at 6 years 11.5 months that the dose is valid.  Another dose should be forecast.
2013-0678	# 2 Pediarix at 7 yrs; # 1 at less than 12 mo. 	42354	F				Not complete	42445	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	45093	45093	45093	POL	44911	Vaccine: Off Label	41275	43994.38771224537	Recommended based on minimum interval from previous dose (catch-up)	Updated the Forecast number dose to 3. Updated DOB to curb future date issues.	3.3	This test case describes when a child is administered a first dose of the Polio vaccine at 3 months of age and a second dose of the vaccine at 7 years of age that the doses are valid.  Another dose should be forecast.
2013-0679	# 2 Pediarix at 7 yrs; # 1 ≥ 12 mo.	42354	F				Not complete	42751	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	45093	45093	45093	POL	44911	Vaccine: Off Label	41275	43994.38762395833	Recommended based on minimum interval from previous dose (catch-up)	Updated the Forecast number dose to 3. Updated DOB to curb future date issues.	3.3	This test case describes when a child is administered a first dose of the Polio vaccine at greater than 12 months of age and a second dose of the vaccine at 7 years of age that the doses are valid.  Another dose should be forecast.
2013-0680	# 1 and 2 Pediarix at ≥7 yrs  with 28 day interval.  Off label	42326	F				Not complete	44883	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	45093	45093	45093	POL	44911	Vaccine: Off Label	41275	43994.38743027778	Recommended based on minimum interval from previous dose (catch-up)	Updated the Forecast number dose to 3. Updated DOB to curb future date issues.	3.3	This test case describes when a child is administered a first dose of the Polio vaccine at 7 years of age and a second dose of the vaccine at 28 days later that the doses are valid.  Another dose should be forecast.
2013-0681	# 3 Pediarix at 14 wks-5 days	44818	F				Not complete	44856	PEDIARIX	110	SKB	Valid		44884	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Not Valid	Age: Too Young																									3	44939	44999	45423	POL	44911	Age: Below Absolute Minimum	41275	43994.38734418982	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published. 
Typo on Past Due Date by one year.  V2.1	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at an interval of 14 weeks - 5 days that the dose is not valid. A repeat dose should be forecast.
2013-0682	# 3 Pediarix at 14 wks-4 days.	44817	F				Not complete	44857	PEDIARIX	110	SKB	Valid		44885	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																										4	46278	46278	47401	POL	44911	Age: At Absolute Minimum	41275	43994.38725612268	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at an interval of 14 weeks - 4 days that the dose is valid. Another dose should be forecast.
2013-0683	# 3 Pediarix at 24 weeks-5 days.	44748	F				Not complete	44790	PEDIARIX	110	SKB	Valid		44851	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																										4	46209	46209	47332	POL	44911	All Valid: Forecast Test	41275	43994.387153125	Recommended based on age		1.0	This test case describes when a child is administered a third dose of the Polio vaccine at an interval of 24 weeks - 5 days that the dose is valid. Another dose should be forecast.
2013-0684	# 3 Pediarix at 24 weeks-4 days.	44747	F				Not complete	44789	PEDIARIX	110	SKB	Valid		44850	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																										4	46208	46208	47331	POL	44911	All Valid: Forecast Test	41275	43994.3870715625	Recommended based on age		1.0	This test case describes when a child is administered a third dose of the Polio vaccine at an interval of 24 weeks - 4 days that the dose is valid. Another dose should be forecast.
2013-0685	# 3 Pediarix at 6 yrs 11.5 mo	42366	F				Complete	43399	PEDIARIX	110	SKB	Valid		43859	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																										-				POL	44911	All Valid: Forecast Test	41275	43994.38697935185	Not recommended: series complete	Update to curb future administration dates	3.3	This test case describes when a child is administered a third dose of the Polio vaccine at age 6 years 11.5 months that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0686	# 4 Pediarix at 1 yr -5 days.	44551	F				Not complete	44613	PEDIARIX	110	SKB	Valid		44672	PEDIARIX	110	SKB	Valid		44739	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																				5	46012	46012	47135	POL	44911	All Valid: Forecast Test	41275	43994.38662467593	Recommended based on age	Updated the 4rth dose as valid due to the new 5 dose IPV supporting data document	3.1	This test case describes when a child is administered a fourth dose of the Polio vaccine at age 1 year - 5 days that the dose is valid.  Another dose should be forecast.
2013-0687	# 1 Pediarix at 6 wks-5 days	44874	F				Not complete	44911	PEDIARIX	110	SKB	Not Valid	Age: Too Young																																					1	44916	44935	44993	POL	44911	Age: Below Absolute Minimum	41275	43994.39289082176	Recommended based on age		1.0	This test case describes when a child is administered a first dose of the Polio vaccine at age 6 weeks - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0688	# 4 Pediarix at 1 yr -4 days	44550	F				Not complete	44612	PEDIARIX	110	SKB	Valid		44701	PEDIARIX	110	SKB	Valid		44776	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																				5	46011	46011	47134	POL	44911	All Valid: Forecast Test	41275	43994.3987621412	Recommended based on age	Updated the 4th dose as valid due to the new 5 dose IPV supporting data document	3.1	This test case describes when a child is administered a fourth dose of the Polio vaccine at age 1 year - 4 days that the dose is valid.  Another dose should be forecast.
2013-0689	# 4 Pediarix at 3 yrs 11.5 mo. 	43467	F				Not complete	43526	PEDIARIX	110	SKB	Valid		43618	PEDIARIX	110	SKB	Valid		43710	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																				5	45093	45093	46051	POL	44911	All Valid: Forecast Test	41275	43994.39855349537	Recommended based on age	Updated the 4rth dose as valid due to the new 5 dose IPV supporting data document	3.1	This test case describes when a child is administered a fourth dose of the Polio vaccine at age 3 years 11.5 months that the dose is valid.  Another dose should be forecast.
2013-0690	# 4 Pediarix at 4 yrs	43450	F				Complete	43574	PEDIARIX	110	SKB	Valid		43750	PEDIARIX	110	SKB	Valid		44246	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																				-				POL	44911	Age: At Minimum	41275	43994.398130601854	Not recommended: series complete	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a fourth dose of the Polio vaccine at age 4 years that the dose is valid.  No additional doses should be forecast.  The series is complete.
2013-0691	# 5 Pediarix at 4 yrs -5 days.	43455	F				Not complete	43517	PEDIARIX	110	SKB	Valid		43545	PEDIARIX	110	SKB	Valid		43668	PEDIARIX	110	SKB	Valid		43920	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Not Valid	Age: Too Young													5	45093	45093	46039	POL	44911	Age: Below Absolute Minimum	41275	43994.39998253472	Recommended based on age	Updated the Forecast dose number to 5.	3.3	This test case describes when a child is administered a fifth dose of the Polio vaccine at age 4 years - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0692	# 5 Pediarix at 4 yrs -4 days	43454	F				Complete	43516	PEDIARIX	110	SKB	Valid		43544	PEDIARIX	110	SKB	Valid		43667	PEDIARIX	110	SKB	Valid		43919	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid														-				POL	44911	Age: At Absolute Minimum	41275	43994.40140018518	Not recommended: series complete	Updated the 4th dose as valid due to the new 5 dose IPV supporting data document	3.1	This test case describes when a child is administered a fifth dose of the Polio vaccine at age 4 years - 4 days that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0693	# 5 Pediarix at 6 yrs 11.5 mo	42371	F				Complete	42431	PEDIARIX	110	SKB	Valid		42492	PEDIARIX	110	SKB	Valid		42553	PEDIARIX	110	SKB	Valid		42768	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid														-				POL	44911	All Valid: Forecast Test	41275	43994.402076631945	Not recommended: series complete	Update to curb future vaccine administration dates	3.3	This test case describes when a child is administered a fifth dose of the Polio vaccine at age 6 years 11.5 months that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0694	# 5 Pediarix at 7 yrs.  Off label	42354	F				Complete	42445	PEDIARIX	110	SKB	Valid		42537	PEDIARIX	110	SKB	Valid		42629	PEDIARIX	110	SKB	Valid		42917	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid														-				POL	44911	Vaccine: Off Label	41275	43994.41539888889	Not recommended: series complete	Updated to curb future vaccine adminstration dates	3.3	This test case describes when a child is administered a fifth dose of the Polio vaccine at at age 7 years that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0695	Invalid age dose 1 as first of others. 	44820	F				Not complete	44856	PEDIARIX	110	SKB	Not Valid	Age: Too Young	44911	PEDIARIX	110	SKB	Valid																																2	44939	44942	45000	POL	44911	Age: Below Absolute Minimum	41275	43997.61864032407	Recommended based on age		1.0	This test case describes when a child is administered an invalid first dose of the Polio vaccine but is administered a repeat dose at an interval greater than 6 weeks that the dose is valid.  Another dose should be forecast.
2013-0696	Invalid age dose 2 in midst of others	44728	F				Not complete	44766	PEDIARIX	110	SKB	Valid		44792	PEDIARIX	110	SKB	Not Valid	Age: Too Young	44911	PEDIARIX	110	SKB	Valid																										3	44939	44939	45334	POL	44911	Age: Below Absolute Minimum	41275	43994.65682534722	Recommended based on minimum interval from previous dose (catch-up)	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published. 
Typo on Past Due Date by one year.  V2.1	1.5	This test case describes when a child is administered an invalid second dose of the Polio vaccine but is administered a repeat  dose at an interval  greater than or equal to 4 weeks that the repeat dose is valid.  Another dose should be forecast.
2013-0697	invalid age dose 3 in midst of others	44546	F				Not complete	44590	PEDIARIX	110	SKB	Valid		44616	PEDIARIX	110	SKB	Valid		44638	PEDIARIX	110	SKB	Not Valid	Age: Too Young	44911	PEDIARIX	110	SKB	Valid																				4	46007	46007	47130	POL	44911	Age: Below Absolute Minimum	41275	43994.659504930554	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered an invalid third dose of the Polio vaccine but is administered a repeat  dose at an interval greater than or equal to 4 weeks that the repeat dose is valid.  Another dose should be forecast.
2013-0698	# 1 Pediarix at 6 wks-4 days	44873	F				Not complete	44911	PEDIARIX	110	SKB	Valid																																						2	44943	44993	45051	POL	44911	Age: At Absolute Minimum	41275	43994.66111206019	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a first dose of the Polio vaccine at an interval of 6 months - 4 days that the dose is valid.  Another dose should be forecast.
2013-0699	dose 1 to 2 Pediarix, interval 28-5 days	44825	F				Not complete	44888	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Not Valid	Interval: too short																															2	44939	44947	45005	POL	44911	Interval: Below Absolute Minimum	41275	43994.662630335646	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a second dose of the Polio vaccine at an interval of 28 - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0700	dose 1 to 2 Pediarix, interval 28-4 days	44826	F				Not complete	44887	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	44939	45007	45431	POL	44911	Interval: At Absolute Minimum	41275	43994.66351204861	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published. 
Typo on Past Due Date by one year.  V2.1	2.1	This test case describes when a child is administered a second dose of the Polio vaccine at an interval of 28 - 4 days that the dose is valid.  Another dose should be forecast.
2013-0701	dose 2 to 3 Pediarix, interval 28-5 days	44763	F				Not complete	44825	PEDIARIX	110	SKB	Valid		44886	PEDIARIX	110	SKB	Valid		44909	PEDIARIX	110	SKB	Not Valid	Interval: too short																									3	44937	44947	45370	POL	44911	Interval: Below Absolute Minimum	41275	44704.45281591435	Recommended based on age	Typo on Past Due Date by one year.  	1.1	This test case describes when a child is administered a third dose of the Polio vaccine at an interval of 28 - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0702	dose 2 to 3 Pediarix, interval 28-4 days	44762	F				Not complete	44824	PEDIARIX	110	SKB	Valid		44885	PEDIARIX	110	SKB	Valid		44909	PEDIARIX	110	SKB	Valid																										4	46223	46223	47346	POL	44911	Interval: At Absolute Minimum	41275	44704.453091840274	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a second dose of the Polio vaccine at an interval of 28 - 4 days that the dose is valid.  Another dose should be forecast.
2013-0704	dose 3 to 4 Pediarix, interval 6m-4 days	44488	F				Not complete	44549	PEDIARIX	110	SKB	Valid		44611	PEDIARIX	110	SKB	Valid		44731	PEDIARIX	110	SKB	Valid		44910	PEDIARIX	110	SKB	Valid																				5	45949	45949	47072	POL	44911	All Valid: Forecast Test	41275	44798.400990104165	Recommended based on age	Updated the 4rth dose as valid due to the new 5 dose IPV supporting data document	3.1	This test case describes when a child is administered a fourth dose of the Polio vaccine at an interval of 6 month - 4 days that the dose is valid.  Another dose should be forecast.
2013-0707	invalid dose 1-2 interval in midst of others	44789	F				Not complete	44850	PEDIARIX	110	SKB	Valid		44869	PEDIARIX	110	SKB	Not Valid	Interval: too short	44911	PEDIARIX	110	SKB	Valid																										3	44939	44973	45394	POL	44911	Interval: Below Absolute Minimum	41275	43997.61701891204	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published. 
Typo on Past Due Date by one year.  V2.1	1.5	This test case describes when a child is administered an invalid second dose of the Polio vaccine but is administered a repeat  dose at an interval  greater than or equal to 4 weeks that the repeat dose is valid.  Another dose should be forecast.
2013-0708	invalid dose 2-3 interval in midst of others	44546	F				Not complete	44608	PEDIARIX	110	SKB	Valid		44667	PEDIARIX	110	SKB	Valid		44690	PEDIARIX	110	SKB	Not Valid	Interval: too short	44911	PEDIARIX	110	SKB	Valid																				4	46007	46007	47130	POL	44911	Interval: Below Absolute Minimum	41275	43997.497735694444	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered an invalid third dose of the Polio vaccine but is administered a repeat  dose at an interval greater than or equal to 4 weeks that the repeat dose is valid.  Another dose should be forecast.
2013-0709	# 1 Pediarix at 6 wks	44869	F				Not complete	44911	PEDIARIX	110	SKB	Valid																																						2	44939	44989	45047	POL	44911	Age: At Minimum	41275	43997.53403486111	Recommended based on age		1.0	This test case describes when a child is administered the first dose of the Polio vaccine (Pediarix) at 6 weeks of age that the dose is valid.  Another dose should be forecast.
2013-0712	# 1 Pediarix at 6 yrs 11.5 mo	42370	F				Not complete	44911	PEDIARIX	110	SKB	Valid																																						2	44939	44939	44939	POL	44911	All Valid: Forecast Test	41275	43997.53393799769	Recommended based on minimum interval from previous dose (catch-up)	Updated DOB to curb future date issues.	3.3	This test case describes when a child is administered a first dose of the Polio vaccine (Pediarix) at 6 years 11.5 months that the dose is valid.  Another dose should be forecast.
2013-0713	# 1 Pediarix at 7 yrs	42354	F				Not complete	44911	PEDIARIX	110	SKB	Valid																																						2	44939	44939	44939	POL	44911	Vaccine: Off Label	41275	43997.533826516206	Recommended based on minimum interval from previous dose (catch-up)	Updated DOB to curb future date issues.	3.3	This test case describes when a child is administered a first dose of the Polio vaccine (Pediarix) at 7 years of age that the dose is valid.  Another dose should be forecast.
2013-0714	# 2 Pediarix at 10 wks-5 days	44846	F				Not complete	44884	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Not Valid	Age: Too Young																															2	44939	44969	45024	POL	44911	Age: Below Absolute Minimum	41275	43997.533643449075	Recommended based on age		1.0	This test case describes when a child is administered a second dose of the Polio (Pediarix) vaccine at 10 weeks - 5 days of age that the dose is not valid.  A repeat dose should be forecast.
2013-0715	# 2 Pediarix at 10 wks-4 days	44845	F				Not complete	44885	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	44943	45027	45450	POL	44911	Age: At Absolute Minimum	41275	43997.53350520833	Recommended based on age	Typo on Past Due Date by one year.  	1.1	This test case describes when a child is administered a second dose of the Polio vaccine (Pediarix) at 10 weeks - 4 days of age that the dose is valid.  Another dose should be forecast.
2013-0716	# 2 Pediarix at 10 wks	44841	F				Not complete	44881	PEDIARIX	110	SKB	Valid		44911	PEDIARIX	110	SKB	Valid																																3	44939	45023	45446	POL	44911	Age: At Minimum	41275	43997.533398761574	Recommended based on age	Typo on Past Due Date by one year.  	1.1	This test case describes when a child is administered a second dose of the Polio vaccine (Pediarix) at 10 weeks of age that the dose is valid.  Another dose should be forecast.
2013-0717	Newborn	44911	F				Not complete																																											1	44953	44973	45028	POL	44911	No Doses Administered	41275	43997.5308297338	Recommended based on age		1.0	This test case describes when a child is a newborn and has not been administered a dose of the Polio vaccine that the first dose should be forecast.
2013-0718	# 2 Pentacel at 6 yrs 11.5 mo. Off label but counts.	42371	F				Not complete	43366	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																																3	45093	45093	45093	POL	44911	Vaccine: Off Label	41275	43997.53316820602	Recommended based on minimum interval from previous dose (catch-up)	Updated the Forecast Dose number to 3. Updated DOB to curb future date issues.	3.3	This test case describes when a child is administered a second dose of the Polio vaccine (Pentacel) at age 6 years 11.5 months that the dose is valid.  Another dose should be forecast.
2013-0719	Pentacel at 7 yrs; # 1 at age < 12 mo.   Off label use. 	42354	F				Not complete	42515	IPOL	10	PMC	Valid		44911	PENTACEL	120	PMC	Valid																																3	45093	45093	45093	POL	44911	Vaccine: Off Label	41275	43997.535804907406	Recommended based on minimum interval from previous dose (catch-up)	Updated the Forecast Dose number to 3. Updated DOB to curb future date issues.	3.3	This test case describes when a child is administered a first dose of the Polio vaccine (Pentacel) at less than 12 months of age and a second dose of the vaccine at 7 years of age that the doses are valid.  Another dose should be forecast.
2013-0720	# 2 Pentacel at 7 yrs; # 1 at age ≥ 12 mo.	42354	F				Not complete	42785	IPOL	10	PMC	Valid		44911	PENTACEL	120	PMC	Valid																																3	45093	45093	45093	POL	44911	Vaccine: Off Label	41275	43997.53666928241	Recommended based on minimum interval from previous dose (catch-up)	Updated the Forecast Dose number to 3. Updated DOB to curb future date issues.	3.3	This test case describes when a child is administered a first dose of the Polio vaccine (Pentacel) at greater than 12 months of age and a second dose of the vaccine at 7 years of age that the doses are valid.  Another dose should be forecast.
2013-0721	# 3 Pentacel at 14 wks-5 days	44818	F				Not complete	44856	PENTACEL	120	PMC	Valid		44884	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Not Valid	Age: Too Young																									3	44939	44999	45423	POL	44911	Age: Below Absolute Minimum	41275	43997.56559520833	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published. 
Typo on Past Due Date by one year.  V2.1	1.5	This test case describes when a child is administered a third dose of the Polio vaccine (Pentacel) at 14 weeks - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0722	# 3 Pentacel at 14 wks-4 days	44817	F				Not complete	44855	PENTACEL	120	PMC	Valid		44883	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																										4	46278	46278	47401	POL	44911	Age: At Absolute Minimum	41275	43997.564583113424	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine (Pentacel) at 14 weeks - 4 days that the dose is valid.  Another dose should be forecast.
2013-0723	# 3 Pentacel at 6 yrs 11.5 mo	42370	F				Complete	42430	IPOL	10	PMC	Valid		42491	IPOL	10	PMC	Valid		44911	PENTACEL	120	PMC	Valid																										-				POL	44911	Vaccine: Off Label	41275	43997.56660892361	Not recommended: series complete	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine at 6 years 11.5 months that the dose is valid.  No further doses should be administered.  The series is complete.
2013-0724	# 4 Pentacel at 1 yr -5 days.  	44551	F				Not complete	44613	PENTACEL	120	PMC	Valid		44672	PENTACEL	120	PMC	Valid		44733	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																				5	46012	46012	47135	POL	44911	All Valid: Forecast Test	41275	43997.568916400465	Recommended based on age	Updated the 4rth dose as valid due to the new 5 dose IPV supporting data document	3.1	This test case describes when a child is administered a fourth dose of the Polio vaccine (Pentacel) at age 1 year - 5 days that the dose is valid.  Another dose should be forecast.
2013-0725	# 4 Pentacel at 1 yr -4 days	44550	F				Not complete	44612	PENTACEL	120	PMC	Valid		44671	PENTACEL	120	PMC	Valid		44732	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																				5	46011	46011	47134	POL	44911	All Valid: Forecast Test	41275	43997.56930824074	Recommended based on age	Updated the 4rth dose as valid due to the new 5 dose IPV supporting data document	3.1	This test case describes when a child is administered a fourth dose of the Polio vaccine (Pentacel) at age 1 year - 4 days that the dose is valid.  Another dose should be forecast.
2013-0726	# 4 Pentacel ≥ age 12 mo	44546	F				Not complete	44608	PENTACEL	120	PMC	Valid		44667	PENTACEL	120	PMC	Valid		44728	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																				5	46007	46007	47130	POL	44911	All Valid: Forecast Test	41275	43997.570148969906	Recommended based on age	Updated the 4rth dose as valid due to the new 5 dose IPV supporting data document	3.1	This test case describes when a child is administered a fourth dose of the Polio vaccine (Pentacel) at age 12 months that the dose is valid.  Another dose should be forecast.
2013-0727	# 4 Pentacel at 4 yrs	43450	F				Complete	43580	PENTACEL	120	PMC	Valid		43807	PENTACEL	120	PMC	Valid		44729	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																				-				POL	44911	Age: At Minimum	41275	43997.57135931713	Not recommended: series complete	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a fourth dose of the Polio vaccine (Pentacel) at age 4 years that the dose is valid.  Another dose should be forecast.
2013-0728	# 1 Pentacel at 6 wks-5 days	44874	F				Not complete	44911	PENTACEL	120	PMC	Not Valid	Age: Too Young																																					1	44916	44935	44993	POL	44911	Age: Below Absolute Minimum	41275	43997.583130046296	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a first dose of the Polio vaccine (Pentacel) at age 6 weeks - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0729	# 5 Pentacel at ≥ 4 yrs	43429	F				Complete	43763	PENTACEL	120	PMC	Valid		43855	PENTACEL	120	PMC	Valid		43946	PENTACEL	120	PMC	Valid		44100	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid														-				POL	44911	All Valid: Forecast Test	41275	43997.58612104167	Not recommended: series complete	Updated the 4rth dose as valid due to the new 5 dose IPV supporting data document	3.1	This test case describes when a child is administered a fifth dose of the Polio vaccine (Pentacel) at equal to or greater than age 4 years that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0730	# 4 Pentacel at 5 yrs=off label 	43083	F				Complete	43204	PENTACEL	120	PMC	Valid		43384	PENTACEL	120	PMC	Valid		43447	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																				-				POL	44911	Vaccine: Off Label	41275	43997.602123703706	Not recommended: series complete	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a fourth dose of the Polio vaccine (Pentacel) at 5 years that the dose is valid.  No further doses should be forecast.  The series is complete.
2013-0731	invalid age dose 1 as first of others	44728	F				Not complete	44763	PENTACEL	120	PMC	Not Valid	Age: Too Young	44850	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																										3	44939	44939	45334	POL	44911	Age: Below Absolute Minimum	41275	43997.61233822917	Recommended based on minimum interval from previous dose (catch-up)	Typo on Past Due Date by one year.  	1.1	This test case describes when a child is administered an invalid first dose of the Polio vaccine but is administered a repeat and second dose at the appropriate interval that the doses are valid.  Another dose should be forecast.
2013-0732	invalid age dose 2 in midst of others	44544	F				Not complete	44582	PENTACEL	120	PMC	Valid		44609	PENTACEL	120	PMC	Not Valid	Age: Too Young	44686	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																				4	46005	46005	47128	POL	44911	Age: Below Absolute Minimum	41275	43997.62131307871	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered an invalid second dose of the Polio vaccine (due to age) but is administered a repeat and third dose at the appropriate interval that the doses are valid.  Another dose should be forecast.
2013-0733	invalid age dose 3 in midst of others	44510	F				Not complete	44548	PENTACEL	120	PMC	Valid		44576	PENTACEL	120	PMC	Valid		44603	PENTACEL	120	PMC	Not Valid	Age: Too Young	44911	PENTACEL	120	PMC	Valid																				4	45971	45971	47094	POL	44911	Age: Below Absolute Minimum	41275	43997.62409140047	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered an invalid third dose of the Polio vaccine but is administered a repeat dose at the appropriate interval that the repeat dose is valid.  Another dose should be forecast.
2013-0734	dose 1 to 2 Pentacel, interval 28-5 days	44833	F				Not complete	44888	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Not Valid	Interval: too short																															2	44939	44955	45013	POL	44911	Interval: Below Absolute Minimum	41275	43997.62604081019	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a second dose of the Polio vaccine (Pentacel) at an interval of 28 - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0735	dose 1 to 2 Pentacel, interval 28-4 days	44824	F				Not complete	44887	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																																3	44939	45005	45429	POL	44911	Interval: At Absolute Minimum	41275	43997.62691622685	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a second dose of the Polio vaccine (Pentacel) at an interval of 28 - 4 days that the dose is valid.  Another dose should be forecast.
2013-0736	dose 2 to 3 Pentacel, interval 28-5 days	44765	F				Not complete	44827	PENTACEL	120	PMC	Valid		44888	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Not Valid	Interval: too short																									3	44939	44949	45372	POL	44911	Interval: Below Absolute Minimum	41275	43997.640280011576	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a third dose of the Polio vaccine (Pentacel) at an interval of 28 - 5 days that the dose is not valid.  A repeat dose should be forecast.
2013-0737	dose 2 to 3 Pentacel, interval 28-4 days	44764	F				Not complete	44826	PENTACEL	120	PMC	Valid		44887	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																										4	46225	46225	47348	POL	44911	Interval: At Absolute Minimum	41275	43997.64251365741	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a second dose of the Polio vaccine (Pentacel) at an interval of 28 - 4 days that the dose is valid.  Another dose should be forecast.
2013-0739	# 1 Pentacel at 6 wks-4 days	44873	F				Not complete	44911	PENTACEL	120	PMC	Valid																																						2	44943	44993	45051	POL	44911	Age: At Absolute Minimum	41275	43997.64349145834	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered the first dose of the Polio vaccine (Pentacel) at 6 weeks - 4 days of age that the dose is valid.  Another dose should be forecast.
2013-0740	dose 3 to 4 Pentacel, interval 6m-4 days	44488	F				Not complete	44549	PENTACEL	120	PMC	Valid		44670	PENTACEL	120	PMC	Valid		44731	PENTACEL	120	PMC	Valid		44910	PENTACEL	120	PMC	Valid																				5	45949	45949	47072	POL	44911	All Valid: Forecast Test	41275	44798.40123052083	Recommended based on age	Updated the 4th dose as valid due to the new 5 dose IPV supporting data document	3.1	This test case describes when a child is administered a fourth dose of the Polio vaccine (Pentacel) at an interval of 6 month - 4 days that the dose is valid.  Another dose should be forecast.
2013-0743	invalid dose 1-2 interval in midst of others	44737	F				Not complete	44798	PENTACEL	120	PMC	Valid		44821	PENTACEL	120	PMC	Not Valid	Interval: too short	44911	PENTACEL	120	PMC	Valid																										3	44939	44939	45343	POL	44911	Interval: Below Absolute Minimum	41275	43997.64650267361	Recommended based on minimum interval from previous dose (catch-up)	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered an invalid second dose of the Polio vaccine (Pentacel) but is administered a repeat dose at an interval greater than or equal to 4 weeks that the repeat dose is valid.  Another dose should be forecast.
2013-0744	invalid dose 2-3 interval in midst of others	44543	F				Not complete	44605	PENTACEL	120	PMC	Valid		44664	PENTACEL	120	PMC	Valid		44685	PENTACEL	120	PMC	Not Valid	Interval: too short	44911	PENTACEL	120	PMC	Valid																				4	46004	46004	47127	POL	44911	Interval: Below Absolute Minimum	41275	43997.647889444444	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered an invalid third dose of the Polio vaccine (Pentacel) but is administered a repeat dose at an interval greater than or equal to 4 weeks that the repeat dose is valid.  Another dose should be forecast.
2013-0747	# 1 Pentacel at 6 wks	44869	F				Not complete	44911	PENTACEL	120	PMC	Valid																																						2	44939	44989	45047	POL	44911	Age: At Minimum	41275	43997.64888752315	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered the first dose of the Polio vaccine (Pentacel) at 6 weeks of age that the dose is valid.  Another dose should be forecast.
2013-0748	# 1 Pentacel at 6 yrs 11.5 mo	42366	F				Not complete	44911	PENTACEL	120	PMC	Valid																																						2	44939	44939	44939	POL	44911	Vaccine: Off Label	41275	43997.65168996528	Recommended based on minimum interval from previous dose (catch-up)	Updated DOB to curb future date issues.	3.3	This test case describes when a child is administered a first dose of the Polio vaccine (Pentacel) at 6 years 11.5 months that the dose is valid.  Another dose should be forecast.
2013-0749	# 1 Pentacel at 7 yrs.  Off label	42354	F				Not complete	44911	PENTACEL	120	PMC	Valid																																						2	44939	44939	44939	POL	44911	Vaccine: Off Label	41275	43997.653248333336	Recommended based on minimum interval from previous dose (catch-up)	Updated DOB to curb future date issues.	3.3	This test case describes when a child is administered a first dose of the Polio vaccine (Pentacel) at 7 years of age that the dose is valid.  Another dose should be forecast.
2013-0750	# 2 Pentacel at 10 wks-5 days	44846	F				Not complete	44884	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Not Valid	Age: Too Young																															2	44939	44969	45024	POL	44911	Age: Below Absolute Minimum	41275	43997.65422440972	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a second dose of the Polio (Pentacel) vaccine at 10 weeks - 5 days of age that the dose is not valid.  A repeat dose should be forecast.
2013-0751	# 2 Pentacel at 10 wks-4 days	44845	F				Not complete	44883	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																																3	44943	45027	45450	POL	44911	Age: At Absolute Minimum	41275	43997.65592246528	Recommended based on age	Rolled birth date forward to 2011 to ensure test was relevant to when ACIP recommendations were made.  Previous dates were before the ACIP recommendations were published.	1.5	This test case describes when a child is administered a second dose of the Polio vaccine (Pentacel) at 10 weeks - 4 days of age that the dose is valid.  Another dose should be forecast.
2013-0752	# 2 Pentacel at 6 yrs .  Off label	42720	F				Not complete	43085	PENTACEL	120	PMC	Valid		44911	PENTACEL	120	PMC	Valid																																3	45093	45093	45303	POL	44911	Vaccine: Off Label	41275	43997.65827037037	Recommended based on minimum interval from previous dose (catch-up)	Updated the Forecast Dose number to 3. Updated DOB to curb future date issues.	3.3	This test case describes when a child is administered a second dose of the Polio vaccine (Pentacel) at 6 years of age that the dose is valid.  Another dose should be forecast.
2013-0753	Newborn forecast	44911	F				Not complete																																											1	44953	44973		ROTA	44911	No Doses Administered	41275	43054.31639590278	Recommended based on age		1.0	This test case describes when a newborn is assessed for the first dose of a Rotavirus vaccine. 
2013-0754	Dose # 3 Rotateq at age 14 weeks	44813	F				Complete	44855	ROTATEQ	116	MSD	Valid		44883	ROTATEQ	116	MSD	Valid		44911	ROTATEQ	116	MSD	Valid																										-				ROTA	44911	Age: At Minimum	41275	43076.447310578704	Not recommended: series complete		1.0	This test case describes when dose #3 of RotaTeq vaccine is administered at 14 weeks of age that the dose is considered to be valid.  The series is complete.
2013-0755	Dose # 3 Rotateq at age 6 months	44728	F				Complete	44789	ROTATEQ	116	MSD	Valid		44850	ROTATEQ	116	MSD	Valid		44911	ROTATEQ	116	MSD	Valid																										-				ROTA	44911	Age: At Recommended	41275	43076.44803465278	Not recommended: series complete		1.0	This test case describes when dose #3 of a RotaTeq vaccine is administered at 6 months of age that the dose is considered to be valid.  The series is complete.
2013-0756	Dose 1 to dose 2 Rotateq interval 28-5 days	44839	F				Not complete	44888	ROTATEQ	116	MSD	Valid		44911	ROTATEQ	116	MSD	Not Valid	Interval: too short																															2	44939	44962	45017	ROTA	44911	Interval: Below Absolute Minimum	41275	44868.54039099537	Recommended based on age		1.0	This test case describes when dose #2 of a RotaTeq vaccine is administered less than 4 weeks - 4 days from the previous dose that the dose is not valid.
2013-0757	Dose 1 to dose 2 Rotateq interval 28-4 days	44838	F				Not complete	44887	ROTATEQ	116	MSD	Valid		44911	ROTATEQ	116	MSD	Valid																																3	44939	45020	45077	ROTA	44911	Interval: At Absolute Minimum	41275	43984.32404400463	Recommended based on age		1.0	This test case describes when dose #2 of a RotaTeq vaccine is administered at least 4 weeks - 4 days from dose #1 that the dose is considered to be valid.  
2013-0758	Dose 1 to dose 2 Rotateq interval 28 days	44834	F				Not complete	44883	ROTATEQ	116	MSD	Valid		44911	ROTATEQ	116	MSD	Valid																																3	44939	45015	45073	ROTA	44911	Interval: At Minimum	41275	43076.452796666665	Recommended based on age		1.0	This test case describes when dose #2 of a RotaTeq vaccine is administered at least 4 weeks from dose #1 that the dose is considered to be valid.  
2013-0759	Dose 2 to dose 3 Rotateq  interval 28-5 days	44795	F				Not complete	44852	ROTATEQ	116	MSD	Valid		44888	ROTATEQ	116	MSD	Valid		44911	ROTATEQ	116	MSD	Not Valid	Interval: too short																									3	44939	44979	45034	ROTA	44911	Interval: Below Absolute Minimum	41275	43076.45405355324	Recommended based on age		1.0	This test case describes when dose #3 of a RotaTeq vaccine is administered at 4 weeks  - 5 days from dose #2 that the dose is not valid.
2013-0760	Dose 2 to dose 3 Rotateq interval  28-4 days	44794	F				Complete	44851	ROTATEQ	116	MSD	Valid		44887	ROTATEQ	116	MSD	Valid		44911	ROTATEQ	116	MSD	Valid																										-				ROTA	44911	Interval: At Absolute Minimum	41275	43984.324180069445	Not recommended: series complete		1.0	This test case describes when dose #3 of a RotaTeq vaccine is administered at 4 weeks  - 4 days from dose #2 that the dose is considered to be valid. The series is complete.
2013-0761	Dose 2 to dose 3 Rotateq interval 28 days	44790	F				Complete	44847	ROTATEQ	116	MSD	Valid		44883	ROTATEQ	116	MSD	Valid		44911	ROTATEQ	116	MSD	Valid																										-				ROTA	44911	Interval: At Minimum	41275	43076.455569756945	Not recommended: series complete		1.0	This test case describes when dose #3 of a RotaTeq vaccine is administered at, at least 14 weeks of age and at least 4 weeks (28 days) from dose #2, that the dose is considered to be valid. The series is complete.
2013-0762	Dose # 1 Rotarix at age 6 weeks-5 days	44874	F				Not complete	44911	ROTARIX	119	SKB	Not Valid	Age: Too Young																																					1	44916	44935		ROTA	44911	Age: Below Absolute Minimum	41275	43076.47517114583	Recommended based on age		1.0	This test case describes when a Rotarix vaccine dose is administered at an age of 6 weeks - 5 days, that the dose is not valid.
2013-0763	Dose # 1 Rotarix at age 6 weeks-4 days 	44873	F				Not complete	44911	ROTARIX	119	SKB	Valid																																						2	44943	44993	45051	ROTA	44911	Age: At Absolute Minimum	41275	43984.32434241898	Recommended based on age		1.0	This test case describes when a Rotarix vaccine dose is administered at an age of 6 weeks - 4 days, that the dose is considered to be valid.
2013-0764	Dose # 1 Rotateq at age 6 weeks-5 days	44874	F				Not complete	44911	ROTATEQ	116	MSD	Not Valid	Age: Too Young																																					1	44916	44935		ROTA	44911	Age: Below Absolute Minimum	41275	43076.47653508102	Recommended based on age		1.0	This test case describes when dose #1 of the RotaTeq vaccine is administered at 6 weeks - 5 days that the dose is not valid.
2013-0765	Dose # 1 Rotarix at age 6 weeks	44869	F				Not complete	44911	ROTARIX	119	SKB	Valid																																						2	44939	44989	45047	ROTA	44911	Age: At Minimum	41275	43076.4786502662	Recommended based on age		1.0	This test case describes when dose #1 of the Rotarix vaccine is administered at 6 weeks of age, that the dose is considered to be valid.
2013-0766	Dose # 2 Rotarix at age 10 weeks-5 days	44846	F				Not complete	44886	ROTARIX	119	SKB	Valid		44911	ROTARIX	119	SKB	Not Valid	Age: Too Young																															2	44939	44969	45024	ROTA	44911	Age: Below Absolute Minimum	41275	43076.48008167824	Recommended based on age		1.0	This test case describes when dose #2 of Rotarix is administered at 10 weeks - 5 days of age that the dose is not valid.
2013-0767	Dose # 2 Rotarix at age 10 weeks-4 days	44845	F				Complete	44887	ROTARIX	119	SKB	Valid		44911	ROTARIX	119	SKB	Valid																																-				ROTA	44911	Age: At Absolute Minimum	41275	43984.32451849537	Not recommended: series complete		1.0	This test case describes when dose #2 of Rotarix is administered at 10 weeks - 4 days of age that the dose is considered to be valid.
2013-0768	Dose # 2 Rotarix at age 10 weeks	44841	F				Complete	44883	ROTARIX	119	SKB	Valid		44911	ROTARIX	119	SKB	Valid																																-				ROTA	44911	Age: At Minimum	41275	43076.481631006944	Not recommended: series complete		1.0	This test case describes when dose #2 of Rotarix is administered at 10 weeks of age that the dose is considered to be valid.
2013-0769	Dose 1 to dose 2 Rotarix interval 28-5 days	44827	F				Not complete	44888	ROTARIX	119	SKB	Valid		44911	ROTARIX	119	SKB	Not Valid	Interval: too short																															2	44939	44949	45007	ROTA	44911	Interval: Below Absolute Minimum	41275	43076.482593368055	Recommended based on age		1.0	This test case describes when dose #2 of Rotarix is administered at an interval of 28 - 5 days that the dose is not valid.
2013-0770	Dose 1 to dose 2 Rotarix interval 28-4 days	44826	F				Complete	44887	ROTARIX	119	SKB	Valid		44911	ROTARIX	119	SKB	Valid																																-				ROTA	44911	Interval: At Absolute Minimum	41275	43984.324666064815	Not recommended: series complete		1.0	This test case describes when dose #2 of Rotarix is administered at an interval of 28 - 4 days that the dose is considered to be valid.
2013-0771	Dose 1 to dose 2 Rotarix interval 28 days	44822	F				Complete	44883	ROTARIX	119	SKB	Valid		44911	ROTARIX	119	SKB	Valid																																-				ROTA	44911	Interval: At Minimum	41275	43076.48441989583	Not recommended: series complete		1.0	This test case describes when dose #2 of Rotarix is administered at an interval of 28 days that the dose is considered to be valid.
2013-0772	≥15 weeks old with no rota vax:  no forecast for rotavirus	44806	F				Aged out																																											-				ROTA	44911	No Doses Administered	41275	43076.48498760417	Not recommended: too old	v1.6: Updated Series Status from "Not Complete" to "Aged Out" to align with updated CDSi Logic Specification Series Statuses.	1.6	This test case describes when a infant reaches 15 weeks of age at assessment, with no previous doses administered, that a Rotavirus vaccine should not be recommended. Patient is Aged Out.
2013-0773	Dose # 1 ≥ 15 weeks old 	44802	F				Not complete	44911	ROTARIX	119	SKB	Valid																																						2	44939	44939	44982	ROTA	44911	All Valid: Forecast Test	41275	43076.48585887731	Recommended based on minimum interval from previous dose (catch-up)		1.0	This test case describes when a infant has received dose #1 of a Rotavirus vaccine at age 15 weeks that dose #2 should be forecasted. 
2013-0774	8 months old with only one rota vax	44667	F				Not complete	44758	ROTARIX	119	SKB	Valid																																						2	44786	44789	44847	ROTA	44911	All Valid: Forecast Test	41275	43109.311082002314	Recommended based on age	Child is exactly 8 months old based on the Assessment Date and should still be recommended for administration.	1.1	This test case describes when an 8 month old infant was administered a previous dose of a Rotavirus vaccine at 3 months of age, that a second dose should be forecasted.
2013-0775	Dose # 1 Rotateq at age 6 weeks-4 days 	44873	F				Not complete	44911	ROTATEQ	116	MSD	Valid																																						2	44943	44993	45051	ROTA	44911	Age: At Absolute Minimum	41275	43984.325024618054	Recommended based on age		1.0	This test case describes when an infant is administered a dose of RotaTeq at age 6 weeks - 4 days that the dose is considered to be valid.
2013-0776	Rotateq at 2 months; rotarix at 4 mo	44789	F				Not complete	44850	ROTATEQ	116	MSD	Valid		44911	ROTARIX	119	SKB	Valid																																3	44939	44973	45028	ROTA	44911	Age: At Recommended	41275	43076.48714134259	Recommended based on age		1.0	This test case describes when an infant is administered doses of RotaTeq at 2 and 4 months of age that the doses are considered to be valid.
2013-0777	Rotatrix at 2 mo; rotateq at 4 mo	44789	F				Not complete	44850	ROTARIX	119	SKB	Valid		44911	ROTATEQ	116	MSD	Valid																																3	44939	44973	45028	ROTA	44911	Age: At Recommended	41275	43076.495655046296	Recommended based on age		1.0	This test case describes when an infant is administered a dose of Rotarix at 2 months of age and a dose of RotaTeq at 4 months of age that the doses are considered to be valid.
2013-0778	Unspecified rotavirus at 2 and 4 mo	44789	F				Not complete	44850	rotavirus, unspecified formulation	122		Valid		44911	rotavirus, unspecified formulation	122		Valid																																3	44939	44973	45028	ROTA	44911	Age: At Recommended	41275	43076.49603751158	Recommended based on age		1.0	This test case describes when an infant is administered doses of Unspecified Rotavirus vaccines at 2 and 4 months of age that the doses are considered to be valid. Forecast a third dose.
2013-0781	Dose # 1 Rotateq at age 6 weeks	44869	F				Not complete	44911	ROTATEQ	116	MSD	Valid																																						2	44939	44989	45047	ROTA	44911	Age: At Minimum	41275	43077.47995275463	Recommended based on age		1.0	This test case describes when an infant is administered a dose of RotaTeq at age 6 weeks, that the dose is considered to be valid.
2013-0782	Dose # 2 Rotateq at age 10 weeks-5 days	44846	F				Not complete	44886	ROTATEQ	116	MSD	Valid		44911	ROTATEQ	116	MSD	Not Valid	Age: Too Young																															2	44939	44969	45024	ROTA	44911	Age: Below Absolute Minimum	41275	43077.4806134375	Recommended based on age		1.0	This test case describes when dose #2 of RotaTeq is administered at 10 weeks - 5 days of age that the dose is not valid.
2013-0783	Dose # 2 Rotateq at age 10 weeks-4 days	44845	F				Not complete	44887	ROTATEQ	116	MSD	Valid		44911	ROTATEQ	116	MSD	Valid																																3	44943	45027	45084	ROTA	44911	Age: At Absolute Minimum	41275	43984.32531813657	Recommended based on age		1.0	This test case describes when dose #2 of RotaTeq is administered at 10 weeks - 4 days of age that the dose is considered to be valid.
2013-0784	Dose # 2 Rotateq at age 10 weeks	44841	F				Not complete	44883	ROTATEQ	116	MSD	Valid		44911	ROTATEQ	116	MSD	Valid																																3	44939	45023	45080	ROTA	44911	Age: At Minimum	41275	43077.48271119213	Recommended based on age		1.0	This test case describes when dose #2 of RotaTeq is administered at 10 weeks of age that the dose is considered to be valid.
2013-0785	Dose # 3 Rotateq at age 14 weeks-5 days	44818	F				Not complete	44857	ROTATEQ	116	MSD	Valid		44885	ROTATEQ	116	MSD	Valid		44911	ROTATEQ	116	MSD	Not Valid	Age: Too Young																									3	44939	44999	45057	ROTA	44911	Age: Below Absolute Minimum	41275	43077.48327023148	Recommended based on age		1.0	This test case describes when dose #3 of RotaTeq vaccine is administered at 14 weeks - 5 days of age that the dose is not valid.  
2013-0786	Dose # 3 Rotateq at age 14 weeks-4 days	44817	F				Complete	44859	ROTATEQ	116	MSD	Valid		44887	ROTATEQ	116	MSD	Valid		44911	ROTATEQ	116	MSD	Valid																										-				ROTA	44911	Age: At Absolute Minimum	41275	43984.32675755787	Not recommended: series complete		1.0	This test case describes when dose #3 of RotaTeq vaccine is administered at 14 weeks - 4 days of age that the dose is considered to be valid.  The series is complete.
2013-0789	#1 at 15 months	44455	F				Not complete	44911	VARIVAX	21	MSD	Valid																																						2	44995	45916	47039	VAR	44911	All Valid: Forecast Test	41275	43102.59719332176	Recommended based on age	Improved test case name and forecast test type to acurately reflect what was being tested	1.1	This test case describes the administering of dose #1 of varicella at 15 months. 
2013-0795	No doses of Varicella: current age 13Y -1D	40164	F				Not complete																																											1	40529	40529	40677	VAR	44911	No Doses Administered	41275	43103.668896875	Recommended based on age		1.0	This test case describes the forecasting of dose #1 of varicella at the age of 13 years - 1 day.
2013-0798	#1 at 1 year	44546	F				Not complete	44911	VARIVAX	21	MSD	Valid																																						2	45001	46007	47130	VAR	44911	Age: At Minimum	41275	43102.60048233796	Recommended based on age		1.0	This test case describes the administering of dose #1 of varicella at 12 months or 1 year of age.
2013-0803	# 1 at 12 months-5 days	44551	F				Not complete	44911	VARIVAX	21	MSD	Not Valid	Age: Too Young																																					1	44939	44939	45064	VAR	44911	Age: Below Absolute Minimum	41275	43102.60104577546	Recommended based on minimum interval from live virus vaccine		1.0	This test case describes that the administering of dose #1 of varicella at 12 months - 5 days is considered not valid.
2013-0804	VAR # 1 at 12 months-4 days	44550	F				Not complete	44911	VARIVAX	21	MSD	Valid																																						2	45005	46011	47134	VAR	44911	Age: At Absolute Minimum	41275	43984.35849918982	Recommended based on age		1.0	This test case describes the administering of dose #1 of varicella at 12 months - 4 days to be considered as a valid dose.
2013-0806	Newborn forecasting	44911	F				Not complete																																											1	45276	45276	45425	VAR	44911	No Doses Administered	41275	43102.601679155094	Recommended based on age		1.0	This test case describes the forecasting of dose #1 of varicella at 12 months of age for a newborn. 
2013-0807	# 2 at age 13 years + 28 days	40135	F				Complete	44883	VARIVAX	21	MSD	Valid		44911	VARIVAX	21	MSD	Valid																																-				VAR	44911	Age: At Minimum	41275	43987.40368671296	Not recommended: series complete		1.0	This test case describes when the second dose of the Varicella vaccine is administered at 13 years + 28 days that the dose is considered to be valid.
2013-0808	Dose 1 to dose 2 interval 28-1 days  in child < 13 years	44518	F				Not complete	44884	VARIVAX	21	MSD	Valid		44911	VARIVAX	21	MSD	Not Valid	Interval: too short																															2	44995	45979	47102	VAR	44911	Interval: Below Absolute Minimum	41275	43102.60305157407	Recommended based on age	v1.6: Incorrect Forecast Test Type was used and has been updated to reflect how the recommended date was forecasted.	1.6	This test case describes when the 2nd dose of varicella vaccine is administered at 28-1 day in a child < 13 years of age that the dose is considered not valid.
2013-0809	Dose 1 to dose 2 interval 28 days  in child < 13 yrs old	41535	F				Complete	44883	VARIVAX	21	MSD	Valid		44911	VARIVAX	21	MSD	Valid																																-				VAR	44911	Interval: At Absolute Minimum	41275	43987.406535532406	Not recommended: series complete		1.0	This test case describes the administering of the 2nd dose of varicella 28 days after the first dose.
2013-0810	Dose 1 to dose 2 interval 28-5 days  in child ≥ 13 yrs old	40048	F				Not complete	44888	VARIVAX	21	MSD	Valid		44911	VARIVAX	21	MSD	Not Valid	Interval: too short																															2	44939	44939	44966	VAR	44911	Interval: Below Absolute Minimum	41275	43104.29241456019	Recommended based on minimum interval from invalid dose	Past Due Date was updated to reflect an 8 week interval per ACIP guidelines after last administered dose.	3.1	This test case describes when the 2nd dose of varicella vaccine is administered at 28-5 days after the 1st dose in a child that is 13 years of age that the dose is considered to be not valid.
2013-0811	Dose 1 to dose 2 interval 28-4 days  in child ≥ 13 years old	40047	F				Complete	44887	VARIVAX	21	MSD	Valid		44911	VARIVAX	21	MSD	Valid																																-				VAR	44911	Interval: At Absolute Minimum	41275	43987.407584189816	Not recommended: series complete		1.0	This test case describes when the 2nd dose of varicella is administered at 28-4 days after the 1st dose in a child that is 13 years of age that the dose is considered to be valid.
2013-0812	Dose 1 to dose 2 interval 28 days in child ≥ 13 years old	39982	F				Complete	44883	VARIVAX	21	MSD	Valid		44911	VARIVAX	21	MSD	Valid																																-				VAR	44911	Interval: At Absolute Minimum	41275	43987.40838340278	Not recommended: series complete		1.0	This test case describes when the 2nd dose of varicella vaccine is administered at least 28 days after the first dose, in a child that is 13 years of age, that the dose is considered valid.
2013-0813	VZ and MMR given on same day at age 12 months	44546	F				Not complete	44911	M-M-R II	03	MSD	Valid		44911	VARIVAX	21	MSD	Valid																																2	45001	46007	47130	VAR	44911	Age: At Minimum	41275	43104.29386953704	Recommended based on age		1.0	This test case describes that when two live virus vaccines (MMR and Varicella) are administered on the same date, that a second dose of the vaccines are recommended.
2013-0814	Doses 1 and 2 of VZ and MMR given at ages 12 months and 4 weeks later	44520	F				Not complete	44881	M-M-R II	03	MSD	Valid		44881	VARIVAX	21	MSD	Valid		44909	M-M-R II	03	MSD	Valid		44909	VARIVAX	21	MSD	Not Valid	Age: Too Young																			2	44993	45981	47104	VAR	44911	Age: At Absolute Minimum	41275	44307.297540555555	Recommended based on interval	V4.8: Made a slight change in the age of the patient to adjust for February-to-March 28 day month issues causing false negatives when cases are generated in March. 
v4.3: Added Evaluation Reason on last dose (too young)
v3.3: Updated per the 2017 General Best Practice Guidelines (Table 3-1, footnote (x) which indicates a 13 month absolute minimum age for Varicella-2.	4.8	This test case describes when dose #2 of the varicella vaccine is administered at less than 13 months of age, that the dose is considered to be invalid and a repeat dose should be administered at 12 weeks later. 
2013-0815	MMR to VZ interval 28-1 day = invalid VZ.	44519	F				Not complete	44884	M-M-R II	03	MSD	Valid		44911	VARIVAX	21	MSD	Not Valid	Live Virus Conflict																															1	44939	44939	45031	VAR	44911	Live Virus: Below Minimum	41275	43104.2963859838	Recommended based on minimum interval from live virus vaccine		1.0	This test case describes when a MMR vaccine is administered first and a Varicella vaccine is administered at 28-1 days after the MMR vaccine dose that the varicella vaccine dose is not valid.
2013-0816	MMR given at age 12 mo; VZ at age 12 mo+28 days	44518	F				Not complete	44883	M-M-R II	03	MSD	Valid		44911	VARIVAX	21	MSD	Valid																																2	44995	45979	47102	VAR	44911	Live Virus: At Minimum	41275	43104.29691586806	Recommended based on age		1.0	This test case describes when a MMR vaccine is administered at age 12 months and a Varicella vaccine is administered at 28 days later that the doses are valid and that a second dose of the varicella vaccine should be forecasted.
2013-0817	# 1 at age 12 mo-5 days	44551	F				Not complete	44911	VARIVAX	21	MSD	Not Valid	Age: Too Young																																					1	44939	44939	45064	VAR	44911	Age: Below Absolute Minimum	41275	43104.29725979167	Recommended based on minimum interval from live virus vaccine		1.0	This test case describes when the first dose of the varicella vaccine is administered at 12 months - 5 days of age, that the vaccine dose is not valid.
2013-0818	# 1 MMRV at 12 m-5 days	44551	F				Not complete	44911	PROQUAD	94	MSD	Not Valid	Age: Too Young																																					1	44939	44939	45064	VAR	44911	Age: Below Absolute Minimum	41275	43104.2977553125	Recommended based on minimum interval from live virus vaccine		1.0	This test case describes when a varicella vaccine (ProQuad) is administered at 12 months - 5 days of age, that the vaccine dose is not considered to be valid, and that the dose should be repeated.
2013-0819	# 1 MMRV at 12 m-4 days	44550	F				Not complete	44911	PROQUAD	94	MSD	Valid																																						2	45005	46011	47134	VAR	44911	Age: At Absolute Minimum	41275	43984.35993885417	Recommended based on age		1.0	This test case describes when the first dose of varicella vaccine (ProQuad) is administered at 12 months - 4 days of age, that it is considered to be valid, and a second dose should be forecasted.
2013-0820	# 1 MMRV at 12 months 	44546	F				Not complete	44911	PROQUAD	94	MSD	Valid																																						2	45001	46007	47130	VAR	44911	Age: At Minimum	41275	43104.29842305555	Recommended based on age		1.0	This test case describes when the first dose of the varicella vaccine (PROQUAD) is administered at 12 months that the dose is considered to be valid.
2013-0821	Dose 1 to dose 2 MMRV interval 28 days in child < 15 months	44487	F				Complete	44883	PROQUAD	94	MSD	Valid		44911	PROQUAD	94	MSD	Valid																																-				VAR	44911	Interval: At Absolute Minimum	41275	43104.29880758102	Not recommended: series complete		1.0	This test case describes when the second dose of the varicella vaccine (PROQUAD)  is administered at 13 months + 28 days that the dose is considered valid.
2013-0822	Dose 1 to dose 2 MMRV interval 28 days in child ≥ 15 months old=valid VZ	44438	F				Complete	44878	PROQUAD	94	MSD	Valid		44906	PROQUAD	94	MSD	Valid																																-				VAR	44911	Interval: At Minimum	41275	44656.29999219908	Not recommended: series complete		1.0	This test case describes when the second dose of the varicella vaccine (PROQUAD)  is administered at 15 months +11 days that the dose is considered valid.
2013-0823	Dose 1 to dose 2 MMRV interval 28-1 days	43389	F				Not complete	44875	PROQUAD	94	MSD	Valid		44902	PROQUAD	94	MSD	Not Valid	Live Virus Conflict																															2	44986	44986	45973	VAR	44911	Interval: Below Absolute Minimum	41275	44656.30074914352	Recommended based on minimum interval from invalid dose		1.0	This test case describes when the second dose of the varicella vaccine (PROQUAD)is administered at 28 - 1 days that the dose is not valid.
2013-0824	MMR to MMRV interval 28 days=valid VZ # 1	44518	F				Not complete	44883	M-M-R II	03	MSD	Valid		44911	PROQUAD	94	MSD	Valid																																2	44995	45979	47102	VAR	44911	Live Virus: At Minimum	41275	43104.30198657407	Recommended based on age		1.0	This test case describes when a MMR vaccine is given at 12 months and a MMRV (PROQUAD) vaccine is administered at one month later that the doses are considered to be valid.
2013-0825	MMR to MMRV interval 27 days=invalid as VZ # 1	44518	F				Not complete	44884	M-M-R II	03	MSD	Valid		44911	PROQUAD	94	MSD	Not Valid	Live Virus Conflict																															1	44939	44939	45030	VAR	44911	Live Virus: Below Minimum	41275	43104.302360092595	Recommended based on minimum interval from live virus vaccine		1.0	This test case describes when a MMR vaccine is given at 12 months + 1 day and a MMRV (PROQUAD) vaccine is administered at one year and 28 days, that  that the MMR vaccine is not valid..
2013-0826	Dose 1 to dose 2  MMRV interval 12 weeks in child < 13 years old  	43540	F				Complete	44820	PROQUAD	94	MSD	Valid		44904	PROQUAD	94	MSD	Valid																																-				VAR	44911	Interval: At Minimum	41275	43104.30321300926	Not recommended: series complete		1.0	This test case describes when the second dose of a MMR vaccine (PROQUAD) is administered > 28 days that the series is considered complete.
2013-0827	Dose 1 to dose 2 interval of 4 wks between VZ and MMRV in any age child=both valid	44504	F				Complete	44879	VARIVAX	21	MSD	Valid		44907	PROQUAD	94	MSD	Valid																																-				VAR	44911	Interval: At Minimum	41275	44656.30145131944	Not recommended: series complete		1.0	This test case describes when a MMRV (PROQUAD) vaccine is administered at least 4 week after a varicella vaccine dose that the Varicella two dose series is considered complete.
2013-0829	28 day interval between invalid VZ and subsequent MMRV=valid VZ	44523	F				Not complete	44883	VARIVAX	21	MSD	Not Valid	Age: Too Young	44911	PROQUAD	94	MSD	Valid																																2	44995	45984	47107	VAR	44911	Live Virus: At Minimum	41275	43104.30445357639	Recommended based on age		1.0	This test case describes when a MMRV (PROQUAD) vaccine is administered at least 4 week after an invalid varicella vaccine dose that the PROQUAD vaccine dose is considered valid. Forecast dose 2.
2013-0831	Interval of < 24 days between an invalid VZ and a subsequent MMRV=not valid VZ	44527	F				Not complete	44887	VARIVAX	21	MSD	Not Valid	Age: Too Young	44911	PROQUAD	94	MSD	Not Valid	Live Virus Conflict																															1	44939	44939	45039	VAR	44911	Live Virus: Below Minimum	41275	43104.30495644676	Recommended based on minimum interval from live virus vaccine	Forecast Dates were forecasting Dose 2, but the patient is still trying to satisfy target dose #1.  Dates were updated to reflect a forecast for dose 1 based on live virus spacing.	1.1	This test case describes when a MMRV (PROQUAD) vaccine is administered less than 24 days from an invalid dose of varicella vaccine dose, that the dose is not valid.  Forecast dose #1 of varicella vaccine.
2013-0832	LAIV given at age 3 years; VZ at age 3 years + 27 days	43788	F				Not complete	44884	Flumist quadrivalent	149	MED	Valid		44911	VARIVAX	21	MSD	Not Valid	Live Virus Conflict																															1	44939	44939	44939	VAR	44911	Live Virus: Below Minimum	41275	43171.70590130787	Recommended based on minimum interval from live virus vaccine		1.0	This test case describes when a varicella vaccine dose is administered at less than 28 days after an Influenza (LAIV) vaccine dose , that the Varicella dose is not valid.
2013-0833	LAIV given at age 3 years; VZ at age 3 years + 28 days	43787	F				Not complete	44883	Flumist quadrivalent	149	MED	Valid		44911	VARIVAX	21	MSD	Valid																																2	44995	45248	46371	VAR	44911	Live Virus: At Minimum	41275	43171.70656571759	Recommended based on age		1.0	This test case describes when a Varicella vaccine is administered at least 28 days after an Influenza (LAIV) vaccine that the Varicella vaccine dose is considered to be valid. Forecast 2nd dose.
2013-0840	# 1 MMR at 12.5 mo; VZ not given=need 28 day interval for VZ	44530	F				Not complete	44910	M-M-R II	03	MSD	Valid																																						1	44938	44938	45042	VAR	44911	All Valid: Forecast Test	41275	43857.42126564815	Recommended based on minimum interval from live virus vaccine	v4.3: moved the assessment date out one day to ensure live virus forecasting is engaged	4.3	This test case describes when an MMR vaccine is administered at 12.5 months of age and Varicella wasn't, that a Varicella vaccine should be forecast 28 days later to provide proper live virus vaccine spacing.
2013-0842	# 2 at age 12 mo+ 4 Weeks	44520	F				Not complete	44881	VARIVAX	21	MSD	Valid		44909	VARIVAX	21	MSD	Not Valid	Age: Too Young																															2	44993	45981	47104	VAR	44911	Age: At Absolute Minimum	41275	44307.29876953704	Recommended based on interval	v4.8: Made a slight change in the age of the patient to adjust for February-to-March 28 day month issues causing false negatives when cases are generated in March. 
V2.x: Updated per the 2017 General Best Practice Guidelines (Table 3-1, footnote (x) which indicates a 13 month absolute minimum age for Varicella-2.	4.8	This test case describes when dose 2 of the Varicella vaccine is administered at less than 13 months of age, that the dose is not valid. 
2013-0843	# 2 at age 15 mo.	44455	F				Complete	44820	VARIVAX	21	MSD	Valid		44911	VARIVAX	21	MSD	Valid																																-				VAR	44911	Age: At Minimum	41275	43104.30964893519	Not recommended: series complete		1.0	This test case describes when the second dose of Varicella Vaccine is administered at age 15 months that the dose is considered valid and the series is complete.
2013-0844	# 1 at age ≥ 13 years old	40160	F				Not complete	44911	VARIVAX	21	MSD	Valid																																						2	44939	44939	44966	VAR	44911	All Valid: Forecast Test	41275	43984.36166599537	Recommended based on minimum interval from previous dose (catch-up)	Past Due Date was updated to reflect an 8 week interval per ACIP guidelines after last administered dose.	3.1	This test case describes when a Varicella vaccine is administered at age 13 years that the  second dose is considered to be valid and a second dose should be forecasted at 4 weeks later.
2015-0001	Varicella: Zoster dose in lieu of  first dose of Varicella for adult patient	31762	F				Not complete	44911	ZOSTAVAX	121	MSD	Valid																																						2	44939	44939	44966	VAR	44911	Vaccine: Off Label	42178	43508.531145671295	Recommended based on interval	Past Due Date was updated to reflect an 8 week interval per ACIP guidelines after last administered dose.	1.0	This test case describes when a ZVL vaccine dose is given in lieu of a Varicella vaccine to an adult less than 50 years, that the dose should be considered as a valid first dose of the Varicella vaccine.
2015-0002	Varicella: Adult patient has received 2 doses of the Varicella Vaccine at least 4 weeks apart	36475	F				Complete	44876	VARIVAX	21	MSD	Valid		44911	VARIVAX	21	MSD	Valid																																-				VAR	44911	All Valid: Forecast Test	42178	43104.31707386574	Not recommended: series complete	New test case for version 2.0 which expanded scope into Adult recommendations	1.0	This test case describes when 2 dose of the Varicella vaccine has been administered to an Adult at least 4 weeks apart that the doses are considered valid and the series is complete.
2019-0023	Adult patient with no doses of the Varicella vaccine.	36876	F				Not complete																																											1	37241	37241	37389	VAR	44911	No doses administered	43782.791666666664	43984.3623347338	Recommended based on age		4.2	This test cases describes when an adult patient has not been administered any doses of the Varicella vaccine that the first dose should be forecast.
2019-0024	Adult patient with dose #2 at 4 weeks	33560	F				Complete	44883	varicella	21		Valid		44911	varicella	21		Valid																																				VAR	44911	All Valid: Forecast Test	43782.791666666664	43984.36245739584	Not recommended: series complete		4.2	This test cases describes when an adult patient has been administered the second dose of the Varicella vaccine at 4 weeks that no additional doses should be forecast.  Series is complete.
2019-0025	Adult patient with dose #2 at 4 weeks - 4 days	33564	F				Complete	44887	varicella	21		Valid		44911	varicella	21		Valid																																				VAR	44911	Interval: At Absolute Minimum	43782.791666666664	43984.362785729165	Not recommended: series complete		4.2	This test cases describes when an adult patient has been administered the second dose of the Varicella vaccine at 4 weeks - 4 days, that no additional doses should be forecast.  Series is complete.
2019-0026	Adult patient with dose #2 at 4 weeks - 5 days	33565	F				Not complete	44888	varicella	21		Valid		44911	varicella	21		Not Valid	Interval: too short																															2	44939	44939	44966	VAR	44911	Interval: Below Absolute Minimum	43782.791666666664	44357.61648202546	Recommended based on interval		4.2	This test cases describes when an adult patient has been administered the second dose of the Varicella vaccine at 4 weeks - 5 days, that another dose should be forecast.
2015-0013	Zoster: Zoster Dose administered at 50 years of age	26649	F				Not complete	44911	ZOSTAVAX	121	MSD	Valid																																						2	44967	44967		ZOSTER	44911	All Valid: Forecast Test	42178	43209.31302758102	Recommended based on age	V3.4: Test case updated to accommodate new ACIP Zoster recommendations.
V2.0: New test case for version 2.0 which expanded scope into Adult recommendations	3.4	This test case describes when a patient is administered ZVL at age 50 years, that the first dose of the RZV vaccine should be forecasted at 8 weeks later.
2015-0014	Zoster: Zoster Dose administered at 60 years of age	22982	F				Not complete	44911	ZOSTAVAX	121	MSD	Valid																																						2	44967	44967		ZOSTER	44911	All Valid: Forecast Test	42178	43209.31345346065	Recommended based on age	V3.4: Test case updated to accommodate new ACIP Zoster recommendations.
V2.0: New test case for version 2.0 which expanded scope into Adult recommendations	3.4	This test case describes when a patient is administered a dose of ZVL (Zostavax) at age 60 years, that the first dose of the RZV (Shingrix) vaccine should be forecasted.
2015-0016	Zoster: Patient is overdue at 62 years of age for Zoster dose 	22250	F				Not complete																																											1	40512	40512		ZOSTER	44911	No Doses Administered	42178	43209.31382715278	Recommended based on age	V3.4: Test case updated to accommodate new ACIP Zoster recommendations.
V2.0: New test case for version 2.0 which expanded scope into Adult recommendations	3.4	This test case describes when a patient is 62 years of age and has not been administered a Zoster vaccine, that dose 1 (Shingrix) of the 2 dose series should be forecasted.
2015-0018	Zoster: MMR to Zoster interval 28 days	25525	F				Not complete	44883	M-M-R II	03	MSD	Valid		44911	ZOSTAVAX	121	MSD	Valid																																2	44967	44967		ZOSTER	44911	Live Virus: At Minimum	42178	43209.31467721065	Recommended based on age	V3.4: Test case updated to accommodate new ACIP Zoster recommendations.
V2.0: New test case for version 2.0 which expanded scope into Adult recommendations	3.4	This test case describes when a patient is administered a Zoster (ZVL) vaccine dose 28 days after a MMR vaccine dose, that the Zoster vaccine dose in considered valid. The engine should forecast dose #1 of the Zoster (Shingrix) vaccine.
2015-0019	Zoster: MMR to Zoster interval 28 - 1 days	26256	F				Not complete	44884	M-M-R II	03	MSD	Valid		44911	ZOSTAVAX	121	MSD	Not Valid	Live Virus Conflict																															1	44967	44967		ZOSTER	44911	Live Virus: Below Minimum	42178	43209.315249733794	Recommended based on minimum interval from live virus vaccine	V3.4: Updated test case to reflect updated Zoster recommendations for Shingrix.
V2.0: New test case for version 2.0 which expanded scope into Adult recommendations	3.4	This test case describes when a patient is in early 50's and is administered a Zoster vaccine dose 28 -1 days after a MMR vaccine dose that the ZVL (Zostavax) vaccine dose is considered invalid. Zoster should be forecast in the future.
2018-0001	Zoster: Patient has received dose 1 of the RZV (Shingrix) series	26649	F				Not complete	44911	zoster recombinant	187		Valid																																						2	44939	44967	45150	ZOSTER	44911	All Valid: Forecast Test	43186.833333333336	44831.36444153935	Recommended based on interval	v 4.27 Updated Forecast minimum interval from 8 weeks to 4 weeks, to align with ACIP recommendations.	4.27	This test case describes when a patient is administered dose #1 of the RZV vaccine, that a second dose should be forecast.
2018-0002	Zoster: Dose #2 of the RZV (Shringrix) vaccine administered at two months after dose #1	26593	M				Complete	44855	zoster recombinant	187		Valid		44911	zoster recombinant	187		Valid																																-				ZOSTER	44911	All Valid: Forecast Test	43186.833333333336	43209.57841890046	Not recommended: series complete		3.4	This test case describes when a patient is administered dose #2 of the RZV vaccine at two months after dose #1, that the dose is considered to be valid.
2018-0003	Zoster: Dose #2 (Shingrix) administered at 4 weeks after dose #1	26621	F				Complete	44883	zoster recombinant	187		Valid		44911	zoster recombinant	187		Valid																																-				ZOSTER	44911	All Valid: Forecast Test	43186.833333333336	43209.57945550926	Not recommended: series complete		3.4	This test case describes when a patient is administered dose #2 of the RZV vaccine 4 weeks after the first dose that the series is considered complete.
2018-0004	Zoster: Dose #2 of Shingrix administered at one year after dose #1	25918	F				Complete	44546	zoster recombinant	187		Valid		44911	zoster recombinant	187		Valid																																-				ZOSTER	44911	All Valid: Forecast Test	43186.833333333336	43980.356121261575	Not recommended: series complete		3.4	This test case describes when an adult patient is administered the second dose, of the Shingrix vaccine, at one year later that the dose is considered to be valid. Series is complete.
2018-0005	Zoster: Dose #2 (Shingrix) administered at 4 weeks - 1 days after dose #1	26621	M				Complete	44883	zoster recombinant	187		Valid		44910	zoster recombinant	187		Valid																																				ZOSTER	44911	Interval: At Absolute Minimum 	43186.833333333336	43980.356793136576	Not recommended: series complete	V4.0 Per SME Guidance, the four day grace period can be used. Second dose has been changed to "valid".
V3.5: Previous version was calculating the forecast from the first dose. This has been corrected to be from the previous dose (invalid dose #2).	4.0	This test case describes when an adult patient is administered the second dose of Shingrix vaccine at 4 weeks - 1 day, that the dose is considered to be valid.
2018-0006	Zoster: Patient is 50 with no previous history of Shringrix vaccine	26649	F				Not complete																																											1	44911	44911		ZOSTER	44911	No Doses Administered	43186.833333333336	43209.586292569446	Recommended based on age		3.4	This test case describes when a patient is age 50 that dose 1 of the Shringrix vaccine should be forecasted.
2018-0008	Zoster: Dose #1 of RZV administered 4 weeks after previous dose of ZVL	26621	F				Not complete	44883	ZOSTAVAX	121	MSD	Valid		44911	zoster recombinant	187		Valid																																3	44939	44967	45150	ZOSTER	44911	Interval: At Absolute Minimum	43187.833333333336	44831.36529173611	Recommended based on minimum interval 	v 4.27 Updated Forecast minimum interval from 8 weeks to 4 weeks, to align with ACIP recommendations.	4.27	This test case describes when a patient is administered the first dose of RZV (Shingrix) at 4 weeks after a previous dose of ZVL (Zostavax), that the dose is considered valid. Per current guidance, RZV is recommended to be spaced 8 weeks after ZVL, but it does not need to be repeated if administered at any point prior to that 8 weeks up to and including the same day.
2018-0009	Zoster: ZVL and RZV (Shingrix) vaccine doses administered on the same day/time	26649	F				Not complete	44911	zoster live	121		Valid		44911	zoster recombinant	187		Valid																																3	44939	44967	45150	ZOSTER	44911	Age: At Recommended	43187.833333333336	44831.365535185185	Recommended based on interval	v 4.27 Updated Forecast minimum interval from 8 weeks to 4 weeks, to align with ACIP recommendations.	4.27	This test case describes when a patient receives a dose of ZVL (Shingrix)  and RZV (Zostavax) on the same day, that the doses are considered to be valid.
2018-0011	Zoster: Dose #1 of Shingrix 8 weeks after Dose #2 of Varicella vaccine	26624	F				Not complete	43759	VARIVAX	21	MSD	Valid		44855	varicella	21		Valid		44911	SHINGRIX	187	SKB	Valid																										2	44939	44967	45150	ZOSTER	44911	All Valid: Forecast Test	43201.833333333336	44831.36576259259	Recommended based on minimum interval	v 4.27 Updated Forecast minimum interval from 8 weeks to 4 weeks, to align with ACIP recommendations.	4.27	This test case describes when a patient is administered a dose of Zoster (Shingrix) vaccine 8 weeks after the second dose of Varicella vaccine, that the doses are considered to be valid.
2018-0012	Zoster: Dose #1 of Shingrix, 4 weeks after Dose #2 of Varicella vaccine	26621	F				Not complete	43787	VARIVAX	21	MSD	Valid		44883	varicella	21		Valid		44911	SHINGRIX	187	SKB	Valid																										2	44939	44967	45150	ZOSTER	44911	All Valid: Forecast Test	43201.833333333336	44831.36626048611	Recommended based on minimum interval	v 4.27 Updated Forecast minimum interval from 8 weeks to 4 weeks, to align with ACIP recommendations.	4.27	This test case describes when dose #1 of the Shingrix vaccine is administered less than 8 weeks after the 2nd dose of the Varicella vaccine that the doses are considered to be valid.
2018-0013	Zoster: Dose #1 of RZV administered 8 weeks after previous dose of ZVL	26227	F				Not complete	44855	ZOSTAVAX	121	MSD	Valid		44911	SHINGRIX	187	SKB	Valid																																3	44939	44967	45150	ZOSTER	44911	Interval: At Minimum	43201.833333333336	44831.36655585648	Recommended based on interval	v 4.27 Updated Forecast minimum interval from 8 weeks to 4 weeks, to align with ACIP recommendations.	4.27	This test case describes when an adult patient is administered the first dose of RZV 8 weeks after a previous dose of ZVL, that the dose is valid.
2018-0014	Zoster: Patient has received all three doses of the zoster vaccine	26227	F				Complete	44490	ZOSTAVAX	121	MSD	Valid		44855	SHINGRIX	187	SKB	Valid		44911	SHINGRIX	187	SKB	Valid																										-				ZOSTER	44911	All Valid: Forecast Test	43208.833333333336	43980.35731277778	Not recommended: series complete		4.0	This test case describes when an adult patient receives three (valid) doses of the Zoster vaccine that the series is considered Complete.
2019-0001	Zoster: Dose #2 (Shingrix) administered at 4 weeks - 5 days after dose #1	26621	M				Not complete	44883	zoster recombinant	187		Valid		44906	zoster recombinant	187		Not Valid	Interval: too short																															2	44934	44962	45145	ZOSTER	44911	Interval: Below Absolute Minimum	43186.833333333336	44831.367129583334	Recommended based on minimum interval from invalid dose	v 4.27 Updated Forecast minimum interval from 8 weeks to 4 weeks, to align with ACIP recommendations.	4.27	This test case describes that when a patient is administered the second dose of Shingrix vaccine at less than 4 weeks - 4 days, that the dose is considered not valid.
2019-0002	Zoster: Dose #2 (Shingrix) administered at 4 weeks - 4 days after dose #1	26621	M				Complete	44883	zoster recombinant	187		Valid		44907	zoster recombinant	187		Valid																																-				ZOSTER	44911	All Valid: Forecast Test	43186.833333333336	43984.29796659722	Recommended based on minimum interval from invalid dose		4.0	This test case describes that when a patient is administered the second dose of Shingrix vaccine at 4 weeks - 4 day, that the dose is considered to be valid.
2019-0003	Zoster: Dose #1 of RZV administered 0 Days after previous dose of ZVL	26227	F				Not complete	44855	ZOSTAVAX	121	MSD	Valid		44855	SHINGRIX	187	SKB	Valid																																3	44883	44911	45094	ZOSTER	44911	All Valid: Forecast Test	43201.833333333336	44831.36750259259	Recommended based on interval	v 4.27 Updated Forecast minimum interval from 8 weeks to 4 weeks, to align with ACIP recommendations.	4.27	This test case describes when an adult patient is administered the first dose of RZV 0 days after a previous dose of ZVL, that the doses are valid.
2020-0011	Dose #1 of Pfizer Covid-19 Vaccine 	33223	M				Not complete	44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																						2	44932	44932	44966	COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44818.62164708333	Recommended based on interval	v4.21 Updated past due date to 8 weeks per 02/22/22 Clinical Considerations guidance.
v4.6 Added latest recommended interval.	4.21	This test case describes when a patient is administered the first dose of the Pfizer Covid-19 vaccine, that the dose is valid.  A second dose should be forecast.
2020-0012	2nd dose of Pfizer Covid-19 Vaccine at 21 days 	32547	F				Not complete	44197	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44218	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44369	44369		COVID-19	44218	All Valid: Forecast Test	44110.833333333336	44831.39512538195	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). 
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).
v4.16 Updated the Forecast Recommended Date based on Clinical Considerations Information (11/29/21), that states all persons aged 18 years and older should received a booster dose of Covid-19 vaccine.
v4.15 Updated per ACIP Recommendation on 11/19/2021, where individuals 18 years and older may receive a booster dose.
v4.12 Updated per ACIP recommendations, on 09/22/2021, for Pfizer booster dose for individuals 65 years and older.	4.27	This test case describes when a patient is administered the second dose of the Pfizer Covid-19 vaccine at 21 days after the first dose, that the dose is valid.  A booster dose should be forecast.
2020-0013	2nd dose of Pfizer Covid-19 Vaccine at 21 - 5 days 	31741	F				Not complete	44890	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44906	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Not Valid	Interval: too short																															2	44927	44927	44961	COVID-19	44911	All Valid Forecast Test	44110.833333333336	44831.37848212963	Recommended based on minimum interval from invalid dose	v4.21 - Updated past due date to 8 weeks per Clinical Consideration guidance 02/22/22.
v4.14 - added past due date.
v4.13 - Updated test case to include ACIP recommendation where if a second dose of a MRNA Covid-19 vaccine is given earlier than the 4-day grace period, and after the 10/24/2021 cessation date, that a repeat dose should be forecast.	4.21	This test case describes when a patient is administered the second dose of the Pfizer Covid-19 vaccine at 21-5 days after the first dose, and after the 10/24/2021 cessation date, that the dose is not valid. A repeat dose should be forecast.
2020-0014	2nd dose of Pfizer Covid-19 Vaccine at 21 - 4 days	33202	M				Not complete	44890	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44907	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44963	44963		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44831.39908491898	Recommended based on interval	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).
v4.16 Updated the Forecast Recommended Date based on Clinical Considerations Information (11/29/21), that states all persons aged 18 years and older should received a booster dose of Covid-19 vaccine.
v4.15 Updated per ACIP Recommendation on 11/19/2021, where individuals 18 years and older may receive a booster dose.
v4.12 Updated per ACIP recommendations, on 09/22/2021, for Pfizer Covid-19 booster dose for individuals 65 years and older.	4.27	This test case describes when a patient is administered the second dose of the Pfizer Covid-19 vaccine at 21 - 4 days after the first dose, that the dose is valid. A booster dose should be forecasted.
2020-0015	2nd dose of Covid-19 Vaccine different product (Moderna) at an interval of 28 days	37431	F				Not complete	44198	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44226	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid																																3	44377	44377		COVID-19	44226	All Valid: Forecast Test	44110.833333333336	44831.39737832176	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). 
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that individuals should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of a primary series (01/06/2022).
v4.16 Updated the Forecast Recommended Date based on Clinical Considerations Information (11/29/21), that states all persons aged 18 years and older should received a booster dose of Covid-19 vaccine.
v4.15 Updated per ACIP Recommendation on 11/19/2021, where individuals 18 years and older may receive a booster dose.
v4.13 - Updated test case to include the forecasting of a booster dose, at an interval of 6 months from most recent dose, for individuals 65 years and older who have completed a primary series.
v4.8: Changed age of patient from 16 to 20. This test case was intended to test mixed product use, but was testing both mixed product and minimum ages. The outcome is the same (2 valid doses with a complete series).	4.27	This test case describes when a patient is administered a different Covid-19 vaccine (Moderna) at 28 days after the first dose,  that the dose is valid.  A booster dose should be forecast.
2020-0016	Dose #1 of the Moderna Covid-19 Vaccine 	21170	F				Not complete	44911	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid																																						2	44939	44939	44966	COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44622.56040434028	Recommended based on interval	v4.21 Updated past due date to 8 weeks per 02/22/22 Clinical Considerations guidelines
v4.5  Added latest recommended interval.	4.21	This test case describes when a patient is administered a first dose of the Covid-19 (Moderna) vaccine that the dose is valid and that a second dose should be forecast.
2020-0017	2nd dose of Moderna Covid-19 Vaccine at 28 days 	21142	F				Not complete	44883	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44911	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44831.39835662037	Recommended based on interval	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group. 
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 18 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).
v4.13 - Updated test case to include the forecasting of a booster dose, at an interval of 6 months from most recent dose, for individuals 65 years and older who have completed a primary series.	4.27	This test case describes when a patient is administered a second dose of the Moderna Covid-19 vaccine at 28 days after the first dose, that the dose is valid.  A booster dose should be forecast.
2020-0018	2nd dose of Moderna Covid-19 Vaccine at 28 - 5 days 	21147	F				Not complete	44888	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44911	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Not Valid	Interval: too short																															2	44939	44939	44966	COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44622.560591967595	Recommended based on minimum interval from invalid dose	v4.21 - Updated past due date to 8 weeks per 02/22/22 Clinical Considerations guidelines
v4.13 - Updated test case to include ACIP recommendation where if a second dose of a MRNA Covid-19 vaccine is given earlier than the 4-day grace period, and after the 10/24/2021 cessation date, that a repeat dose should be forecast.	4.21	This test case describes when a patient is administered the second dose of the Moderna Covid-19 vaccine at 28 - 5 days after the first dose, and after the cessation date of 10/24/21, that the dose is not valid.  A repeat dose should be forecast.
2020-0019	2nd dose of Moderna Covid-19 Vaccine at 28 - 4 days 	20999	F				Not complete	44200	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44224	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid																																3	44375	44375		COVID-19	44224	All Valid: Forecast Test	44110.833333333336	44831.40065335648	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). 
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 18 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).
v4.13 - Updated test case to include the forecasting of a booster dose, at an interval of 6 months from most recent dose, for individuals 65 years and older who have completed a primary series.	4.27	This test case describes when a patient is administered a second dose of the Covid-19 vaccine (Moderna) at 28-4 days after the first dose, that the dose is valid, and that  booster dose should be forecast.
2020-0020	2nd dose of Covid-19 Vaccine different product (Pfizer) at 28 days 	20995	F				Not complete	44564	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44592	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44743	44743		COVID-19	44592	All Valid: Forecast Test	44110.833333333336	44831.40113295139	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). 
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that individuals should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of a primary series (01/06/2022)
v4.13 - Updated test case to include the forecasting of a booster dose, at an interval of 6 months from most recent dose, for individuals 65 years and older who have completed a primary series.	4.27	This test case describes when a patient is administered a different second dose of the Covid-19 vaccine at an interval of 28 days after the first dose, that the dose is valid, and a booster dose should be forecast.
2020-0021	Unspecified Covid 19 vaccine given as dose #1	21142	F				Not complete	44883	SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED	213		Valid																																						2	44911	44911	44938	COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44622.56087386574	Recommended based on interval	v4.21 Updated past due date to 8 weeks per 02/22/22 Clinical Considerations guidelines
v4.6  Added latest recommended interval.	4.21	This test case describes when a patient has been administered an Unspecified Covid-19 Vaccine as a first dose that a second dose should be forecast.
2020-0022	Dose #1 of Pfizer Covid-19 Vaccine (age 12 years)	40528	M				Not complete	44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																						2	44932	44932	44966	COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44622.561077962964	Recommended based on interval	v4.21 Updated past due date to 8 weeks per 02/22/22 Clinical Considerations guidelines
v4.8 Changed age of patient from 16 to 12 years based on new ACIP guidelines for Pfizer vaccine eligibility.
v4.6 Added latest recommended interval.	4.21	This test case describes when a patient is administered the first dose of the Pfizer Covid-19 vaccine (at age 12 years), that the dose is valid.  Another dose should be forecast.
2020-0023	Patient is 6 months of age with no previous dose of the Covid-19 vaccine 	44728	M				Not complete																																											1	44911	44911		COVID-19	44911	No Doses Administered	44110.833333333336	44739.31239413194	Recommended based on age	V4.24 Updated the test case Earliest and Recommended dates to forecast the first dose of the Covid-19 vaccine at age 6 months based on Interim Clinical Consideration guidance (06/19/2022). Updated test case name, age, and description from 5 years to 6 months. 
v4.14 Updated the test case Earliest and Recommended dates to forecast the first dose of the vaccine at age 5, based on new updated ACIP Guideline Recommendations. Updated test case name, age, and description from 12 to 5 years.
v4.8 Changed age of patient from 16 to 12 years based on new ACIP guidelines for Pfizer vaccine eligibility.	4.24	This test case describes when a child that is 6 months of age has no previous history of the Covid-19 vaccine that a dose should be forecast.
2020-0024	 Patient is less than 6 months of age with no previous dose of the Covid-19 vaccine	44733	M				Not complete																																											1	44916	44916		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44739.31281689815	Recommended based on age	V4.24 Updated the test case Earliest and Recommended dates to forecast the first dose of the Covid-19 vaccine at age 6 months based on Interim Clinical Consideration guidance (06/19/2022). Updated test case name, age, and description from less than 5 years of age to less than 6 months. 
v4.14 Updated the test case Earliest and Recommended dates to forecast the first dose of the vaccine at age 5, based on new updated ACIP Guideline Recommendations.  Updated test case name, age, and description from 12 to 5 years.
v4.8 Changed age of patient from 16 to 12 years based on new ACIP guidelines for Pfizer vaccine eligibility.	4.24	This test case describes when a patient is less than 6 months of age and has no previous history of a Covid-19 vaccine that a  dose should be forecast..
2020-0025	Dose #2 of Pfizer Covid-19 Vaccine at 21 days (age 5 years). Forecast booster dose	43064	M				Not complete	44890	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44853.50829060185	Recommended based on interval	v4.28 Updated the test cased based on new updated Interim Clinical Considerations for a new COVID-19 booster recommendation for people ages 5 years and older to receive 1 bivalent MRNA booster dose, at least 2 months, after completion of a monovalent primary series; these recommendations replace all booster recommendations for this age group.
v4.23 Updated the test case based on new updated ACIP Guideline Recommendations (05/19/22) that expands the eligibility for a booster dose for children ages 5-11 years, 5 months after the second dose.
v4.14 Updated the test case based on new updated ACIP Guideline Recommendations (11/3/2021).  Updated test case name, age, and description from 12 to 5 years. Updated CVX Code to 218.
v4.12 Updated per ACIP recommendations, on 09/22/2021, for Pfizer booster dose.
v4.8 Changed age of patient from 16 to 12 years based on new ACIP guidelines for Pfizer vaccine eligibility.	4.28	This test case describes when a patient is administered the second dose of the Pfizer Covid-19 vaccine at 21 days after the first dose that the dose is valid. Another dose should be forecast.
2020-0026	Dose #2 of Pfizer Covid-19 Vaccine at 21 - 4 days (age 5 years). Forecast booster	43064	M				Not complete	44890	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid		44907	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid																																3	44963	44963		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44853.50874118056	Recommended based on interval	v4.28 Updated the test cased based on new updated Interim Clinical Considerations for a new COVID-19 booster recommendation for people ages 5 years and older to receive 1 bivalent MRNA booster dose, at least 2 months, after completion of a monovalent primary series; these recommendations replace all booster recommendations for this age group.
v4.23 Updated the test case based on new updated ACIP Guideline Recommendations (05/19/22) that expands the eligibility for a booster dose for children ages 5-11 years, 5 months after the second dose.
v4.14 Updated the test case based on new updated ACIP Guideline Recommendations (11/3/2021).  Updated test case name, age, and description from 12 to 5 years. Updated CVX Code to 218.
v4.12 Updated per ACIP recommendations, on 09/22/2021, for Pfizer Covid-19 booster dose. 
v4.8 Changed age of patient from 16 to 12 years based on new ACIP guidelines for Pfizer vaccine eligibility.	4.28	This test case describes when a patient is administered the second dose of the Pfizer Covid-19 vaccine at 21 - 4 days after the first dose that the dose is valid. Another dose should be forecast.
2020-0027	Dose #2 of Pfizer Covid-19 Vaccine at 21 - 5 days (age 5 years)	43069	M				Not complete	44895	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Not Valid	Interval: too short																															2	44932	44932	44966	COVID-19	44911	Interval: Below Absolute Minimum	44110.833333333336	44622.56198121528	Recommended based on minimum interval from invalid dose	v4.21 Updated past due date to 8 weeks per 02/22/22 Clinical Considerations guidelines
v4.15 Added a past due date.
v4.14 Updated the test case based on new updated ACIP Guideline Recommendations (11/3/2021).  Updated test case name, age, and description from 12 to 5 years. Updated CVX Code to 218.
v4.12 Updated per ACIP recommendations, on 09/22/2021, for Pfizer Covid-19 booster dose.
v4.8 Changed age of patient from 16 to 12 years based on new ACIP guidelines for Pfizer vaccine eligibility.	4.21	This test case describes when a patient is administered the second dose of the Pfizer Covid-19 vaccine at 21 - 5 days after the first dose that the dose is not valid.
2021-0001	Patient is >18 years and has received the Janssen Covid-19 vaccine	35049	M				Not complete	44911	Janssen (J&J) COVID-19 Vaccine	212	JSN	Valid																																						2	44967	44967		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44498.28556087963	Recommended based on interval	v4.13 - Updated test case to include the forecasting of a Covid-19 booster dose, at an interval of 8 weeks from most recent dose, for individuals who've received only one dose of the Janssen vaccine.	4.13	This test case describes when a patient is administered the Janssen Covid-19 vaccine, that the dose is valid. Another dose should be forecast.
2021-0002	Dose #1 of Covid 19 vaccine given as Pfizer, Dose #2 as Janssen	21142	F				Not complete	44883	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Not Valid	Not a preferable or allowable vaccine	44911	Janssen (J&J) COVID-19 Vaccine	212	JSN	Valid																																2	44967	44967		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44498.300010810184	Recommended based on interval	v4.13 - Updated test case to include ACIP recommendation where if the first dose of a Covid-19 vaccine is an MRNA followed with a second dose of Janssen, that another dose should be forecast.	4.13	This test case describes when a patient has been administered the first dose of the Covid-19 vaccine as Pfizer and a second dose administered at 4 weeks later, as Janssen, that the Pfizer dose is considered to be invalid, and the Janssen dose is to be considered valid.  Another dose should be forecasted.
2021-0003	Dose #1 of Covid 19 vaccine given as Moderna Dose #2 as Janssen	29543	F				Not complete	44883	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Not Valid	Not a preferable or allowable vaccine	44911	Janssen (J&J) COVID-19 Vaccine	212	JSN	Valid																																2	44967	44967		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44498.30030219907	Recommended based on interval	v4.13 - Updated test case to include ACIP recommendation where if the first dose of a Covid-19 vaccine is an MRNA followed with a second dose of Janssen, that another dose should be forecast.	4.13	This test case describes when a patient has been administered the first dose of the Covid-19 vaccine as Moderna and a second dose administered at 4 weeks later, as Janssen, that the Moderna dose is considered to be invalid, and the Janssen dose is to be considered valid.  Another dose should be forecasted.
2021-0004	 Dose #1 Unspecified Covid 19 vaccine, Dose #2 given as Janssen	25525	F				Not complete	44883	SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED	213		Not Valid	Not a preferable or allowable vaccine	44911	Janssen (J&J) COVID-19 Vaccine	212	JSN	Valid																																2	44967	44967		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44498.30121920139	Recommended based on interval	v4.13 - Updated test case to include ACIP recommendation where if the first dose of a Covid-19 vaccine is followed with a second dose of Janssen, that another dose should be forecast.	4.13	This test case describes when a patient has been administered the first dose of the Covid-19 vaccine as Unspecified, and a second dose, given at 4 weeks later,  as Janssen, that the Janssen dose is valid. Another dose should be forecast.
2021-0005	Patient is <18 years and has received the Janssen Covid-19 vaccine	39067	M				Not complete	44911	Janssen (J&J) COVID-19 Vaccine	212	JSN	Not Valid	Not a preferable or allowable vaccine																																					1	44939	44939		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44798.37510575231	Recommended based on interval	v4.26 Updated vaccine dose status from "valid' to "not valid" based on current Covid-19 Clinical Consideration guidelines comments, found in Table C.
v4.21 Updated past due date to 8 weeks per 02/22/22 Clinical Considerations guidelines
v4.19 Updated the interval on the forecast dose to 28 days instead of 8 weeks per the Interim Clinical Considerations guidance concerning "Unauthorized age group".
v4.18 Updated the Forecast Earliest and Recommended dates that individuals should receive a booster dose at least 2 months ( 8 weeks) after a primary Janssen single dose.
v4.17 Test case updated to reflect individuals 16 years and up can receive a booster dose (per updated clinical considerations on 12/10/21).
v4.14  Test case updated to reflect that no additional doses should be forecast if patient is 16 and received a dose of the Janssen vaccine.	4.26	This test case describes when a patient that is less than 18 years of age and is administered the Janssen Covid-19 vaccine, that the dose is not valid.  Another age appropriate dose (preferably a mRNA) should be forecast.
2021-0006	 Dose #1 of a Non-U.S. Covid-19 Vaccine 	37241	M				Not complete	44911	COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL 	210		Valid																																						2	44939	44939		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44608.28980011574	Recommended based on interval	v4.20: Updated test case to align with Interim Clinical Considerations for "People who received Covid-19 vaccine outside of the United States" by changing dose #1 status to "Valid" and updating the test case description.	4.20	This test case describes when a patient is administered only one dose of a two-dose Non-US Covid-19 vaccine schedule, that the dose is considered to be valid.  Another dose should be forecast.
2021-0007	Dose #1 and Dose #2 of a Non-U.S. Covid-19 Vaccine 	37213	M				Not complete	44883	COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL 	210		Valid		44911	COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL 	210		Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44831.40173481481	Recommended based on interval	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group. 
v4.20: Updated test case to align with Interim Clinical Considerations for "People who received Covid-19 vaccine outside of the United States" by forecasting a third dose.	4.27	This test case describes when a patient is administered the first and second dose of a two-dose Non-US Covid-19 vaccine (e.g Astra Zeneca), but still a WHO Covid-19 vaccine, that the doses are considered to be valid.  Another dose should be forecast.
2021-0008	Dose #1 is Pfizer Dose #2 is Astra Zeneca Covid-19 Vaccine 	35759	F				Not complete	44890	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44911	AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD)	210	ASZ	Not Valid	Not a preferable or allowable vaccine																															2	44939	44939	44966	COVID-19	44911	Vaccine: Invalid Usage	44110.833333333336	44622.562558784724	Recommended based on interval	v4.21 Updated past due date to 8 weeks per 02/22/22 Clinical Considerations guidelines	4.21	This test case describes when a patient is administered a first dose of  Pfizer Covid-19 Vaccine and a second dose as AstraZeneca that the second dose is invalid and that another dose should be forecast.
2021-0009	Dose #1 is AstraZeneca Dose #2 is Pfizer Covid-19 Vaccine 	35686	F				Not complete	44600	AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD)	210	ASZ	Valid		44628	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44781	44781		COVID-19	44628	All Valid: Forecast Test	44110.833333333336	44831.40224664352	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). 
v4.20: Updated test case to align with Interim Clinical Considerations for "People who received Covid-19 vaccine outside of the United States" by changing the status of dose #1 to "valid" and by forecasting a third dose.	4.27	This test case describes when a patient is administered a first dose of  AstraZeneca Covid-19 Vaccine and a second dose as Pfizer that a third dose is recommended.
2021-0010	Patient is 5 years old and was administered Moderna as first dose of Covid-19 vaccine.	43085	M				Not complete	44911	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid																																						2	44939	44939	44966	COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44622.56329189815	Recommended based on interval	v4.21 Updated past due date to 8 weeks per 02/22/22 Clinical Considerations guidelines
v4.14 Updated the test case based on new updated ACIP Guideline Recommendations (11/3/2021).  Updated test case name, age, and description from 12 to 5 years. Updated CVX Code to 218.	4.21	This test case describes when a 5 year old child is administered Moderna as the first dose of the Covid-19 vaccine,  that the dose is considered valid, and a second dose should be forecasted.
2021-0011	Dose #1 and dose #2 of the Novavax Covid-19 vaccine.	32472	M				Not complete	44890	Novavax COVID-19 Vaccine	211	NVX	Valid		44911	Novavax COVID-19 Vaccine	211	NVX	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44824.2786272338	Recommended based on interval	v4.27 Added forecast for a bivalent booster
v4.25  Updated test cast to align with the current Interim Clinical Considerations on 07/20/2022 concerning the use of the Novavax Covid-19 vaccine and that two doses with an interval of 21 days is currently considered a completed series.
v4.20 Updated test case to align with Interim Clinical Considerations for "People who received Covid-19 vaccine outside of the United States" by forecasting a third dose.	4.27	This test case describes when an adult is administered the Novavax Covid-19 vaccine as the first and second dose (21 day interval) that the doses are considered valid. Another dose should be forecast.
2021-0012	Dose #2 of the Novavax Covid-19 vaccine administered at an interval of 14 days.	32479	M				Not complete	44897	Novavax COVID-19 Vaccine	211	NVX	Valid		44911	Novavax COVID-19 Vaccine	211	NVX	Not Valid	Interval: too short																															2	44932	44932	44966	COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44764.52970859953	Recommended based on interval	v4.25 -  Updated test case to align with the current Interim Clinical Considerations on 07/20/2022 concerning the use of the Novavax Covid-19 vaccine.
v4.20 - Updated test case to align with Interim Clinical Considerations for "People who received Covid-19 vaccine as part of a clinical trial" by forecasting a third dose.	4.25	This test case describes when an adult is administered the second dose of the Novavax Covid-19 vaccine at an interval of 14 days after the first dose, that the dose is not valid.  Another dose should be forecast.
2021-0013	Dose #2 of the Novavax Covid-19 vaccine administered at 7 days after first dose	32486	M				Not complete	44904	Novavax COVID-19 Vaccine	211	NVX	Valid		44911	Novavax COVID-19 Vaccine	211	NVX	Not Valid	Interval: too short																															2	44932	44932	44966	COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44764.53052712963	Recommended based on interval	v4.25 - Updated test cast to align with the current Interim Clinical Considerations on 07/20/2022 concerning the use of the Novavax Covid-19 vaccine.
v4.20 - Updated test case to align with Interim Clinical Considerations for "People who received Covid-19 vaccine as part of a clinical trial" by forecasting a third dose.	4.25	This test case describes when an adult is administered the second dose of the Novavax Covid-19 vaccine at an interval of 7 days after the first dose, that the dose is not valid. Another dose should be forecast.
2021-0014	Dose #1 of the Novavax Covid-19 Vaccine 	30301	M				Not complete	44911	Novavax COVID-19 Vaccine	211	NVX	Valid																																						2	44932	44932	44966	COVID-19	44911	Vaccine: Invalid Usage	44110.833333333336	44764.534773113424	Recommended based on interval	v4.25:: Updated test cast to align with the current Interim Clinical Considerations on 07/20/2022 concerning the use of the Novavax Covid-19 vaccine.
v4.20: Updated test case to align with Interim Clinical Considerations for "People who received Covid-19 vaccine as part of a clinical trial" by forecasting a second dose.	4.25	This test case describes when a patient is administered the first dose of the two-dose Novavax Covid-19 vaccine, that the dose is considered valid.  Another dose should be forecast.
2021-0015	Patient is 65 years and has received two doses of the Pfizer Covid-19 vaccine	21149	F				Not complete	44890	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44831.4096378125	Recommended based on interval	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).	4.27	This test case describes when a patient that is 65 years or older and has been administered two doses of the Pfizer Covid-19 vaccine that a booster dose should be forecast.
2021-0016	Patient is 64 years and 8 months and has received two doses of the Pfizer Covid-19 vaccine	21271	F				Not complete	44356	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44377	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44530	44530		COVID-19	44377	All Valid: Forecast Test	44110.833333333336	44831.41266710648	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). 
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).	4.27	This test case describes when a patient that is 64 years of age and has been administered two doses of the Pfizer Covid-19 vaccine that a booster dose should be forecast.
2021-0017	Patient is 64 years and has received two doses of the Pfizer Covid-19 vaccine	21514	F				Not complete	44890	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44831.41311236111	Recommended based on interval	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).
v4.15 Updated per ACIP Recommendation on 11/19/2021, where individuals 18 years and older may receive a booster dose.	4.27	This test case describes when a patient that is 64 years of age and has been administered two doses of the Pfizer Covid-19 vaccine that a booster dose should be forecast.
2021-0018	Patient is 65 years and has been administered the third dose of the Pfizer Covid-19 vaccine at an interval of 6 months	20817	F				Not complete	44193	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44214	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44395	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																										4	44518	44518		COVID-19	44395	All Valid: Forecast Test	44110.833333333336	44831.4149105787	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). 
v4.22 - Updated the test case per the updated Clinical Consideration guidance for a second booster dose (March 30, 2022).	4.27	This test case describes when a patient that is 65 years or older and has been administered a third dose of the Pfizer Covid-19 vaccine at an interval of 6 months after the most previous dose, that the dose is valid.  A second monovalent dose should be forecast.
2021-0019	Patient is 65 years and has been administered the third dose of the Pfizer Covid-19 vaccine at an interval of 4 months after the most previous dose	20879	F				Not complete	44470	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44498	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44649	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																										4	44771	44771		COVID-19	44649	All Valid: Forecast Test	44110.833333333336	44831.41647539352	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). 
v4.22 - Updated the test case per the updated Clinical Consideration guidance for a second booster dose (March 30, 2022).	4.27	This test case describes when a patient that is 65 years or older and has been administered the third dose of the Pfizer Covid-19 vaccine  at an interval less than 6 months that the dose is valid and another dose should be forecast.
2021-0020	Patient is 65 years and has received primary and a first booster dose of the Moderna Covid-19 vaccine	21007	F				Not complete	44424	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44453	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44606	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid																										4	44726	44726		COVID-19	44606	All Valid: Forecast Test	44110.833333333336	44831.41827678241	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). 
v4.22 - Updated the test case per the updated Clinical Consideration guidance for a second booster dose (March 30, 2022).	4.27	This test case describes when a patient that is 65 years or older and has been administered a primary series and a booster dose of the Moderna Covid-19 vaccine that another booster dose should be forecast.
2021-0021	Patient is 64 years and 8 months and has received two doses of the Moderna Covid-19 vaccine	21291	F				Not complete	44695	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44723	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid																																3	44779	44779		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44831.419102824075	Recommended based on interval	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group. 
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 18 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).	4.27	This test case describes when a patient that is 64 years of age and has been administered two doses of the Moderna Covid-19 vaccine that a booster dose should be forecast.
2021-0022	Dose #1 Janssen Covid-19 and  Dose #2 Janssen Covid-19 vaccine.	34921	M				Not complete	44510	Janssen (J&J) COVID-19 Vaccine	212	JSN	Valid		44538	Janssen (J&J) COVID-19 Vaccine	212	JSN	Valid																																3	44659	44659		COVID-19	44538	All Valid: Forecast Test	44110.833333333336	44831.420172673614	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). 
v4.22 - Updated the test case per the updated Clinical Consideration guidance for a second booster dose of any mRNA Covid-19  at an interval of at least 4 months after a second Janssen booster dose was administered (March 30, 2022).	4.27	This test case describes when a patient is administered a Janssen Covid-19 as a first booster dose, at an interval greater than or equal to 2 months, that the dose is valid.  Another (second booster of any mRNA Covid-19) dose should be forecast.
2021-0023	Dose #1 Janssen Covid-19 and Dose #2 Moderna Covid-19 vaccine 	30377	M				Not complete	44550	Janssen (J&J) COVID-19 Vaccine	212	JSN	Valid		44578	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid																																3	44698	44698		COVID-19	44578	All Valid: Forecast Test	44110.833333333336	44831.4209212037	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022).	4.27	This test case describes when a patient is administered a Janssen Covid-19 as a first dose and a Moderna Covid-19 vaccine as a second dose that another dose should be forecast.
2021-0024	Dose #1 Janssen Covid-19 and Dose #2 Pfizer Covid-19 vaccine 	28293	M				Not complete	44533	Janssen (J&J) COVID-19 Vaccine	212	JSN	Valid		44561	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44682	44682		COVID-19	44561	All Valid: Forecast Test	44110.833333333336	44831.422961550925	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022).	4.27	This test case describes when a patient is administered a Janssen Covid-19 as a first dose and a Pfizer Covid-19 vaccine as a second dose that another dose should be forecast.
2021-0025	2nd dose of Pfizer Covid-19 Vaccine at 21 - 5 days before ACIP instituted minimum interval	36898	F				Not complete	44475	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44491	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44642	44642		COVID-19	44495	All Valid Forecast Test	44110.833333333336	44831.42350247685	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022).
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).
v4.16 Updated the Forecast Recommended Date based on Clinical Considerations Information (11/29/21), that states all persons aged 18 years and older should received a booster dose of Covid-19 vaccine
v4.15 Updated per ACIP Recommendation on 11/19/2021, where individuals 18 years and older may receive a booster dose.	4.27	This test case describes when a second dose of a MRNA vaccine is administered earlier than the 4-day grace period and administered before ACIP instituted a minimum interval on 10/25/2021, that the dose is valid.  A booster dose should be forecast.
2021-0026	2nd dose of Moderna Covid-19 Vaccine at 28 - 5 days before ACIP instituted minimum interval	20886	F				Not complete	44326	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44349	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid																																3	44502	44502		COVID-19	44410	All Valid: Forecast Test	44110.833333333336	44831.42405270833	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). 
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 18 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).	4.27	This test case describes when a patient is administered the second dose of the Moderna Covid-19 vaccine at 28 - 5 days after the first dose and before ACIP instituted a minimum interval on 10/25/2021, that the dose is valid.  A booster dose should be forecast.
2021-0027	Dose #2 of Pfizer Covid-19 Vaccine at 21 - 5 days (age 12 years) before ACIP instituted minimum interval	39845	M				Not complete	44475	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44491	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44642	44642		COVID-19	44495	All Valid: Forecast Test	44110.833333333336	44831.42448244213	Recommended based on age	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). 
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).
v4.14 Updated the test case to show that the status of the series is complete. Per ACIP guidance, no boosters are recommended for any patient under 18 years of age.	4.27	This test case describes when a patient is administered the second dose of the Pfizer Covid-19 vaccine at 21 - 5 days after the first dose, and before ACIP instituted a minimum interval on 10/25/2021, that the dose is valid. A booster dose should be forecast.
2021-0028	Patient is 3 years old and was administered Pfizer's 5-11 years Covid-19 vaccine formulation	43662	M				Not complete	44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid																																						2	44932	44932	44966	COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44739.31413457176	Recommended based on interval	V4.24  Updated forecast Earliest, Recommended, Past dates to reflect the current Interim Clinical Considerations guidance (06/19/2022). Minor update to description
v4.15 added a past due date	4.24	This test case describes when a child that is less than 5 years old and is administered a dose of the Pfizer's 5-11 years Covid-19 (CVX 218) vaccine formulation, that the dose is valid.  Another dose should be forecast.
2021-0029	Patient is administered Dose #1 at 11 years Dose #2 at 12 years with Pfizer Covid-19 vaccine (different formulation)	40528	M				Not complete	44881	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44831.42544403935	Recommended based on age	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group. 
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).
v4.15 Updated the Forecast Dose Number field to blank.	4.27	This test case describes when a child is administered the first dose of the Pfizer Covid-19 vaccine (CVX 208) at age 11 years and the second dose at age twelve (CVX 218),  that the dose is considered valid.  A booster dose should be forecast.
2021-0030	Patient is 20 years of age and was administered Pfizer's vaccine 5-11 formulation	37606	M				Not complete	44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Not Valid	Inadvertent Vaccine																																					1	44911	44911		COVID-19	44911	Vaccine: Off Label	44504.833333333336	44509.30358930556	Recommended based on age		4.14	This test case describes when a patient who is 18 years or older and is administered the Pfizer vaccine for 5-11 years formulation that the dose is considered not valid and an age appropriate dose should be re-administered immediately (repeat dose).
2021-0031	Patient is 20 years of age and was administered Pfizer's Vaccine 5-11 formulation as a second dose	37303	F				Not complete	44758	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Not Valid	Inadvertent Vaccine																															2	44911	44911	44911	COVID-19	44911	Vaccine: Invalid Usage	44504.833333333336	44572.372353969906	Recommended based on interval	v4.18 Updated past due date.
v4.15 Added a past due date.	4.18	This test case describes when a patient who is 18 years or older and is administered Pfizer's vaccine for 5-11 years formulation as a second dose that the dose is considered not valid and an age appropriate dose should be re-administered immediately (repeat dose).
2021-0032	Patient is 4 years old and was administered a Pfizer Covid-19 vaccine (CVX 208).	43297	M				Not complete	44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																						2	44932	44932	44966	COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44739.31472164352	Recommended based on interval	V4.24  Updated forecast Earliest, Recommended, Past dates to reflect the current Interim Clinical Considerations guidance (06/19/2022). Minor update to description.  
v4.15 added a past due date	4.24	This test case describes when a child that is less than 5 years old and was administered a dose of the Pfizer Covid-19 vaccine (CVX 208),  that the dose is valid.  Another dose should be forecast.
2021-0033	Patient is 7 years old and was administered two dose of Pfizer Covid-19 vaccine (CVX 208). Forecast booster dose.	42333	M				Not complete	44890	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44853.50940510417	Recommended based on interval	v4.28 Updated the test cased based on new updated Interim Clinical Considerations for a new COVID-19 booster recommendation for people ages 5 years and older to receive 1 bivalent MRNA booster dose, at least 2 months, after completion of a monovalent primary series; these recommendations replace all booster recommendations for this age group.
v4.23 Updated the test case based on new updated ACIP Guideline Recommendations (05/19/22) that expands the eligibility for a booster dose for children ages 5-11 years, 5 months after the second dose.
v4.15 Updated the Forecast Dose Number field to blank.	4.28	This test case describes when a child that is less than 12 years old and was administered a first and a second dose of the Pfizer Covid-19 vaccine (CVX 208),  that the doses are considered valid. Another dose should be forecast.
2021-0034	Patient is administered dose #1 at 11 years and dose #2 at 12 years with Pfizer Covid-19 vaccine (CVX 208)	40521	M				Not complete	44890	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44831.444896215275	Recommended based on interval	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group. 
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).
v4.15 Updated the Forecast Dose Number field to blank.	4.27	This test case describes when a child is administered Pfizer Covid-19 vaccine (CVX 208) at age 11 and 12 years of age, that the doses are valid. A booster dose should be forecast.
2021-0035	Patient is 12 years old and has been administered the Janssen Covid-19 vaccine 	40528	M				Not complete	44911	Janssen (J&J) COVID-19 Vaccine	212	JSN	Not Valid	Not a preferable or allowable vaccine																																					1	44939	44939		COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44798.37604427083	Recommended based on interval	v4.26 Updated vaccine dose status from "valid' to "not valid" based on current Covid-19 Clinical Consideration guidelines comments, found in Table C.
v4.21: Updated past due date to 8 weeks per 02/22/22 Clinical Considerations guidelines
v4.19 Updated the interval on the forecast dose to 28 days instead of 8 weeks per the Interim Clinical Considerations guidance concerning "Unauthorized age group".
v4.18 Updated the Forecast Earliest and Recommended dates that individuals should receive a booster dose at least 2 months ( 8 weeks) after a primary Janssen single dose.
v4.15 Updated the Forecast Dose Number field to blank.	4.26	This test case describes when a child, who is 12 years, is administered a Janssen Covid-19 vaccine that the dose is not valid.  Another age appropriate dose (preferably a mRNA) should be forecast.
2021-0036	Patient is 6 years old and has been administered the Janssen Covid-19 vaccine as a first dose	42720	M				Not complete	44911	Janssen (J&J) COVID-19 Vaccine	212	JSN	Not Valid	Not a preferable or allowable vaccine																																					1	44939	44939		COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44798.37631894676	Recommended based on interval	v4.26 Updated vaccine dose status from "valid' to "not valid" based on current Covid-19 Clinical Consideration guidelines comments, found in Table C.
v4.21 Updated past due date to 8 weeks per 02/22/22 Clinical Considerations guidelines
v4.19 Updated the interval on the forecast dose to 28 days instead of 8 weeks per the Interim Clinical Considerations guidance concerning "Unauthorized age group".
v4.15 Updated the Forecast Dose Number field to blank.	4.26	This test case describes when a child, who is 6 years, is administered Janssen Covid-19 vaccine as a first dose that the dose is not valid.  Another age appropriate dose (preferably a mRNA) should be forecast.
2021-0037	Patient is administered dose #1 (CVX 207) and dose #2 (CVX 208) Covid-19 vaccines 	40135	M				Not complete	44883	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44831.445377986114	Recommended based on interval	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that individuals should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of a primary series (01/06/2022)
v4.15 Updated the Forecast Dose Number field to blank.	4.27	This test case describes when a child of 13  years is administered Moderna's Covid-19 vaccine (CVX 207) as the first dose and Pfizer's Covid-19 vaccine (CVX208) as the second dose, at an interval of  28 days,  that the doses are valid.  A booster  dose should be forecast.
2021-0038	Patient is administered dose #1 and dose #2 at 12 years with Pfizer (cvx 218) Covid-19 vaccine 	40507	M				Not complete	44890	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44831.44576165509	Recommended based on interval	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group. 
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).
v4.15 Updated the Forecast Dose Number field to blank.	4.27	This test case describes when a child is administered a second dose of Pfizer's Covid-19 vaccine (CVX 218) at an interval of 21 days from the first dose (CVX218), that the dose is valid. A booster dose should be forecast.
2021-0039	Patient is administered dose #1 (CVX 218) and dose #2 (CVX 208) of Pfizer's Covid-19 vaccine 	40507	M				Not complete	44890	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44831.44613211806	Recommended based on interval	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).
v4.15 Updated the Forecast Dose Number field to blank.	4.27	This test case describes when a child is administered two doses of Pfizer's Covid-19 vaccine (1st dose is CVX 218 , 2nd dose is 208) at age 12, that the doses are valid.  A booster dose should be forecast.
2021-0040	3rd dose of Pfizer Covid-19 Vaccine administered 5 mos after previous dose 	38835	F				Not complete	44514	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44287	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44805	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																										4	44861	44861		COVID-19	44809	All Valid: Forecast Test	44110.833333333336	44831.45561130787	Recommended based on interval	v4.27 Updated test case Assessment Date to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.	4.27	This test case describes when a patient that is 16 years is administered the third dose of the Pfizer Covid-19 vaccine at 5 months after the second dose, that the dose is valid. Another dose should be forecast.
2021-0042	Patient is 16 years of age and has been administered two doses of the Moderna Covid-19 vaccine.	39039	F				Not complete	44883	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44911	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44824.30595378472	Recommended based on interval	v4.27 Updated test case to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.
v4.24 - Test Case description and forecast dates updated to reflect the Interim Clinical Consideration (06/24/2022).	4.27	This test case describes when a patient that is 16 years is administered two doses of the Moderna Covid-19 vaccine that the doses are valid.  Another dose should be forecast.
2021-0043	Patient is 16 years of age and has been administered dose #1 as Pfizer and dose #2 as Moderna	38514	F				Not complete	44474	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44502	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid																																3	44653	44653		COVID-19	44502	All Valid: Forecast Test	44110.833333333336	44831.45227423611	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022).	4.27	This test case describes when a patient that is 16 years is administered the first dose of the Covid-19 vaccine as Pfizer and the second dose as the Moderna Covid-19 vaccine that the doses are considered to be valid. Another dose should be forecast.
2022-0005	 Patient is 6 years of age and is administered Jansen as dose #1 and Pfizer as dose #2. 	42692	F				Not complete	44883	Janssen (J&J) COVID-19 Vaccine	212	JSN	Not Valid	Not a preferable or allowable vaccine	44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																2	44932	44932	44966	COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44853.50987378472	Recommended based on interval	v4.26 Updated vaccine dose status from "valid' to "not valid" based on current Covid-19 Clinical Consideration guidelines comments, found in Table C.
v4.23 Updated the test case based on new updated ACIP Guideline Recommendations (05/19/22) that expands the eligibility for a booster dose for children ages 5-11 years, 5 months after the second dose.	4.26	This test case describes when a patient that is 6 years of age and is administered the Janssen Covid-19 vaccine as a first dose and Pfizer Covid-19 vaccine as the second dose, that the first dose is not valid.  Another dose should be forecast.
2022-0006	Patient is 13 years old and has been administered the Janssen Covid-19 vaccine as dose #1 and Pfizer as dose #2 	40135	M				Not complete	44883	Janssen (J&J) COVID-19 Vaccine	212	JSN	Not Valid	Not a preferable or allowable vaccine	44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																2	44932	44932	44966	COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44798.37762601852	Recommended based on interval	v4.26 Updated vaccine dose status from "valid' to "not valid" based on current Covid-19 Clinical Consideration guidelines comments, found in Table C.	4.26	This test case describes when a child, who is 13 years of age is administered Janssen Covid-19 vaccine as dose #1 and Pfizer Covid-19 as dose #2 that the the first dose is not valid.   Another dose should be forecast.
2022-0007	Dose #1 is AstraZeneca Dose #2 is Sinovac Covid-19 Vaccine 	37943	F				Not complete	44883	AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD)	210	ASZ	Valid		44911	Coronavac (Sinovac) COVID-19 Vaccine	511	SNV	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44831.45282554398	Recommended based on interval	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.	4.27	This test case describes when a patient is administered a first dose of  the Covid-19 vaccine as AstraZeneca and a second dose of the Covid-19 vaccine as Sinovac that both doses are valid.  A booster dose should be forecast.
2022-0008	Dose #1 is a Non-WHO Approved Covid-19 Vaccine Dose #2 is AstraZeneca Covid-19 Vaccine 	33195	F				Not complete	44883	COVID-19 VVnr Non-US Vaccine (Sputnik V)	505		Not Valid	Not a preferable or allowable vaccine	44911	COVID-19 IV Non-US Vaccine (COVAXIN)	502		Valid																																2	44939	44939		COVID-19	44911	Vaccine: Invalid Usage	44110.833333333336	44608.29670388889	Recommended based on interval		4.20	This test case describes when a patient is administered a first dose of the Covid-19 vaccine as a Non-WHO/FDA (Sputnik) vaccine and a second dose of the Covid-19 vaccine as Astrazeneca that a dose of a FDA approved vaccine should be forecast.
2022-0009	Dose #1 and Dose #2 are Non-WHO Approved Covid-19 Vaccine 	29177	F				Not complete	44883	COVID-19 VVnr Non-US Vaccine (Sputnik V)	505		Not Valid	Not a preferable or allowable vaccine	44911	COVID-19 VVnr Non-US Vaccine (Sputnik V)	505		Not Valid	Not a preferable or allowable vaccine																															1	44939	44939		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44608.29559460648	Recommended based on interval		4.20	This test case describes when a patient is administered a first dose and second dose of the Covid-19 vaccine as a Non-WHO/FDA (Sputnik) vaccine that both doses are considered to be invalid.  A first dose of a FDA approved vaccine should be forecast.
2022-0016	Patient is 65 years and has been administered a 2nd Pfizer Covid-19 booster vaccine dose	21040	F				Not complete	44487	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44508	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44659	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44781	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																				5	44837	44837		COVID-19	44809	All Valid: Forecast Test	44110.833333333336	44831.456192997684	Recommended based on interval	v4.27 Updated test case to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.	4.27	This test case describes when a patient that is 65 years or older and has been administered a fourth dose (i.e., 2nd booster) of the Pfizer Covid-19 vaccine at an interval of 4 months after the third dose (first booster), that the dose is valid.  Another dose should be forecast.
2022-0017	Patient is administered Dose #1 as Janssen, Dose#2 as Janssen, Dose #3 as a Pfizer Covid-19 vaccine.	34913	M				Not complete	44440	Janssen (J&J) COVID-19 Vaccine	212	JSN	Valid		44652	Janssen (J&J) COVID-19 Vaccine	212	JSN	Valid		44774	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																										4	44830	44830		COVID-19	44809	All Valid: Forecast Test	44110.833333333336	44831.458351030094	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022).	4.27	This test case describes when a patient is administered two doses of the Janssen Covid-19 vaccine and one dose of the Pfizer Covid-19 as a third dose (second booster) at an interval of 4 months, that the dose is valid.  Another dose should be forecast.
2022-0018	Patient is 52 years and has been administered a 2nd Moderna Covid-19 booster vaccine dose	25750	F				Not complete	44493	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44521	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44672	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44755	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid																				5	44811	44811		COVID-19	44809	All Valid: Forecast Test	44110.833333333336	44909.361910555555	Recommended based on interval	v4.29 Added missing dose number (5) in the Forecast.
v4.27 Updated test case to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.	4.27	This test case describes when a patient that is 50 years or older and has been administered a fourth (2nd booster) dose of the Moderna Covid-19 vaccine at an interval of 4 months after the third (first booster) dose, that the dose is valid.  Another dose should be forecast.
2022-0019	Patient is 50 years and has been administered Dose #1  as Janssen and Dose #2 as a Pfizer Covid-19 vaccine 	26435	M				Not complete	44421	Janssen (J&J) COVID-19 Vaccine	212	JSN	Valid		44449	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44571	44571		COVID-19	44449	All Valid: Forecast Test	44110.833333333336	44831.4588175	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022).	4.27	This test case describes when a patient that is 50 years or older and has been administered a Janssen Covid-19 as a first dose and a Pfizer Covid-19 vaccine as a second (first booster) dose,  that another dose should be forecast.
2022-0020	Patient is 50 years and has been administered Dose #1  as Janssen and Dose #2 as Pfizer and Dose #3 as Moderna	26316	M				Not complete	44426	Janssen (J&J) COVID-19 Vaccine	212	JSN	Valid		44454	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44788	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid																										4	44844	44844		COVID-19	44807	All Valid: Forecast Test	44110.833333333336	44831.46033212963	Recommended based on interval	v4.27 Updated test case to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.	4.27	This test case describes when a patient that is 50 years or older and has been administered a Janssen Covid-19 as a first dose and a Pfizer Covid-19 vaccine as a second (first booster) and Moderna and a third (second booster) dose that another dose (bivalent) should be forecast.
2022-0021	3rd dose of Covid-19 Vaccine different product (Pfizer ) than second dose (Moderna)	23967	F				Not complete	44363	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44702	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44730	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																										4	44786	44786		COVID-19	44809	All Valid: Forecast Test	44110.833333333336	44831.46640452546	Recommended based on interval	v4.27 Updated test case Assessment Date to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.	4.27	This test case describes when a patient is administered a Pfizer Covid-19 vaccine (third dose) 28 days after a second dose Moderna vaccine, that the dose is valid.  A booster dose (preferably a bivalent mRNA) should be forecast.
2022-0022	Dose #1 is AstraZeneca Dose #2 is Sinovac Covid-19 and Vaccine #3 is Pfizer	21643	F				Not complete	44483	AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD)	210	ASZ	Valid		44501	Coronavac (Sinovac) COVID-19 Vaccine	511	SNV	Valid		44652	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																										4	44774	44774		COVID-19	44652	All Valid: Forecast Test	44110.833333333336	44831.46796967593	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022).	4.27	This test case describes when a patient is administered a first dose of the Covid-19 vaccine as AstraZeneca, a second dose of the Covid-19 vaccine as Sinovac, and a third (first booster) dose as Pfizer, that the doses are valid.  Another dose should be forecast.
2022-0023	Patient is 5 years and has been administered a primary series and a booster dose of the Pfizer Covid-19 vaccine	42911	M				Complete	44737	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid		44758	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid																														COVID-19	44911	All Valid: Forecast Test	44697.833333333336	44853.51089144676	Not recommended: series complete	v4.28 Updated the test cased based on new updated Interim Clinical Considerations (10/12/2022) where if a monovalent vaccine is administered for a bivalent booster dose that the dose does not need to be repeated.	4.28	This test cases describes when a patient that is 5 years of age, has been administered a primary series and a monovalent booster dose of the Pfizer Covid-19 that the doses are valid.  Series is complete.
2022-0024	Patient is 6 years of age and is administered Jansen as dose #1 and administered doses #2 and #3 as Pfizer Covid-19 vaccine	42636	F				Not complete	44827	Janssen (J&J) COVID-19 Vaccine	212	JSN	Not Valid	Not a preferable or allowable vaccine	44855	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid																										3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44853.51155538194	Recommended based on interval	v4.28 Updated the test cased based on new updated Interim Clinical Considerations for a new COVID-19 booster recommendation for people ages 5 years and older to receive 1 bivalent MRNA booster dose, at least 2 months, after completion of a monovalent primary series; these recommendations replace all booster recommendations for this age group.
v4.26 Updated vaccine dose status in dose #1 from "valid' to "not valid" for Janssen based on current Covid-19 Clinical Consideration guidelines comments, found in Table C.	4.28	This test case describes when a patient that is 6 years of age is administered the Janssen Covid-19 vaccine as a first dose and Pfizer Covid-19 vaccine as the second and third dose, that the first dose is not valid.  A booster dose should be forecast.
2022-0025	Patient is 10 years and has been administered dose #1 as the Moderna Covid-19 vaccine and dose #2 as the Pfizer Covid-19	41231	M				Not complete	44883	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44697.833333333336	44853.51244510417	Recommended based on interval	v4.28 Updated the test cased based on new updated Interim Clinical Considerations for a new COVID-19 booster recommendation for people ages 5 years and older to receive 1 bivalent MRNA booster dose, at least 2 months, after completion of a monovalent primary series; these recommendations replace all booster recommendations for this age group.	4.28	This test cases describes when a patient that is 10 years of age and has been administered a dose of the Moderna Covid-19 vaccine as a first dose and a dose of Pfizer Covid-19 vaccine as a second dose that another dose (booster) should be forecast.
2022-0026	 Patient is 10 years and has been administered dose #1 as the Moderna Covid-19 vaccine and dose #2 and #3 as the Pfizer Covid-19 vaccine	41076	M				Complete	44728	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44756	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid		44909	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid																														COVID-19	44911	All Valid: Forecast Test	44697.833333333336	44853.512727835645	Not recommended: series complete	v4.28 Updated the test cased based on new updated Interim Clinical Considerations (10/12/2022) where if a monovalent vaccine is administered for a bivalent booster dose that the dose does not need to be repeated.	4.28	This test cases describes when a patient that is 10 years of age has been administered Moderna Covid-19 vaccine as the first dose and Pfizer Covid-19 as second and booster dose that all of the doses are valid. Series is complete.
2022-0027	Patient is 6 months of age and has been administered the first dose of the Pfizer Covid-19 vaccine	44728	F				Not complete	44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid																																						2	44932	44932	44966	COVID-19	44911	All Valid: Forecast Test	44697.833333333336	44739.31913642361	Recommended based on interval		4.24	This test cases describes when a patient that is 6 months of age and has been administered Pfizer's Covid-19 vaccine (CVX 219) as the first dose that the dose is valid.  Another dose should be forecast.
2022-0028	Patient is 6 months of age and has been administered the second dose of the Pfizer Covid-19 vaccine	44706	F				Not complete	44890	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44697.833333333336	44739.320429328705	Recommended based on interval		4.24	This test cases describes when a patient that is 6 months of age has been administered the second dose of Pfizer's Covid-19 (CVX 219) vaccine at an interval of 21 days that the doses is valid.  Another dose should be forecast.
2022-0029	Patient is 8 months of age and has been administered the third dose of the Pfizer Covid-19 vaccine 	44645	F				Complete	44829	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid		44850	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid		44906	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid																														COVID-19	44911	All Valid: Forecast Test	44697.833333333336	44896.67700109954	Not recommended: series complete		4.24	This test cases describes when a patient that is 8 months of age has been administered the third dose of the Pfizer Covid-19 (CVX 219) vaccine at an interval of 8 weeks after the second dose that the dose is valid.  No additional doses should be forecast at this time.  Patient is up to date.
2022-0030	Patient is 12 years of age and has been administered CVX 221 of the Moderna Covid-19 vaccine as the first dose	40528	M				Not complete	44911	Moderna COVID-19 Vaccine (non-US Spikevax)	221	MOD	Valid																																						2	44939	44939	44966	COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44739.37255428241	Recommended based on interval		4.24	This test case describes when a patient that is 12 years is administered Moderna's (CVX 221) Covid-19 vaccine as the first dose that the dose is valid. Another dose should be forecast.
2022-0031	Patient is 12 years of age and has been administered Moderna's (CVX 221) Covid-19 vaccine for the first and second dose	40379	M				Not complete	44752	Moderna COVID-19 Vaccine (non-US Spikevax)	221	MOD	Valid		44780	Moderna COVID-19 Vaccine (non-US Spikevax)	221	MOD	Valid																																3	44836	44836		COVID-19	44811	All Valid: Forecast Test	44110.833333333336	44833.34354983796	Recommended based on interval	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.	4.27	This test case describes when a patient that is 12 years is administered Moderna (CVX 221) Covid-19 vaccine as the first and second dose that the doses are considered to be valid. Another dose should be forecast.
2022-0032	Patient is 15 months of age and has been administered the first dose of the Moderna Covid-19 (CVX 228) vaccine	44455	F				Not complete	44911	Moderna COVID-19 Vaccine (non-US Spikevax)	228	MOD	Valid																																						2	44939	44939	44966	COVID-19	44911	All Valid: Forecast Test	44697.833333333336	44739.32807015046	Recommended based on interval		4.24	This test case describes when a patient that is 15 months of age has been administered the first dose of the Moderna Covid-19 (CVX 228) vaccine that the dose is valid.  Another dose should be forecast.
2022-0033	Patient is 15 months of age and has been administered the second dose of the Moderna Covid-19 (CVX 228) vaccine	44426	F				Not complete	44883	Moderna COVID-19 Vaccine (non-US Spikevax)	228	MOD	Valid		44911	Moderna COVID-19 Vaccine (non-US Spikevax)	228	MOD	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44697.833333333336	44909.36332778935	Recommended based on interval	v4.29 Updated test case to forecast a booster dose based on current Clinical Considerations for Covid-19 (12/9/2022)	4.29	This test case describes when a patient that is 15 months of age has been administered the second dose of tModerna  Covid-19 (CVX 228) vaccine that the dose is valid.  Another dose should be forecast.
2022-0034	Patient is 2 years of age and has been administered the Pfizer Covid-19 vaccine as a first dose and Moderna as second dose for the Covid-19 vaccine	44153	F				Not complete	44883	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid		44911	Moderna COVID-19 Vaccine (non-US Spikevax)	228	MOD	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44697.833333333336	44739.3691728125	Recommended based on interval		4.24	This test case describes when a patient that is 2 years of age has been administered the first dose Pfizer's Covid-19 vaccine (CVX Code 219) and a second dose of the Covid19 vaccine as Moderna (CVX 228), that the doses are valid. Another dose should be forecast.
2022-0035	Patient was age 4 years but turns 5 years old and was administered CVX Code 219 for both Covid-19 doses	43078	F				Not complete	44890	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test Type	44725.833333333336	44831.4807208912	Recommended based on interval	v4.25 - Made updates to the test case based on clarification from the COVID-19 SME that the 6 mo - 4 year Pfizer can be considered valid for those between the ages of 5 years and 6 years, but ONLY IF dose one is administered before 5 years. Subsequent doses can be administered on/after 5 years of age.	4.25	This test cases describes when a patient who was 4 years old when he was administered Pfizer's Covid-19 vaccine (CVX 219) and his first dose of the Covid-19 but then turned 5 years of age and was administered the same vaccine, that the second dose is valid. A third dose should be forecast.
2022-0037	Patient is 4 months of age and has been administered a dose of the Pfizer Covid-19 vaccine	44789	M				Not complete	44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid																																						2	44973	44973	44973	COVID-19	44911	All Valid: Forecast Test	44727.833333333336	44739.37355333333	Recommended based on age		4.24	This test case describes when an infant at age 4 months has been administered a first dose of the Pfizer Covid-19 (CVX 219) vaccine that the dose is considered to be valid.  Another dose should be forecast.
2022-0038	Patient is 2 years of age and has been administered a third dose of the Covid-19 vaccine 	44083	F				Complete	44813	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid		44841	Moderna COVID-19 Vaccine (non-US Spikevax)	228	MOD	Valid		44897	Moderna COVID-19 Vaccine (non-US Spikevax)	228	MOD	Valid																														COVID-19	44911	All Valid: Forecast Test	44697.833333333336	44739.34029723379	Not recommended: series complete		4.24	This test case describes when a patient that is 2 years of age and has been administered the first dose of the Covid-19 vaccine as Pfizer (CVX 219) and the second and third doses of the Covid19 vaccine as Moderna (CVX 228) that the doses are valid. No additional dose should be forecast. Patient is complete.
2022-0039	Patient is 3 years of age and has been administered a third dose of a Covid-19 vaccine at 8 weeks - 5 days	43717	F				Not complete	44813	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid		44834	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid		44885	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Not Valid	Interval: too short																									3	44941	44941		COVID-19	44911	Interval: Below Absolute Minimum	44697.833333333336	44739.34189743055	Recommended based on minimum interval from invalid dose		4.24	This test case describes when a patient that is 3 years of age has been administered the third dose of a Covid-19 (CVX 219) vaccine at 8 weeks - 5 days that the dose is not valid.  A repeat dose should be forecast.
2022-0040	Patient is 5 years of age and is administered Pfizer's Covid-19 (CVX219) vaccine as a first dose.	43085	M				Not complete	44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Not Valid	Not a preferable or allowable vaccine																																					1	44911	44911		COVID-19	44911	Vaccine off label	44725.833333333336	44764.541657141206	Recommended based on interval	v4.25 - Updated test case based on clarification from Covid-19 SME concerning age limits for CVX Code 219 (maroon cap). The 6 mo - 4 year Pfizer can be considered valid for those between the ages of 5 years and 6 years, but ONLY IF dose one is administered before 5 years. Dose 1 of CVX 219 can not be administered on/after 5 years of age. Subsequent doses can be administered on/after 5 years of age.	4.25	This test cases describes when a patient who is 5 years of age and is administered Pfizer's (CVX Code 219) Covid-19 vaccine as his first dose, that the dose is not valid.  A repeat dose should be forecast immediately.
2022-0043	Patient is 9 years of age and is administered Moderna's Covid-19 (CVX221) vaccine as a first dose.	41624	M				Not complete	44911	Moderna COVID-19 Vaccine (non-US Spikevax)	221	MOD	Valid																																						2	44939	44939	44966	COVID-19	44911	All Valid: Forecast Test	44725.833333333336	44739.34809709491	Recommended base on interval		4.24	This test cases describes when a patient who is 9 years of age and is administered a first dose of the Moderna Covid-19 (CVX Code 221), that the dose is valid.  Another dose should be forecast.
2022-0044	Patient is 9 years of age and is administered Moderna's Covid-19 (CVX 221) vaccine as a second dose at an interval of 8 weeks	41568	M				Not complete	44855	Moderna COVID-19 Vaccine (non-US Spikevax)	221	MOD	Valid		44911	Moderna COVID-19 Vaccine (non-US Spikevax)	221	MOD	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44725.833333333336	44853.5130750463	Recommended based on interval	v4.28 Updated the test cased based on new updated Interim Clinical Considerations for a new COVID-19 booster recommendation for people ages 5 years and older to receive 1 bivalent MRNA booster dose, at least 2 months, after completion of a monovalent primary series; these recommendations replace all booster recommendations for this age group.	4.28	This test cases describes when a patient that is 9 years of age is administered a second dose of Moderna's Covid-19 (CVX Code 221) vaccine at an interval of 8 weeks, that the dose is valid.  Another dose should be forecast.
2022-0046	Patient was age 11 years but turns 12 years old and was administered two different Moderna Covid-19 vaccines.	40514	M				Not complete	44881	Moderna COVID-19 Vaccine (non-US Spikevax)	221	MOD	Valid		44909	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid																																3	44965	44965		COVID-19	44911	All Valid: Forecast Test	44725.833333333336	44833.34395778935	Recommended based on interval	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.	4.27	This test cases describes when a patient who was 11 years old when he was administered Moderna Covid-19 (CVX Code 221 for ages 6-11 years) but turned 12 years of age and was administered CVX Code 208 (for ages 12+). Both doses are valid.  Another dose should be forecast.
2022-0050	Patient is 12 months of age and has been administered the Moderna Covid-19 vaccine as a first dose and Pfizer Covid-19 as second dose	44518	F				Not complete	44883	Moderna COVID-19 Vaccine (non-US Spikevax)	228	MOD	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44697.833333333336	44831.484252766204	Recommended based on interval		4.26	This test case describes when a patient that is 12 months of age has been administered the first dose Moderna's Covid-19 vaccine (CVX Code 228) and a second dose of the Covid19 vaccine as Pfizer's (CVX 219), that the doses are valid. Another dose should be forecast.
2022-0051	Dose #1 Novavax Covid-19 vaccine Dose #2 Pfizer Covid-19 vaccine	35752	M				Not complete	44883	Novavax COVID-19 Vaccine	211	NVX	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44831.48511675926	Recommended based on interval	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.	4.27	This test case describes when an adult is administered Novavax Covid-19 vaccine as the first dose and Pfizer's Covid-19 as a second dose that the doses are valid. Another dose should be forecast.
2022-0052	Dose #1 Novavax Covid-19 vaccine Dose #2 Moderna Covid-19 vaccine	35528	M				Not complete	44563	Novavax COVID-19 Vaccine	211	NVX	Valid		44591	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid																																3	44742	44742		COVID-19	44591	All Valid: Forecast Test Type	44430.833333333336	44831.48795876157	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022).	4.27	This test case describes when an adult is administered Novavax Covid-19 vaccine as the first dose and  Moderna's Covid-19 as a second dose that the doses are valid. Another dose should be forecast.
2022-0053	Dose #1 Pfizer Covid-19 vaccine Dose #2 Novavax Covid-19 vaccine	33926	M				Not complete	44883	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44911	Novavax COVID-19 Vaccine	211	NVX	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44831.48884755787	Recommended based on interval	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.	4.27	This test case describes when an adult is administered Pfizer's Covid-19 vaccine as the first dose and Novavax's Covid-19 as a second dose that the doses are valid. Another dose should be forecast.
2022-0054	Patient is 10 years of age and is administered Dose #1 Novavax Covid-19 vaccine 	41259	M				Not complete	44911	Novavax COVID-19 Vaccine	211	NVX	Valid																																						2	44939	44939	44966	COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44798.38264471065	Recommended based on interval		4.26	This test case describes when a 10 year old child is administered Novavax Covid-19 vaccine as a first dose that the dose is considered to be valid.  Another age appropriate dose (preferably a mRNA) should be forecast.
2022-0055	Patient is 10 years of age and is administered Dose #1 Novavax Covid-19 vaccine and dose #2 as Moderna Covid-19 vaccine 	41231	M				Not complete	44883	Novavax COVID-19 Vaccine	211	NVX	Valid		44911	Moderna COVID-19 Vaccine (non-US Spikevax)	221	MOD	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44853.513500243054	Recommended based on interval	v4.28 Updated the test cased based on new updated Interim Clinical Considerations for a new COVID-19 booster recommendation for people ages 5 years and older to receive 1 bivalent MRNA booster dose, at least 2 months, after completion of a monovalent primary series; these recommendations replace all booster recommendations for this age group.	4.28	This test case describes when a 10 year old child is administered Novavax Covid-19 vaccine as a first dose and Moderna Covid-19 as a second dose that the doses are valid. Another dose should be forecasted.
2022-0056	Patient is 10 years of age and is administered Dose #1 Novavax Covid-19 vaccine and dose #2 and #3 as Moderna Covid-19 vaccine 	41076	M				Complete	44728	Novavax COVID-19 Vaccine	211	NVX	Valid		44756	Moderna COVID-19 Vaccine (non-US Spikevax)	221	MOD	Valid		44909	Moderna COVID-19 Vaccine (non-US Spikevax)	221	MOD	Valid																														COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44853.51449342592	Not recommended: series complete	v4.28 Updated the test cased based on new updated Interim Clinical Considerations (10/12/2022) where if a monovalent vaccine is administered for a bivalent booster dose that the dose does not need to be repeated.	4.28	This test case describes when a 10 year old child is administered Novavax Covid-19 vaccine as a first dose and Moderna Covid-19 as the second and third doses that the doses are valid.  Series is complete.
2022-0057	Patient is 11 years of age and is administered Jansen Covid-19 as dose #1 and dose #2	40865	F				Not complete	44883	Janssen (J&J) COVID-19 Vaccine	212	JSN	Not Valid	Not a preferable or allowable vaccine	44911	Janssen (J&J) COVID-19 Vaccine	212	JSN	Not Valid	Not a preferable or allowable vaccine																															1	44939	44939		COVID-19	44911	Vaccine: Invalid Usage	44110.833333333336	44831.514629074074	Recommended based on minimum interval from invalid dose		4.26	This test case describes when a patient that is 11 years of age is administered the Janssen Covid-19 vaccine as a first and second dose, that the doses are not valid.    Another dose should be forecast.
2022-0058	Patient is 8 years of age and has been administered the Pfizer Covid-19 vaccine as first and second dose and Janssen Covid-19 vaccine as a booster dose 	41933	M				Not complete	44855	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid		44883	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid		44911	Janssen (J&J) COVID-19 Vaccine	212	JSN	Not Valid	Not a preferable or allowable vaccine																									3	44967	44967		COVID-19	44911	Vaccine: Invalid Usage	44697.833333333336	44853.51480167824	Recommended based on minimum interval from invalid dose	v4.28 Updated the test cased based on new updated Interim Clinical Considerations for a new COVID-19 booster recommendation for people ages 5 years and older to receive 1 bivalent MRNA booster dose, at least 2 months, after completion of a monovalent primary series; these recommendations replace all booster recommendations for this age group.	4.28	This test case describes when a patient that is 8 years of age has been administered Janssen Covid19 vaccine as a third dose, that the dose is not valid.  Another dose should be forecast.
2022-0060	Patient is 12 years of age and is administered two dose of the Novavax Covid-19 vaccine	40507	M				Not complete	44890	Novavax COVID-19 Vaccine	211	NVX	Valid		44911	Novavax COVID-19 Vaccine	211	NVX	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44830.52384194444	Recommended based on interval		4.27	This test case describes when a 12 year old child is administered Novavax Covid-19 vaccine as a first dose and  second dose that the doses are valid.  A booster is recommended in 8 weeks.
2022-0061	Patient is 5 years of age and is administered a first dose of the Novavax Covid-19 vaccine	43085	F				Not complete	44911	Novavax COVID-19 Vaccine	211	NVX	Valid																																						2	44939	44939	44966	COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44831.51497373843	Recommended based on interval		4.26	This test case describes when a 5 year old child is administered Novavax Covid-19 vaccine as a first dose that the dose is valid. Another (age appropriate) dose should be forecast.
2022-0063	Dose #1 and Dose #2 Novavax Covid-19 vaccine, Dose #3 a mRNA bivalent Covid-19 vaccine	29859	M				Complete	44834	Novavax COVID-19 Vaccine	211	NVX	Valid		44855	Novavax COVID-19 Vaccine	211	NVX	Valid		44911	Moderna COVID-19 Vaccine (non-US Spikevax)	229	MOD	Valid																														COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44824.33811837963	Not recommended: series complete		4.27	This test case describes when an adult is administered the Novavax Covid-19 vaccine as the first and second dose (21 day interval) and a bivalent mRNA vaccine as a third dose that the doses are valid.  Series is complete.
2022-0064	Patient is 65 years and has been administered five doses of the Pfizer Covid-19 vaccine	20812	F				Complete	44553	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44574	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44725	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44847	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44903	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	300	PFR	Valid																		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44831.49161402778	Not Recommended: series complete		4.27	This test case describes when a patient that is 65 years or older and has been administered five doses of the Pfizer Covid-19 vaccine (at appropriate intervals) that the doses are valid.  Series is complete.  Patient is up to date.
2022-0065	Patient is 16 years of age and has been administered two primary and one bivalent dose of the Moderna Covid-19 vaccine	38983	F				Complete	44827	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44855	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44911	Moderna COVID-19 Vaccine (non-US Spikevax)	229	MOD	Valid																														COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44824.339495532404	Not Recommended: series complete		4.27	This test case describes when a patient that is 16 years is administered two primary doses of the Moderna Covid-19 vaccine and one bivalent dose that the doses  are valid.  Series is complete.
2022-0066	Patient is 20 years of age and was administered two primary doses and one bivalent dose of Pfizer's Covid-19 Vaccine 	36146	F				Complete	44698	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44851	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44907	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	300	PFR	Valid																														COVID-19	44911	Vaccine: Invalid Usage	44504.833333333336	44824.340604861114	Not Recommended: series complete		4.27	This test case describes when a patient that is 23 years of age is administered two primary doses and one bivalent dose of Pfizer's Covid-19 vaccine, that the doses are valid.  Series is complete.
2022-0067	Dose #1 Janssen, dose #2 Janssen, dose #3 Pfizer bivalent mRNA Covid-19 vaccine	34567	M				Complete	44794	Janssen (J&J) COVID-19 Vaccine	212	JSN	Valid		44855	Janssen (J&J) COVID-19 Vaccine	212	JSN	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	300	PFR	Valid																														COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44831.49208373843	Not Recommended: series complete		4.27	This test case describes when a patient is administered two doses of a Janssen Covid-19 vaccine and one dose of a mRNA bivalent Covid-19 vaccine that the doses are valid.  Series is complete.  Patient is up to date.
2022-0068	Dose #1 Janssen,  dose #2 Pfizer, dose #3 Moderna dose #4 Bivalent Covid-19 vaccines	30094	M				Complete	44704	Janssen (J&J) COVID-19 Vaccine	212	JSN	Valid		44760	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44822	SPIKEVAX	207	MOD	Valid		44878	Moderna COVID-19 Vaccine (non-US Spikevax)	229	MOD	Valid																								COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44911.28740465278	Not Recommended: series complete	v4.29 - Updated test case minimum and recommended intervals on dose #2 and #3 to align with current recommendations.	4.29	This test case describes when a patient is administered a Janssen Covid-19 as a first dose, a Pfizer Covid-19 vaccine as a second dose, a Moderna Covid-19 vaccine as a third dose, and a Moderna Bivalent Covid-19 vaccine  that no additional doses should be forecast.  Series is complete.
2022-0069	Dose #1 Pfizer Covid-19  Dose #2 Bivalent Pfizer Covid-19 vaccine 	33926	F				Not complete	44883	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	300	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44817.833333333336	44831.51508240741	Recommended based on interval		4.27	This test case describes when a patient is administered a Pfizer Covid-19 as a first dose and the Pfizer Bivalent Covid-19 as a second dose, that the doses are valid.  Another dose should be forecast.
2022-0070	 Dose #1 and 2 Bivalent mRNA Covid-19   	26255	F				Not complete	44883	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	300	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	300	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44817.833333333336	44824.34486871528	Recommended based on interval		4.27	This test case describes when a patient is administered dose #1 and dose #2 as Pfizer Bivalent Covid-19 that the doses are valid.  Another dose should be forecast.
2022-0071	Patient has been administered two dose of Pfizer for Primary Covid-19 and one dose of Pfizer Bivalent vaccine	29483	F				Complete	44823	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44851	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44907	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	300	PFR	Valid																														COVID-19	44911	All Valid: Forecast Test	44817.833333333336	44826.63638548611	Not Recommended: series complete		4.27	This test case describes when a patient is administered two doses of Pfizer's Covid-19 primary series and a third dose as Pfizer's Bivalent Covid-19 vaccine that the doses are valid.  The series is complete.
2022-0075	Patient is administered second dose of Pfizer Covid-19 Vaccine at 21 - 4 days	36493	M				Not complete	44894	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44831.493475324074	Recommended based on interval	v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). 
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 12 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).
v4.16 Updated the Forecast Recommended Date based on Clinical Considerations Information (11/29/21), that states all persons aged 18 years and older should received a booster dose of Covid-19 vaccine.
v4.15 Updated per ACIP Recommendation on 11/19/2021, where individuals 18 years and older may receive a booster dose.
v4.12 Updated per ACIP recommendations, on 09/22/2021, for Pfizer Covid-19 booster dose for individuals 65 years and older.	4.27	This test case describes when a patient is administered the second dose of the Pfizer Covid-19 vaccine at 21 - 4 days after the first dose, that the dose is valid. A booster dose should be forecasted.
2022-0076	Patient is administered the second dose of Moderna Covid-19 Vaccine at 28 - 4 days and a bivalent booster as the third dose	21079	F				Complete	44820	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44844	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44905	Moderna COVID-19 Vaccine (non-US Spikevax)	229	MOD	Valid																														COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44831.49451052083	Not Recommended: series complete	v4.27 Updated Forecast Dates to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster 8 weeks after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.
v4.18 Updated the Forecast Earliest and Recommended dates based on ACIP/Clinical Consideration that all persons aged 18 and older should receive a booster dose of Covid-19 vaccine at an interval of 5 months after completion of the primary series (01/06/2022).
v4.13 - Updated test case to include the forecasting of a booster dose, at an interval of 6 months from most recent dose, for individuals 65 years and older who have completed a primary series.	4.27	This test case describes when a patient is administered a second dose of the Covid-19 vaccine (Moderna) at 28-4 days after the first dose, and a third dose as Moderna's bivalent booster dose, that the doses are valid.  Series is complete.
2022-0077	Patient is administered Dose #1 and Dose #2 as a Non-U.S. Covid-19 Vaccine, bivalent booster dose recommended	38246	M				Complete	44820	COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL 	210		Valid		44848	COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL 	210		Valid		44909	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	300	PFR	Valid																														COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44831.515173472224	Not Recommended: series complete		4.27	This test case describes when a patient is administered the first and second dose of a two-dose Non-US Covid-19 vaccine (e.g Astra Zeneca), but still a WHO Covid-19 vaccine, and a booster dose of the Pfizer Covid-19 Bivalent vaccine that the doses are valid.  Series is complete.  Patient is up to date.
2022-0078	Patient is administered dose #1 as AstraZeneca, dose #2 as Pfizer Covid-19 , dose #3 Bivalent booster	35689	F				Complete	44820	AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD)	210	ASZ	Valid		44848	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44909	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	300	PFR	Valid																														COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44831.50817594907	Not Recommended: series complete		4.27	This test case describes when a patient is administered a first dose of  AstraZeneca Covid-19 Vaccine, second dose as Pfizer Covid-19, and third dose as bivalent Pfizer booster that the doses are valid.  Series is complete.
2022-0079	Patient is 16 years of age and has been administered dose #1 as Pfizer and dose #2 as Moderna and dose #3 bivalent dose	38976	F				Complete	44820	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44848	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44904	Moderna COVID-19 Vaccine (non-US Spikevax)	229	MOD	Valid																														COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44831.508654652775	Recommended based on interval		4.27	This test case describes when a patient that is 16 years is administered the first dose of the Covid-19 vaccine as Pfizer, the second dose as the Moderna Covid-19 vaccine, and the third doses as Bivalent Moderna Covid-19 vaccine that the doses are valid. Series is complete.
2022-0080	Patient has been administered the first dose as AstraZeneca, second dose as Sinovac Covid-19 and third dose as Moderna Bivalent booster vaccine	37150	F				Complete	44820	AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD)	210	ASZ	Valid		44848	Coronavac (Sinovac) COVID-19 Vaccine	511	SNV	Valid		44909	Moderna COVID-19 Vaccine (non-US Spikevax)	229	MOD	Valid																														COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44831.50917025463	Not Recommended: series complete		4.27	This test case describes when a patient is administered a first dose of  the Covid-19 vaccine as AstraZeneca and a second dose of the Covid-19 vaccine as Sinovac that both doses are valid.  A booster (bivalent preferred) dose should be forecast in 8 weeks.
2022-0081	Patient is administered Novavax Covid-19 vaccine as a first dose, Pfizer Covid-19 vaccine as a second dose and Pfizer Bivalent as third dose	34965	M				Complete	44827	Novavax COVID-19 Vaccine	211	NVX	Valid		44855	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	208	PFR	Valid		44911	COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose	300		Valid																														COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44831.51528900463	Recommended based on interval		4.27	This test case describes when an adult is administered Novavax Covid-19 vaccine as the first dose, Pfizer's Covid-19, as a  second dose, and Pfizer's bivalent booster vaccine as the third dose, that the doses are valid.  Series is complete.  Patient is up to date.
2022-0082	Patient is administered Novavax Covid-19 vaccine as the first dose, Moderna Covid-19 vaccine as the second dose, and Moderna Bivalent booster as the third dose	34593	M				Complete	44820	Novavax COVID-19 Vaccine	211	NVX	Valid		44848	Moderna COVID-19 Vaccine (non-US Spikevax)	207	MOD	Valid		44909	Moderna COVID-19 Vaccine (non-US Spikevax)	229	MOD	Valid																														COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44831.51108222222	Recommended based on interval		4.27	This test case describes when an adult is administered Novavax Covid-19 vaccine as the first dose, Moderna's Covid-19 as the second dose, and Moderna's Bivalent Covid-19 vaccine as a third dose, that the doses are valid. Series is complete.
2022-0083	Patient is 7 years old and has been administered the Pfizer Covid-19 Primary series vaccine and one dose of bivalent vaccine	42272	M				Complete	44829	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid		44850	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	218	PFR	Valid		44906	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	301	PFR	Valid																														COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44853.516026296296	Not recommended: series complete		4.28	This test case describes when a child that is 7 years of age has been administered a primary series of the Covid-19 vaccine, and one bivalent booster dose, 8 weeks after the previous dose, that the does are valid.  The series is complete.
2022-0084	Patient is 16 years of age and has been administered two doses of the Moderna Covid-19 vaccine and one bivalent dose	38978	F				Complete	44822	SPIKEVAX	207	MOD	Valid		44850	SPIKEVAX	207	MOD	Valid		44906	Moderna COVID-19 Vaccine (non-US Spikevax)	229	MOD	Valid																														COVID-19	44911	All Valid: Forecast Test	44110.833333333336	44853.51581650463	Not recommended: series complete		4.28	This test case describes when a patient that is 16 years is administered two doses of the Moderna Covid-19 vaccine and one bivalent booster dose that the doses are valid.  Series is complete.
2022-0085	Patient is 4 years old and was administered 2 doses of the Pfizer vaccine (1 mono and 1 bivalent)	43368	M				Not complete	44890	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	302	PFR	Valid																																3	44967	44967		COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44909.364192939815	Recommended based on interval		4.29	This test case describes when a child that is 4 years of age and has been administered one dose of the Pfizer Mono Covid-19 vaccine and one dose of the Pfizer Bivalent vaccine, that the doses are valid.  Another dose should be forecast.
2022-0086	Patient is 15 months of age and has been administered three doses of the Pfizer Covid-19 vaccine	44467	F				Complete	44832	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid		44853	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid		44909	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	302	PFR	Valid																														COVID-19	44911	All Valid: Forecast Test	44697.833333333336	44909.36744248842	Not recommended: series complete		4.29	This test cases describes when a patient that is 15 months of age has been administered the third dose of Pfizer's Covid-19 (bivalent) and that the doses are valid. No further doses are needed at this time.
2022-0087	Patient is 9 months of age and has been administered the third dose of the Moderna Covid-19 (CVX 230) vaccine	44613	F				Complete	44825	Moderna COVID-19 Vaccine (non-US Spikevax)	228	MOD	Valid		44853	Moderna COVID-19 Vaccine (non-US Spikevax)	228	MOD	Valid		44909	Moderna COVID-19 Vaccine (non-US Spikevax)	230	MOD	Valid																														COVID-19	44911	All Valid: Forecast Test	44697.833333333336	44909.369054930554	Not recommended: series complete		4.29	This test case describes when a patient that is 9 months of age has been administered the third dose of Moderna  Covid-19 (CVX 230) vaccine that the dose is valid.  No additional doses should be forecast at this time.
2022-0089	Patient is 2 years of age and has been administered the second and third dose as Pfizer bivalent Covid-19 vaccine 	44104	F				Complete	44834	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	219	PFR	Valid		44855	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	302	PFR	Valid		44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	302	PFR	Valid																														COVID-19	44911	All Valid: Forecast Test	44697.833333333336	44910.338746678244	Not recommended: series complete		4.29	This test cases describes when a patient that is 2 years of age has been administered the second and third dose of the Covid-19 vaccine as Pfizer bivalent booster Covid-19 (CVX 302) that the doses are valid.  No additional doses should be forecast at this time.
2022-0091	Patient is 3 years of age and is administered a bivalent Moderna Covid-19 vaccine (230) as a second dose	43731	F				Not complete	44827	Moderna COVID-19 Vaccine (non-US Spikevax)	228	MOD	Valid		44911	Moderna COVID-19 Vaccine (non-US Spikevax)	230	MOD	Not Valid	Inadvertent Vaccine																															2	44911	44911	44911	COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44911.28790505787	Recommended based on minimum interval from invalid dose		4.29	This test case describes when a patient that is 3 years of age and is administered a Moderna bivalent Covid-19 vaccine as a second dose (CVX 230), that the dose is not valid.  Another dose should be forecast.
2022-0092	Patient is 15 months of age and is administered a bivalent Pfizer Covid-19 vaccine (302) as a third dose	44455	M				Complete	44820	Moderna COVID-19 Vaccine (non-US Spikevax)	228	MOD	Valid		44848	Moderna COVID-19 Vaccine (non-US Spikevax)	228	MOD	Valid		44909	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	302	PFR	Valid																														COVID-19	44911	All Valid: Forecast Test Type	44430.833333333336	44910.34143248843	Not recommended: series complete		4.29	This test case describes when a patient that is 12 months of age and is administered a Pfizer bivalent Covid-19 vaccine as a third dose (CVX 302), that the dose is valid. Series is complete.
2022-0093	Patient is 7 months of age and has been administered CVX230 as the first dose of the Covid-19 vaccine	44697	F				Not complete	44911	Moderna COVID-19 Vaccine (non-US Spikevax)	230	MOD	Not Valid	Inadvertent Vaccine																																					1	44911	44911		COVID-19	44911	All Valid: Forecast Test Type	44906.791666666664	44910.3420240625	Recommended based on minimum interval from invalid dose		4.29	This test case describes when a patient that is 7 months of age is administered the first dose of a Covid-19 vaccine as Moderna's  bivalent (CVX Code 230) that the dose is not valid.  Another dose should be forecast.
2022-0094	Patient is 18 months of age and has been administered Pfizer's bivalent Covid-19 vaccine as the first dose	44363	F				Not complete	44911	Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)	302	PFR	Valid																																						2	44932	44932	44966	COVID-19	44911	All Valid: Forecast Test	44697.833333333336	44911.28814128472	Recommended based on interval		4.29	This test cases describes when a patient that is 18 months of age has been administered a dose of Pfizer's bivalent Covid-19 and that the dose is valid.  Another dose should be forecast.
